WO2012005343A1 - 置換ピリジン化合物 - Google Patents
置換ピリジン化合物 Download PDFInfo
- Publication number
- WO2012005343A1 WO2012005343A1 PCT/JP2011/065651 JP2011065651W WO2012005343A1 WO 2012005343 A1 WO2012005343 A1 WO 2012005343A1 JP 2011065651 W JP2011065651 W JP 2011065651W WO 2012005343 A1 WO2012005343 A1 WO 2012005343A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- group
- alkyl
- methyl
- phenyl
- dimethyl
- Prior art date
Links
- -1 pyridine compound Chemical class 0.000 title claims abstract description 445
- JUJWROOIHBZHMG-UHFFFAOYSA-N pyridine Substances C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 title abstract description 12
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 title abstract description 10
- 150000001875 compounds Chemical class 0.000 claims abstract description 364
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims abstract description 116
- 150000003839 salts Chemical class 0.000 claims abstract description 104
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims abstract description 37
- 125000000623 heterocyclic group Chemical group 0.000 claims abstract description 37
- 125000006517 heterocyclyl carbonyl group Chemical group 0.000 claims abstract description 15
- 125000005844 heterocyclyloxy group Chemical group 0.000 claims abstract description 15
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 119
- 229920006395 saturated elastomer Polymers 0.000 claims description 117
- 238000000034 method Methods 0.000 claims description 100
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 99
- 125000001424 substituent group Chemical group 0.000 claims description 94
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 91
- 125000005843 halogen group Chemical group 0.000 claims description 62
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims description 55
- 208000011775 arteriosclerosis disease Diseases 0.000 claims description 51
- 239000008194 pharmaceutical composition Substances 0.000 claims description 38
- 206010003210 Arteriosclerosis Diseases 0.000 claims description 37
- 208000032928 Dyslipidaemia Diseases 0.000 claims description 37
- 208000017170 Lipid metabolism disease Diseases 0.000 claims description 37
- 201000010099 disease Diseases 0.000 claims description 37
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 37
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 36
- 208000029078 coronary artery disease Diseases 0.000 claims description 35
- 230000002265 prevention Effects 0.000 claims description 34
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 28
- 125000003277 amino group Chemical group 0.000 claims description 25
- 239000004480 active ingredient Substances 0.000 claims description 22
- 235000012000 cholesterol Nutrition 0.000 claims description 22
- 206010003211 Arteriosclerosis coronary artery Diseases 0.000 claims description 20
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims description 20
- 238000004519 manufacturing process Methods 0.000 claims description 20
- 125000004890 (C1-C6) alkylamino group Chemical group 0.000 claims description 19
- 208000035150 Hypercholesterolemia Diseases 0.000 claims description 18
- 208000026106 cerebrovascular disease Diseases 0.000 claims description 17
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims description 15
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 claims description 14
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims description 14
- 208000008589 Obesity Diseases 0.000 claims description 13
- 125000003118 aryl group Chemical group 0.000 claims description 13
- 235000020824 obesity Nutrition 0.000 claims description 13
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims description 12
- 125000006296 sulfonyl amino group Chemical group [H]N(*)S(*)(=O)=O 0.000 claims description 12
- 208000018262 Peripheral vascular disease Diseases 0.000 claims description 11
- 210000004369 blood Anatomy 0.000 claims description 11
- 239000008280 blood Substances 0.000 claims description 11
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 11
- 208000006575 hypertriglyceridemia Diseases 0.000 claims description 11
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 claims description 10
- 238000008214 LDL Cholesterol Methods 0.000 claims description 10
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 10
- 230000007423 decrease Effects 0.000 claims description 10
- 241001465754 Metazoa Species 0.000 claims description 9
- 239000003638 chemical reducing agent Substances 0.000 claims description 9
- 125000004739 (C1-C6) alkylsulfonyl group Chemical group 0.000 claims description 8
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims description 8
- 125000000392 cycloalkenyl group Chemical group 0.000 claims description 8
- 125000006700 (C1-C6) alkylthio group Chemical group 0.000 claims description 7
- 125000006297 carbonyl amino group Chemical group [H]N([*:2])C([*:1])=O 0.000 claims description 7
- 239000003795 chemical substances by application Substances 0.000 claims description 7
- 230000001965 increasing effect Effects 0.000 claims description 7
- 125000000719 pyrrolidinyl group Chemical group 0.000 claims description 7
- 125000004043 oxo group Chemical group O=* 0.000 claims description 6
- 125000004738 (C1-C6) alkyl sulfinyl group Chemical group 0.000 claims description 4
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims description 4
- 239000003354 cholesterol ester transfer protein inhibitor Substances 0.000 claims description 4
- 230000006806 disease prevention Effects 0.000 claims description 4
- 206010068961 Hypo HDL cholesterolaemia Diseases 0.000 claims description 3
- 229940125881 cholesteryl ester transfer protein inhibitor Drugs 0.000 claims description 3
- SZJUYRVLHGGOFC-XSFHMJGTSA-N (2r)-3-[2-[4-[(5s)-4-(4,4-difluorocyclohexyl)-3-[(s)-fluoro-[4-(trifluoromethyl)phenyl]methyl]-5-hydroxy-7,7-dimethyl-6,8-dihydro-5h-quinolin-2-yl]piperidin-1-yl]pyrimidin-5-yl]oxypropane-1,2-diol Chemical compound C1([C@@H](F)C=2C=CC(=CC=2)C(F)(F)F)=C(C2CCC(F)(F)CC2)C([C@@H](O)CC(C2)(C)C)=C2N=C1C(CC1)CCN1C1=NC=C(OC[C@H](O)CO)C=N1 SZJUYRVLHGGOFC-XSFHMJGTSA-N 0.000 claims description 2
- SZJUYRVLHGGOFC-UPFZHXHPSA-N (2s)-3-[2-[4-[(5s)-4-(4,4-difluorocyclohexyl)-3-[(s)-fluoro-[4-(trifluoromethyl)phenyl]methyl]-5-hydroxy-7,7-dimethyl-6,8-dihydro-5h-quinolin-2-yl]piperidin-1-yl]pyrimidin-5-yl]oxypropane-1,2-diol Chemical compound C1([C@@H](F)C=2C=CC(=CC=2)C(F)(F)F)=C(C2CCC(F)(F)CC2)C([C@@H](O)CC(C2)(C)C)=C2N=C1C(CC1)CCN1C1=NC=C(OC[C@@H](O)CO)C=N1 SZJUYRVLHGGOFC-UPFZHXHPSA-N 0.000 claims description 2
- GLGUWQRRDXFPIY-DHIFEGFHSA-N (5s)-4-(4,4-difluorocyclohexyl)-3-[(s)-fluoro-[4-(trifluoromethyl)phenyl]methyl]-2-[1-[5-(2-hydroxyethoxy)pyrimidin-2-yl]piperidin-4-yl]-7,7-dimethyl-6,8-dihydro-5h-quinolin-5-ol Chemical compound C1([C@@H](F)C=2C=CC(=CC=2)C(F)(F)F)=C(C2CCC(F)(F)CC2)C([C@@H](O)CC(C2)(C)C)=C2N=C1C(CC1)CCN1C1=NC=C(OCCO)C=N1 GLGUWQRRDXFPIY-DHIFEGFHSA-N 0.000 claims description 2
- XVUDQBUEUFZZQH-ZQAZVOLISA-N (5s)-4-(4,4-difluorocyclohexyl)-3-[(s)-fluoro-[4-(trifluoromethyl)phenyl]methyl]-2-[1-[5-(3-hydroxy-3-methylbutoxy)pyrimidin-2-yl]piperidin-4-yl]-7,7-dimethyl-6,8-dihydro-5h-quinolin-5-ol Chemical compound N1=CC(OCCC(C)(O)C)=CN=C1N1CCC(C=2C(=C(C3CCC(F)(F)CC3)C=3[C@@H](O)CC(C)(C)CC=3N=2)[C@@H](F)C=2C=CC(=CC=2)C(F)(F)F)CC1 XVUDQBUEUFZZQH-ZQAZVOLISA-N 0.000 claims description 2
- AHHRXARHQJHHBC-IUDBTDONSA-N (5s)-4-(4,4-difluorocyclohexyl)-3-[(s)-fluoro-[4-(trifluoromethyl)phenyl]methyl]-2-[1-[5-(3-hydroxypropoxy)pyrimidin-2-yl]piperidin-4-yl]-7,7-dimethyl-6,8-dihydro-5h-quinolin-5-ol Chemical compound C1([C@@H](F)C=2C=CC(=CC=2)C(F)(F)F)=C(C2CCC(F)(F)CC2)C([C@@H](O)CC(C2)(C)C)=C2N=C1C(CC1)CCN1C1=NC=C(OCCCO)C=N1 AHHRXARHQJHHBC-IUDBTDONSA-N 0.000 claims description 2
- GFZXTTXQXLZSLI-YZNIXAGQSA-N (5s)-4-(4,4-difluorocyclohexyl)-3-[(s)-fluoro-[4-(trifluoromethyl)phenyl]methyl]-7,7-dimethyl-2-[1-(5-methylsulfanylpyrimidin-2-yl)piperidin-4-yl]-6,8-dihydro-5h-quinolin-5-ol Chemical compound N1=CC(SC)=CN=C1N1CCC(C=2C(=C(C3CCC(F)(F)CC3)C=3[C@@H](O)CC(C)(C)CC=3N=2)[C@@H](F)C=2C=CC(=CC=2)C(F)(F)F)CC1 GFZXTTXQXLZSLI-YZNIXAGQSA-N 0.000 claims description 2
- UICIOFWFWRPASW-YZNIXAGQSA-N (5s)-4-(4,4-difluorocyclohexyl)-3-[(s)-fluoro-[4-(trifluoromethyl)phenyl]methyl]-7,7-dimethyl-2-[1-(5-methylsulfonylpyrimidin-2-yl)piperidin-4-yl]-6,8-dihydro-5h-quinolin-5-ol Chemical compound C1([C@@H](F)C=2C=CC(=CC=2)C(F)(F)F)=C(C2CCC(F)(F)CC2)C([C@@H](O)CC(C2)(C)C)=C2N=C1C(CC1)CCN1C1=NC=C(S(C)(=O)=O)C=N1 UICIOFWFWRPASW-YZNIXAGQSA-N 0.000 claims description 2
- HEZZZOOYRSIMQM-DHIFEGFHSA-N 2-[4-[(5s)-4-(4,4-difluorocyclohexyl)-3-[(s)-fluoro-[4-(trifluoromethyl)phenyl]methyl]-5-hydroxy-7,7-dimethyl-6,8-dihydro-5h-quinolin-2-yl]piperidin-1-yl]-n,n-dimethylpyrimidine-5-carboxamide Chemical compound N1=CC(C(=O)N(C)C)=CN=C1N1CCC(C=2C(=C(C3CCC(F)(F)CC3)C=3[C@@H](O)CC(C)(C)CC=3N=2)[C@@H](F)C=2C=CC(=CC=2)C(F)(F)F)CC1 HEZZZOOYRSIMQM-DHIFEGFHSA-N 0.000 claims description 2
- LQSAZYLHGXGUTB-YZNIXAGQSA-N 2-[4-[(5s)-4-(4,4-difluorocyclohexyl)-3-[(s)-fluoro-[4-(trifluoromethyl)phenyl]methyl]-5-hydroxy-7,7-dimethyl-6,8-dihydro-5h-quinolin-2-yl]piperidin-1-yl]-n-methylpyrimidine-5-carboxamide Chemical compound N1=CC(C(=O)NC)=CN=C1N1CCC(C=2C(=C(C3CCC(F)(F)CC3)C=3[C@@H](O)CC(C)(C)CC=3N=2)[C@@H](F)C=2C=CC(=CC=2)C(F)(F)F)CC1 LQSAZYLHGXGUTB-YZNIXAGQSA-N 0.000 claims description 2
- XFRBZMKTOLBBLD-ZQAZVOLISA-N 2-[[2-[4-[(5s)-4-(4,4-difluorocyclohexyl)-3-[(s)-fluoro-[4-(trifluoromethyl)phenyl]methyl]-5-hydroxy-7,7-dimethyl-6,8-dihydro-5h-quinolin-2-yl]piperidin-1-yl]pyrimidin-5-yl]oxymethyl]-2-methylpropane-1,3-diol Chemical compound N1=CC(OCC(CO)(CO)C)=CN=C1N1CCC(C=2C(=C(C3CCC(F)(F)CC3)C=3[C@@H](O)CC(C)(C)CC=3N=2)[C@@H](F)C=2C=CC(=CC=2)C(F)(F)F)CC1 XFRBZMKTOLBBLD-ZQAZVOLISA-N 0.000 claims description 2
- ZFYKWILUKCWEAH-ZQAZVOLISA-N 2-[[2-[4-[(5s)-4-(4,4-difluorocyclohexyl)-3-[(s)-fluoro-[4-(trifluoromethyl)phenyl]methyl]-5-hydroxy-7,7-dimethyl-6,8-dihydro-5h-quinolin-2-yl]piperidin-1-yl]pyrimidin-5-yl]oxymethyl]propane-1,3-diol Chemical compound C1([C@@H](F)C=2C=CC(=CC=2)C(F)(F)F)=C(C2CCC(F)(F)CC2)C([C@@H](O)CC(C2)(C)C)=C2N=C1C(CC1)CCN1C1=NC=C(OCC(CO)CO)C=N1 ZFYKWILUKCWEAH-ZQAZVOLISA-N 0.000 claims description 2
- IXDHYAMRWBIMJB-ZJJOJAIXSA-N 3-[2-[4-[(5s)-4-(4,4-difluorocyclohexyl)-3-[(s)-fluoro-[4-(trifluoromethyl)phenyl]methyl]-5-hydroxy-7,7-dimethyl-6,8-dihydro-5h-quinolin-2-yl]piperidin-1-yl]pyrimidin-5-yl]benzoic acid Chemical compound C1([C@@H](F)C=2C=CC(=CC=2)C(F)(F)F)=C(C2CCC(F)(F)CC2)C([C@@H](O)CC(C2)(C)C)=C2N=C1C(CC1)CCN1C(N=C1)=NC=C1C1=CC=CC(C(O)=O)=C1 IXDHYAMRWBIMJB-ZJJOJAIXSA-N 0.000 claims description 2
- VMEJAMYBFBMTSY-DODOAAEWSA-N 5-[2-[4-[(5s)-4-(4,4-difluorocyclohexyl)-3-[(s)-fluoro-[4-(trifluoromethyl)phenyl]methyl]-5-hydroxy-7,7-dimethyl-6,8-dihydro-5h-quinolin-2-yl]piperidin-1-yl]pyrimidin-5-yl]oxypentanoic acid Chemical compound C1([C@@H](F)C=2C=CC(=CC=2)C(F)(F)F)=C(C2CCC(F)(F)CC2)C([C@@H](O)CC(C2)(C)C)=C2N=C1C(CC1)CCN1C1=NC=C(OCCCCC(O)=O)C=N1 VMEJAMYBFBMTSY-DODOAAEWSA-N 0.000 claims description 2
- WLWTUSIXNDINEV-DODOAAEWSA-N 5-[2-[4-[(5s)-4-(4,4-difluorocyclohexyl)-3-[(s)-fluoro-[4-(trifluoromethyl)phenyl]methyl]-5-hydroxy-7,7-dimethyl-6,8-dihydro-5h-quinolin-2-yl]piperidin-1-yl]pyrimidin-5-yl]pentanoic acid Chemical compound C1([C@@H](F)C=2C=CC(=CC=2)C(F)(F)F)=C(C2CCC(F)(F)CC2)C([C@@H](O)CC(C2)(C)C)=C2N=C1C(CC1)CCN1C1=NC=C(CCCCC(O)=O)C=N1 WLWTUSIXNDINEV-DODOAAEWSA-N 0.000 claims description 2
- SCRJMUARSWJLQL-UHFFFAOYSA-N CS(=O)(=O)CCCOC=1C=NC(=NC=1)N1CCC(CC1)C1=NC=2CCCC(C=2C=C1)O Chemical compound CS(=O)(=O)CCCOC=1C=NC(=NC=1)N1CCC(CC1)C1=NC=2CCCC(C=2C=C1)O SCRJMUARSWJLQL-UHFFFAOYSA-N 0.000 claims description 2
- 210000005259 peripheral blood Anatomy 0.000 claims 2
- 239000011886 peripheral blood Substances 0.000 claims 2
- 101000880514 Homo sapiens Cholesteryl ester transfer protein Proteins 0.000 abstract description 35
- KEWSCDNULKOKTG-UHFFFAOYSA-N 4-cyano-4-ethylsulfanylcarbothioylsulfanylpentanoic acid Chemical compound CCSC(=S)SC(C)(C#N)CCC(O)=O KEWSCDNULKOKTG-UHFFFAOYSA-N 0.000 abstract description 33
- 102100037637 Cholesteryl ester transfer protein Human genes 0.000 abstract description 33
- 125000000217 alkyl group Chemical group 0.000 abstract description 31
- 230000002401 inhibitory effect Effects 0.000 abstract description 19
- 125000004390 alkyl sulfonyl group Chemical group 0.000 abstract description 2
- 229910052736 halogen Inorganic materials 0.000 abstract 1
- 150000002367 halogens Chemical class 0.000 abstract 1
- 125000005415 substituted alkoxy group Chemical group 0.000 abstract 1
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 351
- 239000000243 solution Substances 0.000 description 262
- 238000006243 chemical reaction Methods 0.000 description 220
- 239000000203 mixture Substances 0.000 description 139
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 134
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 127
- 230000002829 reductive effect Effects 0.000 description 109
- 239000002904 solvent Substances 0.000 description 105
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 102
- 125000001153 fluoro group Chemical group F* 0.000 description 97
- 238000000425 proton nuclear magnetic resonance spectrum Methods 0.000 description 97
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 87
- 239000007787 solid Substances 0.000 description 84
- 238000001819 mass spectrum Methods 0.000 description 74
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 68
- 239000011780 sodium chloride Substances 0.000 description 67
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 66
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 66
- 239000012044 organic layer Substances 0.000 description 66
- 102000015779 HDL Lipoproteins Human genes 0.000 description 65
- 108010010234 HDL Lipoproteins Proteins 0.000 description 65
- 125000004482 piperidin-4-yl group Chemical group N1CCC(CC1)* 0.000 description 63
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 60
- 125000004217 4-methoxybenzyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1OC([H])([H])[H])C([H])([H])* 0.000 description 58
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 50
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 49
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 47
- 238000010898 silica gel chromatography Methods 0.000 description 47
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 46
- 239000000047 product Substances 0.000 description 43
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 35
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 34
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 33
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 33
- 235000017557 sodium bicarbonate Nutrition 0.000 description 33
- 125000000246 pyrimidin-2-yl group Chemical group [H]C1=NC(*)=NC([H])=C1[H] 0.000 description 30
- 238000012360 testing method Methods 0.000 description 30
- 239000002585 base Substances 0.000 description 28
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 27
- 102000007330 LDL Lipoproteins Human genes 0.000 description 26
- 108010007622 LDL Lipoproteins Proteins 0.000 description 26
- 239000003814 drug Substances 0.000 description 25
- 238000001914 filtration Methods 0.000 description 25
- 230000008569 process Effects 0.000 description 25
- 230000035484 reaction time Effects 0.000 description 24
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 22
- 230000005484 gravity Effects 0.000 description 21
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 20
- 239000003153 chemical reaction reagent Substances 0.000 description 20
- 239000002244 precipitate Substances 0.000 description 20
- JHJLBTNAGRQEKS-UHFFFAOYSA-M sodium bromide Chemical compound [Na+].[Br-] JHJLBTNAGRQEKS-UHFFFAOYSA-M 0.000 description 20
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 19
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical class CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 19
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 18
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 18
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 18
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 18
- 239000002253 acid Substances 0.000 description 18
- 125000006239 protecting group Chemical group 0.000 description 18
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 16
- 238000003756 stirring Methods 0.000 description 16
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 15
- 238000000926 separation method Methods 0.000 description 15
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 14
- RDOXTESZEPMUJZ-UHFFFAOYSA-N anisole Chemical compound COC1=CC=CC=C1 RDOXTESZEPMUJZ-UHFFFAOYSA-N 0.000 description 14
- GQHTUMJGOHRCHB-UHFFFAOYSA-N 2,3,4,6,7,8,9,10-octahydropyrimido[1,2-a]azepine Chemical compound C1CCCCN2CCCN=C21 GQHTUMJGOHRCHB-UHFFFAOYSA-N 0.000 description 13
- DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 description 12
- 239000000126 substance Substances 0.000 description 12
- 102000004895 Lipoproteins Human genes 0.000 description 11
- 108090001030 Lipoproteins Proteins 0.000 description 11
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 description 11
- MFRIHAYPQRLWNB-UHFFFAOYSA-N sodium tert-butoxide Chemical compound [Na+].CC(C)(C)[O-] MFRIHAYPQRLWNB-UHFFFAOYSA-N 0.000 description 11
- XPGIBDJXEVAVTO-UHFFFAOYSA-N 5-bromo-2-chloropyrimidine Chemical compound ClC1=NC=C(Br)C=N1 XPGIBDJXEVAVTO-UHFFFAOYSA-N 0.000 description 10
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 10
- 235000019270 ammonium chloride Nutrition 0.000 description 10
- 239000003054 catalyst Substances 0.000 description 10
- 238000001816 cooling Methods 0.000 description 10
- 238000000432 density-gradient centrifugation Methods 0.000 description 10
- 229940079593 drug Drugs 0.000 description 10
- 239000006260 foam Substances 0.000 description 10
- 229910052757 nitrogen Inorganic materials 0.000 description 10
- 239000011541 reaction mixture Substances 0.000 description 10
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 9
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 9
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 9
- FJDQFPXHSGXQBY-UHFFFAOYSA-L caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 description 9
- 229910000024 caesium carbonate Inorganic materials 0.000 description 9
- 238000002360 preparation method Methods 0.000 description 9
- 239000012298 atmosphere Substances 0.000 description 8
- 125000001309 chloro group Chemical group Cl* 0.000 description 8
- 229910052763 palladium Inorganic materials 0.000 description 8
- 238000003786 synthesis reaction Methods 0.000 description 8
- NXFFJDQHYLNEJK-UHFFFAOYSA-N 2-[4-[(4-chlorophenyl)methyl]-7-fluoro-5-methylsulfonyl-2,3-dihydro-1h-cyclopenta[b]indol-3-yl]acetic acid Chemical compound C1=2C(S(=O)(=O)C)=CC(F)=CC=2C=2CCC(CC(O)=O)C=2N1CC1=CC=C(Cl)C=C1 NXFFJDQHYLNEJK-UHFFFAOYSA-N 0.000 description 7
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 7
- 229910052783 alkali metal Inorganic materials 0.000 description 7
- 239000012230 colorless oil Substances 0.000 description 7
- 239000007789 gas Substances 0.000 description 7
- 150000008282 halocarbons Chemical class 0.000 description 7
- 238000010438 heat treatment Methods 0.000 description 7
- 238000004128 high performance liquid chromatography Methods 0.000 description 7
- 230000005764 inhibitory process Effects 0.000 description 7
- HVTICUPFWKNHNG-UHFFFAOYSA-N iodoethane Chemical compound CCI HVTICUPFWKNHNG-UHFFFAOYSA-N 0.000 description 7
- UZKWTJUDCOPSNM-UHFFFAOYSA-N methoxybenzene Substances CCCCOC=C UZKWTJUDCOPSNM-UHFFFAOYSA-N 0.000 description 7
- YJVFFLUZDVXJQI-UHFFFAOYSA-L palladium(ii) acetate Chemical compound [Pd+2].CC([O-])=O.CC([O-])=O YJVFFLUZDVXJQI-UHFFFAOYSA-L 0.000 description 7
- HZNVUJQVZSTENZ-UHFFFAOYSA-N 2,3-dichloro-5,6-dicyano-1,4-benzoquinone Chemical compound ClC1=C(Cl)C(=O)C(C#N)=C(C#N)C1=O HZNVUJQVZSTENZ-UHFFFAOYSA-N 0.000 description 6
- BVZBDAUMHWIPCS-UHFFFAOYSA-N 2-chloro-5-(1-methylpiperidin-4-yl)oxypyrimidine Chemical compound C1CN(C)CCC1OC1=CN=C(Cl)N=C1 BVZBDAUMHWIPCS-UHFFFAOYSA-N 0.000 description 6
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 6
- 208000024172 Cardiovascular disease Diseases 0.000 description 6
- YNQLUTRBYVCPMQ-UHFFFAOYSA-N Ethylbenzene Chemical compound CCC1=CC=CC=C1 YNQLUTRBYVCPMQ-UHFFFAOYSA-N 0.000 description 6
- MZRVEZGGRBJDDB-UHFFFAOYSA-N N-Butyllithium Chemical compound [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 6
- OFBQJSOFQDEBGM-UHFFFAOYSA-N Pentane Chemical compound CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 6
- 150000001408 amides Chemical class 0.000 description 6
- 150000001412 amines Chemical class 0.000 description 6
- 150000004945 aromatic hydrocarbons Chemical class 0.000 description 6
- 229910052799 carbon Inorganic materials 0.000 description 6
- 125000004432 carbon atom Chemical group C* 0.000 description 6
- 239000011203 carbon fibre reinforced carbon Substances 0.000 description 6
- 238000004440 column chromatography Methods 0.000 description 6
- 239000000543 intermediate Substances 0.000 description 6
- 238000005259 measurement Methods 0.000 description 6
- 125000004433 nitrogen atom Chemical group N* 0.000 description 6
- NFHFRUOZVGFOOS-UHFFFAOYSA-N palladium;triphenylphosphane Chemical compound [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 NFHFRUOZVGFOOS-UHFFFAOYSA-N 0.000 description 6
- 239000000546 pharmaceutical excipient Substances 0.000 description 6
- 230000002285 radioactive effect Effects 0.000 description 6
- 230000001603 reducing effect Effects 0.000 description 6
- 238000006722 reduction reaction Methods 0.000 description 6
- 239000012279 sodium borohydride Substances 0.000 description 6
- 229910000033 sodium borohydride Inorganic materials 0.000 description 6
- CYPYTURSJDMMMP-WVCUSYJESA-N (1e,4e)-1,5-diphenylpenta-1,4-dien-3-one;palladium Chemical compound [Pd].[Pd].C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1.C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1.C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1 CYPYTURSJDMMMP-WVCUSYJESA-N 0.000 description 5
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 5
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 5
- 201000001320 Atherosclerosis Diseases 0.000 description 5
- 229910052786 argon Inorganic materials 0.000 description 5
- 125000004429 atom Chemical group 0.000 description 5
- 239000012043 crude product Substances 0.000 description 5
- 239000013078 crystal Substances 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 5
- 230000003287 optical effect Effects 0.000 description 5
- 239000007858 starting material Substances 0.000 description 5
- 125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 description 5
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 5
- BTUGGGLMQBJCBN-UHFFFAOYSA-N 1-iodo-2-methylpropane Chemical compound CC(C)CI BTUGGGLMQBJCBN-UHFFFAOYSA-N 0.000 description 4
- BAUWRHPMUVYFOD-UHFFFAOYSA-N 1-methylpiperidin-4-ol Chemical compound CN1CCC(O)CC1 BAUWRHPMUVYFOD-UHFFFAOYSA-N 0.000 description 4
- WYELXQWPKPKTGF-UHFFFAOYSA-N 2-[1-(5-bromopyrimidin-2-yl)piperidin-4-yl]-4-(4,4-difluorocyclohexyl)-3-[fluoro-[4-(trifluoromethyl)phenyl]methyl]-5-[(4-methoxyphenyl)methoxy]-7,7-dimethyl-6,8-dihydro-5h-quinoline Chemical compound C1=CC(OC)=CC=C1COC1C2=C(C3CCC(F)(F)CC3)C(C(F)C=3C=CC(=CC=3)C(F)(F)F)=C(C3CCN(CC3)C=3N=CC(Br)=CN=3)N=C2CC(C)(C)C1 WYELXQWPKPKTGF-UHFFFAOYSA-N 0.000 description 4
- LJYQVOPFBNMTKJ-UHFFFAOYSA-N 2-chloropyrimidine-5-carbaldehyde Chemical compound ClC1=NC=C(C=O)C=N1 LJYQVOPFBNMTKJ-UHFFFAOYSA-N 0.000 description 4
- APOYTRAZFJURPB-UHFFFAOYSA-N 2-methoxy-n-(2-methoxyethyl)-n-(trifluoro-$l^{4}-sulfanyl)ethanamine Chemical compound COCCN(S(F)(F)F)CCOC APOYTRAZFJURPB-UHFFFAOYSA-N 0.000 description 4
- BKOOMYPCSUNDGP-UHFFFAOYSA-N 2-methylbut-2-ene Chemical compound CC=C(C)C BKOOMYPCSUNDGP-UHFFFAOYSA-N 0.000 description 4
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 4
- 206010002383 Angina Pectoris Diseases 0.000 description 4
- 108010061846 Cholesterol Ester Transfer Proteins Proteins 0.000 description 4
- 102000012336 Cholesterol Ester Transfer Proteins Human genes 0.000 description 4
- 206010019280 Heart failures Diseases 0.000 description 4
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 4
- 239000012359 Methanesulfonyl chloride Substances 0.000 description 4
- 241000699666 Mus <mouse, genus> Species 0.000 description 4
- 241000699670 Mus sp. Species 0.000 description 4
- 208000006011 Stroke Diseases 0.000 description 4
- 150000001298 alcohols Chemical class 0.000 description 4
- 125000003545 alkoxy group Chemical group 0.000 description 4
- 238000005576 amination reaction Methods 0.000 description 4
- QGZKDVFQNNGYKY-UHFFFAOYSA-N ammonia Natural products N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 4
- 235000011114 ammonium hydroxide Nutrition 0.000 description 4
- 230000002491 angiogenic effect Effects 0.000 description 4
- 125000001246 bromo group Chemical group Br* 0.000 description 4
- PFKFTWBEEFSNDU-UHFFFAOYSA-N carbonyldiimidazole Chemical compound C1=CN=CN1C(=O)N1C=CN=C1 PFKFTWBEEFSNDU-UHFFFAOYSA-N 0.000 description 4
- 239000001913 cellulose Substances 0.000 description 4
- 235000010980 cellulose Nutrition 0.000 description 4
- 229920002678 cellulose Polymers 0.000 description 4
- 206010008118 cerebral infarction Diseases 0.000 description 4
- 201000009101 diabetic angiopathy Diseases 0.000 description 4
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 4
- 150000002148 esters Chemical class 0.000 description 4
- 125000005745 ethoxymethyl group Chemical group [H]C([H])([H])C([H])([H])OC([H])([H])* 0.000 description 4
- 239000000706 filtrate Substances 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- ZXEKIIBDNHEJCQ-UHFFFAOYSA-N isobutanol Chemical compound CC(C)CO ZXEKIIBDNHEJCQ-UHFFFAOYSA-N 0.000 description 4
- 239000010410 layer Substances 0.000 description 4
- ZCSHNCUQKCANBX-UHFFFAOYSA-N lithium diisopropylamide Chemical compound [Li+].CC(C)[N-]C(C)C ZCSHNCUQKCANBX-UHFFFAOYSA-N 0.000 description 4
- VNWKTOKETHGBQD-UHFFFAOYSA-N methane Chemical compound C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 description 4
- QARBMVPHQWIHKH-UHFFFAOYSA-N methanesulfonyl chloride Chemical compound CS(Cl)(=O)=O QARBMVPHQWIHKH-UHFFFAOYSA-N 0.000 description 4
- 238000002156 mixing Methods 0.000 description 4
- DNIAPMSPPWPWGF-UHFFFAOYSA-N monopropylene glycol Natural products CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 4
- 208000010125 myocardial infarction Diseases 0.000 description 4
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- 238000012746 preparative thin layer chromatography Methods 0.000 description 4
- 208000037803 restenosis Diseases 0.000 description 4
- UKLNMMHNWFDKNT-UHFFFAOYSA-M sodium chlorite Chemical compound [Na+].[O-]Cl=O UKLNMMHNWFDKNT-UHFFFAOYSA-M 0.000 description 4
- 229960002218 sodium chlorite Drugs 0.000 description 4
- 125000004568 thiomorpholinyl group Chemical group 0.000 description 4
- 238000012546 transfer Methods 0.000 description 4
- AQRLNPVMDITEJU-UHFFFAOYSA-N triethylsilane Chemical compound CC[SiH](CC)CC AQRLNPVMDITEJU-UHFFFAOYSA-N 0.000 description 4
- UGOMMVLRQDMAQQ-UHFFFAOYSA-N xphos Chemical group CC(C)C1=CC(C(C)C)=CC(C(C)C)=C1C1=CC=CC=C1P(C1CCCCC1)C1CCCCC1 UGOMMVLRQDMAQQ-UHFFFAOYSA-N 0.000 description 4
- VNDYJBBGRKZCSX-UHFFFAOYSA-L zinc bromide Chemical compound Br[Zn]Br VNDYJBBGRKZCSX-UHFFFAOYSA-L 0.000 description 4
- LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide Chemical compound CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 3
- ZWEHNKRNPOVVGH-UHFFFAOYSA-N 2-Butanone Chemical compound CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 description 3
- UGWJTFHCCZHCDI-UHFFFAOYSA-N 2-chloro-5-methylsulfanylpyrimidine Chemical compound CSC1=CN=C(Cl)N=C1 UGWJTFHCCZHCDI-UHFFFAOYSA-N 0.000 description 3
- BOGPIHXNWPTGNH-UHFFFAOYSA-N 2-chloropyrimidin-5-ol Chemical compound OC1=CN=C(Cl)N=C1 BOGPIHXNWPTGNH-UHFFFAOYSA-N 0.000 description 3
- FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 description 3
- GLGUWQRRDXFPIY-UHFFFAOYSA-N 4-(4,4-difluorocyclohexyl)-3-[fluoro-[4-(trifluoromethyl)phenyl]methyl]-2-[1-[5-(2-hydroxyethoxy)pyrimidin-2-yl]piperidin-4-yl]-7,7-dimethyl-6,8-dihydro-5h-quinolin-5-ol Chemical compound C1C(C)(C)CC(O)C(C(=C2C(F)C=3C=CC(=CC=3)C(F)(F)F)C3CCC(F)(F)CC3)=C1N=C2C(CC1)CCN1C1=NC=C(OCCO)C=N1 GLGUWQRRDXFPIY-UHFFFAOYSA-N 0.000 description 3
- MQVUSOQYDVVOJZ-UHFFFAOYSA-N 4-(4,4-difluorocyclohexyl)-3-[fluoro-[4-(trifluoromethyl)phenyl]methyl]-2-[1-[5-[[2-hydroxyethyl(methyl)amino]methyl]pyrimidin-2-yl]piperidin-4-yl]-7,7-dimethyl-6,8-dihydro-5h-quinolin-5-ol Chemical compound N1=CC(CN(CCO)C)=CN=C1N1CCC(C=2C(=C(C3CCC(F)(F)CC3)C=3C(O)CC(C)(C)CC=3N=2)C(F)C=2C=CC(=CC=2)C(F)(F)F)CC1 MQVUSOQYDVVOJZ-UHFFFAOYSA-N 0.000 description 3
- YQDGQEKUTLYWJU-UHFFFAOYSA-N 5,6,7,8-tetrahydroquinoline Chemical compound C1=CC=C2CCCCC2=N1 YQDGQEKUTLYWJU-UHFFFAOYSA-N 0.000 description 3
- VMEJAMYBFBMTSY-UHFFFAOYSA-N 5-[2-[4-[4-(4,4-difluorocyclohexyl)-3-[fluoro-[4-(trifluoromethyl)phenyl]methyl]-5-hydroxy-7,7-dimethyl-6,8-dihydro-5h-quinolin-2-yl]piperidin-1-yl]pyrimidin-5-yl]oxypentanoic acid Chemical compound C1C(C)(C)CC(O)C(C(=C2C(F)C=3C=CC(=CC=3)C(F)(F)F)C3CCC(F)(F)CC3)=C1N=C2C(CC1)CCN1C1=NC=C(OCCCCC(O)=O)C=N1 VMEJAMYBFBMTSY-UHFFFAOYSA-N 0.000 description 3
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 3
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 3
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 3
- XTHFKEDIFFGKHM-UHFFFAOYSA-N Dimethoxyethane Chemical compound COCCOC XTHFKEDIFFGKHM-UHFFFAOYSA-N 0.000 description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 3
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 3
- 229920000881 Modified starch Polymers 0.000 description 3
- FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 description 3
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 3
- SJRJJKPEHAURKC-UHFFFAOYSA-N N-Methylmorpholine Chemical compound CN1CCOCC1 SJRJJKPEHAURKC-UHFFFAOYSA-N 0.000 description 3
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 3
- IPMRFNJFZBOIKO-UHFFFAOYSA-M [Br-].FC(F)(F)C1=CC=C([Mg+])C=C1 Chemical compound [Br-].FC(F)(F)C1=CC=C([Mg+])C=C1 IPMRFNJFZBOIKO-UHFFFAOYSA-M 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- KZIBQYUFIVUOHY-UHFFFAOYSA-N bis(2-methylpropyl)alumane toluene Chemical compound Cc1ccccc1.[H][Al](CC(C)C)CC(C)C KZIBQYUFIVUOHY-UHFFFAOYSA-N 0.000 description 3
- BTANRVKWQNVYAZ-UHFFFAOYSA-N butan-2-ol Chemical compound CCC(C)O BTANRVKWQNVYAZ-UHFFFAOYSA-N 0.000 description 3
- 150000001721 carbon Chemical group 0.000 description 3
- 239000003085 diluting agent Substances 0.000 description 3
- 239000003480 eluent Substances 0.000 description 3
- 125000004185 ester group Chemical group 0.000 description 3
- 125000003754 ethoxycarbonyl group Chemical group C(=O)(OCC)* 0.000 description 3
- RUJPPJYDHHAEEK-UHFFFAOYSA-N ethyl piperidine-4-carboxylate Chemical compound CCOC(=O)C1CCNCC1 RUJPPJYDHHAEEK-UHFFFAOYSA-N 0.000 description 3
- 238000001640 fractional crystallisation Methods 0.000 description 3
- 239000011521 glass Substances 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 125000002346 iodo group Chemical group I* 0.000 description 3
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 3
- JJWLVOIRVHMVIS-UHFFFAOYSA-N isopropylamine Chemical compound CC(C)N JJWLVOIRVHMVIS-UHFFFAOYSA-N 0.000 description 3
- 239000008101 lactose Substances 0.000 description 3
- 229910052744 lithium Inorganic materials 0.000 description 3
- 229910052749 magnesium Inorganic materials 0.000 description 3
- 239000011777 magnesium Substances 0.000 description 3
- 150000007522 mineralic acids Chemical class 0.000 description 3
- 239000011259 mixed solution Substances 0.000 description 3
- 235000019426 modified starch Nutrition 0.000 description 3
- 208000031225 myocardial ischemia Diseases 0.000 description 3
- 239000003921 oil Substances 0.000 description 3
- 235000019198 oils Nutrition 0.000 description 3
- 150000007524 organic acids Chemical class 0.000 description 3
- 239000007800 oxidant agent Substances 0.000 description 3
- 125000004430 oxygen atom Chemical group O* 0.000 description 3
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 description 3
- 229910052698 phosphorus Inorganic materials 0.000 description 3
- 239000011574 phosphorus Substances 0.000 description 3
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 3
- 150000003222 pyridines Chemical class 0.000 description 3
- 125000000714 pyrimidinyl group Chemical group 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 239000012321 sodium triacetoxyborohydride Substances 0.000 description 3
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 description 3
- 230000002459 sustained effect Effects 0.000 description 3
- 238000003260 vortexing Methods 0.000 description 3
- LBUJPTNKIBCYBY-UHFFFAOYSA-N 1,2,3,4-tetrahydroquinoline Chemical compound C1=CC=C2CCCNC2=C1 LBUJPTNKIBCYBY-UHFFFAOYSA-N 0.000 description 2
- WORJRXHJTUTINR-UHFFFAOYSA-N 1,4-dioxane;hydron;chloride Chemical compound Cl.C1COCCO1 WORJRXHJTUTINR-UHFFFAOYSA-N 0.000 description 2
- GIGRWGTZFONRKA-UHFFFAOYSA-N 1-(bromomethyl)-4-methoxybenzene Chemical compound COC1=CC=C(CBr)C=C1 GIGRWGTZFONRKA-UHFFFAOYSA-N 0.000 description 2
- XLQSXGGDTHANLN-UHFFFAOYSA-N 1-bromo-4-(trifluoromethyl)benzene Chemical compound FC(F)(F)C1=CC=C(Br)C=C1 XLQSXGGDTHANLN-UHFFFAOYSA-N 0.000 description 2
- MEKOFIRRDATTAG-UHFFFAOYSA-N 2,2,5,8-tetramethyl-3,4-dihydrochromen-6-ol Chemical compound C1CC(C)(C)OC2=C1C(C)=C(O)C=C2C MEKOFIRRDATTAG-UHFFFAOYSA-N 0.000 description 2
- OISVCGZHLKNMSJ-UHFFFAOYSA-N 2,6-dimethylpyridine Chemical compound CC1=CC=CC(C)=N1 OISVCGZHLKNMSJ-UHFFFAOYSA-N 0.000 description 2
- ZGABKSLHHLLKOZ-UHFFFAOYSA-N 2-[4-[4-(4,4-difluorocyclohexyl)-3-[fluoro-[4-(trifluoromethyl)phenyl]methyl]-5-[(4-methoxyphenyl)methoxy]-7,7-dimethyl-6,8-dihydro-5h-quinolin-2-yl]piperidin-1-yl]pyrimidine-5-carbaldehyde Chemical compound C1=CC(OC)=CC=C1COC1C2=C(C3CCC(F)(F)CC3)C(C(F)C=3C=CC(=CC=3)C(F)(F)F)=C(C3CCN(CC3)C=3N=CC(C=O)=CN=3)N=C2CC(C)(C)C1 ZGABKSLHHLLKOZ-UHFFFAOYSA-N 0.000 description 2
- HEZZZOOYRSIMQM-UHFFFAOYSA-N 2-[4-[4-(4,4-difluorocyclohexyl)-3-[fluoro-[4-(trifluoromethyl)phenyl]methyl]-5-hydroxy-7,7-dimethyl-6,8-dihydro-5h-quinolin-2-yl]piperidin-1-yl]-n,n-dimethylpyrimidine-5-carboxamide Chemical compound N1=CC(C(=O)N(C)C)=CN=C1N1CCC(C=2C(=C(C3CCC(F)(F)CC3)C=3C(O)CC(C)(C)CC=3N=2)C(F)C=2C=CC(=CC=2)C(F)(F)F)CC1 HEZZZOOYRSIMQM-UHFFFAOYSA-N 0.000 description 2
- LQSAZYLHGXGUTB-UHFFFAOYSA-N 2-[4-[4-(4,4-difluorocyclohexyl)-3-[fluoro-[4-(trifluoromethyl)phenyl]methyl]-5-hydroxy-7,7-dimethyl-6,8-dihydro-5h-quinolin-2-yl]piperidin-1-yl]-n-methylpyrimidine-5-carboxamide Chemical compound N1=CC(C(=O)NC)=CN=C1N1CCC(C=2C(=C(C3CCC(F)(F)CC3)C=3C(O)CC(C)(C)CC=3N=2)C(F)C=2C=CC(=CC=2)C(F)(F)F)CC1 LQSAZYLHGXGUTB-UHFFFAOYSA-N 0.000 description 2
- JWUQRVZLWADKAB-UHFFFAOYSA-N 2-chloro-5-(4,4,4-trifluorobutyl)pyrimidine Chemical compound FC(F)(F)CCCC1=CN=C(Cl)N=C1 JWUQRVZLWADKAB-UHFFFAOYSA-N 0.000 description 2
- WTSWSBPEZJCSMC-UHFFFAOYSA-N 2-chloro-5-(difluoromethoxy)pyrimidine Chemical compound FC(F)OC1=CN=C(Cl)N=C1 WTSWSBPEZJCSMC-UHFFFAOYSA-N 0.000 description 2
- GOSMJUUBILUVOL-UHFFFAOYSA-N 2-chloro-5-[(2,2,5-trimethyl-1,3-dioxan-5-yl)methoxy]pyrimidine Chemical compound C=1N=C(Cl)N=CC=1OCC1(C)COC(C)(C)OC1 GOSMJUUBILUVOL-UHFFFAOYSA-N 0.000 description 2
- OJBZGBZRCAUPQZ-UHFFFAOYSA-N 2-chloro-5-methylsulfonylpyrimidine Chemical compound CS(=O)(=O)C1=CN=C(Cl)N=C1 OJBZGBZRCAUPQZ-UHFFFAOYSA-N 0.000 description 2
- NHQDETIJWKXCTC-UHFFFAOYSA-N 3-chloroperbenzoic acid Chemical compound OOC(=O)C1=CC=CC(Cl)=C1 NHQDETIJWKXCTC-UHFFFAOYSA-N 0.000 description 2
- DNSDOTKSZMHDOR-UHFFFAOYSA-N 4,4-difluorocyclohexane-1-carbaldehyde Chemical compound FC1(F)CCC(C=O)CC1 DNSDOTKSZMHDOR-UHFFFAOYSA-N 0.000 description 2
- HZEFPXIJZGLJAS-UHFFFAOYSA-N 4-(4,4-difluorocyclohexyl)-2-[1-[5-(ethoxymethyl)pyrimidin-2-yl]piperidin-4-yl]-3-[fluoro-[4-(trifluoromethyl)phenyl]methyl]-5-[(4-methoxyphenyl)methoxy]-7,7-dimethyl-6,8-dihydro-5h-quinoline Chemical compound N1=CC(COCC)=CN=C1N1CCC(C=2C(=C(C3CCC(F)(F)CC3)C=3C(OCC=4C=CC(OC)=CC=4)CC(C)(C)CC=3N=2)C(F)C=2C=CC(=CC=2)C(F)(F)F)CC1 HZEFPXIJZGLJAS-UHFFFAOYSA-N 0.000 description 2
- ZLXMEKUSNLBNSL-UHFFFAOYSA-N 4-(4,4-difluorocyclohexyl)-3-[fluoro-[4-(trifluoromethyl)phenyl]methyl]-2-[1-(5-hydroxypyrimidin-2-yl)piperidin-4-yl]-7,7-dimethyl-6,8-dihydro-5h-quinolin-5-ol Chemical compound C1C(C)(C)CC(O)C(C(=C2C(F)C=3C=CC(=CC=3)C(F)(F)F)C3CCC(F)(F)CC3)=C1N=C2C(CC1)CCN1C1=NC=C(O)C=N1 ZLXMEKUSNLBNSL-UHFFFAOYSA-N 0.000 description 2
- PWKUBPFHUCVTFA-UHFFFAOYSA-N 4-(4,4-difluorocyclohexyl)-3-[fluoro-[4-(trifluoromethyl)phenyl]methyl]-2-[1-[5-(2-hydroxy-2-methylpropoxy)pyrimidin-2-yl]piperidin-4-yl]-7,7-dimethyl-6,8-dihydro-5h-quinolin-5-ol Chemical compound N1=CC(OCC(C)(O)C)=CN=C1N1CCC(C=2C(=C(C3CCC(F)(F)CC3)C=3C(O)CC(C)(C)CC=3N=2)C(F)C=2C=CC(=CC=2)C(F)(F)F)CC1 PWKUBPFHUCVTFA-UHFFFAOYSA-N 0.000 description 2
- XVUDQBUEUFZZQH-UHFFFAOYSA-N 4-(4,4-difluorocyclohexyl)-3-[fluoro-[4-(trifluoromethyl)phenyl]methyl]-2-[1-[5-(3-hydroxy-3-methylbutoxy)pyrimidin-2-yl]piperidin-4-yl]-7,7-dimethyl-6,8-dihydro-5h-quinolin-5-ol Chemical compound N1=CC(OCCC(C)(O)C)=CN=C1N1CCC(C=2C(=C(C3CCC(F)(F)CC3)C=3C(O)CC(C)(C)CC=3N=2)C(F)C=2C=CC(=CC=2)C(F)(F)F)CC1 XVUDQBUEUFZZQH-UHFFFAOYSA-N 0.000 description 2
- XKPAIDSFDIJJKP-GVYFSNLUSA-N 4-(4,4-difluorocyclohexyl)-3-[fluoro-[4-(trifluoromethyl)phenyl]methyl]-2-[1-[5-[(2r)-2-hydroxypropoxy]pyrimidin-2-yl]piperidin-4-yl]-7,7-dimethyl-6,8-dihydro-5h-quinolin-5-ol Chemical compound N1=CC(OC[C@H](O)C)=CN=C1N1CCC(C=2C(=C(C3CCC(F)(F)CC3)C=3C(O)CC(C)(C)CC=3N=2)C(F)C=2C=CC(=CC=2)C(F)(F)F)CC1 XKPAIDSFDIJJKP-GVYFSNLUSA-N 0.000 description 2
- PAAMQYJKNSBESW-UHFFFAOYSA-N 4-(4,4-difluorocyclohexyl)-3-[fluoro-[4-(trifluoromethyl)phenyl]methyl]-5-[(4-methoxyphenyl)methoxy]-7,7-dimethyl-2-piperidin-4-yl-6,8-dihydro-5h-quinoline Chemical compound C1=CC(OC)=CC=C1COC1C2=C(C3CCC(F)(F)CC3)C(C(F)C=3C=CC(=CC=3)C(F)(F)F)=C(C3CCNCC3)N=C2CC(C)(C)C1 PAAMQYJKNSBESW-UHFFFAOYSA-N 0.000 description 2
- GFZXTTXQXLZSLI-UHFFFAOYSA-N 4-(4,4-difluorocyclohexyl)-3-[fluoro-[4-(trifluoromethyl)phenyl]methyl]-7,7-dimethyl-2-[1-(5-methylsulfanylpyrimidin-2-yl)piperidin-4-yl]-6,8-dihydro-5h-quinolin-5-ol Chemical compound N1=CC(SC)=CN=C1N1CCC(C=2C(=C(C3CCC(F)(F)CC3)C=3C(O)CC(C)(C)CC=3N=2)C(F)C=2C=CC(=CC=2)C(F)(F)F)CC1 GFZXTTXQXLZSLI-UHFFFAOYSA-N 0.000 description 2
- UICIOFWFWRPASW-UHFFFAOYSA-N 4-(4,4-difluorocyclohexyl)-3-[fluoro-[4-(trifluoromethyl)phenyl]methyl]-7,7-dimethyl-2-[1-(5-methylsulfonylpyrimidin-2-yl)piperidin-4-yl]-6,8-dihydro-5h-quinolin-5-ol Chemical compound C1C(C)(C)CC(O)C(C(=C2C(F)C=3C=CC(=CC=3)C(F)(F)F)C3CCC(F)(F)CC3)=C1N=C2C(CC1)CCN1C1=NC=C(S(C)(=O)=O)C=N1 UICIOFWFWRPASW-UHFFFAOYSA-N 0.000 description 2
- WJOGSZFWTRQDJL-UHFFFAOYSA-N 4-(4,4-difluorocyclohexyl)-3-[fluoro-[4-(trifluoromethyl)phenyl]methyl]-7,7-dimethyl-2-[1-[5-(1-methylpiperidin-4-yl)oxypyrimidin-2-yl]piperidin-4-yl]-6,8-dihydro-5h-quinolin-5-ol Chemical compound C1CN(C)CCC1OC1=CN=C(N2CCC(CC2)C=2C(=C(C3CCC(F)(F)CC3)C=3C(O)CC(C)(C)CC=3N=2)C(F)C=2C=CC(=CC=2)C(F)(F)F)N=C1 WJOGSZFWTRQDJL-UHFFFAOYSA-N 0.000 description 2
- QVLAFBXIVWTSGO-UHFFFAOYSA-N 4-(4,4-difluorocyclohexyl)-3-[fluoro-[4-(trifluoromethyl)phenyl]methyl]-7,7-dimethyl-2-[1-[5-(3,3,3-trifluoropropoxy)pyrimidin-2-yl]piperidin-4-yl]-6,8-dihydro-5h-quinolin-5-ol Chemical compound C1C(C)(C)CC(O)C(C(=C2C(F)C=3C=CC(=CC=3)C(F)(F)F)C3CCC(F)(F)CC3)=C1N=C2C(CC1)CCN1C1=NC=C(OCCC(F)(F)F)C=N1 QVLAFBXIVWTSGO-UHFFFAOYSA-N 0.000 description 2
- JFRGZYPFMNMPPX-UHFFFAOYSA-N 4-(4,4-difluorocyclohexyl)-3-[fluoro-[4-(trifluoromethyl)phenyl]methyl]-7,7-dimethyl-2-[1-[5-(4-methylpiperazin-1-yl)pyrimidin-2-yl]piperidin-4-yl]-6,8-dihydro-5h-quinolin-5-ol Chemical compound C1CN(C)CCN1C1=CN=C(N2CCC(CC2)C=2C(=C(C3CCC(F)(F)CC3)C=3C(O)CC(C)(C)CC=3N=2)C(F)C=2C=CC(=CC=2)C(F)(F)F)N=C1 JFRGZYPFMNMPPX-UHFFFAOYSA-N 0.000 description 2
- OSRMCWGWYYJXKO-UHFFFAOYSA-N 4-(4,4-difluorocyclohexyl)-3-[fluoro-[4-(trifluoromethyl)phenyl]methyl]-7,7-dimethyl-2-[1-[5-(methylaminomethyl)pyrimidin-2-yl]piperidin-4-yl]-6,8-dihydro-5h-quinolin-5-ol Chemical compound N1=CC(CNC)=CN=C1N1CCC(C=2C(=C(C3CCC(F)(F)CC3)C=3C(O)CC(C)(C)CC=3N=2)C(F)C=2C=CC(=CC=2)C(F)(F)F)CC1 OSRMCWGWYYJXKO-UHFFFAOYSA-N 0.000 description 2
- VQRCBISZGIKQAG-UHBGNVCTSA-N 4-(4,4-difluorocyclohexyl)-3-[fluoro-[4-(trifluoromethyl)phenyl]methyl]-7,7-dimethyl-2-[1-[5-[(3r)-1-methylpyrrolidin-3-yl]oxypyrimidin-2-yl]piperidin-4-yl]-6,8-dihydro-5h-quinolin-5-ol Chemical compound C1N(C)CC[C@H]1OC1=CN=C(N2CCC(CC2)C=2C(=C(C3CCC(F)(F)CC3)C=3C(O)CC(C)(C)CC=3N=2)C(F)C=2C=CC(=CC=2)C(F)(F)F)N=C1 VQRCBISZGIKQAG-UHBGNVCTSA-N 0.000 description 2
- HUKQEMALXBFWSK-UHFFFAOYSA-N 4-[2-[4-[4-(4,4-difluorocyclohexyl)-3-[fluoro-[4-(trifluoromethyl)phenyl]methyl]-5-[(4-methoxyphenyl)methoxy]-7,7-dimethyl-6,8-dihydro-5h-quinolin-2-yl]piperidin-1-yl]pyrimidin-5-yl]morpholine Chemical compound C1=CC(OC)=CC=C1COC1C2=C(C3CCC(F)(F)CC3)C(C(F)C=3C=CC(=CC=3)C(F)(F)F)=C(C3CCN(CC3)C=3N=CC(=CN=3)N3CCOCC3)N=C2CC(C)(C)C1 HUKQEMALXBFWSK-UHFFFAOYSA-N 0.000 description 2
- RBFVGQWGOARJRU-UHFFFAOYSA-N 4-bromo-2-methylbutan-2-ol Chemical compound CC(C)(O)CCBr RBFVGQWGOARJRU-UHFFFAOYSA-N 0.000 description 2
- WLWTUSIXNDINEV-UHFFFAOYSA-N 5-[2-[4-[4-(4,4-difluorocyclohexyl)-3-[fluoro-[4-(trifluoromethyl)phenyl]methyl]-5-hydroxy-7,7-dimethyl-6,8-dihydro-5h-quinolin-2-yl]piperidin-1-yl]pyrimidin-5-yl]pentanoic acid Chemical compound C1C(C)(C)CC(O)C(C(=C2C(F)C=3C=CC(=CC=3)C(F)(F)F)C3CCC(F)(F)CC3)=C1N=C2C(CC1)CCN1C1=NC=C(CCCCC(O)=O)C=N1 WLWTUSIXNDINEV-UHFFFAOYSA-N 0.000 description 2
- 101150102415 Apob gene Proteins 0.000 description 2
- 0 CCC=NC(C)(*)N(CC1)CCC1c1c(C(c2ccc(C(C=CC)(F)F)cc2)F)c(C(CC2)CCC2(F)F)c(C(CC(C)(C)C2)O)c2n1 Chemical compound CCC=NC(C)(*)N(CC1)CCC1c1c(C(c2ccc(C(C=CC)(F)F)cc2)F)c(C(CC2)CCC2(F)F)c(C(CC(C)(C)C2)O)c2n1 0.000 description 2
- GAWIXWVDTYZWAW-UHFFFAOYSA-N C[CH]O Chemical group C[CH]O GAWIXWVDTYZWAW-UHFFFAOYSA-N 0.000 description 2
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 2
- ZAFNJMIOTHYJRJ-UHFFFAOYSA-N Diisopropyl ether Chemical compound CC(C)OC(C)C ZAFNJMIOTHYJRJ-UHFFFAOYSA-N 0.000 description 2
- 206010013710 Drug interaction Diseases 0.000 description 2
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 2
- JLTDJTHDQAWBAV-UHFFFAOYSA-N N,N-dimethylaniline Chemical compound CN(C)C1=CC=CC=C1 JLTDJTHDQAWBAV-UHFFFAOYSA-N 0.000 description 2
- OPKOKAMJFNKNAS-UHFFFAOYSA-N N-methylethanolamine Chemical compound CNCCO OPKOKAMJFNKNAS-UHFFFAOYSA-N 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
- SMWDFEZZVXVKRB-UHFFFAOYSA-N Quinoline Chemical compound N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 description 2
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- WQDUMFSSJAZKTM-UHFFFAOYSA-N Sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- YZCKVEUIGOORGS-NJFSPNSNSA-N Tritium Chemical compound [3H] YZCKVEUIGOORGS-NJFSPNSNSA-N 0.000 description 2
- CIRBILLHZJTIAZ-CFMCSPIPSA-N [(2s)-2-(oxan-2-yloxy)propyl] 4-methylbenzenesulfonate Chemical compound C([C@H](C)OC1OCCCC1)OS(=O)(=O)C1=CC=C(C)C=C1 CIRBILLHZJTIAZ-CFMCSPIPSA-N 0.000 description 2
- SRKDUHUULIWXFT-NSHDSACASA-N [(4s)-2,2-dimethyl-1,3-dioxolan-4-yl]methyl 4-methylbenzenesulfonate Chemical compound C1=CC(C)=CC=C1S(=O)(=O)OC[C@H]1OC(C)(C)OC1 SRKDUHUULIWXFT-NSHDSACASA-N 0.000 description 2
- CQGQBHXUMLJVQG-UHFFFAOYSA-N [2-[4-[4-(4,4-difluorocyclohexyl)-3-[fluoro-[4-(trifluoromethyl)phenyl]methyl]-5-hydroxy-7,7-dimethyl-6,8-dihydro-5h-quinolin-2-yl]piperidin-1-yl]pyrimidin-5-yl]-morpholin-4-ylmethanone Chemical compound C1C(C)(C)CC(O)C(C(=C2C(F)C=3C=CC(=CC=3)C(F)(F)F)C3CCC(F)(F)CC3)=C1N=C2C(CC1)CCN1C(N=C1)=NC=C1C(=O)N1CCOCC1 CQGQBHXUMLJVQG-UHFFFAOYSA-N 0.000 description 2
- XIUKZXDZUHYJMQ-UHFFFAOYSA-M [Br-].CC(C)C[Mg+].C1CCOC1 Chemical compound [Br-].CC(C)C[Mg+].C1CCOC1 XIUKZXDZUHYJMQ-UHFFFAOYSA-M 0.000 description 2
- VAPFAAVJYYWRHJ-UHFFFAOYSA-M [Br-].CC(C)[Mg+].C1CCOC1 Chemical compound [Br-].CC(C)[Mg+].C1CCOC1 VAPFAAVJYYWRHJ-UHFFFAOYSA-M 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 150000001338 aliphatic hydrocarbons Chemical class 0.000 description 2
- 229910000288 alkali metal carbonate Inorganic materials 0.000 description 2
- 150000008041 alkali metal carbonates Chemical class 0.000 description 2
- 229910000102 alkali metal hydride Inorganic materials 0.000 description 2
- 125000004453 alkoxycarbonyl group Chemical group 0.000 description 2
- 125000003282 alkyl amino group Chemical group 0.000 description 2
- 229940024606 amino acid Drugs 0.000 description 2
- 125000004202 aminomethyl group Chemical group [H]N([H])C([H])([H])* 0.000 description 2
- 229960000686 benzalkonium chloride Drugs 0.000 description 2
- 229940077388 benzenesulfonate Drugs 0.000 description 2
- SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 2
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- SIPUZPBQZHNSDW-UHFFFAOYSA-N bis(2-methylpropyl)aluminum Chemical compound CC(C)C[Al]CC(C)C SIPUZPBQZHNSDW-UHFFFAOYSA-N 0.000 description 2
- YNHIGQDRGKUECZ-UHFFFAOYSA-L bis(triphenylphosphine)palladium(ii) dichloride Chemical compound [Cl-].[Cl-].[Pd+2].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 YNHIGQDRGKUECZ-UHFFFAOYSA-L 0.000 description 2
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 2
- CREMABGTGYGIQB-UHFFFAOYSA-N carbon carbon Chemical compound C.C CREMABGTGYGIQB-UHFFFAOYSA-N 0.000 description 2
- RBHJBMIOOPYDBQ-UHFFFAOYSA-N carbon dioxide;propan-2-one Chemical compound O=C=O.CC(C)=O RBHJBMIOOPYDBQ-UHFFFAOYSA-N 0.000 description 2
- 210000000170 cell membrane Anatomy 0.000 description 2
- MVPPADPHJFYWMZ-UHFFFAOYSA-N chlorobenzene Chemical compound ClC1=CC=CC=C1 MVPPADPHJFYWMZ-UHFFFAOYSA-N 0.000 description 2
- OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 description 2
- 238000005859 coupling reaction Methods 0.000 description 2
- FFOUKPWWRMCPEL-UHFFFAOYSA-N cyclohexylphosphane;toluene Chemical compound CC1=CC=CC=C1.PC1CCCCC1 FFOUKPWWRMCPEL-UHFFFAOYSA-N 0.000 description 2
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 2
- WLVKDFJTYKELLQ-UHFFFAOYSA-N cyclopropylboronic acid Chemical compound OB(O)C1CC1 WLVKDFJTYKELLQ-UHFFFAOYSA-N 0.000 description 2
- 238000006297 dehydration reaction Methods 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 229960000633 dextran sulfate Drugs 0.000 description 2
- BADXJIPKFRBFOT-UHFFFAOYSA-N dimedone Chemical compound CC1(C)CC(=O)CC(=O)C1 BADXJIPKFRBFOT-UHFFFAOYSA-N 0.000 description 2
- WQOXQRCZOLPYPM-UHFFFAOYSA-N dimethyl disulfide Chemical compound CSSC WQOXQRCZOLPYPM-UHFFFAOYSA-N 0.000 description 2
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N diphenyl Chemical compound C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 description 2
- 239000007884 disintegrant Substances 0.000 description 2
- BOBUBHOXRCYKLI-UHFFFAOYSA-N ditert-butyl(cyclopenta-2,4-dien-1-yl)phosphane;iron(2+);(2,3,4,5-tetraphenylcyclopenta-1,4-dien-1-yl)benzene Chemical compound [Fe+2].CC(C)(C)P(C(C)(C)C)C1=CC=C[CH-]1.C1=CC=CC=C1C1=C(C=2C=CC=CC=2)[C-](C=2C=CC=CC=2)C(C=2C=CC=CC=2)=C1C1=CC=CC=C1 BOBUBHOXRCYKLI-UHFFFAOYSA-N 0.000 description 2
- CNXMDTWQWLGCPE-UHFFFAOYSA-N ditert-butyl-(2-phenylphenyl)phosphane Chemical group CC(C)(C)P(C(C)(C)C)C1=CC=CC=C1C1=CC=CC=C1 CNXMDTWQWLGCPE-UHFFFAOYSA-N 0.000 description 2
- PTXJGGGNGMPMBG-UHFFFAOYSA-N ditert-butyl-[2-(1,3,5-triphenylpyrazol-4-yl)pyrazol-3-yl]phosphane Chemical compound CC(C)(C)P(C(C)(C)C)C1=CC=NN1C1=C(C=2C=CC=CC=2)N(C=2C=CC=CC=2)N=C1C1=CC=CC=C1 PTXJGGGNGMPMBG-UHFFFAOYSA-N 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 239000003995 emulsifying agent Substances 0.000 description 2
- 150000002170 ethers Chemical class 0.000 description 2
- LWNURHWYMYKPPX-UHFFFAOYSA-N ethyl 2-[2-[4-[4-(4,4-difluorocyclohexyl)-3-[fluoro-[4-(trifluoromethyl)phenyl]methyl]-5-hydroxy-7,7-dimethyl-6,8-dihydro-5h-quinolin-2-yl]piperidin-1-yl]pyrimidin-5-yl]oxyacetate Chemical compound N1=CC(OCC(=O)OCC)=CN=C1N1CCC(C=2C(=C(C3CCC(F)(F)CC3)C=3C(O)CC(C)(C)CC=3N=2)C(F)C=2C=CC(=CC=2)C(F)(F)F)CC1 LWNURHWYMYKPPX-UHFFFAOYSA-N 0.000 description 2
- 238000001704 evaporation Methods 0.000 description 2
- 230000005284 excitation Effects 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 238000003682 fluorination reaction Methods 0.000 description 2
- 235000013355 food flavoring agent Nutrition 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 239000007902 hard capsule Substances 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 239000003999 initiator Substances 0.000 description 2
- 239000008011 inorganic excipient Substances 0.000 description 2
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- WMFOQBRAJBCJND-UHFFFAOYSA-M lithium hydroxide Inorganic materials [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- 229910001629 magnesium chloride Inorganic materials 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 230000014759 maintenance of location Effects 0.000 description 2
- 230000002503 metabolic effect Effects 0.000 description 2
- 229910052751 metal Inorganic materials 0.000 description 2
- 239000002184 metal Substances 0.000 description 2
- UKVIEHSSVKSQBA-UHFFFAOYSA-N methane;palladium Chemical compound C.[Pd] UKVIEHSSVKSQBA-UHFFFAOYSA-N 0.000 description 2
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 2
- 125000001160 methoxycarbonyl group Chemical group [H]C([H])([H])OC(*)=O 0.000 description 2
- 125000004184 methoxymethyl group Chemical group [H]C([H])([H])OC([H])([H])* 0.000 description 2
- UERZIVAQVSUXQU-UHFFFAOYSA-N methyl 3-(2-chloropyrimidin-5-yl)benzoate Chemical compound COC(=O)C1=CC=CC(C=2C=NC(Cl)=NC=2)=C1 UERZIVAQVSUXQU-UHFFFAOYSA-N 0.000 description 2
- JWBVNZWNLUDOJH-UHFFFAOYSA-N methyl 5-(2-chloropyrimidin-5-yl)pentanoate Chemical compound COC(=O)CCCCC1=CN=C(Cl)N=C1 JWBVNZWNLUDOJH-UHFFFAOYSA-N 0.000 description 2
- 125000006533 methyl amino methyl group Chemical group [H]N(C([H])([H])[H])C([H])([H])* 0.000 description 2
- 125000000250 methylamino group Chemical group [H]N(*)C([H])([H])[H] 0.000 description 2
- 125000004458 methylaminocarbonyl group Chemical group [H]N(C(*)=O)C([H])([H])[H] 0.000 description 2
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 2
- 125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 description 2
- 229910000403 monosodium phosphate Inorganic materials 0.000 description 2
- 235000019799 monosodium phosphate Nutrition 0.000 description 2
- 125000002757 morpholinyl group Chemical group 0.000 description 2
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
- 150000002825 nitriles Chemical class 0.000 description 2
- 239000008012 organic excipient Substances 0.000 description 2
- 125000001715 oxadiazolyl group Chemical group 0.000 description 2
- KJIFKLIQANRMOU-UHFFFAOYSA-N oxidanium;4-methylbenzenesulfonate Chemical compound O.CC1=CC=C(S(O)(=O)=O)C=C1 KJIFKLIQANRMOU-UHFFFAOYSA-N 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- 230000001590 oxidative effect Effects 0.000 description 2
- LXNAVEXFUKBNMK-UHFFFAOYSA-N palladium(II) acetate Substances [Pd].CC(O)=O.CC(O)=O LXNAVEXFUKBNMK-UHFFFAOYSA-N 0.000 description 2
- 230000035699 permeability Effects 0.000 description 2
- 125000004193 piperazinyl group Chemical group 0.000 description 2
- 125000003386 piperidinyl group Chemical group 0.000 description 2
- 125000005936 piperidyl group Chemical group 0.000 description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- 229910000027 potassium carbonate Inorganic materials 0.000 description 2
- 235000011181 potassium carbonates Nutrition 0.000 description 2
- TYJJADVDDVDEDZ-UHFFFAOYSA-M potassium hydrogencarbonate Chemical compound [K+].OC([O-])=O TYJJADVDDVDEDZ-UHFFFAOYSA-M 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- 235000019260 propionic acid Nutrition 0.000 description 2
- 125000002572 propoxy group Chemical group [*]OC([H])([H])C(C([H])([H])[H])([H])[H] 0.000 description 2
- 235000013772 propylene glycol Nutrition 0.000 description 2
- 125000004076 pyridyl group Chemical group 0.000 description 2
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 238000010992 reflux Methods 0.000 description 2
- SQGYOTSLMSWVJD-UHFFFAOYSA-N silver(1+) nitrate Chemical compound [Ag+].[O-]N(=O)=O SQGYOTSLMSWVJD-UHFFFAOYSA-N 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 description 2
- 239000012312 sodium hydride Substances 0.000 description 2
- 229910000104 sodium hydride Inorganic materials 0.000 description 2
- GEHJYWRUCIMESM-UHFFFAOYSA-L sodium sulfite Chemical compound [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 description 2
- 239000007901 soft capsule Substances 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 150000003462 sulfoxides Chemical class 0.000 description 2
- 229910052717 sulfur Inorganic materials 0.000 description 2
- 125000004434 sulfur atom Chemical group 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- FPGGTKZVZWFYPV-UHFFFAOYSA-M tetrabutylammonium fluoride Chemical compound [F-].CCCC[N+](CCCC)(CCCC)CCCC FPGGTKZVZWFYPV-UHFFFAOYSA-M 0.000 description 2
- VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- IMNIMPAHZVJRPE-UHFFFAOYSA-N triethylenediamine Chemical compound C1CN2CCN1CC2 IMNIMPAHZVJRPE-UHFFFAOYSA-N 0.000 description 2
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 2
- LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 2
- 229910052722 tritium Inorganic materials 0.000 description 2
- 229940102001 zinc bromide Drugs 0.000 description 2
- GNLJBJNONOOOQC-UHFFFAOYSA-N $l^{3}-carbane;magnesium Chemical compound [Mg]C GNLJBJNONOOOQC-UHFFFAOYSA-N 0.000 description 1
- UKSZBOKPHAQOMP-SVLSSHOZSA-N (1e,4e)-1,5-diphenylpenta-1,4-dien-3-one;palladium Chemical compound [Pd].C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1.C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1 UKSZBOKPHAQOMP-SVLSSHOZSA-N 0.000 description 1
- MEMQNQJNNXQQHK-UHFFFAOYSA-N (2,2,5-trimethyl-1,3-dioxan-5-yl)methyl methanesulfonate Chemical compound CS(=O)(=O)OCC1(C)COC(C)(C)OC1 MEMQNQJNNXQQHK-UHFFFAOYSA-N 0.000 description 1
- QBYIENPQHBMVBV-HFEGYEGKSA-N (2R)-2-hydroxy-2-phenylacetic acid Chemical group O[C@@H](C(O)=O)c1ccccc1.O[C@@H](C(O)=O)c1ccccc1 QBYIENPQHBMVBV-HFEGYEGKSA-N 0.000 description 1
- ALTLCJHSJMGSLT-UHFFFAOYSA-N (3-methoxycarbonylphenyl)boronic acid Chemical compound COC(=O)C1=CC=CC(B(O)O)=C1 ALTLCJHSJMGSLT-UHFFFAOYSA-N 0.000 description 1
- FLVFPAIGVBQGET-YFKPBYRVSA-N (3s)-1-methylpyrrolidin-3-ol Chemical compound CN1CC[C@H](O)C1 FLVFPAIGVBQGET-YFKPBYRVSA-N 0.000 description 1
- 125000004768 (C1-C4) alkylsulfinyl group Chemical group 0.000 description 1
- 125000004769 (C1-C4) alkylsulfonyl group Chemical group 0.000 description 1
- 125000006729 (C2-C5) alkenyl group Chemical group 0.000 description 1
- 125000006645 (C3-C4) cycloalkyl group Chemical group 0.000 description 1
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 description 1
- 239000001211 (E)-4-phenylbut-3-en-2-one Substances 0.000 description 1
- DNIAPMSPPWPWGF-GSVOUGTGSA-N (R)-(-)-Propylene glycol Chemical compound C[C@@H](O)CO DNIAPMSPPWPWGF-GSVOUGTGSA-N 0.000 description 1
- MIOPJNTWMNEORI-GMSGAONNSA-N (S)-camphorsulfonic acid Chemical compound C1C[C@@]2(CS(O)(=O)=O)C(=O)C[C@@H]1C2(C)C MIOPJNTWMNEORI-GMSGAONNSA-N 0.000 description 1
- SCYULBFZEHDVBN-UHFFFAOYSA-N 1,1-Dichloroethane Chemical compound CC(Cl)Cl SCYULBFZEHDVBN-UHFFFAOYSA-N 0.000 description 1
- AACROBBFQRNFHE-UHFFFAOYSA-N 1,2,3,4-tetrahydroquinolin-5-ol Chemical compound N1CCCC2=C1C=CC=C2O AACROBBFQRNFHE-UHFFFAOYSA-N 0.000 description 1
- OCJBOOLMMGQPQU-UHFFFAOYSA-N 1,4-dichlorobenzene Chemical compound ClC1=CC=C(Cl)C=C1 OCJBOOLMMGQPQU-UHFFFAOYSA-N 0.000 description 1
- NDOVLWQBFFJETK-UHFFFAOYSA-N 1,4-thiazinane 1,1-dioxide Chemical compound O=S1(=O)CCNCC1 NDOVLWQBFFJETK-UHFFFAOYSA-N 0.000 description 1
- SGUVLZREKBPKCE-UHFFFAOYSA-N 1,5-diazabicyclo[4.3.0]-non-5-ene Chemical compound C1CCN=C2CCCN21 SGUVLZREKBPKCE-UHFFFAOYSA-N 0.000 description 1
- ASOKPJOREAFHNY-UHFFFAOYSA-N 1-Hydroxybenzotriazole Chemical compound C1=CC=C2N(O)N=NC2=C1 ASOKPJOREAFHNY-UHFFFAOYSA-N 0.000 description 1
- PVOAHINGSUIXLS-UHFFFAOYSA-N 1-Methylpiperazine Chemical compound CN1CCNCC1 PVOAHINGSUIXLS-UHFFFAOYSA-N 0.000 description 1
- TWJIYXRDTIEEQR-UHFFFAOYSA-N 1-[2-[4-[4-(4,4-difluorocyclohexyl)-3-[fluoro-[4-(trifluoromethyl)phenyl]methyl]-5-[(4-methoxyphenyl)methoxy]-7,7-dimethyl-6,8-dihydro-5h-quinolin-2-yl]piperidin-1-yl]pyrimidin-5-yl]-3-methylbutan-1-ol Chemical compound C1=CC(OC)=CC=C1COC1C2=C(C3CCC(F)(F)CC3)C(C(F)C=3C=CC(=CC=3)C(F)(F)F)=C(C3CCN(CC3)C=3N=CC(=CN=3)C(O)CC(C)C)N=C2CC(C)(C)C1 TWJIYXRDTIEEQR-UHFFFAOYSA-N 0.000 description 1
- BUZZUHJODKQYTF-UHFFFAOYSA-N 1-iodo-3-methylbutane Chemical compound CC(C)CCI BUZZUHJODKQYTF-UHFFFAOYSA-N 0.000 description 1
- LRMSQVBRUNSOJL-UHFFFAOYSA-N 2,2,3,3,3-pentafluoropropanoic acid Chemical compound OC(=O)C(F)(F)C(F)(F)F LRMSQVBRUNSOJL-UHFFFAOYSA-N 0.000 description 1
- YQIJPSMCDBTCAM-UHFFFAOYSA-N 2,3-dimethyl-5,6,7,8-tetrahydroquinoline Chemical compound C1CCCC2=C1C=C(C)C(C)=N2 YQIJPSMCDBTCAM-UHFFFAOYSA-N 0.000 description 1
- LXFQSRIDYRFTJW-UHFFFAOYSA-M 2,4,6-trimethylbenzenesulfonate Chemical compound CC1=CC(C)=C(S([O-])(=O)=O)C(C)=C1 LXFQSRIDYRFTJW-UHFFFAOYSA-M 0.000 description 1
- JGFXUYLYPITYGR-UHFFFAOYSA-N 2-(2-diphenylphosphanylphenyl)-n,n-dimethylaniline Chemical group CN(C)C1=CC=CC=C1C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 JGFXUYLYPITYGR-UHFFFAOYSA-N 0.000 description 1
- QNZFUMVTUFOLRT-UHFFFAOYSA-N 2-(cyclohexen-1-yl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane Chemical compound O1C(C)(C)C(C)(C)OB1C1=CCCCC1 QNZFUMVTUFOLRT-UHFFFAOYSA-N 0.000 description 1
- KQUCYJXFXOBDOR-UHFFFAOYSA-N 2-[1-(5-bromopyrimidin-2-yl)piperidin-4-yl]-4-(4,4-difluorocyclohexyl)-3-[fluoro-[4-(trifluoromethyl)phenyl]methyl]-7,7-dimethyl-6,8-dihydro-5h-quinolin-5-ol Chemical compound C1C(C)(C)CC(O)C(C(=C2C(F)C=3C=CC(=CC=3)C(F)(F)F)C3CCC(F)(F)CC3)=C1N=C2C(CC1)CCN1C1=NC=C(Br)C=N1 KQUCYJXFXOBDOR-UHFFFAOYSA-N 0.000 description 1
- KXTXKQGJYKAOIS-UHFFFAOYSA-N 2-[1-(5-cyclopropylpyrimidin-2-yl)piperidin-4-yl]-4-(4,4-difluorocyclohexyl)-3-[fluoro-[4-(trifluoromethyl)phenyl]methyl]-7,7-dimethyl-6,8-dihydro-5h-quinolin-5-ol Chemical compound C1C(C)(C)CC(O)C(C(=C2C(F)C=3C=CC(=CC=3)C(F)(F)F)C3CCC(F)(F)CC3)=C1N=C2C(CC1)CCN1C(N=C1)=NC=C1C1CC1 KXTXKQGJYKAOIS-UHFFFAOYSA-N 0.000 description 1
- JLROQRNYXOHRHE-UHFFFAOYSA-N 2-[1-[5-(cyclohexen-1-yl)pyrimidin-2-yl]piperidin-4-yl]-4-(4,4-difluorocyclohexyl)-3-[fluoro-[4-(trifluoromethyl)phenyl]methyl]-5-[(4-methoxyphenyl)methoxy]-7,7-dimethyl-6,8-dihydro-5h-quinoline Chemical compound C1=CC(OC)=CC=C1COC1C2=C(C3CCC(F)(F)CC3)C(C(F)C=3C=CC(=CC=3)C(F)(F)F)=C(C3CCN(CC3)C=3N=CC(=CN=3)C=3CCCCC=3)N=C2CC(C)(C)C1 JLROQRNYXOHRHE-UHFFFAOYSA-N 0.000 description 1
- OVKQDPXOYGMZJG-UHFFFAOYSA-N 2-[1-[5-(cyclohexen-1-yl)pyrimidin-2-yl]piperidin-4-yl]-4-(4,4-difluorocyclohexyl)-3-[fluoro-[4-(trifluoromethyl)phenyl]methyl]-7,7-dimethyl-6,8-dihydro-5h-quinolin-5-ol Chemical compound C1C(C)(C)CC(O)C(C(=C2C(F)C=3C=CC(=CC=3)C(F)(F)F)C3CCC(F)(F)CC3)=C1N=C2C(CC1)CCN1C(N=C1)=NC=C1C1=CCCCC1 OVKQDPXOYGMZJG-UHFFFAOYSA-N 0.000 description 1
- IEWIHCACHNZCGB-UHFFFAOYSA-N 2-[1-[5-[3-[tert-butyl(dimethyl)silyl]oxypropoxy]pyrimidin-2-yl]piperidin-4-yl]-4-(4,4-difluorocyclohexyl)-3-[fluoro-[4-(trifluoromethyl)phenyl]methyl]-7,7-dimethyl-6,8-dihydro-5h-quinolin-5-ol Chemical compound N1=CC(OCCCO[Si](C)(C)C(C)(C)C)=CN=C1N1CCC(C=2C(=C(C3CCC(F)(F)CC3)C=3C(O)CC(C)(C)CC=3N=2)C(F)C=2C=CC(=CC=2)C(F)(F)F)CC1 IEWIHCACHNZCGB-UHFFFAOYSA-N 0.000 description 1
- DIQXSVRFUJJOSD-UHFFFAOYSA-N 2-[4-[4-(4,4-difluorocyclohexyl)-3-[fluoro-[4-(trifluoromethyl)phenyl]methyl]-5-[(4-methoxyphenyl)methoxy]-7,7-dimethyl-6,8-dihydro-5h-quinolin-2-yl]piperidin-1-yl]pyrimidine-5-carboxylic acid Chemical compound C1=CC(OC)=CC=C1COC1C2=C(C3CCC(F)(F)CC3)C(C(F)C=3C=CC(=CC=3)C(F)(F)F)=C(C3CCN(CC3)C=3N=CC(=CN=3)C(O)=O)N=C2CC(C)(C)C1 DIQXSVRFUJJOSD-UHFFFAOYSA-N 0.000 description 1
- RGMKPSNTGGGEDF-UHFFFAOYSA-N 2-[4-[4-(4,4-difluorocyclohexyl)-3-[fluoro-[4-(trifluoromethyl)phenyl]methyl]-5-hydroxy-7,7-dimethyl-6,8-dihydro-5h-quinolin-2-yl]piperidin-1-yl]pyrimidine-5-carbaldehyde Chemical compound C1C(C)(C)CC(O)C(C(=C2C(F)C=3C=CC(=CC=3)C(F)(F)F)C3CCC(F)(F)CC3)=C1N=C2C(CC1)CCN1C1=NC=C(C=O)C=N1 RGMKPSNTGGGEDF-UHFFFAOYSA-N 0.000 description 1
- ANPNVRIFRYOAPY-UHFFFAOYSA-N 2-[4-[4-(4,4-difluorocyclohexyl)-3-[fluoro-[4-(trifluoromethyl)phenyl]methyl]-5-hydroxy-7,7-dimethyl-6,8-dihydro-5h-quinolin-2-yl]piperidin-1-yl]pyrimidine-5-carbonitrile Chemical compound C1C(C)(C)CC(O)C(C(=C2C(F)C=3C=CC(=CC=3)C(F)(F)F)C3CCC(F)(F)CC3)=C1N=C2C(CC1)CCN1C1=NC=C(C#N)C=N1 ANPNVRIFRYOAPY-UHFFFAOYSA-N 0.000 description 1
- LIWHJGWJILYEPG-UHFFFAOYSA-N 2-[[2-[4-[4-(4,4-difluorocyclohexyl)-3-[fluoro-[4-(trifluoromethyl)phenyl]methyl]-5-[(4-methoxyphenyl)methoxy]-7,7-dimethyl-6,8-dihydro-5h-quinolin-2-yl]piperidin-1-yl]pyrimidin-5-yl]-methylamino]ethanol Chemical compound C1=CC(OC)=CC=C1COC1C2=C(C3CCC(F)(F)CC3)C(C(F)C=3C=CC(=CC=3)C(F)(F)F)=C(C3CCN(CC3)C=3N=CC(=CN=3)N(C)CCO)N=C2CC(C)(C)C1 LIWHJGWJILYEPG-UHFFFAOYSA-N 0.000 description 1
- ZFFBIQMNKOJDJE-UHFFFAOYSA-N 2-bromo-1,2-diphenylethanone Chemical compound C=1C=CC=CC=1C(Br)C(=O)C1=CC=CC=C1 ZFFBIQMNKOJDJE-UHFFFAOYSA-N 0.000 description 1
- PGFIHORVILKHIA-UHFFFAOYSA-N 2-bromopyrimidine Chemical compound BrC1=NC=CC=N1 PGFIHORVILKHIA-UHFFFAOYSA-N 0.000 description 1
- BIFZBCZMDZHBEP-UHFFFAOYSA-N 2-chloro-5-(3,3,3-trifluoropropoxy)pyrimidine Chemical compound FC(F)(F)CCOC1=CN=C(Cl)N=C1 BIFZBCZMDZHBEP-UHFFFAOYSA-N 0.000 description 1
- CNIPWARAIQHOSI-UHFFFAOYSA-N 2-chloro-5-(4,4,4-trifluorobut-1-enyl)pyrimidine Chemical compound FC(F)(F)CC=CC1=CN=C(Cl)N=C1 CNIPWARAIQHOSI-UHFFFAOYSA-N 0.000 description 1
- ZVRPJXQDGYCMLP-SSDOTTSWSA-N 2-chloro-5-[(3r)-1-methylpyrrolidin-3-yl]oxypyrimidine Chemical compound C1N(C)CC[C@H]1OC1=CN=C(Cl)N=C1 ZVRPJXQDGYCMLP-SSDOTTSWSA-N 0.000 description 1
- RSUBGBZOMBTDTI-UHFFFAOYSA-N 2-chloro-5-methoxypyrimidine Chemical compound COC1=CN=C(Cl)N=C1 RSUBGBZOMBTDTI-UHFFFAOYSA-N 0.000 description 1
- WMARUIMXVALOMF-UHFFFAOYSA-N 2-chloro-5-pentylpyrimidine Chemical compound CCCCCC1=CN=C(Cl)N=C1 WMARUIMXVALOMF-UHFFFAOYSA-N 0.000 description 1
- QFLAUXDLHKYUIA-UHFFFAOYSA-N 2-chloro-5-propan-2-ylpyrimidine Chemical compound CC(C)C1=CN=C(Cl)N=C1 QFLAUXDLHKYUIA-UHFFFAOYSA-N 0.000 description 1
- FXQSUQZXESNFNH-UHFFFAOYSA-N 2-chloropyrimidine-5-carbonitrile Chemical compound ClC1=NC=C(C#N)C=N1 FXQSUQZXESNFNH-UHFFFAOYSA-N 0.000 description 1
- 125000004398 2-methyl-2-butyl group Chemical group CC(C)(CC)* 0.000 description 1
- LBLYYCQCTBFVLH-UHFFFAOYSA-M 2-methylbenzenesulfonate Chemical compound CC1=CC=CC=C1S([O-])(=O)=O LBLYYCQCTBFVLH-UHFFFAOYSA-M 0.000 description 1
- ALRXDIKPRCRYAU-UHFFFAOYSA-N 2-methylpropan-2-ol Chemical compound CC(C)(C)O.CC(C)(C)O ALRXDIKPRCRYAU-UHFFFAOYSA-N 0.000 description 1
- BSKHPKMHTQYZBB-UHFFFAOYSA-N 2-methylpyridine Chemical compound CC1=CC=CC=N1 BSKHPKMHTQYZBB-UHFFFAOYSA-N 0.000 description 1
- IAGROJPXACRRDT-UHFFFAOYSA-N 2-piperidin-1-ylpyrimidine Chemical class C1CCCCN1C1=NC=CC=N1 IAGROJPXACRRDT-UHFFFAOYSA-N 0.000 description 1
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 1
- JMTMSDXUXJISAY-UHFFFAOYSA-N 2H-benzotriazol-4-ol Chemical compound OC1=CC=CC2=C1N=NN2 JMTMSDXUXJISAY-UHFFFAOYSA-N 0.000 description 1
- KIUMMUBSPKGMOY-UHFFFAOYSA-N 3,3'-Dithiobis(6-nitrobenzoic acid) Chemical compound C1=C([N+]([O-])=O)C(C(=O)O)=CC(SSC=2C=C(C(=CC=2)[N+]([O-])=O)C(O)=O)=C1 KIUMMUBSPKGMOY-UHFFFAOYSA-N 0.000 description 1
- HDBGBTNNPRCVND-UHFFFAOYSA-N 3,3,3-trifluoropropan-1-ol Chemical compound OCCC(F)(F)F HDBGBTNNPRCVND-UHFFFAOYSA-N 0.000 description 1
- QKNPGPYFWRUKRM-UHFFFAOYSA-N 3,4,5,6,7,8-hexahydro-1h-quinolin-2-one Chemical compound N1C(=O)CCC2=C1CCCC2 QKNPGPYFWRUKRM-UHFFFAOYSA-N 0.000 description 1
- WADSJYLPJPTMLN-UHFFFAOYSA-N 3-(cycloundecen-1-yl)-1,2-diazacycloundec-2-ene Chemical compound C1CCCCCCCCC=C1C1=NNCCCCCCCC1 WADSJYLPJPTMLN-UHFFFAOYSA-N 0.000 description 1
- IXDHYAMRWBIMJB-UHFFFAOYSA-N 3-[2-[4-[4-(4,4-difluorocyclohexyl)-3-[fluoro-[4-(trifluoromethyl)phenyl]methyl]-5-hydroxy-7,7-dimethyl-6,8-dihydro-5h-quinolin-2-yl]piperidin-1-yl]pyrimidin-5-yl]benzoic acid Chemical compound C1C(C)(C)CC(O)C(C(=C2C(F)C=3C=CC(=CC=3)C(F)(F)F)C3CCC(F)(F)CC3)=C1N=C2C(CC1)CCN1C(N=C1)=NC=C1C1=CC=CC(C(O)=O)=C1 IXDHYAMRWBIMJB-UHFFFAOYSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- QGMROEZDWJTIDW-UHFFFAOYSA-N 3-bromopropoxy-tert-butyl-dimethylsilane Chemical compound CC(C)(C)[Si](C)(C)OCCCBr QGMROEZDWJTIDW-UHFFFAOYSA-N 0.000 description 1
- 125000004917 3-methyl-2-butyl group Chemical group CC(C(C)*)C 0.000 description 1
- AXUFUWARAAYMCG-UHFFFAOYSA-N 3-methylsulfonylpropyl 4-methylbenzenesulfonate Chemical compound CC1=CC=C(S(=O)(=O)OCCCS(C)(=O)=O)C=C1 AXUFUWARAAYMCG-UHFFFAOYSA-N 0.000 description 1
- PQOBAICDGYSPLH-UHFFFAOYSA-N 4,5-dimethylimidazol-2-one Chemical compound CC1=NC(=O)N=C1C PQOBAICDGYSPLH-UHFFFAOYSA-N 0.000 description 1
- SVEYXTMHBZHHTG-UHFFFAOYSA-N 4-(4,4-difluorocyclohexyl)-2-[1-(5-ethoxypyrimidin-2-yl)piperidin-4-yl]-3-[fluoro-[4-(trifluoromethyl)phenyl]methyl]-7,7-dimethyl-6,8-dihydro-5h-quinolin-5-ol Chemical compound N1=CC(OCC)=CN=C1N1CCC(C=2C(=C(C3CCC(F)(F)CC3)C=3C(O)CC(C)(C)CC=3N=2)C(F)C=2C=CC(=CC=2)C(F)(F)F)CC1 SVEYXTMHBZHHTG-UHFFFAOYSA-N 0.000 description 1
- AWODGYHPIMOJLG-UHFFFAOYSA-N 4-(4,4-difluorocyclohexyl)-2-[1-[5-(difluoromethoxy)pyrimidin-2-yl]piperidin-4-yl]-3-[fluoro-[4-(trifluoromethyl)phenyl]methyl]-7,7-dimethyl-6,8-dihydro-5h-quinolin-5-ol Chemical compound C1C(C)(C)CC(O)C(C(=C2C(F)C=3C=CC(=CC=3)C(F)(F)F)C3CCC(F)(F)CC3)=C1N=C2C(CC1)CCN1C1=NC=C(OC(F)F)C=N1 AWODGYHPIMOJLG-UHFFFAOYSA-N 0.000 description 1
- GMNNBRHXBUYJQR-UHFFFAOYSA-N 4-(4,4-difluorocyclohexyl)-2-[1-[5-(ethoxymethyl)pyrimidin-2-yl]piperidin-4-yl]-3-[fluoro-[4-(trifluoromethyl)phenyl]methyl]-7,7-dimethyl-6,8-dihydro-5h-quinolin-5-ol Chemical compound N1=CC(COCC)=CN=C1N1CCC(C=2C(=C(C3CCC(F)(F)CC3)C=3C(O)CC(C)(C)CC=3N=2)C(F)C=2C=CC(=CC=2)C(F)(F)F)CC1 GMNNBRHXBUYJQR-UHFFFAOYSA-N 0.000 description 1
- XXNXYWQMKTZYQX-UHFFFAOYSA-N 4-(4,4-difluorocyclohexyl)-3-[fluoro-[4-(trifluoromethyl)phenyl]methyl]-2-[1-(5-methoxypyrimidin-2-yl)piperidin-4-yl]-7,7-dimethyl-6,8-dihydro-5h-quinolin-5-ol Chemical compound N1=CC(OC)=CN=C1N1CCC(C=2C(=C(C3CCC(F)(F)CC3)C=3C(O)CC(C)(C)CC=3N=2)C(F)C=2C=CC(=CC=2)C(F)(F)F)CC1 XXNXYWQMKTZYQX-UHFFFAOYSA-N 0.000 description 1
- AHHRXARHQJHHBC-UHFFFAOYSA-N 4-(4,4-difluorocyclohexyl)-3-[fluoro-[4-(trifluoromethyl)phenyl]methyl]-2-[1-[5-(3-hydroxypropoxy)pyrimidin-2-yl]piperidin-4-yl]-7,7-dimethyl-6,8-dihydro-5h-quinolin-5-ol Chemical compound C1C(C)(C)CC(O)C(C(=C2C(F)C=3C=CC(=CC=3)C(F)(F)F)C3CCC(F)(F)CC3)=C1N=C2C(CC1)CCN1C1=NC=C(OCCCO)C=N1 AHHRXARHQJHHBC-UHFFFAOYSA-N 0.000 description 1
- ANOPNZMZDISQDN-UHFFFAOYSA-N 4-(4,4-difluorocyclohexyl)-3-[fluoro-[4-(trifluoromethyl)phenyl]methyl]-2-[1-[5-(4-hydroxypiperidin-1-yl)pyrimidin-2-yl]piperidin-4-yl]-7,7-dimethyl-6,8-dihydro-5h-quinolin-5-ol Chemical compound C1C(C)(C)CC(O)C(C(=C2C(F)C=3C=CC(=CC=3)C(F)(F)F)C3CCC(F)(F)CC3)=C1N=C2C(CC1)CCN1C(N=C1)=NC=C1N1CCC(O)CC1 ANOPNZMZDISQDN-UHFFFAOYSA-N 0.000 description 1
- SPTLJLBTCVPAPI-UHFFFAOYSA-N 4-(4,4-difluorocyclohexyl)-3-[fluoro-[4-(trifluoromethyl)phenyl]methyl]-2-[1-[5-(hydroxymethyl)pyrimidin-2-yl]piperidin-4-yl]-7,7-dimethyl-6,8-dihydro-5h-quinolin-5-ol Chemical compound C1C(C)(C)CC(O)C(C(=C2C(F)C=3C=CC(=CC=3)C(F)(F)F)C3CCC(F)(F)CC3)=C1N=C2C(CC1)CCN1C1=NC=C(CO)C=N1 SPTLJLBTCVPAPI-UHFFFAOYSA-N 0.000 description 1
- DRGRXTPJORYOMN-UHFFFAOYSA-N 4-(4,4-difluorocyclohexyl)-3-[fluoro-[4-(trifluoromethyl)phenyl]methyl]-2-[1-[5-(methoxymethyl)pyrimidin-2-yl]piperidin-4-yl]-5-[(4-methoxyphenyl)methoxy]-7,7-dimethyl-6,8-dihydro-5h-quinoline Chemical compound N1=CC(COC)=CN=C1N1CCC(C=2C(=C(C3CCC(F)(F)CC3)C=3C(OCC=4C=CC(OC)=CC=4)CC(C)(C)CC=3N=2)C(F)C=2C=CC(=CC=2)C(F)(F)F)CC1 DRGRXTPJORYOMN-UHFFFAOYSA-N 0.000 description 1
- VFBJTBVKUFUUAG-UHFFFAOYSA-N 4-(4,4-difluorocyclohexyl)-3-[fluoro-[4-(trifluoromethyl)phenyl]methyl]-2-[1-[5-(methoxymethyl)pyrimidin-2-yl]piperidin-4-yl]-7,7-dimethyl-6,8-dihydro-5h-quinolin-5-ol Chemical compound N1=CC(COC)=CN=C1N1CCC(C=2C(=C(C3CCC(F)(F)CC3)C=3C(O)CC(C)(C)CC=3N=2)C(F)C=2C=CC(=CC=2)C(F)(F)F)CC1 VFBJTBVKUFUUAG-UHFFFAOYSA-N 0.000 description 1
- ZWAMSDVUBYDSBS-UHFFFAOYSA-N 4-(4,4-difluorocyclohexyl)-3-[fluoro-[4-(trifluoromethyl)phenyl]methyl]-5-[(4-methoxyphenyl)methoxy]-7,7-dimethyl-2-(1-pyrimidin-2-ylpiperidin-4-yl)-6,8-dihydro-5h-quinoline Chemical compound C1=CC(OC)=CC=C1COC1C2=C(C3CCC(F)(F)CC3)C(C(F)C=3C=CC(=CC=3)C(F)(F)F)=C(C3CCN(CC3)C=3N=CC=CN=3)N=C2CC(C)(C)C1 ZWAMSDVUBYDSBS-UHFFFAOYSA-N 0.000 description 1
- IXSGIWHECUCATC-UHFFFAOYSA-N 4-(4,4-difluorocyclohexyl)-3-[fluoro-[4-(trifluoromethyl)phenyl]methyl]-5-[(4-methoxyphenyl)methoxy]-7,7-dimethyl-2-[1-[5-(1-methylpiperidin-4-yl)oxypyrimidin-2-yl]piperidin-4-yl]-6,8-dihydro-5h-quinoline Chemical compound C1=CC(OC)=CC=C1COC1C2=C(C3CCC(F)(F)CC3)C(C(F)C=3C=CC(=CC=3)C(F)(F)F)=C(C3CCN(CC3)C=3N=CC(OC4CCN(C)CC4)=CN=3)N=C2CC(C)(C)C1 IXSGIWHECUCATC-UHFFFAOYSA-N 0.000 description 1
- JQCSLBIKFDQKFM-UHFFFAOYSA-N 4-(4,4-difluorocyclohexyl)-3-[fluoro-[4-(trifluoromethyl)phenyl]methyl]-5-[(4-methoxyphenyl)methoxy]-7,7-dimethyl-2-[1-[5-(2-methylpropoxymethyl)pyrimidin-2-yl]piperidin-4-yl]-6,8-dihydro-5h-quinoline Chemical compound C1=CC(OC)=CC=C1COC1C2=C(C3CCC(F)(F)CC3)C(C(F)C=3C=CC(=CC=3)C(F)(F)F)=C(C3CCN(CC3)C=3N=CC(COCC(C)C)=CN=3)N=C2CC(C)(C)C1 JQCSLBIKFDQKFM-UHFFFAOYSA-N 0.000 description 1
- DOHOKWYKRKMSIO-UHFFFAOYSA-N 4-(4,4-difluorocyclohexyl)-3-[fluoro-[4-(trifluoromethyl)phenyl]methyl]-5-[(4-methoxyphenyl)methoxy]-7,7-dimethyl-2-[1-[5-(propan-2-yloxymethyl)pyrimidin-2-yl]piperidin-4-yl]-6,8-dihydro-5h-quinoline Chemical compound C1=CC(OC)=CC=C1COC1C2=C(C3CCC(F)(F)CC3)C(C(F)C=3C=CC(=CC=3)C(F)(F)F)=C(C3CCN(CC3)C=3N=CC(COC(C)C)=CN=3)N=C2CC(C)(C)C1 DOHOKWYKRKMSIO-UHFFFAOYSA-N 0.000 description 1
- XLJHVHIAAQICKH-UHFFFAOYSA-N 4-(4,4-difluorocyclohexyl)-3-[fluoro-[4-(trifluoromethyl)phenyl]methyl]-7,7-dimethyl-2-(1-pyrimidin-2-ylpiperidin-4-yl)-6,8-dihydro-5h-quinolin-5-ol Chemical compound C1C(C)(C)CC(O)C(C(=C2C(F)C=3C=CC(=CC=3)C(F)(F)F)C3CCC(F)(F)CC3)=C1N=C2C(CC1)CCN1C1=NC=CC=N1 XLJHVHIAAQICKH-UHFFFAOYSA-N 0.000 description 1
- MIEBJFXGCPSWOC-UHFFFAOYSA-N 4-(4,4-difluorocyclohexyl)-3-[fluoro-[4-(trifluoromethyl)phenyl]methyl]-7,7-dimethyl-2-[1-(5-morpholin-4-ylpyrimidin-2-yl)piperidin-4-yl]-6,8-dihydro-5h-quinolin-5-ol Chemical compound C1C(C)(C)CC(O)C(C(=C2C(F)C=3C=CC(=CC=3)C(F)(F)F)C3CCC(F)(F)CC3)=C1N=C2C(CC1)CCN1C(N=C1)=NC=C1N1CCOCC1 MIEBJFXGCPSWOC-UHFFFAOYSA-N 0.000 description 1
- PABUCHWCHXEJOO-UHFFFAOYSA-N 4-(4,4-difluorocyclohexyl)-3-[fluoro-[4-(trifluoromethyl)phenyl]methyl]-7,7-dimethyl-2-[1-(5-pentylpyrimidin-2-yl)piperidin-4-yl]-6,8-dihydro-5h-quinolin-5-ol Chemical compound N1=CC(CCCCC)=CN=C1N1CCC(C=2C(=C(C3CCC(F)(F)CC3)C=3C(O)CC(C)(C)CC=3N=2)C(F)C=2C=CC(=CC=2)C(F)(F)F)CC1 PABUCHWCHXEJOO-UHFFFAOYSA-N 0.000 description 1
- CLXANZOEKNNINY-UHFFFAOYSA-N 4-(4,4-difluorocyclohexyl)-3-[fluoro-[4-(trifluoromethyl)phenyl]methyl]-7,7-dimethyl-2-[1-(5-piperidin-1-ylpyrimidin-2-yl)piperidin-4-yl]-6,8-dihydro-5h-quinolin-5-ol Chemical compound C1C(C)(C)CC(O)C(C(=C2C(F)C=3C=CC(=CC=3)C(F)(F)F)C3CCC(F)(F)CC3)=C1N=C2C(CC1)CCN1C(N=C1)=NC=C1N1CCCCC1 CLXANZOEKNNINY-UHFFFAOYSA-N 0.000 description 1
- IYWWXKZDHUTOJR-UHFFFAOYSA-N 4-(4,4-difluorocyclohexyl)-3-[fluoro-[4-(trifluoromethyl)phenyl]methyl]-7,7-dimethyl-2-[1-(5-propan-2-yloxypyrimidin-2-yl)piperidin-4-yl]-6,8-dihydro-5h-quinolin-5-ol Chemical compound N1=CC(OC(C)C)=CN=C1N1CCC(C=2C(=C(C3CCC(F)(F)CC3)C=3C(O)CC(C)(C)CC=3N=2)C(F)C=2C=CC(=CC=2)C(F)(F)F)CC1 IYWWXKZDHUTOJR-UHFFFAOYSA-N 0.000 description 1
- TVXGCOLTAQGLQA-UHFFFAOYSA-N 4-(4,4-difluorocyclohexyl)-3-[fluoro-[4-(trifluoromethyl)phenyl]methyl]-7,7-dimethyl-2-[1-(5-propan-2-ylpyrimidin-2-yl)piperidin-4-yl]-6,8-dihydro-5h-quinolin-5-ol Chemical compound N1=CC(C(C)C)=CN=C1N1CCC(C=2C(=C(C3CCC(F)(F)CC3)C=3C(O)CC(C)(C)CC=3N=2)C(F)C=2C=CC(=CC=2)C(F)(F)F)CC1 TVXGCOLTAQGLQA-UHFFFAOYSA-N 0.000 description 1
- KTWMPGDJFFWXKI-UHFFFAOYSA-N 4-(4,4-difluorocyclohexyl)-3-[fluoro-[4-(trifluoromethyl)phenyl]methyl]-7,7-dimethyl-2-[1-(5-thiomorpholin-4-ylpyrimidin-2-yl)piperidin-4-yl]-6,8-dihydro-5h-quinolin-5-ol Chemical compound C1C(C)(C)CC(O)C(C(=C2C(F)C=3C=CC(=CC=3)C(F)(F)F)C3CCC(F)(F)CC3)=C1N=C2C(CC1)CCN1C(N=C1)=NC=C1N1CCSCC1 KTWMPGDJFFWXKI-UHFFFAOYSA-N 0.000 description 1
- YIFYEEWRFUPFBF-UHFFFAOYSA-N 4-(4,4-difluorocyclohexyl)-3-[fluoro-[4-(trifluoromethyl)phenyl]methyl]-7,7-dimethyl-2-[1-[5-(2-methylpropoxy)pyrimidin-2-yl]piperidin-4-yl]-6,8-dihydro-5h-quinolin-5-ol Chemical compound N1=CC(OCC(C)C)=CN=C1N1CCC(C=2C(=C(C3CCC(F)(F)CC3)C=3C(O)CC(C)(C)CC=3N=2)C(F)C=2C=CC(=CC=2)C(F)(F)F)CC1 YIFYEEWRFUPFBF-UHFFFAOYSA-N 0.000 description 1
- ZQKRIGGBHMMJNI-UHFFFAOYSA-N 4-(4,4-difluorocyclohexyl)-3-[fluoro-[4-(trifluoromethyl)phenyl]methyl]-7,7-dimethyl-2-[1-[5-(2-methylpropoxymethyl)pyrimidin-2-yl]piperidin-4-yl]-6,8-dihydro-5h-quinolin-5-ol Chemical compound N1=CC(COCC(C)C)=CN=C1N1CCC(C=2C(=C(C3CCC(F)(F)CC3)C=3C(O)CC(C)(C)CC=3N=2)C(F)C=2C=CC(=CC=2)C(F)(F)F)CC1 ZQKRIGGBHMMJNI-UHFFFAOYSA-N 0.000 description 1
- RPCFSMBCYWIYSW-UHFFFAOYSA-N 4-(4,4-difluorocyclohexyl)-3-[fluoro-[4-(trifluoromethyl)phenyl]methyl]-7,7-dimethyl-2-[1-[5-(2-methylpropyl)pyrimidin-2-yl]piperidin-4-yl]-6,8-dihydro-5h-quinolin-5-ol Chemical compound N1=CC(CC(C)C)=CN=C1N1CCC(C=2C(=C(C3CCC(F)(F)CC3)C=3C(O)CC(C)(C)CC=3N=2)C(F)C=2C=CC(=CC=2)C(F)(F)F)CC1 RPCFSMBCYWIYSW-UHFFFAOYSA-N 0.000 description 1
- BEUGJZDVPMRJAD-UHFFFAOYSA-N 4-(4,4-difluorocyclohexyl)-3-[fluoro-[4-(trifluoromethyl)phenyl]methyl]-7,7-dimethyl-2-[1-[5-(3-methylbutoxy)pyrimidin-2-yl]piperidin-4-yl]-6,8-dihydro-5h-quinolin-5-ol Chemical compound N1=CC(OCCC(C)C)=CN=C1N1CCC(C=2C(=C(C3CCC(F)(F)CC3)C=3C(O)CC(C)(C)CC=3N=2)C(F)C=2C=CC(=CC=2)C(F)(F)F)CC1 BEUGJZDVPMRJAD-UHFFFAOYSA-N 0.000 description 1
- ZLSUNYHFHNHQMW-UHFFFAOYSA-N 4-(4,4-difluorocyclohexyl)-3-[fluoro-[4-(trifluoromethyl)phenyl]methyl]-7,7-dimethyl-2-[1-[5-(4,4,4-trifluorobutyl)pyrimidin-2-yl]piperidin-4-yl]-6,8-dihydro-5h-quinolin-5-ol Chemical compound C1C(C)(C)CC(O)C(C(=C2C(F)C=3C=CC(=CC=3)C(F)(F)F)C3CCC(F)(F)CC3)=C1N=C2C(CC1)CCN1C1=NC=C(CCCC(F)(F)F)C=N1 ZLSUNYHFHNHQMW-UHFFFAOYSA-N 0.000 description 1
- JADLTSHXELHFFR-UHFFFAOYSA-N 4-(4,4-difluorocyclohexyl)-3-[fluoro-[4-(trifluoromethyl)phenyl]methyl]-7,7-dimethyl-2-[1-[5-(propan-2-yloxymethyl)pyrimidin-2-yl]piperidin-4-yl]-6,8-dihydro-5h-quinolin-5-ol Chemical compound N1=CC(COC(C)C)=CN=C1N1CCC(C=2C(=C(C3CCC(F)(F)CC3)C=3C(O)CC(C)(C)CC=3N=2)C(F)C=2C=CC(=CC=2)C(F)(F)F)CC1 JADLTSHXELHFFR-UHFFFAOYSA-N 0.000 description 1
- KWCJJOGPVQTULR-ZZWXMOCLSA-N 4-(4,4-difluorocyclohexyl)-3-[fluoro-[4-(trifluoromethyl)phenyl]methyl]-7,7-dimethyl-2-[1-[5-[(2s)-2-(oxan-2-yloxy)propoxy]pyrimidin-2-yl]piperidin-4-yl]-6,8-dihydro-5h-quinolin-5-ol Chemical compound C([C@H](C)OC1OCCCC1)OC(C=N1)=CN=C1N(CC1)CCC1C(C=1C(F)C=2C=CC(=CC=2)C(F)(F)F)=NC=2CC(C)(C)CC(O)C=2C=1C1CCC(F)(F)CC1 KWCJJOGPVQTULR-ZZWXMOCLSA-N 0.000 description 1
- NKUBOSZSOVYFAO-AATRIKPKSA-N 4-(4,4-difluorocyclohexyl)-3-[fluoro-[4-(trifluoromethyl)phenyl]methyl]-7,7-dimethyl-2-[1-[5-[(e)-3-methylbut-1-enyl]pyrimidin-2-yl]piperidin-4-yl]-6,8-dihydro-5h-quinolin-5-ol Chemical compound N1=CC(/C=C/C(C)C)=CN=C1N1CCC(C=2C(=C(C3CCC(F)(F)CC3)C=3C(O)CC(C)(C)CC=3N=2)C(F)C=2C=CC(=CC=2)C(F)(F)F)CC1 NKUBOSZSOVYFAO-AATRIKPKSA-N 0.000 description 1
- BRIXOPDYGQCZFO-UHFFFAOYSA-M 4-ethylbenzenesulfonate Chemical compound CCC1=CC=C(S([O-])(=O)=O)C=C1 BRIXOPDYGQCZFO-UHFFFAOYSA-M 0.000 description 1
- RGUKYNXWOWSRET-UHFFFAOYSA-N 4-pyrrolidin-1-ylpyridine Chemical compound C1CCCN1C1=CC=NC=C1 RGUKYNXWOWSRET-UHFFFAOYSA-N 0.000 description 1
- SGKURJURKCHGJG-UHFFFAOYSA-N 5,6,7,8-tetrahydro-1h-quinolin-2-one Chemical compound C1CCCC2=C1C=CC(=O)N2 SGKURJURKCHGJG-UHFFFAOYSA-N 0.000 description 1
- OTJLLOAGJYOWCJ-UHFFFAOYSA-N 5-[(4-methoxyphenyl)methoxy]-7,7-dimethyl-6,8-dihydro-5H-quinoline Chemical compound COC1=CC=C(COC2C=3C=CC=NC=3CC(C2)(C)C)C=C1 OTJLLOAGJYOWCJ-UHFFFAOYSA-N 0.000 description 1
- LDRNGESLATXCHM-UHFFFAOYSA-N 7,7-dimethyl-6,8-dihydro-5h-quinoline Chemical compound C1=CN=C2CC(C)(C)CCC2=C1 LDRNGESLATXCHM-UHFFFAOYSA-N 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 102000005666 Apolipoprotein A-I Human genes 0.000 description 1
- 108010059886 Apolipoprotein A-I Proteins 0.000 description 1
- 102000018616 Apolipoproteins B Human genes 0.000 description 1
- 108010027006 Apolipoproteins B Proteins 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 description 1
- DKPFZGUDAPQIHT-UHFFFAOYSA-N Butyl acetate Natural products CCCCOC(C)=O DKPFZGUDAPQIHT-UHFFFAOYSA-N 0.000 description 1
- HVZBRUFSPGRUNP-HAVNEIBRSA-N CC(C)(C1)Cc2nc(C(CC3)CCN3c3ncc(CCCCC(O)=O)cn3)c(C(c3ccc(C(/C=C/C)(F)F)cc3)F)c(C(CC3)CCC3(F)F)c2C1O Chemical compound CC(C)(C1)Cc2nc(C(CC3)CCN3c3ncc(CCCCC(O)=O)cn3)c(C(c3ccc(C(/C=C/C)(F)F)cc3)F)c(C(CC3)CCC3(F)F)c2C1O HVZBRUFSPGRUNP-HAVNEIBRSA-N 0.000 description 1
- KMQWOJJBLHIQCV-UHFFFAOYSA-N CC(C)(C1)Cc2nc(C(CCN(C3)C(N(C)C4)=NC=C4N4CCCCC4)C3c3c(C4F)ccc(C(F)(F)F)c3)c4c(C(CC3)CCC3(F)F)c2C1O Chemical compound CC(C)(C1)Cc2nc(C(CCN(C3)C(N(C)C4)=NC=C4N4CCCCC4)C3c3c(C4F)ccc(C(F)(F)F)c3)c4c(C(CC3)CCC3(F)F)c2C1O KMQWOJJBLHIQCV-UHFFFAOYSA-N 0.000 description 1
- CSRNVFCXRADNOE-UHFFFAOYSA-N CC(C)OCc1cnc(N(CC2)CCC2c2c(C(c3ccc(C)cc3)F)c(C(CC3)CCC3(F)F)c(C(CC(C)(C)C3)O)c3n2)nc1 Chemical compound CC(C)OCc1cnc(N(CC2)CCC2c2c(C(c3ccc(C)cc3)F)c(C(CC3)CCC3(F)F)c(C(CC(C)(C)C3)O)c3n2)nc1 CSRNVFCXRADNOE-UHFFFAOYSA-N 0.000 description 1
- ZLSHRGSRFIPZFX-UHFFFAOYSA-N CC1=C(C(=NC2=C1CCCC2)C3CCNCC3)C Chemical compound CC1=C(C(=NC2=C1CCCC2)C3CCNCC3)C ZLSHRGSRFIPZFX-UHFFFAOYSA-N 0.000 description 1
- JCQBZZLOWFAMJU-UHFFFAOYSA-N CC1CC(C2=C(C1)N=CC(=C2)C)O Chemical compound CC1CC(C2=C(C1)N=CC(=C2)C)O JCQBZZLOWFAMJU-UHFFFAOYSA-N 0.000 description 1
- OKTJSMMVPCPJKN-NJFSPNSNSA-N Carbon-14 Chemical compound [14C] OKTJSMMVPCPJKN-NJFSPNSNSA-N 0.000 description 1
- 229940126062 Compound A Drugs 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 229920002785 Croscarmellose sodium Polymers 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- XBPCUCUWBYBCDP-UHFFFAOYSA-N Dicyclohexylamine Chemical class C1CCCCC1NC1CCCCC1 XBPCUCUWBYBCDP-UHFFFAOYSA-N 0.000 description 1
- 241000255925 Diptera Species 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical class NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- NLDMNSXOCDLTTB-UHFFFAOYSA-N Heterophylliin A Natural products O1C2COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC2C(OC(=O)C=2C=C(O)C(O)=C(O)C=2)C(O)C1OC(=O)C1=CC(O)=C(O)C(O)=C1 NLDMNSXOCDLTTB-UHFFFAOYSA-N 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- 208000031226 Hyperlipidaemia Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical class NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical class OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Chemical compound CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- 239000012448 Lithium borohydride Substances 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-L Malonate Chemical compound [O-]C(=O)CC([O-])=O OFOBLEOULBTSOW-UHFFFAOYSA-L 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- NTIZESTWPVYFNL-UHFFFAOYSA-N Methyl isobutyl ketone Chemical compound CC(C)CC(C)=O NTIZESTWPVYFNL-UHFFFAOYSA-N 0.000 description 1
- UIHCLUNTQKBZGK-UHFFFAOYSA-N Methyl isobutyl ketone Natural products CCC(C)C(C)=O UIHCLUNTQKBZGK-UHFFFAOYSA-N 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 239000004368 Modified starch Substances 0.000 description 1
- 241000699660 Mus musculus Species 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 1
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
- 239000004373 Pullulan Substances 0.000 description 1
- 229920001218 Pullulan Polymers 0.000 description 1
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 1
- 208000034189 Sclerosis Diseases 0.000 description 1
- 239000005708 Sodium hypochlorite Substances 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- DTQVDTLACAAQTR-UHFFFAOYSA-M Trifluoroacetate Chemical compound [O-]C(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-M 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- CIRBILLHZJTIAZ-AFYYWNPRSA-N [(2r)-2-(oxan-2-yloxy)propyl] 4-methylbenzenesulfonate Chemical compound C([C@@H](C)OC1OCCCC1)OS(=O)(=O)C1=CC=C(C)C=C1 CIRBILLHZJTIAZ-AFYYWNPRSA-N 0.000 description 1
- QYSNJTMSLNHSMH-UHFFFAOYSA-N [2-[4-[4-(4,4-difluorocyclohexyl)-3-[fluoro-[4-(trifluoromethyl)phenyl]methyl]-5-[(4-methoxyphenyl)methoxy]-7,7-dimethyl-6,8-dihydro-5h-quinolin-2-yl]piperidin-1-yl]pyrimidin-5-yl]methanol Chemical compound C1=CC(OC)=CC=C1COC1C2=C(C3CCC(F)(F)CC3)C(C(F)C=3C=CC(=CC=3)C(F)(F)F)=C(C3CCN(CC3)C=3N=CC(CO)=CN=3)N=C2CC(C)(C)C1 QYSNJTMSLNHSMH-UHFFFAOYSA-N 0.000 description 1
- YKTSYUJCYHOUJP-UHFFFAOYSA-N [O--].[Al+3].[Al+3].[O-][Si]([O-])([O-])[O-] Chemical compound [O--].[Al+3].[Al+3].[O-][Si]([O-])([O-])[O-] YKTSYUJCYHOUJP-UHFFFAOYSA-N 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- KXKVLQRXCPHEJC-UHFFFAOYSA-N acetic acid trimethyl ester Natural products COC(C)=O KXKVLQRXCPHEJC-UHFFFAOYSA-N 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 150000008046 alkali metal hydrides Chemical class 0.000 description 1
- 150000001340 alkali metals Chemical class 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- 229910001860 alkaline earth metal hydroxide Inorganic materials 0.000 description 1
- 125000003342 alkenyl group Chemical group 0.000 description 1
- 125000005205 alkoxycarbonyloxyalkyl group Chemical group 0.000 description 1
- 125000005197 alkyl carbonyloxy alkyl group Chemical group 0.000 description 1
- 150000005215 alkyl ethers Chemical class 0.000 description 1
- 125000004644 alkyl sulfinyl group Chemical group 0.000 description 1
- 125000004414 alkyl thio group Chemical group 0.000 description 1
- 238000005804 alkylation reaction Methods 0.000 description 1
- 125000000304 alkynyl group Chemical group 0.000 description 1
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 1
- AZDRQVAHHNSJOQ-UHFFFAOYSA-N alumane Chemical class [AlH3] AZDRQVAHHNSJOQ-UHFFFAOYSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- 239000003945 anionic surfactant Substances 0.000 description 1
- 125000000637 arginyl group Chemical class N[C@@H](CCCNC(N)=N)C(=O)* 0.000 description 1
- 125000006615 aromatic heterocyclic group Chemical group 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- RQPZNWPYLFFXCP-UHFFFAOYSA-L barium dihydroxide Chemical compound [OH-].[OH-].[Ba+2] RQPZNWPYLFFXCP-UHFFFAOYSA-L 0.000 description 1
- 229910001863 barium hydroxide Inorganic materials 0.000 description 1
- 235000013871 bee wax Nutrition 0.000 description 1
- 239000012166 beeswax Substances 0.000 description 1
- 239000000440 bentonite Substances 0.000 description 1
- 229910000278 bentonite Inorganic materials 0.000 description 1
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- 229930008407 benzylideneacetone Natural products 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 239000004305 biphenyl Substances 0.000 description 1
- 235000010290 biphenyl Nutrition 0.000 description 1
- 230000036765 blood level Effects 0.000 description 1
- 125000005998 bromoethyl group Chemical group 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 125000004369 butenyl group Chemical group C(=CCC)* 0.000 description 1
- 229940043232 butyl acetate Drugs 0.000 description 1
- 125000004744 butyloxycarbonyl group Chemical group 0.000 description 1
- 125000000480 butynyl group Chemical group [*]C#CC([H])([H])C([H])([H])[H] 0.000 description 1
- KVNRLNFWIYMESJ-UHFFFAOYSA-N butyronitrile Chemical compound CCCC#N KVNRLNFWIYMESJ-UHFFFAOYSA-N 0.000 description 1
- AXCZMVOFGPJBDE-UHFFFAOYSA-L calcium dihydroxide Chemical compound [OH-].[OH-].[Ca+2] AXCZMVOFGPJBDE-UHFFFAOYSA-L 0.000 description 1
- 239000000920 calcium hydroxide Substances 0.000 description 1
- 229910001861 calcium hydroxide Inorganic materials 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 150000001735 carboxylic acids Chemical class 0.000 description 1
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 description 1
- 238000006555 catalytic reaction Methods 0.000 description 1
- 239000003093 cationic surfactant Substances 0.000 description 1
- 239000007806 chemical reaction intermediate Substances 0.000 description 1
- 229960004926 chlorobutanol Drugs 0.000 description 1
- 125000002603 chloroethyl group Chemical group [H]C([*])([H])C([H])([H])Cl 0.000 description 1
- KRVSOGSZCMJSLX-UHFFFAOYSA-L chromic acid Chemical compound O[Cr](O)(=O)=O KRVSOGSZCMJSLX-UHFFFAOYSA-L 0.000 description 1
- 150000001868 cobalt Chemical class 0.000 description 1
- 239000008119 colloidal silica Substances 0.000 description 1
- 229940075614 colloidal silicon dioxide Drugs 0.000 description 1
- 238000013329 compounding Methods 0.000 description 1
- 238000006482 condensation reaction Methods 0.000 description 1
- 150000001879 copper Chemical class 0.000 description 1
- GBRBMTNGQBKBQE-UHFFFAOYSA-L copper;diiodide Chemical compound I[Cu]I GBRBMTNGQBKBQE-UHFFFAOYSA-L 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 229960001681 croscarmellose sodium Drugs 0.000 description 1
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 238000002447 crystallographic data Methods 0.000 description 1
- 125000001047 cyclobutenyl group Chemical group C1(=CCC1)* 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000004850 cyclobutylmethyl group Chemical group C1(CCC1)C* 0.000 description 1
- 125000001162 cycloheptenyl group Chemical group C1(=CCCCCC1)* 0.000 description 1
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000006622 cycloheptylmethyl group Chemical group 0.000 description 1
- 125000000596 cyclohexenyl group Chemical group C1(=CCCCC1)* 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000004210 cyclohexylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- JHIVVAPYMSGYDF-UHFFFAOYSA-N cyclohexyloxide Natural products O=C1CCCCC1 JHIVVAPYMSGYDF-UHFFFAOYSA-N 0.000 description 1
- ZBCKWHYWPLHBOK-UHFFFAOYSA-N cyclohexylphosphane Chemical compound PC1CCCCC1 ZBCKWHYWPLHBOK-UHFFFAOYSA-N 0.000 description 1
- 125000000522 cyclooctenyl group Chemical group C1(=CCCCCCC1)* 0.000 description 1
- 125000000640 cyclooctyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 125000006623 cyclooctylmethyl group Chemical group 0.000 description 1
- 125000002433 cyclopentenyl group Chemical group C1(=CCCC1)* 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000004851 cyclopentylmethyl group Chemical group C1(CCCC1)C* 0.000 description 1
- 125000000298 cyclopropenyl group Chemical group [H]C1=C([H])C1([H])* 0.000 description 1
- 125000004186 cyclopropylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C1([H])[H] 0.000 description 1
- 239000002274 desiccant Substances 0.000 description 1
- 229910052805 deuterium Inorganic materials 0.000 description 1
- 229960002086 dextran Drugs 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 229940039227 diagnostic agent Drugs 0.000 description 1
- 239000000032 diagnostic agent Substances 0.000 description 1
- 238000002059 diagnostic imaging Methods 0.000 description 1
- 239000012973 diazabicyclooctane Substances 0.000 description 1
- WMKGGPCROCCUDY-PHEQNACWSA-N dibenzylideneacetone Chemical compound C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1 WMKGGPCROCCUDY-PHEQNACWSA-N 0.000 description 1
- 125000004915 dibutylamino group Chemical group C(CCC)N(CCCC)* 0.000 description 1
- 229940117389 dichlorobenzene Drugs 0.000 description 1
- 125000004772 dichloromethyl group Chemical group [H]C(Cl)(Cl)* 0.000 description 1
- HDULBKVLSJEMGN-UHFFFAOYSA-N dicyclohexylphosphane Chemical compound C1CCCCC1PC1CCCCC1 HDULBKVLSJEMGN-UHFFFAOYSA-N 0.000 description 1
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical class OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
- 150000005332 diethylamines Chemical class 0.000 description 1
- 125000006001 difluoroethyl group Chemical group 0.000 description 1
- 125000004786 difluoromethoxy group Chemical group [H]C(F)(F)O* 0.000 description 1
- 125000001028 difluoromethyl group Chemical group [H]C(F)(F)* 0.000 description 1
- SBZXBUIDTXKZTM-UHFFFAOYSA-N diglyme Chemical compound COCCOCCOC SBZXBUIDTXKZTM-UHFFFAOYSA-N 0.000 description 1
- 125000004925 dihydropyridyl group Chemical group N1(CC=CC=C1)* 0.000 description 1
- 125000000118 dimethyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 description 1
- HPYNZHMRTTWQTB-UHFFFAOYSA-N dimethylpyridine Natural products CC1=CC=CN=C1C HPYNZHMRTTWQTB-UHFFFAOYSA-N 0.000 description 1
- 229910001873 dinitrogen Inorganic materials 0.000 description 1
- 125000000532 dioxanyl group Chemical group 0.000 description 1
- 125000005879 dioxolanyl group Chemical group 0.000 description 1
- 125000005883 dithianyl group Chemical group 0.000 description 1
- 125000005411 dithiolanyl group Chemical group S1SC(CC1)* 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- GEDLHFYWJIIVQP-UHFFFAOYSA-N ethyl 1-[2-[4-[4-(4,4-difluorocyclohexyl)-3-[fluoro-[4-(trifluoromethyl)phenyl]methyl]-5-[(4-methoxyphenyl)methoxy]-7,7-dimethyl-6,8-dihydro-5h-quinolin-2-yl]piperidin-1-yl]pyrimidin-5-yl]piperidine-4-carboxylate Chemical compound C1CC(C(=O)OCC)CCN1C1=CN=C(N2CCC(CC2)C=2C(=C(C3CCC(F)(F)CC3)C=3C(OCC=4C=CC(OC)=CC=4)CC(C)(C)CC=3N=2)C(F)C=2C=CC(=CC=2)C(F)(F)F)N=C1 GEDLHFYWJIIVQP-UHFFFAOYSA-N 0.000 description 1
- UBAPJGFNZAJGQK-UHFFFAOYSA-N ethyl 1-[2-[4-[4-(4,4-difluorocyclohexyl)-3-[fluoro-[4-(trifluoromethyl)phenyl]methyl]-5-hydroxy-7,7-dimethyl-6,8-dihydro-5h-quinolin-2-yl]piperidin-1-yl]pyrimidin-5-yl]piperidine-4-carboxylate Chemical compound C1CC(C(=O)OCC)CCN1C1=CN=C(N2CCC(CC2)C=2C(=C(C3CCC(F)(F)CC3)C=3C(O)CC(C)(C)CC=3N=2)C(F)C=2C=CC(=CC=2)C(F)(F)F)N=C1 UBAPJGFNZAJGQK-UHFFFAOYSA-N 0.000 description 1
- HZZDWLBBNSDYQM-UHFFFAOYSA-N ethyl 4,4-difluorocyclohexane-1-carboxylate Chemical compound CCOC(=O)C1CCC(F)(F)CC1 HZZDWLBBNSDYQM-UHFFFAOYSA-N 0.000 description 1
- FQRRSJYWLVWURY-UHFFFAOYSA-N ethyl 5-[2-[4-[4-(4,4-difluorocyclohexyl)-3-[fluoro-[4-(trifluoromethyl)phenyl]methyl]-5-hydroxy-7,7-dimethyl-6,8-dihydro-5h-quinolin-2-yl]piperidin-1-yl]pyrimidin-5-yl]oxypentanoate Chemical compound N1=CC(OCCCCC(=O)OCC)=CN=C1N1CCC(C=2C(=C(C3CCC(F)(F)CC3)C=3C(O)CC(C)(C)CC=3N=2)C(F)C=2C=CC(=CC=2)C(F)(F)F)CC1 FQRRSJYWLVWURY-UHFFFAOYSA-N 0.000 description 1
- AFRWBGJRWRHQOV-UHFFFAOYSA-N ethyl 5-bromopentanoate Chemical compound CCOC(=O)CCCCBr AFRWBGJRWRHQOV-UHFFFAOYSA-N 0.000 description 1
- 229940093499 ethyl acetate Drugs 0.000 description 1
- 125000006534 ethyl amino methyl group Chemical group [H]N(C([H])([H])*)C([H])([H])C([H])([H])[H] 0.000 description 1
- PQJJJMRNHATNKG-UHFFFAOYSA-N ethyl bromoacetate Chemical compound CCOC(=O)CBr PQJJJMRNHATNKG-UHFFFAOYSA-N 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 125000006260 ethylaminocarbonyl group Chemical group [H]N(C(*)=O)C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 125000005817 fluorobutyl group Chemical group [H]C([H])(F)C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000003784 fluoroethyl group Chemical group [H]C([H])(F)C([H])([H])* 0.000 description 1
- 125000004785 fluoromethoxy group Chemical group [H]C([H])(F)O* 0.000 description 1
- 125000004216 fluoromethyl group Chemical group [H]C([H])(F)* 0.000 description 1
- 125000005816 fluoropropyl group Chemical group [H]C([H])(F)C([H])([H])C([H])([H])* 0.000 description 1
- 238000005187 foaming Methods 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 125000002541 furyl group Chemical group 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 150000002301 glucosamine derivatives Chemical class 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 150000002306 glutamic acid derivatives Chemical class 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 150000002332 glycine derivatives Chemical class 0.000 description 1
- 150000002334 glycols Chemical class 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 150000002357 guanidines Chemical class 0.000 description 1
- 125000005842 heteroatom Chemical group 0.000 description 1
- FUZZWVXGSFPDMH-UHFFFAOYSA-N hexanoic acid Chemical compound CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 1
- 125000006038 hexenyl group Chemical group 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001245 hexylamino group Chemical group [H]N([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C(C([H])([H])[H])([H])[H] 0.000 description 1
- 125000003707 hexyloxy group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])O* 0.000 description 1
- 125000005935 hexyloxycarbonyl group Chemical group 0.000 description 1
- 125000005980 hexynyl group Chemical group 0.000 description 1
- 102000052454 human CETP Human genes 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 1
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- 229940071870 hydroiodic acid Drugs 0.000 description 1
- RCBVKBFIWMOMHF-UHFFFAOYSA-L hydroxy-(hydroxy(dioxo)chromio)oxy-dioxochromium;pyridine Chemical compound C1=CC=NC=C1.C1=CC=NC=C1.O[Cr](=O)(=O)O[Cr](O)(=O)=O RCBVKBFIWMOMHF-UHFFFAOYSA-L 0.000 description 1
- NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 1
- 239000005457 ice water Substances 0.000 description 1
- 239000012216 imaging agent Substances 0.000 description 1
- 125000002632 imidazolidinyl group Chemical group 0.000 description 1
- 125000002883 imidazolyl group Chemical group 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 239000002198 insoluble material Substances 0.000 description 1
- XMBWDFGMSWQBCA-YPZZEJLDSA-N iodane Chemical compound [125IH] XMBWDFGMSWQBCA-YPZZEJLDSA-N 0.000 description 1
- 229940044173 iodine-125 Drugs 0.000 description 1
- 150000002505 iron Chemical class 0.000 description 1
- 125000002510 isobutoxy group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])O* 0.000 description 1
- LRDFRRGEGBBSRN-UHFFFAOYSA-N isobutyronitrile Chemical compound CC(C)C#N LRDFRRGEGBBSRN-UHFFFAOYSA-N 0.000 description 1
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- JMMWKPVZQRWMSS-UHFFFAOYSA-N isopropanol acetate Natural products CC(C)OC(C)=O JMMWKPVZQRWMSS-UHFFFAOYSA-N 0.000 description 1
- 229940011051 isopropyl acetate Drugs 0.000 description 1
- FMKOJHQHASLBPH-UHFFFAOYSA-N isopropyl iodide Chemical compound CC(C)I FMKOJHQHASLBPH-UHFFFAOYSA-N 0.000 description 1
- 125000001786 isothiazolyl group Chemical group 0.000 description 1
- GWYFCOCPABKNJV-UHFFFAOYSA-N isovaleric acid Chemical compound CC(C)CC(O)=O GWYFCOCPABKNJV-UHFFFAOYSA-N 0.000 description 1
- 125000000842 isoxazolyl group Chemical group 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- AFRJJFRNGGLMDW-UHFFFAOYSA-N lithium amide Chemical compound [Li+].[NH2-] AFRJJFRNGGLMDW-UHFFFAOYSA-N 0.000 description 1
- YNESATAKKCNGOF-UHFFFAOYSA-N lithium bis(trimethylsilyl)amide Chemical compound [Li+].C[Si](C)(C)[N-][Si](C)(C)C YNESATAKKCNGOF-UHFFFAOYSA-N 0.000 description 1
- XGZVUEUWXADBQD-UHFFFAOYSA-L lithium carbonate Chemical compound [Li+].[Li+].[O-]C([O-])=O XGZVUEUWXADBQD-UHFFFAOYSA-L 0.000 description 1
- 229910052808 lithium carbonate Inorganic materials 0.000 description 1
- 229910000103 lithium hydride Inorganic materials 0.000 description 1
- 229910000032 lithium hydrogen carbonate Inorganic materials 0.000 description 1
- JILPJDVXYVTZDQ-UHFFFAOYSA-N lithium methoxide Chemical compound [Li+].[O-]C JILPJDVXYVTZDQ-UHFFFAOYSA-N 0.000 description 1
- 229910003002 lithium salt Inorganic materials 0.000 description 1
- 159000000002 lithium salts Chemical class 0.000 description 1
- UBJFKNSINUCEAL-UHFFFAOYSA-N lithium;2-methylpropane Chemical compound [Li+].C[C-](C)C UBJFKNSINUCEAL-UHFFFAOYSA-N 0.000 description 1
- WGOPGODQLGJZGL-UHFFFAOYSA-N lithium;butane Chemical compound [Li+].CC[CH-]C WGOPGODQLGJZGL-UHFFFAOYSA-N 0.000 description 1
- PZEHLGURHZERFE-UHFFFAOYSA-N lithium;di(propan-2-yl)azanide;heptane Chemical compound [Li+].CCCCCCC.CC(C)[N-]C(C)C PZEHLGURHZERFE-UHFFFAOYSA-N 0.000 description 1
- HQRPHMAXFVUBJX-UHFFFAOYSA-M lithium;hydrogen carbonate Chemical compound [Li+].OC([O-])=O HQRPHMAXFVUBJX-UHFFFAOYSA-M 0.000 description 1
- 159000000003 magnesium salts Chemical class 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- LULAYUGMBFYYEX-UHFFFAOYSA-N metachloroperbenzoic acid Natural products OC(=O)C1=CC=CC(Cl)=C1 LULAYUGMBFYYEX-UHFFFAOYSA-N 0.000 description 1
- CEAJFNBWKBTRQE-UHFFFAOYSA-N methanamine;methanol Chemical compound NC.OC CEAJFNBWKBTRQE-UHFFFAOYSA-N 0.000 description 1
- 125000005948 methanesulfonyloxy group Chemical group 0.000 description 1
- AWUPLMYXZJKHEG-UHFFFAOYSA-N methyl 2-chloro-2,2-difluoroacetate Chemical compound COC(=O)C(F)(F)Cl AWUPLMYXZJKHEG-UHFFFAOYSA-N 0.000 description 1
- XTOZFAQLXCWMMZ-UHFFFAOYSA-N methyl 3-[2-[4-[4-(4,4-difluorocyclohexyl)-3-[fluoro-[4-(trifluoromethyl)phenyl]methyl]-5-hydroxy-7,7-dimethyl-6,8-dihydro-5h-quinolin-2-yl]piperidin-1-yl]pyrimidin-5-yl]benzoate Chemical compound COC(=O)C1=CC=CC(C=2C=NC(=NC=2)N2CCC(CC2)C=2C(=C(C3CCC(F)(F)CC3)C=3C(O)CC(C)(C)CC=3N=2)C(F)C=2C=CC(=CC=2)C(F)(F)F)=C1 XTOZFAQLXCWMMZ-UHFFFAOYSA-N 0.000 description 1
- GEYAXBDOJSOODP-UHFFFAOYSA-N methyl 5-(2-chloropyrimidin-5-yl)pent-4-ynoate Chemical compound COC(=O)CCC#CC1=CN=C(Cl)N=C1 GEYAXBDOJSOODP-UHFFFAOYSA-N 0.000 description 1
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- WCSNOLUUFIWIHY-UHFFFAOYSA-N methyl pent-4-ynoate Chemical compound COC(=O)CCC#C WCSNOLUUFIWIHY-UHFFFAOYSA-N 0.000 description 1
- 229960002216 methylparaben Drugs 0.000 description 1
- 125000002816 methylsulfanyl group Chemical group [H]C([H])([H])S[*] 0.000 description 1
- 125000006216 methylsulfinyl group Chemical group [H]C([H])([H])S(*)=O 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 239000012046 mixed solvent Substances 0.000 description 1
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 description 1
- 150000002780 morpholines Chemical class 0.000 description 1
- AEXITZJSLGALNH-UHFFFAOYSA-N n'-hydroxyethanimidamide Chemical compound CC(N)=NO AEXITZJSLGALNH-UHFFFAOYSA-N 0.000 description 1
- YKYONYBAUNKHLG-UHFFFAOYSA-N n-Propyl acetate Natural products CCCOC(C)=O YKYONYBAUNKHLG-UHFFFAOYSA-N 0.000 description 1
- 125000001280 n-hexyl group Chemical group C(CCCCC)* 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- PSZYNBSKGUBXEH-UHFFFAOYSA-M naphthalene-1-sulfonate Chemical compound C1=CC=C2C(S(=O)(=O)[O-])=CC=CC2=C1 PSZYNBSKGUBXEH-UHFFFAOYSA-M 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 239000002736 nonionic surfactant Substances 0.000 description 1
- 230000000414 obstructive effect Effects 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 125000001181 organosilyl group Chemical group [SiH3]* 0.000 description 1
- 125000000160 oxazolidinyl group Chemical group 0.000 description 1
- 125000002971 oxazolyl group Chemical group 0.000 description 1
- PIBWKRNGBLPSSY-UHFFFAOYSA-L palladium(II) chloride Chemical compound Cl[Pd]Cl PIBWKRNGBLPSSY-UHFFFAOYSA-L 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 125000006340 pentafluoro ethyl group Chemical group FC(F)(F)C(F)(F)* 0.000 description 1
- 125000003538 pentan-3-yl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000002255 pentenyl group Chemical group C(=CCCC)* 0.000 description 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
- 125000001148 pentyloxycarbonyl group Chemical group 0.000 description 1
- 125000005981 pentynyl group Chemical group 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 238000005502 peroxidation Methods 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- XNGIFLGASWRNHJ-UHFFFAOYSA-L phthalate(2-) Chemical compound [O-]C(=O)C1=CC=CC=C1C([O-])=O XNGIFLGASWRNHJ-UHFFFAOYSA-L 0.000 description 1
- 150000004885 piperazines Chemical class 0.000 description 1
- HDOWRFHMPULYOA-UHFFFAOYSA-N piperidin-4-ol Chemical compound OC1CCNCC1 HDOWRFHMPULYOA-UHFFFAOYSA-N 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 description 1
- 229910000028 potassium bicarbonate Inorganic materials 0.000 description 1
- 235000015497 potassium bicarbonate Nutrition 0.000 description 1
- 239000011736 potassium bicarbonate Substances 0.000 description 1
- 229910000105 potassium hydride Inorganic materials 0.000 description 1
- NTTOTNSKUYCDAV-UHFFFAOYSA-N potassium hydride Chemical compound [KH] NTTOTNSKUYCDAV-UHFFFAOYSA-N 0.000 description 1
- 229940086066 potassium hydrogencarbonate Drugs 0.000 description 1
- 239000012286 potassium permanganate Substances 0.000 description 1
- LPNYRYFBWFDTMA-UHFFFAOYSA-N potassium tert-butoxide Chemical compound [K+].CC(C)(C)[O-] LPNYRYFBWFDTMA-UHFFFAOYSA-N 0.000 description 1
- 239000000651 prodrug Substances 0.000 description 1
- 229940002612 prodrug Drugs 0.000 description 1
- DRINJBFRTLBHNF-UHFFFAOYSA-N propane-2-sulfonyl chloride Chemical compound CC(C)S(Cl)(=O)=O DRINJBFRTLBHNF-UHFFFAOYSA-N 0.000 description 1
- 125000004368 propenyl group Chemical group C(=CC)* 0.000 description 1
- FVSKHRXBFJPNKK-UHFFFAOYSA-N propionitrile Chemical compound CCC#N FVSKHRXBFJPNKK-UHFFFAOYSA-N 0.000 description 1
- 125000005767 propoxymethyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])[#8]C([H])([H])* 0.000 description 1
- 229940090181 propyl acetate Drugs 0.000 description 1
- 125000006308 propyl amino group Chemical group 0.000 description 1
- QQONPFPTGQHPMA-UHFFFAOYSA-N propylene Natural products CC=C QQONPFPTGQHPMA-UHFFFAOYSA-N 0.000 description 1
- 125000004805 propylene group Chemical group [H]C([H])([H])C([H])([*:1])C([H])([H])[*:2] 0.000 description 1
- 125000004742 propyloxycarbonyl group Chemical group 0.000 description 1
- 125000002568 propynyl group Chemical group [*]C#CC([H])([H])[H] 0.000 description 1
- 235000019423 pullulan Nutrition 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 125000004309 pyranyl group Chemical group O1C(C=CC=C1)* 0.000 description 1
- 125000003373 pyrazinyl group Chemical group 0.000 description 1
- 125000003072 pyrazolidinyl group Chemical group 0.000 description 1
- 125000003226 pyrazolyl group Chemical group 0.000 description 1
- 125000002098 pyridazinyl group Chemical group 0.000 description 1
- FREJAOSUHFGDBW-UHFFFAOYSA-N pyrimidine-5-carbaldehyde Chemical compound O=CC1=CN=CN=C1 FREJAOSUHFGDBW-UHFFFAOYSA-N 0.000 description 1
- 125000000168 pyrrolyl group Chemical group 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 238000006268 reductive amination reaction Methods 0.000 description 1
- 238000001226 reprecipitation Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 150000004760 silicates Chemical class 0.000 description 1
- RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 229910001961 silver nitrate Inorganic materials 0.000 description 1
- 230000000391 smoking effect Effects 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- ODZPKZBBUMBTMG-UHFFFAOYSA-N sodium amide Chemical compound [NH2-].[Na+] ODZPKZBBUMBTMG-UHFFFAOYSA-N 0.000 description 1
- WRIKHQLVHPKCJU-UHFFFAOYSA-N sodium bis(trimethylsilyl)amide Chemical compound C[Si](C)(C)N([Na])[Si](C)(C)C WRIKHQLVHPKCJU-UHFFFAOYSA-N 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- NRHMKIHPTBHXPF-TUJRSCDTSA-M sodium cholate Chemical compound [Na+].C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC([O-])=O)C)[C@@]2(C)[C@@H](O)C1 NRHMKIHPTBHXPF-TUJRSCDTSA-M 0.000 description 1
- BEOOHQFXGBMRKU-UHFFFAOYSA-N sodium cyanoborohydride Chemical compound [Na+].[B-]C#N BEOOHQFXGBMRKU-UHFFFAOYSA-N 0.000 description 1
- QDRKDTQENPPHOJ-UHFFFAOYSA-N sodium ethoxide Chemical compound [Na+].CC[O-] QDRKDTQENPPHOJ-UHFFFAOYSA-N 0.000 description 1
- SUKJFIGYRHOWBL-UHFFFAOYSA-N sodium hypochlorite Chemical compound [Na+].Cl[O-] SUKJFIGYRHOWBL-UHFFFAOYSA-N 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 229910052938 sodium sulfate Inorganic materials 0.000 description 1
- 235000011152 sodium sulphate Nutrition 0.000 description 1
- 235000010265 sodium sulphite Nutrition 0.000 description 1
- 239000012453 solvate Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- VNFWTIYUKDMAOP-UHFFFAOYSA-N sphos Chemical compound COC1=CC=CC(OC)=C1C1=CC=CC=C1P(C1CCCCC1)C1CCCCC1 VNFWTIYUKDMAOP-UHFFFAOYSA-N 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 125000000475 sulfinyl group Chemical group [*:2]S([*:1])=O 0.000 description 1
- HXJUTPCZVOIRIF-UHFFFAOYSA-N sulfolane Chemical compound O=S1(=O)CCCC1 HXJUTPCZVOIRIF-UHFFFAOYSA-N 0.000 description 1
- 150000003457 sulfones Chemical class 0.000 description 1
- 150000003467 sulfuric acid derivatives Chemical class 0.000 description 1
- YBBRCQOCSYXUOC-UHFFFAOYSA-N sulfuryl dichloride Chemical compound ClS(Cl)(=O)=O YBBRCQOCSYXUOC-UHFFFAOYSA-N 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- UWKHZHFDKODMEC-UHFFFAOYSA-N tert-butyl 4-(1-amino-2-cyanoethenyl)piperidine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCC(C(N)=CC#N)CC1 UWKHZHFDKODMEC-UHFFFAOYSA-N 0.000 description 1
- UQADQTBQNVARAP-UHFFFAOYSA-N tert-butyl 4-cyanopiperidine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCC(C#N)CC1 UQADQTBQNVARAP-UHFFFAOYSA-N 0.000 description 1
- QKSQWQOAUQFORH-UHFFFAOYSA-N tert-butyl n-[(2-methylpropan-2-yl)oxycarbonylimino]carbamate Chemical compound CC(C)(C)OC(=O)N=NC(=O)OC(C)(C)C QKSQWQOAUQFORH-UHFFFAOYSA-N 0.000 description 1
- QCIWZIYBBNEPKB-UHFFFAOYSA-N tert-butyl(dimethyl)silane Chemical compound C[SiH](C)C(C)(C)C QCIWZIYBBNEPKB-UHFFFAOYSA-N 0.000 description 1
- 125000001981 tert-butyldimethylsilyl group Chemical group [H]C([H])([H])[Si]([H])(C([H])([H])[H])[*]C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- DZLFLBLQUQXARW-UHFFFAOYSA-N tetrabutylammonium Chemical compound CCCC[N+](CCCC)(CCCC)CCCC DZLFLBLQUQXARW-UHFFFAOYSA-N 0.000 description 1
- 125000001412 tetrahydropyranyl group Chemical group 0.000 description 1
- 125000000147 tetrahydroquinolinyl group Chemical group N1(CCCC2=CC=CC=C12)* 0.000 description 1
- 125000004632 tetrahydrothiopyranyl group Chemical group S1C(CCCC1)* 0.000 description 1
- QEMXHQIAXOOASZ-UHFFFAOYSA-N tetramethylammonium Chemical class C[N+](C)(C)C QEMXHQIAXOOASZ-UHFFFAOYSA-N 0.000 description 1
- 125000003831 tetrazolyl group Chemical group 0.000 description 1
- 125000001113 thiadiazolyl group Chemical group 0.000 description 1
- 125000001984 thiazolidinyl group Chemical group 0.000 description 1
- 125000000335 thiazolyl group Chemical group 0.000 description 1
- 125000001544 thienyl group Chemical group 0.000 description 1
- RTKIYNMVFMVABJ-UHFFFAOYSA-L thimerosal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 description 1
- 229940033663 thimerosal Drugs 0.000 description 1
- 239000010409 thin film Substances 0.000 description 1
- 238000004809 thin layer chromatography Methods 0.000 description 1
- 125000003396 thiol group Chemical class [H]S* 0.000 description 1
- 125000005503 thioxanyl group Chemical group 0.000 description 1
- BWHOZHOGCMHOBV-BQYQJAHWSA-N trans-benzylideneacetone Chemical compound CC(=O)\C=C\C1=CC=CC=C1 BWHOZHOGCMHOBV-BQYQJAHWSA-N 0.000 description 1
- 238000011830 transgenic mouse model Methods 0.000 description 1
- 125000001425 triazolyl group Chemical group 0.000 description 1
- IMFACGCPASFAPR-UHFFFAOYSA-N tributylamine Chemical compound CCCCN(CCCC)CCCC IMFACGCPASFAPR-UHFFFAOYSA-N 0.000 description 1
- 125000006000 trichloroethyl group Chemical group 0.000 description 1
- 125000003866 trichloromethyl group Chemical group ClC(Cl)(Cl)* 0.000 description 1
- ITMCEJHCFYSIIV-UHFFFAOYSA-N triflic acid Chemical compound OS(=O)(=O)C(F)(F)F ITMCEJHCFYSIIV-UHFFFAOYSA-N 0.000 description 1
- 125000004205 trifluoroethyl group Chemical group [H]C([H])(*)C(F)(F)F 0.000 description 1
- 125000005951 trifluoromethanesulfonyloxy group Chemical group 0.000 description 1
- OILVALOYRFDGPW-UHFFFAOYSA-M triphenyl(3,3,3-trifluoropropyl)phosphanium;iodide Chemical compound [I-].C=1C=CC=CC=1[P+](C=1C=CC=CC=1)(CCC(F)(F)F)C1=CC=CC=C1 OILVALOYRFDGPW-UHFFFAOYSA-M 0.000 description 1
- 229910000404 tripotassium phosphate Inorganic materials 0.000 description 1
- 235000019798 tripotassium phosphate Nutrition 0.000 description 1
- 125000005455 trithianyl group Chemical group 0.000 description 1
- 238000005292 vacuum distillation Methods 0.000 description 1
- NQPDZGIKBAWPEJ-UHFFFAOYSA-N valeric acid Chemical compound CCCCC(O)=O NQPDZGIKBAWPEJ-UHFFFAOYSA-N 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- 238000010792 warming Methods 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- 239000008096 xylene Substances 0.000 description 1
- 150000003751 zinc Chemical class 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/541—Non-condensed thiazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
- C07F7/02—Silicon compounds
- C07F7/08—Compounds having one or more C—Si linkages
- C07F7/18—Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
- C07F7/1804—Compounds having Si-O-C linkages
Definitions
- the present invention has excellent CETP inhibitory activity and is useful as a medicament (particularly, a medicament for the treatment or prevention of dyslipidemia, low HDL cholesterolemia, arteriosclerosis, or coronary heart disease).
- the present invention relates to a novel substituted pyridine compound or a pharmacologically acceptable salt thereof.
- Serum lipoprotein levels are associated with diseases such as dyslipidemia and arteriosclerosis, as shown in many epidemiological studies (eg, Badimon, J.Clin.Invest., 1990, 85, pp. 1234-1241).
- LDL low density lipoprotein
- HDL high density lipoprotein
- CETP cholesteryl ester transfer protein
- pyridine compounds having CETP inhibitory activity are known (see, for example, Patent Documents 1 to 8).
- pyrimidinyl piperidine compounds having CETP inhibitory activity are known (see, for example, Patent Documents 9 to 13).
- JP-A-10-067746 (corresponding US patent: US Pat. No. 6,069,148, US Pat. No. 6,207,671) JP-T-2001-516757 (corresponding US patent: US Pat. No. 6,387,929) JP 2001-517655 (corresponding US patent: US Pat. No. 6,291,477, US Pat. No. 6,562,976, US Pat. No. 6,897,317) JP 2005-508341 A (corresponding US application: US Patent Application Publication 2005/0043341) Japanese Patent Laid-Open No. 10-167967 (corresponding US patent: US Pat. No.
- JP 2008-524145 A (corresponding US application: US Patent Application Publication 2008/0255068) JP 2008-524137 A (corresponding US application: US Patent Application Publication 2008/0194609) International Publication 2009/109549 JP 2009-516649 A (corresponding US application: US Patent Application Publication 2009/0264405) International Publication 2008/156715 JP 2009-524579 A (corresponding US application: US Patent Application Publication 2009/0023729) International Publication 2008/009435 (Corresponding US Application: US Patent Application Publication 2009/0286790) International Publication 2009/071509
- the present inventors have studied novel substituted pyridine compounds with the aim of developing excellent CETP inhibitors, and substituted pyridine compounds having a specific structure or pharmacologically acceptable salts thereof have excellent CETP inhibitory activity. And is useful as a medicament (particularly, a medicament for the treatment or prevention of dyslipidemia, low HDL cholesterolemia, arteriosclerosis, or coronary heart disease).
- the present invention has been completed based on the above findings.
- the present invention relates to a novel substituted pyridine compound having excellent CETP inhibitory activity or a pharmacologically acceptable salt thereof;
- R 1 represents a hydrogen atom, a C 1 -C 6 alkyl group, a hydroxy (C 1 -C 6 alkyl) group, a (C 1 -C 6 alkoxy)-(C 1 -C 6 alkyl) group, a hydroxy group, (C 1 -C 6 alkoxy)-(C 1 -C 6 alkyl) group, (C 1 -C 6 alkyl) amino- (C 1 -C 6 alkyl) group, hydroxy (C 1 -C 6 alkyl) amino- (C 1 -C 6 alkyl) group, [N- (C 1 -C 6 alkyl) -N-hydroxy (C 1 -C 6 alkyl) amino]-(C 1 -C 6 alkyl) group, (C 1- C 6 alkyl) sulfonylamino- (C 1 -C 6 alkyl) group, [N- (C 1 -C 6 alkyl) -N- (C 1 -(C
- R 1 is a hydrogen atom, a C 1 -C 6 alkyl group, a hydroxy (C 1 -C 6 alkyl) group, a (C 1 -C 6 alkoxy)-(C 1 -C 6 alkyl) group, (C 1- C 6 alkyl) amino- (C 1 -C 6 alkyl) group, [N- (C 1 -C 6 alkyl) -N-hydroxy (C 1 -C 6 alkyl) amino]-(C 1 -C 6 Alkyl) group, [N- (C 1 -C 6 alkyl) -N- (C 1 -C 6 alkyl) sulfonylamino]-(C 1 -C 6 alkyl) group, carboxy (C 1 -C 6 alkyl) group Halogeno (C 1 -C 6 alkyl) group, C 2 -C 6 alkenyl group, C 3 -C
- R 1 is a hydrogen atom, a C 1 -C 4 alkyl group, a hydroxy (C 1 -C 4 alkyl) group, a (C 1 -C 4 alkoxy)-(C 1 -C 4 alkyl) group, a halogeno ( (C 1 -C 4 alkyl) group, C 1 -C 4 alkoxy group, hydroxy (C 1 -C 6 alkoxy) group, or (C 1 -C 4 alkyl) sulfonyl- (C 1 -C 4 alkoxy) group
- R 1 is a C 1 -C 4 alkyl group, a halogeno (C 1 -C 4 alkyl) group, a C 1 -C 4 alkoxy group, or a hydroxy (C 1 -C 6 alkoxy) group, 2A) or a pharmacologically acceptable salt thereof.
- R 1 is a substituted phenyl group (the substituent is independently 1 to 4 groups selected from the substituent group ⁇ 1), a substituted 5- or 6-membered aromatic heterocyclyl group (the substituent Represents 1 to 4 groups independently selected from the substituent group ⁇ 1), a 5- or 6-membered saturated heterocyclyl group, a substituted 5- or 6-membered saturated heterocyclyl group (the substituent is independently a substituent) 1 to 4 groups selected from group ⁇ 1), substituted 5 or 6-membered saturated heterocyclyloxy group (the substituents independently represent 1 to 4 groups selected from substituent group ⁇ 1) Or a 5- or 6-membered saturated heterocyclylcarbonyl group,
- the substituent group ⁇ 1 represents the group consisting of a C 1 -C 6 alkyl group, a hydroxy group, a carboxy group, and an oxo group, or the pharmacologically acceptable salt thereof described in (2A).
- R 1 is a 5- or 6-membered nitrogen-containing saturated heterocyclyl group, a substituted 5- or 6-membered nitrogen-containing saturated heterocyclyl group (the substituent is independently 1 to 4 groups selected from the substituent group ⁇ 2) A substituted 5- or 6-membered nitrogen-containing saturated heterocyclyloxy group (the substituent is independently 1 to 4 groups selected from the substituent group ⁇ 2), or a 5- or 6-membered nitrogen-containing group A saturated heterocyclylcarbonyl group,
- the substituent group ⁇ 2 is a compound described in (2A) or a pharmacologically acceptable salt thereof, which represents a group consisting of a C 1 -C 4 alkyl group and a hydroxy group.
- R 1 is a substituted pyrrolidinyl group, a substituted piperazyl group, a substituted pyrrolidinyloxy group, or a substituted piperidyloxy group (the pyrrolidinyl group, piperazil group, pyrrolidinyloxy group, and a piperidyloxy group substituent)
- the substituent group ⁇ 3 is a compound described in (2A) or a pharmacologically acceptable salt thereof, which represents a group consisting of a methyl group and a hydroxy group.
- (16A) A pharmaceutical composition comprising as an active ingredient the compound described in any of (1A) to (15A) or a pharmacologically acceptable salt thereof.
- 21A The pharmaceutical composition described in (16A) for treatment or prevention of a disease caused by a decrease in blood concentration of HDL cholesterol.
- 22A The pharmaceutical composition described in (16) for the treatment or prevention of a disease caused by an increase in the blood concentration of LDL cholesterol.
- 23A A CETP inhibitor comprising the compound described in any one of (1A) to (15A) or a pharmacologically acceptable salt thereof as an active ingredient.
- a HDL cholesterol concentration increasing agent comprising as an active ingredient the compound described in any of (1A) to (15A) or a pharmacologically acceptable salt thereof.
- (28A) Use according to (26A) for the manufacture of a pharmaceutical composition for the treatment or prevention of dyslipidemia, low HDL cholesterolemia, arteriosclerosis or coronary heart disease.
- (29A) Use according to (26A) for the manufacture of a pharmaceutical composition for the treatment or prevention of low HDL cholesterolemia.
- (30A) Use according to (26A) for the manufacture of a pharmaceutical composition for the treatment or prevention of arteriosclerosis.
- the disease is dyslipidemia, hypercholesterolemia, low HDL cholesterolemia, high LDL cholesterolemia, hypertriglyceridemia, arteriosclerosis, arteriosclerotic heart disease, coronary heart disease, The compound or a pharmacologically acceptable salt thereof according to (31A), which is a cerebrovascular disease, a peripheral vascular disease, or obesity.
- the compound according to (31A) or a pharmacologically acceptable salt thereof, wherein the disease is hypoHDL cholesterolemia.
- (35A) The compound according to (31A) or a pharmacologically acceptable salt thereof, wherein the disease is arteriosclerosis.
- (36A) A method for treating or preventing a disease by administering to a warm-blooded animal a pharmacologically effective amount of the compound described in any of (1A) to (15A) or a pharmacologically acceptable salt thereof. .
- (37A) The disease is dyslipidemia, hypercholesterolemia, low HDL cholesterolemia, high LDL cholesterolemia, hypertriglyceridemia, arteriosclerosis, arteriosclerotic heart disease, coronary heart disease, The method according to (36A), which is cerebrovascular disease, peripheral vascular disease, or obesity.
- R 1 represents a hydrogen atom, a C 1 -C 6 alkyl group, a hydroxy (C 1 -C 6 alkyl) group, a (C 1 -C 6 alkoxy)-(C 1 -C 6 alkyl) group, a hydroxy group, (C 1 -C 6 alkoxy)-(C 1 -C 6 alkyl) group, (C 1 -C 6 alkyl) amino- (C 1 -C 6 alkyl) group, hydroxy (C 1 -C 6 alkyl) amino- (C 1 -C 6 alkyl) group, [N- (C 1 -C 6 alkyl) -N-hydroxy (C 1 -C 6 alkyl) amino]-(C 1 -C 6 alkyl) group, (C 1- C 6 alkyl) sulfonylamino- (C 1 -C 6 alkyl) group, [N- (C 1 -C 6 alkyl) -N- (C 1 -(C
- R 1 is a hydrogen atom, a C 1 -C 6 alkyl group, a hydroxy (C 1 -C 6 alkyl) group, a (C 1 -C 6 alkoxy)-(C 1 -C 6 alkyl) group, [N -(C 1 -C 6 alkyl) -N-hydroxy (C 1 -C 6 alkyl) amino]-(C 1 -C 6 alkyl) group, [N- (C 1 -C 6 alkyl) -N- (C 1- C 6 alkyl) sulfonylamino]-(C 1 -C 6 alkyl) group, carboxy (C 1 -C 6 alkyl) group, halogeno (C 1 -C 6 alkyl) group, C 2 -C 6 alkenyl group, C 3 -C 8 cycloalkyl group, C 3 -C 8 cycloalkenyl group, hydroxy group
- R 1 is a hydrogen atom, a C 1 -C 4 alkyl group, a hydroxy (C 1 -C 4 alkyl) group, a (C 1 -C 4 alkoxy)-(C 1 -C 4 alkyl) group, a halogeno ( (C 1 -C 4 alkyl) group, C 1 -C 4 alkoxy group, hydroxy (C 1 -C 6 alkoxy) group, or (C 1 -C 4 alkyl) sulfonyl- (C 1 -C 4 alkoxy) group
- R 1 is a C 1 -C 4 alkyl group, a halogeno (C 1 -C 4 alkyl) group, a C 1 -C 4 alkoxy group, or a hydroxy (C 1 -C 6 alkoxy) group, The compound described in 1) or a pharmacologically acceptable salt thereof.
- R 1 is a halogeno (C 1 -C 4 alkyl) group.
- R 1 is a substituted phenyl group (the substituent is independently 1 to 4 groups selected from the substituent group ⁇ 1), a substituted 5- or 6-membered aromatic heterocyclyl group (the substituent Represents 1 to 4 groups independently selected from the substituent group ⁇ 1), a 5- or 6-membered saturated heterocyclyl group, a substituted 5- or 6-membered saturated heterocyclyl group (the substituent is independently a substituent) 1 to 4 groups selected from group ⁇ 1), substituted 5 or 6-membered saturated heterocyclyloxy group (the substituents independently represent 1 to 4 groups selected from substituent group ⁇ 1) Or a 5- or 6-membered saturated heterocyclylcarbonyl group,
- the substituent group ⁇ 1 is a compound described in (1) or a pharmacologically acceptable salt thereof, which represents a group consisting of a C 1 -C 6 alkyl group, a hydroxy group, a carboxy group, and an oxo group.
- R 1 is a 5- or 6-membered nitrogen-containing saturated heterocyclyl group, a substituted 5- or 6-membered nitrogen-containing saturated heterocyclyl group (the substituent is independently 1 to 4 groups selected from the substituent group ⁇ 2) Or a substituted 5- or 6-membered nitrogen-containing saturated heterocyclyloxy group (the substituent independently represents 1 to 4 groups selected from the substituent group ⁇ 2),
- the substituent group ⁇ 2 is a compound described in (1) or a pharmacologically acceptable salt thereof, which represents a group consisting of a C 1 -C 4 alkyl group and a hydroxy group.
- R 1 is a substituted pyrrolidinyl group, a substituted piperidyl group, a substituted piperazyl group, a substituted thiomorpholinyl group, a substituted pyrrolidinyloxy group, or a substituted piperidyloxy group (the pyrrolidinyl group, piperidyl group, piperazyl group, thiomorpholinyl group, The pyrrolidinyloxy group and the substituent of the piperidyloxy group independently represent 1 to 2 groups selected from the substituent group ⁇ 3),
- the substituent group ⁇ 3 is a compound described in (1) or a pharmacologically acceptable salt thereof, which represents a group consisting of a methyl group and a hydroxy group.
- a pharmaceutical composition comprising the compound described in any one of (1) to (12) or a pharmacologically acceptable salt thereof as an active ingredient.
- Dyslipidemia, hypercholesterolemia, low HDL cholesterolemia, high LDL cholesterolemia, hypertriglyceridemia, arteriosclerosis, arteriosclerotic heart disease, coronary heart disease, cerebrovascular disease The pharmaceutical composition as described in (13) for treatment or prevention of peripheral vascular disease or obesity.
- a CETP inhibitor comprising as an active ingredient the compound described in any one of (1) to (12) or a pharmacologically acceptable salt thereof.
- An HDL cholesterol concentration increasing agent comprising the compound described in any of (1) to (12) or a pharmacologically acceptable salt thereof as an active ingredient.
- An LDL cholesterol concentration reducing agent comprising as an active ingredient the compound described in any one of (1) to (12) or a pharmacologically acceptable salt thereof.
- C 1 -C 6 alkyl refers to straight or branched chain alkyl having 1 to 6 carbon atoms, eg, methyl, ethyl, 1-propyl, 2-propyl, 1-butyl, 2- Butyl, 2-methyl-1-propyl, 2-methyl-2-propyl, 1-pentyl, 2-pentyl, 3-pentyl, 2-methyl-2-butyl, 3-methyl-2-butyl, 1-hexyl, 2-hexyl, 3-hexyl, 2-methyl-1-pentyl, 3-methyl-1-pentyl, 2-ethyl-1-butyl, 2,2-dimethyl-1-butyl, or 2,3-dimethyl- It can be 1-butyl.
- C 1 -C 6 alkyl in R 1 is preferably C 2 -C 5 alkyl, and most preferably 2-propyl, 1-pentyl, or 2-methyl-1-propyl.
- C 1 -C 6 alkyl in the substituent group ⁇ is preferably C 1 -C 4 alkyl, more preferably C 1 -C 2 alkyl, and most preferably methyl.
- “Hydroxy (C 1 -C 6 alkyl)” refers to the above C 1 -C 6 alkyl substituted with 1 to 4 hydroxy, such as hydroxymethyl, hydroxyethyl, hydroxypropyl, hydroxybutyl, hydroxypentyl, It can be hydroxyhexyl, dihydroxypropyl, dihydroxybutyl, dihydroxypentyl, dihydroxyhexyl, trihydroxybutyl, trihydroxypentyl, trihydroxyhexyl, tetrahydroxypentyl or tetrahydroxyhexyl, preferably hydroxy (C 1 -C 4 alkyl), more preferably hydroxy (C 1 -C 2 alkyl), and most preferably hydroxymethyl.
- (C 1 -C 6 alkoxy)-(C 1 -C 6 alkyl) refers to the above C 1 -C 6 alkyl substituted with one of the following C 1 -C 6 alkoxy, eg, methoxymethyl, It can be ethoxymethyl, propoxymethyl, butoxymethyl, pentyloxymethyl, hexyloxymethyl, methoxyethyl, methoxypropyl, methoxybutyl, methoxypentyl or methoxyhexyl, preferably (C 1 -C 4 alkoxy)- (C 1 -C 4 alkyl), more preferably (C 1 -C 4 alkoxy)-(C 1 -C 2 alkyl), most preferably methoxymethyl, ethoxymethyl, 2-propoxy Methyl or (2-methyl-1-propoxy) methyl.
- “Hydroxy (C 1 -C 6 alkoxy)-(C 1 -C 6 alkyl)” refers to the above C 1 -C 6 alkyl substituted with one of the following hydroxy (C 1 -C 6 alkoxy), for example Hydroxymethoxymethyl, hydroxyethoxymethyl, hydroxypropoxymethyl, hydroxybutoxymethyl, hydroxypentyloxymethyl, hydroxyhexyloxymethyl, hydroxyethoxyethyl, hydroxyethoxypropyl, hydroxyethoxybutyl, hydroxyethoxypentyl, or hydroxyethoxyhexyl And preferably hydroxy (C 1 -C 4 alkoxy)-(C 1 -C 4 alkyl), more preferably hydroxy (C 1 -C 2 alkoxy)-(C 1 -C 2 alkyl) It is.
- (C 1 -C 6 alkyl) amino- (C 1 -C 6 alkyl) refers to the above C 1 -C 6 alkyl substituted with one of the following (C 1 -C 6 alkyl) amino, for example , Methylaminomethyl, ethylaminomethyl, propylaminomethyl, butylaminomethyl, pentylaminomethyl, hexylaminomethyl, methylaminoethyl, methylaminopropyl, methylaminobutyl, methylaminopentyl, or methylaminohexyl; (C 1 -C 4 alkyl) amino- (C 1 -C 4 alkyl) is preferred, and (C 1 -C 2 alkyl) amino- (C 1 -C 2 alkyl) is more preferred. Most preferably, it is methylaminomethyl.
- “Hydroxy (C 1 -C 6 alkyl) amino- (C 1 -C 6 alkyl)” refers to the above C 1 -C 6 alkyl substituted with one of the following hydroxy (C 1 -C 6 alkyl) amino
- N— (C 1 -C 6 alkyl) -N-hydroxy (C 1 -C 6 alkyl) amino]-(C 1 -C 6 alkyl) represents one N— (C 1 -C 6 alkyl)
- the above C 1 -C 6 alkyl substituted with (alkyl) -N-hydroxy (C 1 -C 6 alkyl) amino such as (N-methyl-N-hydroxymethylamino) methyl, (N-methyl-N -Hydroxyethylamino) methyl, (N-methyl-N-hydroxypropylamino) methyl, (N-methyl-N-hydroxybutylamino) methyl, (N-methyl-N-hydroxypentylamino) methyl, (N-methyl) -N-hydroxyhexylamino) methyl, (N-methyl-N-hydroxyethylamino) ethyl, (N-methyl-N-hydroxyethylamino) propyl, (N-methyl
- (C 1 -C 6 alkyl) sulfonylamino- (C 1 -C 6 alkyl) is a group in which the C 1 -C 6 alkyl is substituted with one amino, and the amino is further substituted with one of the following C 1- Represents a group substituted with C 6 alkylsulfonyl, such as methanesulfonylaminomethyl, ethanesulfonylaminomethyl, propanesulfonylaminomethyl, butanesulfonylaminomethyl, pentanesulfonylaminomethyl, hexanesulfonylaminomethyl, methanesulfonylaminoethyl, methane May be sulfonylaminopropyl, methanesulfonylaminobutyl, methanesulfonylaminopentyl, or methanesulfonylaminohexyl, preferably (
- Carboxy (C 1 -C 6 alkyl) refers to the above C 1 -C 6 alkyl substituted with 1 or 2 carboxy, for example, carboxymethyl, carboxyethyl, carboxypropyl, carboxybutyl, carboxypentyl, It can be carboxyhexyl, dicarboxypropyl, dicarboxybutyl, dicarboxypentyl, or dicarboxyhexyl, preferably carboxy (C 1 -C 4 alkyl), more preferably carboxy (C 3- it is a C 4 alkyl), and most preferably a 4-carboxy-1-butyl.
- Halogeno (C 1 -C 6 alkyl) refers to the above C 1 -C 6 alkyl substituted with 1 to 7 of the following independently selected halogeno, eg, fluoromethyl, difluoromethyl, dichloromethyl , Dibromomethyl, trifluoromethyl, trichloromethyl, fluoroethyl, chloroethyl, bromoethyl, iodoethyl, difluoroethyl, trifluoroethyl, trichloroethyl, pentafluoroethyl, fluoropropyl, chloropropyl, fluorobutyl, trifluorobutyl, fluoropentyl, Or it may be fluorohexyl.
- halogeno eg, fluoromethyl, difluoromethyl, dichloromethyl , Dibromomethyl, trifluoromethyl, trichloromethyl, fluoroeth
- the halogeno (C 1 -C 6 alkyl) in R 1 is preferably halogeno (C 1 -C 4 alkyl) (wherein the halogeno is 1 to 5 groups selected from the group consisting of fluoro and chloro) More preferably halogeno (C 2 -C 4 alkyl) (wherein the halogeno is 1 to 5 fluoro), most preferably 4,4,4-trifluoro-1 -Butyl.
- the halogeno (C 1 -C 6 alkyl) in the substituent group ⁇ is preferably halogeno (C 1 -C 4 alkyl) (wherein the halogeno is 1 to 5 groups selected from the group consisting of fluoro and chloro) And more preferably halogeno (C 1 -C 2 alkyl) (wherein the halogeno is 1 to 5 fluoro).
- (C 3 -C 8 cycloalkyl)-(C 1 -C 6 alkyl) refers to the above C 1 -C 6 alkyl substituted with one of the following C 3 -C 8 cycloalkyl, eg, cyclo Propylmethyl, cyclobutylmethyl, cyclopentylmethyl, cyclohexylmethyl, cycloheptylmethyl, cyclooctylmethyl, cyclopropylethyl, cyclopropylpropyl, cyclopropylbutyl, cyclopropylpentyl, or cyclopropylhexyl, preferably (C 3 -C 6 cycloalkyl)-(C 1 -C 4 alkyl), more preferably (C 3 -C 4 cycloalkyl)-(C 1 -C 2 alkyl).
- C 2 -C 6 alkenyl refers to a straight or branched alkenyl having 2 to 6 carbon atoms and having one or more carbon-carbon double bonds, such as vinyl, propenyl (eg, Allyl), butenyl, pentenyl, or hexenyl, preferably C 2 -C 5 alkenyl, more preferably C 3 -C 5 alkenyl, most preferably 3-methyl -But-1-en-1-yl.
- C 2 -C 6 alkynyl refers to a straight or branched alkynyl having 2 to 6 carbon atoms and having one or more carbon-carbon triple bonds, such as ethynyl, propynyl, butynyl, It can be pentynyl or hexynyl, preferably C 3 -C 5 alkynyl.
- C 3 -C 8 cycloalkyl refers to a cyclic alkyl having 3 to 8 carbon atoms and may be, for example, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, or cyclooctyl, preferably , C 3 -C 6 cycloalkyl, more preferably C 3 -C 4 cycloalkyl, and most preferably cyclopropyl.
- C 3 -C 8 cycloalkenyl refers to cyclic alkenyl having 3 to 8 carbon atoms and having one or more carbon-carbon double bonds, for example, cyclopropenyl, cyclobutenyl, cyclopentenyl, cyclohexenyl , Cycloheptenyl, or cyclooctenyl, preferably C 4 -C 6 cycloalkenyl, and most preferably 1-cyclohexenyl.
- C 1 -C 6 alkoxy refers to hydroxy substituted with one of the above C 1 -C 6 alkyl and may be, for example, methoxy, ethoxy, propoxy, butoxy, pentyloxy, or hexyloxy.
- C 1 -C 6 alkoxy in R 1 is preferably methoxy, ethoxy, 2-propoxy, 2-methyl-1-propoxy or 3-methyl-1-butoxy.
- C 1 -C 6 alkoxy in the substituent group ⁇ is preferably C 1 -C 4 alkoxy, more preferably C 1 -C 2 alkoxy.
- “Hydroxy (C 1 -C 6 alkoxy)” refers to the above C 1 -C 6 alkoxy substituted with 1 to 4 hydroxy, such as hydroxymethoxy, hydroxyethoxy, hydroxypropoxy, hydroxybutoxy, hydroxypentyloxy Hydroxyhexyloxy, dihydroxypropoxy, dihydroxybutoxy, dihydroxypentyloxy, dihydroxyhexyloxy, trihydroxybutoxy, trihydroxypentyloxy, trihydroxyhexyloxy, tetrahydroxypentyloxy, or tetrahydroxyhexyloxy, preferably is hydroxy is (C 2 -C 6 alkoxy), and most preferably, 2-hydroxyethoxy, 3-hydroxy-1-propoxy, (2R)-2-hydroxy-1-propoxy (2S) -2-hydroxy-1-propoxy, (2R) -2,3-dihydroxy-1-propoxy, (2S) -2,3-dihydroxy-1-propoxy, 2-hydroxy-2-methyl-1 -Propoxy, 3-hydroxy-2
- (C 1 -C 6 alkoxy)-(C 1 -C 6 alkoxy) refers to the above C 1 -C 6 alkoxy substituted with one C 1 -C 6 alkoxy, for example, methoxymethoxy, It may be ethoxymethoxy, propoxymethoxy, butoxymethoxy, pentyloxymethoxy, hexyloxymethoxy, methoxyethoxy, methoxypropoxy, methoxybutoxy, methoxypentyloxy, or methoxyhexyloxy, preferably (C 1 -C 4 alkoxy )-(C 1 -C 4 alkoxy).
- (C 1 -C 6 alkyl) sulfonyl- (C 1 -C 6 alkoxy) refers to the above C 1 -C 6 alkoxy substituted with one of the following C 1 -C 6 alkylsulfonyl, eg, methane May be sulfonylmethoxy, ethanesulfonylmethoxy, propanesulfonylmethoxy, butanesulfonylmethoxy, pentanesulfonylmethoxy, hexanesulfonylmethoxy, methanesulfonylethoxy, methanesulfonylpropoxy, methanesulfonylbutoxy, methanesulfonylpentyloxy, or methanesulfonylhexyloxy, Preferred is (C 1 -C 4 alkyl) sulfonyl- (C 1 -C 4 alkoxy), more preferred
- Carboxy (C 1 -C 6 alkoxy) refers to the above C 1 -C 6 alkoxy substituted with 1 or 2 carboxy, eg, carboxymethoxy, carboxyethoxy, carboxypropoxy, carboxybutoxy, carboxypentyloxy , Carboxyhexyloxy, dicarboxypropoxy, dicarboxybutoxy, dicarboxypentyloxy, or dicarboxyhexyloxy, preferably carboxy (C 2 -C 5 alkoxy), more preferably carboxy (C 3 -C 4 alkoxy), most preferably 4-carboxy-1-butoxy.
- Halogeno (C 1 -C 6 alkoxy) refers to the above C 1 -C 6 alkoxy substituted with 1 to 7 of the following independently selected halogeno, for example, fluoromethoxy, difluoromethoxy, dichloromethoxy , Dibromomethoxy, trifluoromethoxy, trichloromethoxy, fluoroethoxy, chloroethoxy, bromoethoxy, iodoethoxy, difluoroethoxy, trifluoroethoxy, trichloroethoxy, pentafluoroethoxy, fluoropropoxy, chloropropoxy, fluorobutoxy, fluoropentyloxy, Or it may be fluorohexyloxy.
- the halogeno (C 1 -C 6 alkoxy) in R 1 is preferably halogeno (C 1 -C 4 alkoxy) (wherein the halogeno is 1 to 5 groups selected from the group consisting of fluoro and chloro) More preferably halogeno (C 1 -C 3 alkoxy) (wherein the halogeno is 1 to 5 fluoro), most preferably difluoromethoxy or 3,3,3 -Trifluoro-1-propoxy.
- the halogeno (C 1 -C 6 alkoxy) in the substituent group ⁇ is preferably halogeno (C 1 -C 4 alkoxy) (wherein the halogeno is 1 to 5 groups selected from the group consisting of fluoro and chloro) And more preferably halogeno (C 1 -C 2 alkoxy) (wherein the halogeno is 1 to 5 fluoro).
- C 1 -C 6 alkylthio refers to a mercapto (—SH) substituted with one of the above C 1 -C 6 alkyl, and may be, for example, methylthio, ethylthio, propylthio, butylthio, pentylthio, or hexylthio , Preferably C 1 -C 4 alkylthio, more preferably C 1 -C 2 alkylthio, and most preferably methylthio.
- C 1 -C 6 alkylsulfinyl refers to sulfinyl (—SO—) substituted with one of the above C 1 -C 6 alkyl, eg, methylsulfinyl, ethylsulfinyl, propylsulfinyl, butylsulfinyl, pentylsulfinyl Or hexylsulfinyl, preferably C 1 -C 4 alkylsulfinyl, more preferably C 1 -C 2 alkylsulfinyl.
- C 1 -C 6 alkylsulfonyl refers to a sulfonyl (—SO 2 —) substituted with one of the above C 1 -C 6 alkyl, eg, methanesulfonyl, ethanesulfonyl, propanesulfonyl, butanesulfonyl, pentane It may be sulfonyl or hexanesulfonyl, preferably C 1 -C 4 alkylsulfonyl, more preferably C 1 -C 2 alkylsulfonyl, and most preferably methanesulfonyl.
- C 1 -C 6 alkylamino refers to amino substituted with one of the above C 1 -C 6 alkyl, eg, methylamino, ethylamino, propylamino, butylamino, pentylamino, or hexylamino And is preferably C 1 -C 4 alkylamino, more preferably C 1 -C 2 alkylamino.
- Di (C 1 -C 6 alkyl) amino refers to an amino substituted with two independently selected C 1 -C 6 alkyls, for example, dimethylamino, ethylmethylamino, methylpropylamino , Butylmethylamino, methylpentylamino, hexylmethylamino, diethylamino, ethylpropylamino, butylethylamino, dipropylamino, butylpropylamino, dibutylamino, dipentylamino, or dihexylamino, preferably di (C 1 -C 4 alkyl) amino, more preferably di (C 1 -C 2 alkyl) amino.
- “Hydroxy (C 1 -C 6 alkyl) amino” refers to amino substituted with one of the above hydroxy (C 1 -C 6 alkyl), for example, hydroxymethylamino, hydroxyethylamino, hydroxypropylamino, hydroxy Butylamino, hydroxypentylamino, hydroxyhexylamino, dihydroxypropylamino, dihydroxybutylamino, dihydroxypentylamino, dihydroxyhexylamino, trihydroxybutylamino, trihydroxypentylamino, trihydroxyhexylamino, tetrahydroxypentylamino, or tetra It can be hydroxyhexylamino, preferably hydroxy (C 1 -C 4 alkyl) amino.
- N- (C 1 -C 6 alkyl) -N-hydroxy (C 1 -C 6 alkyl) amino means one hydroxy (C 1 -C 6 alkyl) and one C 1 -C 6 above.
- Amino substituted with alkyl eg N-methyl-N-hydroxymethylamino, N-methyl-N-hydroxyethylamino, N-methyl-N-hydroxypropylamino, N-methyl-N-hydroxybutylamino N-methyl-N-hydroxypentylamino, N-methyl-N-hydroxyhexylamino, N-ethyl-N-hydroxyethylamino, N-propyl-N-hydroxyethylamino, N-butyl-N-hydroxyethylamino , N- pentyl -N- hydroxyethylamino or, can be a N- hexyl -N- hydroxyethylamino, preferably, N- (C 1 - 4 al
- (C 1 -C 6 alkyl) carbonylamino refers to a group in which the carbon atom of carbonylamino (—CONH—) is substituted with one C 1 -C 6 alkyl as described above.
- Amino ethylcarbonylamino, propylcarbonylamino, butylcarbonylamino, pentylcarbonylamino, or hexylcarbonylamino, preferably (C 1 -C 4 alkyl) carbonylamino, more preferably (C 1 -C 2 alkyl) carbonylamino.
- (C 1 -C 6 alkoxy) carbonyl refers to carbonyl (—CO—) substituted with one of the above C 1 -C 6 alkoxy, for example, methoxycarbonyl, ethoxycarbonyl, propoxycarbonyl, butoxycarbonyl, It may be pentyloxycarbonyl or hexyloxycarbonyl, preferably (C 1 -C 4 alkoxy) carbonyl, more preferably (C 1 -C 2 alkoxy) carbonyl.
- (C 1 -C 6 alkoxy) carbonyl in the substituent group ⁇ is preferably (C 1 -C 4 alkoxy) carbonyl, more preferably (C 1 -C 2 alkoxy) carbonyl, most preferably Preferred is ethoxycarbonyl.
- (C 1 -C 6 alkylamino) carbonyl refers to carbonyl (—CO—) substituted with one of the above C 1 -C 6 alkylamino, for example, methylaminocarbonyl, ethylaminocarbonyl, propylamino Can be carbonyl, butylaminocarbonyl, pentylaminocarbonyl, or hexylaminocarbonyl, preferably (C 1 -C 4 alkylamino) carbonyl, more preferably (C 1 -C 2 alkylamino) Carbonyl, and most preferably methylaminocarbonyl.
- Di (C 1 -C 6 alkyl) aminocarbonyl refers to carbonyl (—CO—) substituted with one of the above di (C 1 -C 6 alkyl) amino, for example, dimethylaminocarbonyl, (N -Ethyl-N-methylamino) carbonyl, (N-methyl-N-propylamino) carbonyl, (N-butyl-N-methylamino) carbonyl, (N-methyl-N-pentylamino) carbonyl, (N-hexyl) -N-methylamino) carbonyl, diethylaminocarbonyl, dipropylaminocarbonyl, dibutylaminocarbonyl, dipentylaminocarbonyl, or dihexylaminocarbonyl, preferably di (C 1 -C 4 alkyl) aminocarbonyl , more preferably a di (C 1 -C 2 alkyl) aminocarbonyl, most preferably,
- Halogeno can be fluoro, chloro, bromo or iodo, preferably fluoro, chloro or bromo.
- “5- or 6-membered aromatic heterocyclyl” refers to a 5- or 6-membered aromatic heterocyclic group containing 1 to 4 atoms selected from the group consisting of a nitrogen atom, an oxygen atom, and a sulfur atom;
- “5- or 6-membered saturated heterocyclyl” refers to a 5- or 6-membered saturated heterocyclic group containing 1 to 3 atoms selected from the group consisting of a nitrogen atom, an oxygen atom, and a sulfur atom, for example, Pyrrolidinyl, imidazolidinyl, pyrazolidinyl, oxazolidinyl, thiazolidinyl, dioxolanyl, dithiolanyl, piperidinyl, tetrahydropyranyl, tetrahydrothiopyranyl, piperazinyl, morpholinyl, thiomorpholinyl, dioxanyl, thioxanyl, dithianyl, trioxanyl, or trithianyl, preferred 5- or 6-membered nitrogen-containing saturated heterocyclyl, and more preferably pyrrolidinyl, piperidinyl, piperazinyl, morpholinyl, or thiomorpholinyl.
- “5- or 6-membered saturated heterocyclyl- (C 1 -C 6 alkyl)” refers to the above C 1 -C 6 alkyl substituted with one of the above 5 or 6-membered saturated heterocyclyl, for example, pyrrolidinylmethyl, May be piperidinylmethyl, piperazinylmethyl, morpholinylmethyl, or thiomorpholinylmethyl, preferably 5 or 6-membered nitrogen-containing saturated heterocyclyl- (C 1 -C 4 alkyl); More preferred is 5- or 6-membered nitrogen-containing saturated heterocyclyl- (C 1 -C 2 alkyl).
- “5- or 6-membered saturated heterocyclyloxy” refers to hydroxy substituted with one of the above 5- or 6-membered saturated heterocyclyl, for example, pyrrolidinyloxy, piperidinyloxy, piperazinyloxy, morpholinyloxy Or thiomorpholinyloxy, preferably 5- or 6-membered nitrogen-containing saturated heterocyclyloxy, and more preferably pyrrolidinyloxy or piperidinyloxy.
- the heteroatom of the heterocyclyl moiety and the oxygen atom of the oxy moiety are not directly bonded.
- “5- or 6-membered saturated heterocyclylcarbonyl” refers to a carbonyl (—CO—) substituted with one of the above 5- or 6-membered saturated heterocyclyl, for example, pyrrolidinylcarbonyl, piperidinylcarbonyl, piperazinylcarbonyl , Morpholinylcarbonyl, or thiomorpholinylcarbonyl, preferably 5 or 6-membered nitrogen-containing saturated heterocyclylcarbonyl, and most preferably morpholinylcarbonyl.
- the nitrogen atom of the nitrogen-containing saturated heterocyclyl moiety is preferably bonded to the carbonyl moiety.
- the compound having the general formula (I) of the present invention or a pharmacologically acceptable salt thereof has one or more asymmetric centers, carbon-carbon double bonds, axial asymmetry, etc., optical isomers (enantiomers, and (Including diastereomers), geometric isomers, tautomers, and rotamers, and these isomers and mixtures thereof are described in a single formula such as formula (I)
- the present invention includes each of these isomers and mixtures thereof in any proportion (including racemates).
- the compound having the general formula (I) in the present invention is a compound having the formula (I-1), (I-2), (I-3) or (I-4), or a mixture thereof (racemate and Including a mixture of diastereomers, preferably a compound having the formula (I-1) or (I-2), or a mixture thereof (including a racemate), more preferably A compound having the formula (I-1).
- the compound having the formula (I-1) may contain a certain amount of the compound having the formula (I-2), (I-3) or (I-4).
- the “compound having the formula (I-1)” in the present invention means “the formula (I-1) containing a certain amount of the compound having the formula (I-2), (I-3) or (I-4)”.
- a compound having the formula (I-1) containing a certain amount of the compound having the formula (I-2) “a certain amount of the formula (I-3)
- compound having formula (I-1) containing a certain amount of compound having formula (I-4) is particularly, “the compound having the formula (I-1) containing a certain amount of the compound having the formula (I-4)”.
- each compound having the formula (I-2), (I-3) or (I-4) in the compound having the formula (I-1) is, for example, 5% or less, and preferably 3% or less, more preferably 1% or less, even more preferably 0.5% or less, even more preferably 0.3% or less, and particularly preferably 0% or less. .1% or less, and most preferably 0.05% or less.
- the content of each of the compounds having the above formula (I-2), (I-3) or (I-4) is preferable depending on, for example, the peak area ratio or weight ratio in high performance liquid chromatography (HPLC). Can be calculated by the peak area ratio in HPLC.
- the compounds having general formula (I) of the present invention are capable of forming acid addition salts, such as hydrochloride, hydrobromide, sulfate, nitrate, phosphate, Acetate, oxalate, malonate, fumarate, maleate, phthalate, trifluoroacetate, methanesulfonate, benzenesulfonate, p-toluenesulfonate, 2,4-dimethyl It can be benzene sulfonate, 2,4,6-trimethylbenzene sulfonate, 4-ethylbenzene sulfonate, or naphthalene sulfonate.
- acid addition salts such as hydrochloride, hydrobromide, sulfate, nitrate, phosphate, Acetate, oxalate, malonate, fumarate, maleate, phthalate, trifluoroacetate, methanesulfonate, benzen
- acid addition salts are included in the pharmacologically acceptable salts of the present invention.
- the compound having the general formula (I) of the present invention can form an acid addition salt with any proportion of acid, each of them (eg, monohydrochloride or dihydrochloride), or their Mixtures are encompassed by the present invention.
- the compound having the general formula (I) of the present invention when it has an acidic group, it can form a base addition salt, and these base addition salts are, for example, metal salts, inorganic amine salts, organic amine salts, or May be an amino acid salt.
- Metal salts include, for example, alkali metal salts such as sodium salt, potassium salt and lithium salt; alkaline earth metal salts such as calcium salt and magnesium salt; aluminum salt; iron salt; zinc salt; copper salt; It can be a cobalt salt.
- the inorganic amine salt can be, for example, an ammonium salt.
- the organic amine salt can be, for example, a morpholine salt, glucosamine salt, ethylenediamine salt, guanidine salt, diethylamine salt, triethylamine salt, dicyclohexylamine salt, diethanolamine salt, piperazine salt, or tetramethylammonium salt.
- the amino acid salt can be, for example, a glycine salt, a lysine salt, an arginine salt, an ornithine salt, a glutamate salt or an aspartate salt. These base addition salts are included in the pharmacologically acceptable salts of the present invention.
- the acid addition salt or base addition salt of the compound having the general formula (I) of the present invention can be produced, for example, by the following method.
- the precipitated solid is collected by filtration.
- a pharmacologically acceptable ester of a compound having the general formula (I) can be a prodrug of the compound having the general formula (I) and can be metabolized (eg, hydrolyzed) when administered in vivo in a warm-blooded animal. ) To yield compounds having the general formula (I).
- the group capable of forming an ester group with a hydroxy group is, for example, aliphatic acyl [eg (C 1 -C 20 alkyl) carbonyl], aromatic acyl or alkoxycarbonyl [eg (C 1 -C 6 alkoxy) Carbonyl].
- Examples of the group capable of forming an ester group with a carboxy group include aliphatic alkyl [eg C 1 -C 6 alkyl], alkylcarbonyloxyalkyl [eg (C 1 -C 6 alkyl) carbonyloxy- (C 1- C 6 alkyl)], cycloalkylcarbonyloxyalkyl [eg (C 3 -C 8 cycloalkyl) carbonyloxy- (C 1 -C 6 alkyl)], alkoxycarbonyloxyalkyl [eg (C 1 -C 6 alkoxy) ) Carbonyloxy- (C 1 -C 6 alkyl)], or cycloalkyloxycarbonyloxyalkyl [eg (C 3 -C 8 cycloalkyl) oxycarbonyloxy- (C 1 -C 6 alkyl)] .
- alkylcarbonyloxyalkyl eg (C 1 -C 6 alkyl) carbonyloxy- (C
- the compound having the general formula (I) of the present invention or a pharmacologically acceptable salt thereof can form a hydrate or a solvate, and each or a mixture thereof is included in the present invention.
- the compound having the general formula (I) of the present invention or a pharmacologically acceptable salt thereof forms an isotope compound in which one or more atoms constituting the compound are substituted with isotope atoms in an unnatural ratio.
- Isotope atoms can be radioactive or non-radioactive, such as deuterium ( 2 H; D), tritium ( 3 H; T), carbon-14 ( 14 C), iodine-125 ( 125 I), and the like.
- Radioactive or non-radioactive isotope compounds can be used as medicaments, research reagents (eg, assay reagents), diagnostic agents (eg, diagnostic imaging agents), etc. for the treatment or prevention of diseases.
- the present invention includes radioactive or non-radioactive isotope compounds.
- “dyslipidemia” includes hyperlipidemia.
- “Arteriosclerosis” refers to (i) arteriosclerosis due to various factors (including complex factors) such as smoking and heredity; and (ii) dyslipidemia, low HDL cholesterolemia, high Includes atherosclerosis resulting from atherosclerosis such as LDL cholesterolemia, lipid-related diseases, inflammatory diseases, diabetes, obesity, or hypertension, such as atherosclerosis, Includes arteriosclerosis, obstructive arteriosclerosis, and atherosclerosis.
- “Arteriosclerotic heart disease” refers to a cardiovascular disease caused by arteriosclerosis as one cause.
- Chronic heart disease refers to cardiovascular disease that develops due to arteriosclerosis or other diseases, such as heart failure, myocardial infarction, angina, cardioischemia, cardiovascular disorder, Or it includes angiogenic restenosis.
- Cerebrovascular disease includes, for example, stroke or cerebral infarction.
- Peripheral vascular disease includes, for example, diabetic vascular complications.
- the compound having the general formula (I) of the present invention or a pharmacologically acceptable salt thereof includes (i) diseases caused by a decrease in blood concentration of HDL cholesterol in addition to the specific diseases shown above or below.
- the present invention can be applied without limitation to the treatment or prevention of (ii) diseases caused by increased blood levels of LDL cholesterol, and (iii) diseases that can be treated or prevented by inhibition of CETP activity.
- the pharmaceutical composition comprises (i) a combination comprising a compound having the general formula (I) of the present invention or a pharmacologically acceptable salt thereof as an active ingredient, and a preparation comprising another drug as an active ingredient Or (ii) a single preparation (compound) containing both the compound having the general formula (I) of the present invention or a pharmacologically acceptable salt thereof and another drug as active ingredients
- a compounding agent is preferable.
- the pharmaceutical compositions can be administered at the same time or separately over time.
- the dosage form is not particularly limited as long as it can be administered separately at different times.
- the time from administration of one active ingredient to administration of the other active ingredient is not particularly limited, and the other active ingredient can be administered within the time during which the action of the previously administered active ingredient is sustained. preferable.
- the other drug that can be used in combination with the compound having the general formula (I) of the present invention or a pharmacologically acceptable salt thereof is not particularly limited as long as it has an effect according to its purpose.
- the compound having the general formula (I) of the present invention [hereinafter also referred to as compound (I); the same applies to other formulas] is prepared by the following method A (Method A-1, 2, 3, and 4). , B method (B method-1 and 2), C method, D method, E method, or F method.
- R 1 has the same meaning as in formula (I), and R a represents a C 1 -C 6 alkyl group or a hydroxy (C 1 -C 6 alkyl) group.
- R a represents a C 1 -C 6 alkyl group or a hydroxy (C 1 -C 6 alkyl) group.
- the group having the formula R a O— is a C 1 -C 6 alkoxy group, a hydroxy (C 1 -C 6 alkoxy) group as defined for R 1 , (C 1 -C 6 alkoxy)-(C 1 -C 6 alkoxy) group, (C 1 -C
- X a is chloro group, bromo group, iodo group, a methanesulfonyloxy group, trifluoromethanesulfonyloxy group Or represents a p- toluenesulfonyloxy group
- X b is chloro group, bromo group or represents an iodo group
- Boc represents a tert- butoxycarbonyl group
- PMB represents a p- methoxybenzyl group.
- the acid used in the reaction in each step of the following methods A to F is not particularly limited as long as it does not inhibit the reaction, and is selected from the following acid group.
- the acid group consists of an organic acid such as acetic acid, propionic acid, trifluoroacetic acid, or pentafluoropropionic acid; an organic sulfonic acid such as p-toluenesulfonic acid, camphorsulfonic acid, or trifluoromethanesulfonic acid; and It consists of inorganic acids such as hydrochloric acid, hydrobromic acid, hydroiodic acid, phosphoric acid, sulfuric acid, or nitric acid.
- the base used in the reaction in each step of the following methods A to F is not particularly limited as long as it does not inhibit the reaction, and is selected from the following base group.
- the base group is an alkali metal carbonate such as lithium carbonate, sodium carbonate, potassium carbonate, or cesium carbonate; an alkali metal bicarbonate such as lithium hydrogen carbonate, sodium hydrogen carbonate, or potassium hydrogen carbonate; lithium hydroxide Alkali metal hydroxides such as sodium hydroxide or potassium hydroxide; alkaline earth metal hydroxides such as calcium hydroxide or barium hydroxide; lithium hydride, sodium hydride or hydrogen Alkali metal hydrides such as potassium hydride; alkali metal amides such as lithium amide, sodium amide or potassium amide; lithium methoxide, sodium methoxide, sodium ethoxide, sodium tert-butoxide or potassium tert-butoxide No Alkali metal alkoxides; lithium alkylamides such as lithium diisopropylamide; alkal
- solvent used in the reaction in each step of the following methods A to F is not particularly limited as long as it does not inhibit the reaction and partially dissolves the starting material, and is selected from the following solvent group, for example.
- Solvent groups include hexane (eg, n-hexane), pentane (eg, n-pentane), heptane (eg, n-heptane), petroleum ether, or aliphatic hydrocarbons such as cyclohexane; benzene, toluene, Aromatic hydrocarbons such as xylene or ethylbenzene; halogenated hydrocarbons such as dichloromethane, chloroform, carbon tetrachloride, dichloroethane, chlorobenzene, or dichlorobenzene; diethyl ether, diisopropyl ether, tetrahydrofuran, 2-methyl Ethers such as tetrahydrofuran, 1,4-dio
- reaction temperature varies depending on the solvent, starting material, reagent, etc.
- reaction time varies depending on the solvent, starting material, reagent, reaction temperature, and the like.
- the target compound of each step can be isolated from the reaction mixture according to a method well known in the field of organic chemistry.
- the target compound is, for example, (i) if necessary, filtered off insoluble matters such as a catalyst, and (ii) water and a solvent immiscible with water (for example, dichloromethane, diethyl ether, ethyl acetate, etc.) And (iii) the organic layer is washed with water and dried using a desiccant such as anhydrous magnesium sulfate, and (iv) the solvent is distilled off.
- a desiccant such as anhydrous magnesium sulfate
- the obtained target compound can be further purified by a method well known in the field of organic chemistry (for example, recrystallization, reprecipitation, silica gel column chromatography, etc.) as necessary.
- the target compound in each step can be directly used in the next reaction without purification.
- a mixture of two diastereomers (mixture of four enantiomers) by column chromatography, crystallization, or the like A single diastereomer (racemate) can be separated from an optically active column chromatography, or a fractional crystallization method using an optically active compound (for example, an optically active carboxylic acid compound or an optically active amine compound) Etc., separation of a single enantiomer from a single diastereomer (racemate) can be performed.
- separation of a single enantiomer from a mixture of two diastereomers (a mixture of four enantiomers) can be performed by optically active column chromatography.
- the separation of a single diastereomer (racemate) and the separation of a single enantiomer are not limited to the above examples, and can be performed in any step (same or different step) of methods A to F, respectively.
- Step A-7 when separation of a single diastereomer (racemate) is not performed in Step A-7, Steps A-8 to A-9, Steps A-11 to A-14, Steps B-1 to B-4 Steps C-1 to C-2, Steps D-1 to D-2, Steps E-1 to E-3, or Step F-1 are each performed using a mixture of two diastereomers as a raw material. Can be broken.
- the subsequent steps can be performed using a single diastereomer (racemate) as a starting material.
- a single enantiomer is further separated in any of the above steps, the subsequent steps can be performed using a single enantiomer as a raw material, respectively, and the single enantiomer compound (I) [preferably, Compound (I-1)] is obtained.
- a single diastereomer (racemic) compound (I) is obtained, and a single enantiomer is further separated.
- a single enantiomer of compound (I) [preferably, compound (I-1)] is obtained.
- a compound (I) of a mixture of two diastereomers is obtained, and a single diastereomer is obtained.
- Separation of a stereomer (racemate) and separation of a single enantiomer are carried out to obtain a single enantiomer of compound (I) [preferably, compound (I-1)].
- Method A is a method for producing compounds (Ia) and (Ib) included in compound (I).
- Step A-1 is a step for producing compound (2) by reducing compound (1).
- Compound (1) is known.
- the reducing agent used is not limited as long as it can be used for the reduction reaction of an alkoxycarbonyl group to a formyl group, and is preferably diisobutylaluminum hydride.
- the solvent used is preferably an aromatic hydrocarbon, and more preferably toluene.
- the reaction temperature is preferably ⁇ 100 to 0 ° C.
- Step A-2 is a step for producing compound (4) by reacting compound (3) with acetonitrile in the presence of a base.
- Compound (3) is known.
- a protecting group for the amino group in the compound (3) a protecting group well known in the field of organic chemistry can be used instead of the tert-butoxycarbonyl group (for example, T. W. Greene, P. G. Wuts, Greene's Protective Groups in Organic Synthesis.Fourth Edition, 2007, John Wiley & Sons, Inc.).
- the base used is preferably lithium alkylamide, and more preferably lithium diisopropylamide.
- the solvent used is preferably an aliphatic hydrocarbon, an aromatic hydrocarbon, an ether, or a mixture thereof, and more preferably n-heptane, ethylbenzene, tetrahydrofuran, or these It is a mixture.
- the reaction temperature is preferably ⁇ 78 to 50 ° C.
- Step A-3 is a step of producing compound (6) by reacting compounds (2) and (4) and then reacting compound (5).
- Compound (5) is known.
- step A-3 an excessive amount of compound (5) can be used.
- the solvent used is preferably an aromatic hydrocarbon, and more preferably toluene.
- the reaction temperature is preferably 50 to 150 ° C.
- Step A-4 is a step for producing compound (7) by oxidizing compound (6).
- the oxidizing agent used is not limited as long as it can be used for the oxidation reaction of a dihydropyridyl group to a pyridyl group, and preferably 2,3-dichloro-5,6-dicyano-p-benzoquinone (DDQ ).
- the solvent used is preferably a halogenated hydrocarbon, and more preferably dichloromethane.
- the reaction temperature is preferably 0 to 50 ° C.
- Step A-5 is a step for producing compound (8) by reducing compound (7).
- the reducing agent used is not limited as long as it can be used for the reduction reaction of a cyano group to a formyl group, and is preferably diisobutylaluminum hydride.
- the solvent used is preferably an aromatic hydrocarbon, and more preferably toluene.
- the reaction temperature is preferably ⁇ 100 to 0 ° C.
- Step A-6 is a step for producing compound (9) by reacting compound (8) with p-methoxybenzyl bromide in the presence of a base.
- the base used is not particularly limited as long as it can be used for the alkylation reaction of a hydroxy group, and is preferably an alkali metal hydride, and more preferably sodium hydride.
- the solvent used is preferably an amide, and more preferably N, N-dimethylformamide.
- the reaction temperature is preferably ⁇ 50 to 50 ° C.
- the reaction time is preferably 30 minutes to 12 hours.
- Step A-6 a protecting group well known in the field of organic chemistry can be used in place of the p-methoxybenzyl group as the protecting group for the hydroxy group (for example, TW Greene, PG Wuts, Greene's Protective Groups in Organic Synthesis). Fourth Edition, 2007, John Wiley & Sons, Inc.).
- Step A-7 is a step for producing compound (10) by reacting compound (9) with 4-trifluoromethylphenylmagnesium bromide.
- 4-trifluoromethylphenylmagnesium bromide can be prepared from 4-trifluoromethylphenylbromide and magnesium by methods well known in the field of organic chemistry.
- the solvent used is preferably an ether, and more preferably tetrahydrofuran.
- the reaction temperature is preferably ⁇ 20 to 50 ° C.
- the reaction time is preferably 30 minutes to 12 hours.
- step A-7 compound (10) has two asymmetric carbon atoms (carbon atom to which a hydroxy group or p-methoxybenzyloxy group is bonded), and a mixture of stereoisomers (four kinds of optical isomerism).
- Body mixture that is, a mixture of diastereomers).
- the diastereomeric mixture obtained in step A-7 can be separated into single diastereomeric compounds depending on the properties of the mixture. This separation can be performed by a method well known in the field of organic chemistry (for example, resolution by column chromatography or fractional crystallization of a diastereomeric mixture).
- Each separated diastereomeric compound (mixture of enantiomers) can be separated into a single enantiomer compound depending on the properties of the compound.
- Step A-8 is a step for producing compound (11) by reacting compound (10) with a fluorinating reagent.
- the fluorination reagent used is not limited as long as it can be used for the fluorination reaction of a hydroxy group, and is preferably bis (methoxyethyl) aminosulfur trifluoride [Deoxo-Fluor (trade name)]. .
- the solvent used is preferably a halogenated hydrocarbon, and more preferably dichloromethane.
- the reaction temperature is preferably ⁇ 100 to 0 ° C.
- Step A-9 is a step for producing compound (12) by reacting compound (11) with zinc bromide.
- the solvent used is preferably a halogenated hydrocarbon, and more preferably dichloromethane.
- the reaction temperature is preferably 0 to 50 ° C.
- the reaction time is preferably 1 hour to 5 days.
- the diastereomeric mixture obtained in step A-9 can be separated into a single diastereomeric compound, and the compound (12) is obtained as a single diastereomeric compound.
- Step A-10 is a step of subjecting compound (12) to optical resolution by optically active column chromatography to obtain compound (13) which is a single enantiomer.
- Step A-11 is a step for producing compound (14) by reacting compound (13) with 5-bromo-2-chloropyrimidine in the presence of a base.
- the base used is preferably an organic amine, more preferably diisopropylethylamine or 1,8-diazabicyclo [5,4,0] undec-7-ene (DBU).
- organic amine more preferably diisopropylethylamine or 1,8-diazabicyclo [5,4,0] undec-7-ene (DBU).
- the solvent used is preferably an ether or an amide, and more preferably 1,4-dioxane.
- the reaction temperature is preferably 20 to 150 ° C.
- Step A-12 is a step for producing compound (15) by reacting compound (14) with morpholine in the presence of a palladium catalyst, a phosphorus reagent and a base.
- the palladium catalyst used is not limited as long as it can be used for the amination reaction on the aromatic ring.
- J. Tsuji Palladium Reagents and Catalysis: New Perspectives for the 21 st Centuty, 2004, It may be a palladium catalyst described in John Wiley & Sons, Inc. et al.
- the palladium catalyst used is preferably tetrakis (triphenylphosphine) palladium (0), tris (dibenzylideneacetone) dipalladium (0), palladium (II) chloride, palladium (II) acetate, or dichlorobis ( Triphenylphosphine) palladium (II), more preferably palladium acetate (II).
- the phosphorus reagent to be used is not limited as long as it can be used for the amination reaction on the aromatic ring, and preferably 2- (di-tert-butylphosphino) biphenyl, 2- (dicyclohexylphosphine).
- the base used is preferably an alkali metal alkoxide, more preferably sodium tert-butoxide.
- the solvent used is preferably an aromatic hydrocarbon, an alcohol, or a mixture thereof, more preferably toluene, 2-methyl-2-propanol, or a mixture thereof.
- the reaction temperature is preferably 20 to 150 ° C.
- the reaction time is preferably 30 minutes to 12 hours.
- an amination reaction can be carried out using a 5- or 6-membered nitrogen-containing saturated cyclic amine other than morpholine which may be substituted in place of morpholine.
- the palladium catalyst used in this amination reaction is preferably tris (dibenzylideneacetone) dipalladium (0), and is preferably stirred under microwave irradiation.
- R 1 may be substituted in compound (I) to a 5- or 6-membered nitrogen-containing saturated group.
- a compound that is a telocyclyl group and in which the nitrogen atom is bonded to the 5-position of the pyrimidine can be produced.
- Step A-12 instead of morpholine, the formula R g B (OH) 2 (wherein R g is a C 3 -C 8 cycloalkyl group, C 3 -C 8 cycloalkenyl group defined in R 1 , A compound having a phenyl group, a substituted phenyl group, a 5- or 6-membered aromatic heterocyclyl group, or a substituted 5- or 6-membered aromatic heterocyclyl group), or a boronic acid ester thereof, and a carbon-carbon coupling reaction It can be performed.
- the palladium catalyst used in this carbon-carbon coupling reaction is preferably palladium (II) acetate.
- Step A-13 is a step of producing compound (Ia) by treating compound (15) with an acid.
- the acid used is preferably an inorganic acid, and more preferably hydrochloric acid.
- the solvent used is preferably an ether, an alcohol, or a mixture thereof, and more preferably 1,4-dioxane, methanol, or a mixture thereof.
- the reaction temperature is preferably 20 to 150 ° C.
- Step A-14 is a step for producing compound (Ib) by reacting compound (Ia) with compound (16) in the presence of a base.
- the base used is preferably an alkali metal carbonate, more preferably cesium carbonate.
- the solvent used is preferably an ether or an amide, more preferably tetrahydrofuran, N, N-dimethylformamide, or 1-methyl-2-pyrrolidone.
- the reaction temperature is preferably 0 to 100 ° C.
- the reaction time is preferably 30 minutes to 50 hours.
- Method B is a method for producing compound (Ic) included in compound (I).
- Step B-1 is a step for producing compound (17) by reacting compound (13) with 2-chloro-5-formylpyrimidine in the presence of a base.
- the base used is preferably an organic amine, and more preferably 1,8-diazabicyclo [5,4,0] undec-7-ene (DBU).
- DBU 1,8-diazabicyclo [5,4,0] undec-7-ene
- the solvent used is preferably an amide, and more preferably 1-methyl-2-pyrrolidone.
- the reaction temperature is preferably 0 to 100 ° C.
- Step B-2 is a step of producing compound (18) by reducing compound (17).
- the reducing agent used is not limited as long as it can be used for the reduction reaction of formyl group to hydroxy group, and preferably sodium borohydride, sodium triacetoxyborohydride, sodium cyanoborohydride, An alkali metal borohydride such as lithium borohydride, more preferably sodium borohydride.
- the solvent used is preferably ethers, alcohols, or a mixture thereof, and more preferably tetrahydrofuran, ethanol, or a mixture thereof.
- the reaction temperature is preferably ⁇ 20 to 50 ° C.
- Step B-3 is a step for producing compound (20) by reacting compound (18) with methanesulfonyl chloride in the presence of a base and then reacting with compound (19).
- Compound (19) is known.
- the base used is preferably an organic amine, and more preferably diisopropylethylamine.
- the solvent used is preferably a halogenated hydrocarbon, and more preferably dichloromethane.
- the reaction temperature is preferably 0 to 100 ° C.
- Step B-4 is a step for producing compound (Ic) by removing the p-methoxybenzyl group of compound (20) in the presence of anisole and an acid.
- the acid used is preferably an organic acid, more preferably trifluoroacetic acid.
- the solvent used is preferably a halogenated hydrocarbon, and more preferably dichloromethane.
- the reaction temperature is preferably 0 to 100 ° C.
- the reaction time is preferably 30 minutes to 48 hours.
- the removal reaction of the p-methoxybenzyl group in the step B-4 can also be performed by a method well known in the field of organic chemistry (for example, T. W. Greene, P. G. Wuts, Greene's Protective Groups in Organic Synthesis. Fourth Edition, 2007, John Wiley & Sons, Inc.
- Method C is a method for producing compound (I).
- Step C-1 is a step for producing compound (22) by reacting compound (13) with compound (21) in the presence of a base.
- Compound (21) is publicly known, can be easily produced from a publicly known compound, or can be produced according to Reference Examples. Step C-1 can also be performed using the same palladium catalyst, phosphorus reagent, and base as in step A-12.
- the base used is preferably an organic amine, more preferably diisopropylethylamine, 1,8-diazabicyclo [5,4,0] undec-7-ene (DBU), or mixtures thereof. is there.
- organic amine more preferably diisopropylethylamine, 1,8-diazabicyclo [5,4,0] undec-7-ene (DBU), or mixtures thereof. is there.
- the solvent used is preferably an ether, alcohol, or amide, and more preferably 1,4-dioxane, 2-propanol, 2-methyl-2-propanol, N, N— Dimethylformamide or 1-methyl-2-pyrrolidone.
- the reaction temperature is preferably 20 to 160 ° C.
- the reaction time is preferably 30 minutes to 12 hours.
- Step C-1 can be performed under microwave irradiation.
- Step C-2 is a step for producing compound (I) by removing the p-methoxybenzyl group of compound (22) in the presence of anisole and an acid.
- Step C-2 can be performed according to the same method as step B-4.
- Method D is a method for producing compound (Id) included in compound (I).
- Step D-1 is a step for producing compound (24) by reacting compound (17) with compound (23).
- Compound (23) is known or can be easily produced from a known compound.
- the solvent used is preferably an ether, and more preferably tetrahydrofuran.
- the reaction temperature is preferably 0 to 60 ° C.
- Step D-2 a step of removing the p-methoxybenzyl group of the compound (24) in the presence of an acid; and (Step D-2B) The step comprises the step of producing the compound (Id) by subjecting the compound obtained in Step D-2A to a dehydration reaction or a reduction reaction.
- the removal reaction of the p-methoxybenzyl group and the dehydration reaction can proceed simultaneously.
- the acid used in these reactions is preferably an inorganic acid or an organic acid, and more preferably hydrochloric acid or trifluoroacetic acid.
- the solvent used is preferably a halogenated hydrocarbon or an ether, and more preferably dichloromethane or 1,4-dioxane.
- the reaction temperature is preferably 0 to 110 ° C.
- the reaction time is preferably 30 minutes to 48 hours.
- the reducing agent used in the reduction reaction is not limited as long as it can be used for the hydroxyl group reduction reaction, and is preferably triethylsilane.
- the removal reaction of the p-methoxybenzyl group in the step D-2 can also be performed by a method well known in the field of organic chemistry (for example, T. W. Greene, P. G. Wuts, Greene's Protective Groups in Organic Synthesis. Fourth Edition, 2007, John Wiley & Sons, Inc.
- Step E is a method for producing compound (Ie) included in compound (I).
- Step E-1 is a step for producing compound (25) by oxidizing compound (17).
- the oxidizing agent used is not limited as long as it can be used for the oxidation reaction of formyl group to carboxyl group, and preferably potassium permanganate, sodium chlorite, sodium hypochlorite, peroxidation. Hydrogen, chromic acid, metachloroperbenzoic acid, silver nitrate, or pyridinium dichromate, and more preferably sodium chlorite.
- sodium chlorite it is preferable to use a combination of 2-methyl-2-butene and sodium dihydrogen phosphate.
- the solvent used is preferably ethers, alcohols, water, or a mixture thereof, more preferably tetrahydrofuran, tert-butanol, water, or a mixture thereof.
- the reaction temperature is preferably 0 to 70 ° C.
- Step E-2 is a step of producing compound (26) by reacting compound (25) with an alcohol compound or an amine compound in the presence of a condensing agent.
- the condensing agent to be used is not limited as long as it can be used for the condensation reaction of a carboxy group with a hydroxy group or an amino group, and preferably 1,1′-carbonyldiimidazole, 1-ethyl-3- (3-dimethylaminopropyl) carbodiimide or a combination thereof with 1-hydroxybenzotriazole.
- a base can be used in combination with the above condensing agent.
- the base used is preferably an organic amine, more preferably triethylamine.
- the solvent used is preferably an ether, nitrile, amide, or a mixture thereof, more preferably tetrahydrofuran, acetonitrile, N, N-dimethylacetamide, or a mixture thereof. .
- the reaction temperature is preferably 0 to 120 ° C.
- Step E-3 is a step for producing compound (Ie) by removing the p-methoxybenzyl group of compound (26) in the presence of anisole and an acid.
- the step E-3 can be performed according to the same method as the step B-4.
- Method F is a method for producing a compound (If) included in compound (I).
- the F-1 process is (Step F-1A) a step of removing the p-methoxybenzyl group of compound (17) in the presence of anisole and an acid; and (Step F-1B) The step comprises the step of producing the compound (If) by reacting the compound obtained in Step F-1A with an amine compound in the presence of a reducing agent.
- the F-1A step can be performed according to the same method as the B-4 step.
- the reducing agent used is not limited as long as it can be used for the reductive amination reaction of the formyl group, and is preferably sodium triacetoxyborohydride or sodium borohydride.
- the solvent used is preferably an ether, an alcohol, or a mixture thereof, more preferably tetrahydrofuran, methanol, or a mixture thereof.
- the reaction temperature is preferably 0 to 60 ° C.
- the reaction time is preferably 30 minutes to 14 hours.
- R 1 is [N— (C 1 -C 6 alkyl)
- compounds that are —N— (C 1 -C 6 alkyl) sulfonylamino] methyl groups can be prepared.
- the compound having the general formula (I) or the pharmacologically acceptable salt thereof of the present invention when used as a medicament, is (i) itself as a bulk; (ii) an appropriate pharmacologically acceptable Orally prepared as a tablet, capsule, granule, powder, or syrup preparation prepared by mixing with excipients, diluents, etc .; or (iii) manufactured as described above Can be administered parenterally as a preparation such as an injection or a suppository. It is preferred that it be administered orally.
- compositions are produced by well-known methods using additives such as excipients, binders, disintegrants, lubricants, emulsifiers, stabilizers, flavoring agents, diluents, or solvents for injections. Is done.
- the excipient can be, for example, an organic excipient or an inorganic excipient.
- Organic excipients include, for example, sugar derivatives such as lactose, sucrose, glucose, mannitol, or sorbitol; starch derivatives such as corn starch; cellulose derivatives such as crystalline cellulose; gum arabic; dextran; or pullulan Etc.
- the inorganic excipient may be, for example, light anhydrous silicic acid or a silicate derivative such as synthetic aluminum silicate; or a sulfate such as calcium sulfate.
- the binder may be, for example, a compound shown in the above excipient; gelatin; polyvinyl pyrrolidone; or polyethylene glycol.
- the disintegrant can be, for example, a compound shown in the above excipients; a chemically modified starch or cellulose derivative such as croscarmellose sodium or sodium carboxymethyl starch; or a cross-linked polyvinyl pyrrolidone or the like .
- Lubricants include, for example, talc; colloidal silica; waxes such as beeswax or gallows; glycols; D, L-leucine; sulfates such as sodium sulfate; or starch derivatives in the above excipients Etc.
- Emulsifiers are, for example, bentonite or colloidal clays such as bee gum; anionic surfactants such as sodium lauryl sulfate; cationic surfactants such as benzalkonium chloride; or polyoxyethylene alkyl ethers Such nonionic surfactants can be used.
- Stabilizers can be, for example, parahydroxybenzoates such as methyl paraben; alcohols such as chlorobutanol; benzalkonium chloride; phenol; or thimerosal.
- the flavoring agent can be, for example, a commonly used sweetener, acidulant, or fragrance.
- Diluent can be, for example, water, ethanol, propylene glycol, or the like.
- the solvent for injection can be, for example, water, ethanol, glycerin or the like.
- the dose of the compound having the general formula (I), which is the active ingredient of the present invention, or a pharmacologically acceptable salt thereof varies depending on the patient's symptoms, age and the like.
- the compound having the general formula (I) or a pharmacologically acceptable salt thereof has a lower limit of 0.01 mg / kg (preferably 0.05 mg / kg) and an upper limit of 500 mg / kg per administration.
- a lower limit of 0.001 mg / kg (preferably 0.005 mg / kg) per dose an upper limit of 50 mg / kg (preferably 5 mg / Kg) can be administered to adults 1 to 6 times per day, depending on symptoms.
- the compound having the general formula (I) of the present invention or a pharmacologically acceptable salt thereof has CETP inhibitory activity, HDL cholesterol concentration increasing action, LDL cholesterol concentration reducing action, rapid onset of drug efficacy, sustained drug efficacy, Excellent properties in terms of physical stability, solubility, oral absorption, blood concentration, cell membrane permeability, metabolic stability, tissue transfer, bioavailability (BA), drug interaction, toxicity, etc. It is useful as a pharmaceutical for warm-blooded animals (particularly for humans).
- the medicament is preferably dyslipidemia, hypercholesterolemia, low HDL cholesterolemia, high LDL cholesterolemia, hypertriglyceridemia, arteriosclerosis, arteriosclerotic heart disease, coronary heart Diseases (including heart failure, myocardial infarction, angina pectoris, cardiac ischemia, cardiovascular disorders, and angiogenic restenosis), cerebrovascular diseases (including stroke and cerebral infarction), peripheral vascular diseases (diabetic vascular complications) ), Or obesity, more preferably dyslipidemia, low HDL cholesterolemia, high LDL cholesterolemia, arteriosclerosis, arteriosclerotic heart disease, or coronary heart disease, Preferably also for the treatment of dyslipidemia, low HDL cholesterolemia, arteriosclerosis or coronary heart disease, even more preferably hypoHDL cholesterolemia or arteriosclerosis Ku is a medicament for the prevention.
- the present invention will be described in more detail with reference to Examples, Reference Examples, Test Examples, and Formulation Examples, but the scope of the present invention is not limited thereto.
- the bond between the fluoro group or hydroxy group and the carbon atom shown below may be represented by a planar structural formula, respectively, but includes (+) or (-)
- the compound indicated by the compound name is a single enantiomer produced using the intermediate compound of Reference Example 10 which is a single enantiomer.
- each is a single enantiomer prepared using the intermediate compound of Reference Example 10 which is a single enantiomer.
- the chemical structural formula in parentheses indicates the chemical structural formula of the reaction intermediate in each example or reference example.
- Boc tert-butoxycarbonyl PMB: p-methoxybenzyl TBS: tert-butyldimethylsilyl
- reaction solution was poured into a saturated aqueous sodium hydrogen carbonate solution and extracted with ethyl acetate.
- organic layer was washed with a saturated aqueous sodium chloride solution and dried over anhydrous magnesium sulfate, and then the solvent was distilled off under reduced pressure.
- Example 7 4- (4,4-difluorocyclohexyl) -2- (1- ⁇ 5- [4- (ethoxycarbonyl) piperidin-1-yl] pyrimidin-2-yl ⁇ piperidin-4-yl) -3- ⁇ fluoro [ 4- (Trifluoromethyl) phenyl] methyl ⁇ -7,7-dimethyl-5,6,7,8-tetrahydroquinolin-5-ol
- reaction solution was poured into a saturated aqueous sodium hydrogen carbonate solution and extracted with ethyl acetate. The organic layer was washed with a saturated aqueous sodium chloride solution and dried over anhydrous magnesium sulfate, and then the solvent was distilled off under reduced pressure.
- reaction solution was poured into a saturated aqueous sodium hydrogen carbonate solution and extracted with ethyl acetate.
- the organic layer was washed with a saturated aqueous sodium chloride solution and dried over anhydrous magnesium sulfate, and then the solvent was distilled off under reduced pressure.
- reaction solution was poured into a saturated aqueous sodium hydrogen carbonate solution and extracted with ethyl acetate.
- the organic layer was washed with a saturated aqueous sodium chloride solution and dried over anhydrous magnesium sulfate, and then the solvent was distilled off under reduced pressure.
- Example 1 except that 2-chloro-5- (4,4,4-trifluorobutyl) pyrimidine produced in the same manner as in Reference Example 26 was used instead of 5-bromo-2-chloropyrimidine.
- reaction solution was poured into water and extracted with ethyl acetate.
- organic layer was washed successively with 0.1N hydrochloric acid, saturated aqueous sodium hydrogen carbonate solution and saturated aqueous sodium chloride solution and dried over anhydrous sodium sulfate, and the solvent was evaporated under reduced pressure.
- the obtained crude product was dissolved in 2 ml of N, N-dimethylacetamide and stirred at 120 ° C. for 2 hours. After completion of the reaction, the reaction solution was poured into water and extracted with ethyl acetate.
- (2S) -2- (tetrahydro-2H-pyran-2-yloxy) propyl 4-methylbenzenesulfonate (2R) -2- (tetrahydro-2H-pyran-2-yloxy) propyl 4-methylbenzenesulfonate (Synthesis by the method described in B.A. Jones et al., Journal of Heterocyclic Chemistry, 1982, Vol. 19, p. 551-556). 4- (4,4-difluorocyclohexyl) -3- ⁇ fluoro [4- (trifluoromethyl) phenyl] methyl ⁇ -2- [1- (5-hydroxypyrimidin-2-yl) prepared in the same manner as in Example 4.
- Example 14 The same reaction as in Example 13 was carried out except that (3-bromopropoxy) (tert-butyl) dimethylsilane was used instead of ethyl iodide, and the same procedure as in Example 4 was carried out ( ⁇ )-4- ( 4,4-difluorocyclohexyl) -3- ⁇ fluoro [4- (trifluoromethyl) phenyl] methyl ⁇ -2- [1- (5-hydroxypyrimidin-2-yl) piperidin-4-yl] -7,7 -Dimethyl-5,6,7,8-tetrahydroquinolin-5-ol from 61 mg (94 ⁇ mol) to 2- ⁇ 1- [5- (3- ⁇ [tert-butyl (dimethyl) silyl] oxy ⁇ propoxy) pyrimidine- 2-yl] piperidin-4-yl ⁇ -4- (4,4-difluorocyclohexyl) -3- ⁇ fluoro [4- (tri
- Example 4 was carried out in the same manner as in Example 39 except that toluene sulfonate (synthesized by the method described in J. Dubois et al., Terahedron, 1991, Vol. 47, p. 1001-1012) was used.
- reaction solution was poured into a saturated aqueous sodium hydrogen carbonate solution and extracted with ethyl acetate.
- organic layer was washed with a saturated aqueous sodium chloride solution and dried over anhydrous magnesium sulfate, and then the solvent was distilled off under reduced pressure.
- Example 2 The first step of Example 2, and Example 38, except that 2-chloro-5- (methylsulfonyl) pyrimidine prepared in the same manner as in Reference Example 14 was used instead of 5-bromo-2-chloropyrimidine, The same reaction was carried out, and (-)-4- (4,4-difluorocyclohexyl) -3- ⁇ fluoro [4- (trifluoromethyl) phenyl] methyl ⁇ -5- [ From 49 mg (72 ⁇ mol) of (4-methoxybenzyl) oxy] -7,7-dimethyl-2- (piperidin-4-yl) -5,6,7,8-tetrahydroquinoline, 45 mg of the title compound was obtained as a white solid.
- reaction solution was poured into a saturated aqueous sodium hydrogen carbonate solution and extracted with ethyl acetate.
- organic layer was washed with a saturated aqueous sodium chloride solution and dried over anhydrous magnesium sulfate, and then the solvent was distilled off under reduced pressure.
- the fraction was concentrated under reduced pressure to give 128 mg of the title compound as a colorless oil (yield 76%).
- reaction solution was filtered on Celite (trade name), and the filtrate was washed with a saturated aqueous sodium hydrogen carbonate solution.
- organic layer was washed successively with a saturated aqueous sodium bicarbonate solution and a saturated aqueous sodium chloride solution and dried over anhydrous magnesium sulfate, and then the solvent was distilled off under reduced pressure. Methanol was added to the resulting residue, and the precipitate was collected by filtration to obtain 20.7 g of the title compound as a white solid (yield 87%).
- the reaction solution was poured into a saturated aqueous sodium hydrogen carbonate solution and extracted with ethyl acetate.
- the obtained organic layer was washed with a saturated aqueous sodium chloride solution and dried over anhydrous magnesium sulfate, and then the solvent was distilled off under reduced pressure.
- the reaction solution was added to a saturated aqueous ammonium chloride solution and extracted with ethyl acetate.
- the obtained organic layer was washed successively with a saturated aqueous sodium bicarbonate solution and a saturated aqueous sodium chloride solution and dried over anhydrous magnesium sulfate, and then the solvent was distilled off under reduced pressure.
- diastereomer 1 eluting first was obtained.
- reaction solution was added to a mixture of ice and saturated aqueous sodium hydrogen carbonate solution, and extracted with chloroform.
- the obtained organic layer was washed with a saturated aqueous sodium chloride solution and dried over anhydrous magnesium sulfate, and then the solvent was distilled off under reduced pressure. Cyclohexane was added to the resulting residue, and the precipitate was collected by filtration to obtain 2.55 g of the title compound as a white solid (yield 82%).
- the organic layer was washed successively with a saturated aqueous sodium chloride solution, a saturated aqueous sodium hydrogen carbonate solution, and a saturated aqueous sodium chloride solution and dried over anhydrous magnesium sulfate, and then the solvent was distilled off under reduced pressure. N-Heptane was added to the obtained residue, and the precipitate was collected by filtration to obtain 5.09 g of the title compound as a white solid (yield 86%).
- reaction solution was poured into water and extracted with ethyl acetate.
- organic layer was washed with a saturated aqueous sodium chloride solution and dried over anhydrous magnesium sulfate, and then the solvent was distilled off under reduced pressure.
- the insoluble material was filtered off and washed with ethyl acetate, and 0.5N aqueous sodium hydroxide solution was added to the filtrate to carry out a liquid separation operation.
- the resulting aqueous layer was further extracted with ethyl acetate.
- the obtained organic layers were combined, washed successively with water and saturated aqueous sodium chloride solution and dried over anhydrous magnesium sulfate, and then the solvent was distilled off under reduced pressure. Toluene was added to the resulting residue, and the precipitate was collected by filtration and washed with toluene and n-heptane to obtain 6.00 g of the title compound as a white solid (yield 30%).
- Diffraction intensity data was collected using a single crystal X-ray structural analyzer Rigaku R-AXIS RAPID under a cryogenic airflow (-150 ° C). After determining the structure by the direct method using the software CrystalStructure, the temperature refinement of the non-hydrogen atom was anisotropic and the temperature factor of the non-hydrogen atom was anisotropic by the full-matrix least square method.
- the absolute configuration of the other chiral carbons of the title compound was determined by the R configuration of the asymmetric carbon of the mandelic acid moiety introduced into the compound.
- the absolute configuration of the 5-position carbon of 5,6,7,8-tetrahydroquinoline is the S configuration
- the absolute configuration of the 1-position carbon of the fluoro [4- (trifluoromethyl) phenyl] methyl group is the S configuration.
- the chemical structural formula including the absolute configuration of the compound was as shown above.
- CETP inhibitory activity test in vitro, buffer system
- HDL Cholesterol (1.125 ⁇ mol
- phosphatidylcholine 4.5 ⁇ mol
- [ 14 C] -labeled cholesteryl ester 2.0 ⁇ Ci; 40 ⁇ l
- the obtained mixture was dissolved in ethanol (200 ⁇ l) to obtain a solution A.
- PBS solution [Na 2 HPO 4 (30 mM), KH 2 PO 4 (8.8 mM), NaCl (60 mM), EDTA (pH 7.4; 0.67 mM) mixed solution; 4 ml] is taken into a tube, and nitrogen stream Under vigorous stirring by vortexing.
- the solution A was gently poured into this mixture with a syringe and vigorously stirred by vortexing for 5 minutes under a nitrogen stream.
- Sodium cholate 200 mM; 0.38 ml
- ApoA-I protein (3 mg) was added to the resulting mixture and stirred for 2 minutes.
- the obtained fraction was dialyzed against a PBS solution, and the resulting mixture was used as an acceptor lipoprotein.
- (3) Measurement of CETP inhibitory activity Recombinant human CETP protein (Roar Biomedical Inc .; 4.5 ng), acceptor lipoprotein (32.5 ⁇ g) of (2) above, and 5,5′-dithio-bis- ( 2-nitrobenzoic acid) (7 mM, 15 ⁇ l) was placed in a 96-well plate, and the total volume was adjusted to 48.5 ⁇ l with a PBS solution.
- test compound [DMSO solution (concentration: 0.15, 0.5, 1.5, 5, 15, 50, 150, and 500 ⁇ M; 1.5 ⁇ l)] was added to each well, and incubated in a 37 ° C. constant temperature bath for 60 minutes.
- the 96-well plate was transferred onto ice and the precipitation reagent [magnesium chloride (60 mM) and 0.1% dextran sulfate [1/1 (v / v)] mixed solution (15 ⁇ l) was added to each well and left on ice for 15 minutes, and the reaction solution (80 ⁇ l) in each well was transferred to a filter plate at 1500 rpm.
- the radioactivity was measured with a scintillation counter using the filtrate that passed through the filter as an HDL fraction, and the rate of decrease in radioactivity when a test compound was added compared to when no test compound was added. From the CETP inhibition rate I It was calculated 50 value.
- Table 1 shows the test results of the compounds of the present invention.
- Phosphatidylcholine (5 mg) and [ 3 H] -labeled cholesteryl ester (0.5 mCi; 0.5 ml) were placed in a glass test tube and dried under a nitrogen stream.
- a PBS solution 500 ⁇ l was added to the obtained mixture, and mixed for 30 minutes under ultrasonic irradiation.
- HDL 3 fraction (1.75 mg) and lipoprotein-removed human serum (LPDS; 12 mg) were added to the resulting mixture, and the total amount was adjusted to 3.5 ml with a PBS solution.
- the resulting mixture was incubated at 37 ° C for 48 hours.
- Cholesteryl ester transfer rate (%) [[Radioactivity of LDL fraction (after reaction) ⁇ Radioactivity of LDL fraction (unreacted)] / [Radioactivity of LDL fraction (after reaction) + Radioactivity of HDL fraction (after reaction)]] ⁇ 100
- the rate of decrease in the cholesteryl ester transfer rate when a test compound was added compared to when no test compound was added was defined as the CETP inhibition rate.
- IC 50 value was calculated from CETP inhibition rate.
- the compounds of the present invention exhibit excellent CETP inhibitory activity in this test, and are dyslipidemia, hypercholesterolemia, low HDL cholesterolemia, high LDL cholesterolemia, arteriosclerosis, arteriosclerotic heart disease, Alternatively, it is useful as a medicament for the treatment or prevention of coronary heart disease and the like.
- CETP inhibitory activity test in vitro, fluorescence, plasma system
- Reagent C was prepared by mixing Reagent B (311 ⁇ l) with Reagent A (73 ⁇ l) of Ex vivo CETP Activity Assay (RB-EVAK) manufactured by Roar Biomedical Inc. 2.5 ⁇ l of Reagent C was mixed with human plasma or plasma collected from CETP / ApoB Tg mice (46.5 ⁇ l) and added to a 96-well black plate (Half Area, Corning No. 3694).
- test compound [DMSO solution (concentration: 0.15, 0.5, 1.5, 5, 15, 50, 150, and 500 ⁇ M; 1 ⁇ l)] to each well, mix gently, and react for 90 minutes in a 37 ° C constant temperature bath.
- the fluorescence intensity of the sample in each well was measured with a fluorescence plate reader (manufactured by LJL Biosystems; Analyst HT) (excitation wavelength: 485 nm, fluorescence wavelength: 530 nm) .Fluorescence of reaction using plasma of wild-type mouse The intensity was subtracted as a blank, and the decrease rate of the fluorescence intensity when the test compound was added compared to the case where the test compound was not added was defined as the CETP inhibition rate, and the IC 50 value was calculated from the CETP inhibition rate.
- the compounds of the present invention exhibit excellent CETP inhibitory activity in this test, and are dyslipidemia, hypercholesterolemia, low HDL cholesterolemia, high LDL cholesterolemia, arteriosclerosis, arteriosclerotic heart disease, Alternatively, it is useful as a medicament for the treatment or prevention of coronary heart disease and the like.
- Test Example 4 Mouse drug efficacy test (mouse in vivo and mouse ex vivo) (1) Administration of compound A test compound was dissolved in a propylene glycol-Tween 80 (trade name) mixed solvent [4/1 (v / v)] and orally administered to CETP / apoB Tg mice for 2 or 7 days. Blood was collected before dosing on day 2 or 7 and 14 or 24 hours after dosing. (2) Measurement of plasma cholesterol content Plasma cholesterol content was measured using a commercially available measurement kit (cholesterol-E Wako, manufactured by Wako Pure Chemical Industries, Ltd.).
- the obtained fraction was dialyzed against a PBS solution, and the resulting mixture was defined as an HDL 3 fraction.
- Phosphatidylcholine (5 mg) and tritium labeled cholesteryl ester (0.5 mCi; 0.5 ml) were placed in a glass test tube and dried under a stream of nitrogen.
- a PBS solution 500 ⁇ l was added to the resulting mixture, and mixed for 30 minutes under ultrasonic irradiation.
- HDL 3 fraction (1.75 mg) and lipoprotein-removed human serum (12 mg) were added to the resulting mixture, and the total amount was adjusted to 3.5 ml with a PBS solution.
- the resulting mixture was incubated at 37 ° C. for 48 hours.
- Ex vivo CETP Activity Assay (RB-EVAK). 1 ⁇ l of Reagent C and plasma (19 ⁇ l) collected from the test animal were added to a black 384 well round bottom plate (No. 3676 manufactured by corning). The reaction was carried out in a constant temperature bath at 37 ° C. for 90 minutes, and the fluorescence intensity of the sample in each well was measured with a fluorescence plate reader (LJL Biosystems: Analyst HT) (excitation wavelength: 485 nm, fluorescence wavelength: 530 nm). The fluorescence intensity of the reaction using plasma of wild-type mice was subtracted as a blank, and the rate of decrease in fluorescence intensity when the test compound was administered compared to the case where the test compound was not administered was defined as the CETP inhibition rate.
- a fluorescence plate reader LJL Biosystems: Analyst HT
- the compound of the present invention exhibits excellent CETP inhibitory activity, HDL cholesterol concentration increasing action or LDL cholesterol concentration reducing action in this test, and dyslipidemia, hypercholesterolemia, low HDL cholesterolemia, high LDL It is useful as a medicament for the treatment or prevention of cholesterolemia, arteriosclerosis, arteriosclerotic heart disease, coronary heart disease and the like.
- Example 3 Tablets The compound of Example 3 (100 mg), colloidal silicon dioxide (0.2 mg), magnesium stearate (0.2 mg), microcrystalline cellulose (0.2 mg), starch (0. 2 mg) and lactose (98.8 mg) are used to make tablets according to methods well known in the pharmaceutical field. The obtained tablets can be coated as necessary.
- the compound having the general formula (I) of the present invention or a pharmacologically acceptable salt thereof has CETP inhibitory activity, HDL cholesterol concentration increasing action, LDL cholesterol concentration reducing action, rapid onset of drug efficacy, sustained drug efficacy, Excellent properties in terms of physical stability, solubility, oral absorption, blood concentration, cell membrane permeability, metabolic stability, tissue transfer, bioavailability (BA), drug interaction, toxicity, etc. It is useful as a pharmaceutical for warm-blooded animals (particularly for humans).
- the medicament is preferably dyslipidemia, hypercholesterolemia, low HDL cholesterolemia, high LDL cholesterolemia, hypertriglyceridemia, arteriosclerosis, arteriosclerotic heart disease, coronary heart Diseases (including heart failure, myocardial infarction, angina pectoris, cardiac ischemia, cardiovascular disorders, and angiogenic restenosis), cerebrovascular diseases (including stroke and cerebral infarction), peripheral vascular diseases (diabetic vascular complications)
- obesity more preferably dyslipidemia, hypercholesterolemia, low HDL cholesterolemia, high LDL cholesterolemia, arteriosclerosis, arteriosclerotic heart disease, or Coronary heart disease, more preferably dyslipidemia, low HDL cholesterolemia, arteriosclerosis, or coronary heart disease, even more preferably low HDL cholesterolemia or Arteriosclerosis, is a medicament for the treatment or prevention.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Obesity (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Vascular Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pyridine Compounds (AREA)
Abstract
Description
置換ピリジン化合物またはその薬理上許容される塩を有効成分として含有する、医薬組成物、好適には、脂質異常症、高コレステロ-ル血症、低HDLコレステロール血症、高LDLコレステロール血症、高トリグリセリド血症、動脈硬化症、動脈硬化性心疾患、冠状動脈性心疾患(心不全、心筋梗塞、狭心症、心虚血、心血管障害、および、血管形成性再狭窄を含む)、脳血管疾患(脳卒中、および、脳梗塞を含む)、末梢血管疾患(糖尿病血管合併症を含む)、または、肥満症、より好適には、脂質異常症、低HDLコレステロール血症、高LDLコレステロール血症、動脈硬化症、動脈硬化性心疾患、または、冠状動脈性心疾患、さらに好適には、脂質異常症、低HDLコレステロール血症、動脈硬化症、または、冠状動脈性心疾患、さらにより好適には、低HDLコレステロール血症または動脈硬化症、の治療もしくは予防のための医薬組成物;
疾患(好適には、上記疾患)の治療もしくは予防(好適には、治療)のためのの医薬組成物の製造のための置換ピリジン化合物またはその薬理上許容される塩の使用;
置換ピリジン化合物またはその薬理上許容される塩の薬剤的な有効量を温血動物(好適には、ヒト)に投与することによる疾患(好適には、上記疾患)の治療もしくは予防(好適には、治療)のための方法;および、
置換ピリジン化合物またはその薬理上許容される塩あるいはその中間体の製造方法
を提供する。
(1A) 一般式(I)
置換基群αは、C1-C6アルキル基、ヒドロキシ(C1-C6アルキル)基、ハロゲノ(C1-C6アルキル)基、(C3-C8シクロアルキル)-(C1-C6アルキル)基、C3-C8シクロアルキル基、ヒドロキシ基、C1-C6アルコキシ基、ハロゲノ(C1-C6アルコキシ)基、C1-C6アルキルアミノ基、ジ(C1-C6アルキル)アミノ基、カルボキシ基、(C1-C6アルコキシ)カルボニル基、カルバモイル基、(C1-C6アルキルアミノ)カルボニル基、ジ(C1-C6アルキル)アミノカルボニル基、シアノ基、ハロゲノ基、および、オキソ基からなる群を示す。]
を有する化合物またはその薬理上許容される塩。
(2A) 一般式(I-1)
(3A) R1が、水素原子、C1-C6アルキル基、ヒドロキシ(C1-C6アルキル)基、(C1-C6アルコキシ)-(C1-C6アルキル)基、(C1-C6アルキル)アミノ-(C1-C6アルキル)基、[N-(C1-C6アルキル)-N-ヒドロキシ(C1-C6アルキル)アミノ]-(C1-C6アルキル)基、[N-(C1-C6アルキル)-N-(C1-C6アルキル)スルホニルアミノ]-(C1-C6アルキル)基、カルボキシ(C1-C6アルキル)基、ハロゲノ(C1-C6アルキル)基、C2-C6アルケニル基、C3-C8シクロアルキル基、C3-C8シクロアルケニル基、ヒドロキシ基、C1-C6アルコキシ基、ヒドロキシ(C1-C6アルコキシ)基、(C1-C6アルキル)スルホニル-(C1-C6アルコキシ)基、カルボキシ(C1-C6アルコキシ)基、ハロゲノ(C1-C6アルコキシ)基、C1-C6アルキルチオ基、C1-C6アルキルスルホニル基、N-(C1-C6アルキル)-N-ヒドロキシ(C1-C6アルキル)アミノ基、(C1-C6アルキルアミノ)カルボニル基、ジ(C1-C6アルキル)アミノカルボニル基、シアノ基、または、ハロゲノ基である、(2A)に記載された化合物またはその薬理上許容される塩。
(4A) R1が、水素原子、C1-C4アルキル基、ヒドロキシ(C1-C4アルキル)基、(C1-C4アルコキシ)-(C1-C4アルキル)基、ハロゲノ(C1-C4アルキル)基、C1-C4アルコキシ基、ヒドロキシ(C1-C6アルコキシ)基、または、(C1-C4アルキル)スルホニル-(C1-C4アルコキシ)基である、(2A)に記載された化合物またはその薬理上許容される塩。
(5A) R1が、C1-C4アルキル基、ハロゲノ(C1-C4アルキル)基、C1-C4アルコキシ基、または、ヒドロキシ(C1-C6アルコキシ)基である、(2A)に記載された化合物またはその薬理上許容される塩。
(6A) R1が、C1-C4アルキル基である、(2A)に記載された化合物またはその薬理上許容される塩。
(7A) R1が、ハロゲノ(C1-C4アルキル)基である、(2A)に記載された化合物またはその薬理上許容される塩。
(8A) R1が、C1-C4アルコキシ基である、(2A)に記載された化合物またはその薬理上許容される塩。
(9A) R1が、ヒドロキシ(C1-C6アルコキシ)基である、(2A)に記載された化合物またはその薬理上許容される塩。
(10A) R1が、(C1-C4アルキル)スルホニル-(C1-C4アルコキシ)基である、(2A)に記載された化合物またはその薬理上許容される塩。
(11A) R1が、置換フェニル基(当該置換基は、独立して置換基群α1から選択される1乃至4個の基を示す)、置換5または6員芳香族ヘテロシクリル基(当該置換基は、独立して置換基群α1から選択される1乃至4個の基を示す)、5または6員飽和ヘテロシクリル基、置換5または6員飽和ヘテロシクリル基(当該置換基は、独立して置換基群α1から選択される1乃至4個の基を示す)、置換5または6員飽和ヘテロシクリルオキシ基(当該置換基は、独立して置換基群α1から選択される1乃至4個の基を示す)、または、5または6員飽和ヘテロシクリルカルボニル基であり、
置換基群α1は、C1-C6アルキル基、ヒドロキシ基、カルボキシ基、および、オキソ基からなる群を示す、(2A)に記載された化合物またはその薬理上許容される塩。
(12A) R1が、5または6員含窒素飽和ヘテロシクリル基、置換5または6員含窒素飽和ヘテロシクリル基(当該置換基は、独立して置換基群α2から選択される1乃至4個の基を示す)、置換5または6員含窒素飽和ヘテロシクリルオキシ基(当該置換基は、独立して置換基群α2から選択される1乃至4個の基を示す)、または、5または6員含窒素飽和ヘテロシクリルカルボニル基であり、
置換基群α2は、C1-C4アルキル基、および、ヒドロキシ基からなる群を示す、(2A)に記載された化合物またはその薬理上許容される塩。
(13A) R1が、置換ピロリジニル基、置換ピペラジル基、置換ピロリジニルオキシ基、または、置換ピペリジルオキシ基(当該ピロリジニル基、ピペラジル基、ピロリジニルオキシ基、および、ピペリジルオキシ基の置換基は、独立して置換基群α3から選択される1乃至2個の基を示す)、または、モルホリニルカルボニル基であり、
置換基群α3は、メチル基、および、ヒドロキシ基からなる群を示す、(2A)に記載された化合物またはその薬理上許容される塩。
(14A) R1が、置換フェニル基(当該置換基は、独立して置換基群α1から選択される1乃至2個の基を示す)である、(2A)に記載された化合物またはその薬理上許容される塩。
(15A) (5S)-4-(4,4-ジフルオロシクロヘキシル)-3-{(S)-フルオロ[4-(トリフルオロメチル)フェニル]メチル}-7,7-ジメチル-2-{1-[5-(4-メチルピペラジン-1-イル)ピリミジン-2-イル]ピペリジン-4-イル}-5,6,7,8-テトラヒドロキノリン-5-オール、
(5S)-4-(4,4-ジフルオロシクロヘキシル)-3-{(S)-フルオロ[4-(トリフルオロメチル)フェニル]メチル}-2-{1-[5-(2-ヒドロキシエトキシ)ピリミジン-2-イル]ピペリジン-4-イル}-7,7-ジメチル-5,6,7,8-テトラヒドロキノリン-5-オール、
(5S)-2-{1-[5-(4-カルボキシブトキシ)ピリミジン-2-イル]ピペリジン-4-イル}-4-(4,4-ジフルオロシクロヘキシル)-3-{(S)-フルオロ[4-(トリフルオロメチル)フェニル]メチル}-7,7-ジメチル-5,6,7,8-テトラヒドロキノリン-5-オール、
(5S)-2-{1-[5-(4-カルボキシブチル)ピリミジン-2-イル]ピペリジン-4-イル}-4-(4,4-ジフルオロシクロヘキシル)-3-{(S)-フルオロ[4-(トリフルオロメチル)フェニル]メチル}-7,7-ジメチル-5,6,7,8-テトラヒドロキノリン-5-オール、
(5S)-4-(4,4-ジフルオロシクロヘキシル)-3-{(S)-フルオロ[4-(トリフルオロメチル)フェニル]メチル}-7,7-ジメチル-2-{1-[5-(メチルカルバモイル)ピリミジン-2-イル]ピペリジン-4-イル}-5,6,7,8-テトラヒドロキノリン-5-オール、
(5S)-4-(4,4-ジフルオロシクロヘキシル)-2-{1-[5-(ジメチルカルバモイル)ピリミジン-2-イル]ピペリジン-4-イル}-3-{(S)-フルオロ[4-(トリフルオロメチル)フェニル]メチル}-7,7-ジメチル-5,6,7,8-テトラヒドロキノリン-5-オール、
(5S)-4-(4,4-ジフルオロシクロヘキシル)-3-{(S)-フルオロ[4-(トリフルオロメチル)フェニル]メチル}-7,7-ジメチル-2-{1-[5-(モルホリン-4-イルカルボニル)ピリミジン-2-イル]ピペリジン-4-イル}-5,6,7,8-テトラヒドロキノリン-5-オール、
(5S)-4-(4,4-ジフルオロシクロヘキシル)-3-{(S)-フルオロ[4-(トリフルオロメチル)フェニル]メチル}-2-{1-(5-{[(2-ヒドロキシエチル)(メチル)アミノ]メチル}ピリミジン-2-イル)ピペリジン-4-イル}-7,7-ジメチル-5,6,7,8-テトラヒドロキノリン-5-オール、
(5S)-4-(4,4-ジフルオロシクロヘキシル)-3-{(S)-フルオロ[4-(トリフルオロメチル)フェニル]メチル}-2-[1-(5-{[(2S)-2-ヒドロキシプロピル]オキシ}ピリミジン-2-イル)ピペリジン-4-イル]-7,7-ジメチル-5,6,7,8-テトラヒドロキノリン-5-オール、
(5S)-4-(4,4-ジフルオロシクロヘキシル)-3-{(S)-フルオロ[4-(トリフルオロメチル)フェニル]メチル}-7,7-ジメチル-2-(1-{5-[(1-メチルピペリジン-4-イル)オキシ]ピリミジン-2-イル}ピペリジン-4-イル)-5,6,7,8-テトラヒドロキノリン-5-オール、
(5S)-4-(4,4-ジフルオロシクロヘキシル)-2-[1-(5-{[(2S)-2,3-ジヒドロキシプロピル]オキシ}ピリミジン-2-イル)ピペリジン-4-イル]-3-{(S)-フルオロ[4-(トリフルオロメチル)フェニル]メチル}-7,7-ジメチル-5,6,7,8-テトラヒドロキノリン-5-オール、
(5S)-4-(4,4-ジフルオロシクロヘキシル)-2-[1-(5-{[(2R)-2,3-ジヒドロキシプロピル]オキシ}ピリミジン-2-イル)ピペリジン-4-イル]-3-{(S)-フルオロ[4-(トリフルオロメチル)フェニル]メチル}-7,7-ジメチル-5,6,7,8-テトラヒドロキノリン-5-オール、
(5S)-4-(4,4-ジフルオロシクロヘキシル)-3-{(S)-フルオロ[4-(トリフルオロメチル)フェニル]メチル}-7,7-ジメチル-2-[1-(5-{[(3R)-1-メチルピロリジン-3-イル]オキシ}ピリミジン-2-イル)ピペリジン-4-イル]-5,6,7,8-テトラヒドロキノリン-5-オール、
(5S)-4-(4,4-ジフルオロシクロヘキシル)-3-{(S)-フルオロ[4-(トリフルオロメチル)フェニル]メチル}-2-[1-(5-{[(2R)-2-ヒドロキシプロピル]オキシ}ピリミジン-2-イル)ピペリジン-4-イル]-7,7-ジメチル-5,6,7,8-テトラヒドロキノリン-5-オール、
(5S)-4-(4,4-ジフルオロシクロヘキシル)-3-{(S)-フルオロ[4-(トリフルオロメチル)フェニル]メチル}-2-{1-[5-(3-ヒドロキシ-3-メチルブトキシ)ピリミジン-2-イル]ピペリジン-4-イル}-7,7-ジメチル-5,6,7,8-テトラヒドロキノリン-5-オール、
(5S)-4-(4,4-ジフルオロシクロヘキシル)-3-{(S)-フルオロ[4-(トリフルオロメチル)フェニル]メチル}-2-{1-[5-(2-ヒドロキシ-2-メチルプロポキシ)ピリミジン-2-イル]ピペリジン-4-イル}-7,7-ジメチル-5,6,7,8-テトラヒドロキノリン-5-オール、
(5S)-4-(4,4-ジフルオロシクロヘキシル)-3-{(S)-フルオロ[4-(トリフルオロメチル)フェニル]メチル}-7,7-ジメチル-2-(1-{5-[3-(メチルスルホニル)プロポキシ]ピリミジン-2-イル}ピペリジン-4-イル)-5,6,7,8-テトラヒドロキノリン-5-オール、
(5S)-4-(4,4-ジフルオロシクロヘキシル)-3-{(S)-フルオロ[4-(トリフルオロメチル)フェニル]メチル}-2-{1-[5-(3-ヒドロキシプロポキシ)ピリミジン-2-イル]ピペリジン-4-イル}-7,7-ジメチル-5,6,7,8-テトラヒドロキノリン-5-オール、
(5S)-4-(4,4-ジフルオロシクロヘキシル)-3-{(S)-フルオロ[4-(トリフルオロメチル)フェニル]メチル}-7,7-ジメチル-2-{1-[5-(3,3,3-トリフルオロプロポキシ)ピリミジン-2-イル]ピペリジン-4-イル}-5,6,7,8-テトラヒドロキノリン-5-オール、
(5S)-4-(4,4-ジフルオロシクロヘキシル)-3-{(S)-フルオロ[4-(トリフルオロメチル)フェニル]メチル}-2-(1-{5-[3-ヒドロキシ-2-(ヒドロキシメチル)プロポキシ]ピリミジン-2-イル}ピペリジン-4-イル)-7,7-ジメチル-5,6,7,8-テトラヒドロキノリン-5-オール、
(5S)-4-(4,4-ジフルオロシクロヘキシル)-3-{(S)-フルオロ[4-(トリフルオロメチル)フェニル]メチル}-2-(1-{5-[3-ヒドロキシ-2-(ヒドロキシメチル)-2-メチルプロポキシ]ピリミジン-2-イル}ピペリジン-4-イル)-7,7-ジメチル-5,6,7,8-テトラヒドロキノリン-5-オール、
(5S)-4-(4,4-ジフルオロシクロヘキシル)-3-{(S)-フルオロ[4-(トリフルオロメチル)フェニル]メチル}-7,7-ジメチル-2-[1-(5-{[メチル(メチルスルホニル)アミノ]メチル}ピリミジン-2-イル)ピペリジン-4-イル]-5,6,7,8-テトラヒドロキノリン-5-オール、
(5S)-4-(4,4-ジフルオロシクロヘキシル)-3-{(S)-フルオロ[4-(トリフルオロメチル)フェニル]メチル}-7,7-ジメチル-2-[1-(5-{[メチル(プロパン-2-イルスルホニル)アミノ]メチル}ピリミジン-2-イル)ピペリジン-4-イル]-5,6,7,8-テトラヒドロキノリン-5-オール、
(5S)-4-(4,4-ジフルオロシクロヘキシル)-3-{(S)-フルオロ[4-(トリフルオロメチル)フェニル]メチル}-7,7-ジメチル-2-[1-(5-メチルチオピリミジン-2-イル)ピペリジン-4-イル]-5,6,7,8-テトラヒドロキノリン-5-オール、
(5S)-4-(4,4-ジフルオロシクロヘキシル)-3-{(S)-フルオロ[4-(トリフルオロメチル)フェニル]メチル}-7,7-ジメチル-2-{1-[5-(メチルスルホニル)ピリミジン-2-イル]ピペリジン-4-イル}-5,6,7,8-テトラヒドロキノリン-5-オール、
(5S)-2-{1-[5-(3-カルボキシフェニル)ピリミジン-2-イル]ピペリジン-4-イル}-4-(4,4-ジフルオロシクロヘキシル)-3-{(S)-フルオロ[4-(トリフルオロメチル)フェニル]メチル}-7,7-ジメチル-5,6,7,8-テトラヒドロキノリン-5-オール、
(5S)-4-(4,4-ジフルオロシクロヘキシル)-3-{(S)-フルオロ[4-(トリフルオロメチル)フェニル]メチル}-2-(1-{5-[(2-ヒドロキシエチル)(メチル)アミノ]ピリミジン-2-イル}ピペリジン-4-イル)-7,7-ジメチル-5,6,7,8-テトラヒドロキノリン-5-オール、および、
(5S)-4-(4,4-ジフルオロシクロヘキシル)-3-{(S)-フルオロ[4-(トリフルオロメチル)フェニル]メチル}-2-(1-{5-[(3S)-3-ヒドロキシピロリジン-1-イル]ピリミジン-2-イル}ピペリジン-4-イル)-7,7-ジメチル-5,6,7,8-テトラヒドロキノリン-5-オール
からなる群より選択される、(2A)に記載された化合物またはその薬理上許容される塩。
(16A) (1A)乃至(15A)のいずれかに記載された化合物またはその薬理上許容される塩を有効成分として含有する医薬組成物。
(17A) 脂質異常症、高コレステロ-ル血症、低HDLコレステロール血症、高LDLコレステロール血症、高トリグリセリド血症、動脈硬化症、動脈硬化性心疾患、冠状動脈性心疾患、脳血管疾患、末梢血管疾患、または、肥満症の治療もしくは予防のための(16A)に記載された医薬組成物。
(18A) 脂質異常症、低HDLコレステロール血症、動脈硬化症、または、冠状動脈性心疾患の治療もしくは予防のための(16A)に記載された医薬組成物。
(19A) 低HDLコレステロール血症の治療もしくは予防のための(16A)に記載された医薬組成物。
(20A) 動脈硬化症の治療もしくは予防のための(16A)に記載された医薬組成物。
(21A) HDLコレステロールの血中濃度の低下により引き起こされる疾患の治療もしくは予防のための(16A)に記載された医薬組成物。
(22A) LDLコレステロールの血中濃度の上昇により引き起こされる疾患の治療もしくは予防のための(16)に記載された医薬組成物。
(23A) (1A)乃至(15A)のいずれかに記載された化合物またはその薬理上許容される塩を有効成分として含有するCETP阻害剤。
(24A) (1A)乃至(15A)のいずれかに記載された化合物またはその薬理上許容される塩を有効成分として含有するHDLコレステロール濃度上昇剤。
(25A) (1A)乃至(15A)のいずれかに記載された化合物またはその薬理上許容される塩を有効成分として含有するLDLコレステロール濃度低下剤。
(26A) 医薬組成物の製造のための、(1A)乃至(15A)のいずれかに記載された化合物またはその薬理上許容される塩の使用。
(27A) 脂質異常症、高コレステロ-ル血症、低HDLコレステロール血症、高LDLコレステロール血症、高トリグリセリド血症、動脈硬化症、動脈硬化性心疾患、冠状動脈性心疾患、脳血管疾患、末梢血管疾患、または、肥満症の治療もしくは予防のための医薬組成物の製造のための、(26A)に記載された使用。
(28A) 脂質異常症、低HDLコレステロール血症、動脈硬化症、または、冠状動脈性心疾患の治療もしくは予防のための医薬組成物の製造のための、(26A)に記載された使用。
(29A) 低HDLコレステロール血症の治療もしくは予防のための医薬組成物の製造のための、(26A)に記載された使用。
(30A) 動脈硬化症の治療もしくは予防のための医薬組成物の製造のための、(26A)に記載された使用。
(31A) 疾患の治療もしくは予防のための方法における使用のための、(1A)乃至(15A)のいずれかに記載された化合物またはその薬理上許容される塩。
(32A) 疾患が、脂質異常症、高コレステロ-ル血症、低HDLコレステロール血症、高LDLコレステロール血症、高トリグリセリド血症、動脈硬化症、動脈硬化性心疾患、冠状動脈性心疾患、脳血管疾患、末梢血管疾患、または、肥満症である、(31A)に記載された化合物またはその薬理上許容される塩。
(33A) 疾患が、脂質異常症、低HDLコレステロール血症、動脈硬化症、または、冠状動脈性心疾患である、(31A)に記載された化合物またはその薬理上許容される塩。
(34A) 疾患が、低HDLコレステロール血症である、(31A)に記載された化合物またはその薬理上許容される塩。
(35A) 疾患が、動脈硬化症である、(31A)に記載された化合物またはその薬理上許容される塩。
(36A) (1A)乃至(15A)のいずれかに記載された化合物またはその薬理上許容される塩の薬理的有効量を温血動物に投与することによる、疾患の治療もしくは予防のための方法。
(37A) 疾患が、脂質異常症、高コレステロ-ル血症、低HDLコレステロール血症、高LDLコレステロール血症、高トリグリセリド血症、動脈硬化症、動脈硬化性心疾患、冠状動脈性心疾患、脳血管疾患、末梢血管疾患、または、肥満症である、(36A)に記載された方法。
(38A) 疾患が、脂質異常症、低HDLコレステロール血症、動脈硬化症、または、冠状動脈性心疾患である、(36A)に記載された方法。
(39A) 疾患が、低HDLコレステロール血症である、(36A)に記載された方法。
(40A) 疾患が、動脈硬化症である、(36A)に記載された方法。
(41A) 温血動物が、ヒトである、(36A)乃至(40A)のいずれかに記載された方法。
(1) 一般式(I)
置換基群αは、C1-C6アルキル基、ヒドロキシ(C1-C6アルキル)基、ハロゲノ(C1-C6アルキル)基、(C3-C8シクロアルキル)-(C1-C6アルキル)基、C3-C8シクロアルキル基、ヒドロキシ基、C1-C6アルコキシ基、ハロゲノ(C1-C6アルコキシ)基、C1-C6アルキルアミノ基、ジ(C1-C6アルキル)アミノ基、カルボキシ基、(C1-C6アルコキシ)カルボニル基、カルバモイル基、(C1-C6アルキルアミノ)カルボニル基、ジ(C1-C6アルキル)アミノカルボニル基、シアノ基、ハロゲノ基、および、オキソ基からなる群を示す。]
を有する化合物またはその薬理上許容される塩。
(2) R1が、水素原子、C1-C6アルキル基、ヒドロキシ(C1-C6アルキル)基、(C1-C6アルコキシ)-(C1-C6アルキル)基、[N-(C1-C6アルキル)-N-ヒドロキシ(C1-C6アルキル)アミノ]-(C1-C6アルキル)基、[N-(C1-C6アルキル)-N-(C1-C6アルキル)スルホニルアミノ]-(C1-C6アルキル)基、カルボキシ(C1-C6アルキル)基、ハロゲノ(C1-C6アルキル)基、C2-C6アルケニル基、C3-C8シクロアルキル基、C3-C8シクロアルケニル基、ヒドロキシ基、C1-C6アルコキシ基、ヒドロキシ(C1-C6アルコキシ)基、(C1-C6アルキル)スルホニル-(C1-C6アルコキシ)基、カルボキシ(C1-C6アルコキシ)基、ハロゲノ(C1-C6アルコキシ)基、C1-C6アルキルチオ基、C1-C6アルキルスルホニル基、N-(C1-C6アルキル)-N-ヒドロキシ(C1-C6アルキル)アミノ基、(C1-C6アルキルアミノ)カルボニル基、ジ(C1-C6アルキル)アミノカルボニル基、シアノ基、または、ハロゲノ基である、(1)に記載された化合物またはその薬理上許容される塩。
(3) R1が、水素原子、C1-C4アルキル基、ヒドロキシ(C1-C4アルキル)基、(C1-C4アルコキシ)-(C1-C4アルキル)基、ハロゲノ(C1-C4アルキル)基、C1-C4アルコキシ基、ヒドロキシ(C1-C6アルコキシ)基、または、(C1-C4アルキル)スルホニル-(C1-C4アルコキシ)基である、(1)に記載された化合物またはその薬理上許容される塩。
(4) R1が、C1-C4アルキル基、ハロゲノ(C1-C4アルキル)基、C1-C4アルコキシ基、または、ヒドロキシ(C1-C6アルコキシ)基である、(1)に記載された化合物またはその薬理上許容される塩。
(5) R1が、C1-C4アルキル基である、(1)に記載された化合物またはその薬理上許容される塩。
(6) R1が、ハロゲノ(C1-C4アルキル)基である、(1)に記載された化合物またはその薬理上許容される塩。
(7) R1が、C1-C4アルコキシ基である、(1)に記載された化合物またはその薬理上許容される塩。
(8) R1が、ヒドロキシ(C1-C6アルコキシ)基である、(1)に記載された化合物またはその薬理上許容される塩。
(9) R1が、置換フェニル基(当該置換基は、独立して置換基群α1から選択される1乃至4個の基を示す)、置換5または6員芳香族ヘテロシクリル基(当該置換基は、独立して置換基群α1から選択される1乃至4個の基を示す)、5または6員飽和ヘテロシクリル基、置換5または6員飽和ヘテロシクリル基(当該置換基は、独立して置換基群α1から選択される1乃至4個の基を示す)、置換5または6員飽和ヘテロシクリルオキシ基(当該置換基は、独立して置換基群α1から選択される1乃至4個の基を示す)、または、5または6員飽和ヘテロシクリルカルボニル基であり、
置換基群α1は、C1-C6アルキル基、ヒドロキシ基、カルボキシ基、および、オキソ基からなる群を示す、(1)に記載された化合物またはその薬理上許容される塩。
(10) R1が、5または6員含窒素飽和ヘテロシクリル基、置換5または6員含窒素飽和ヘテロシクリル基(当該置換基は、独立して置換基群α2から選択される1乃至4個の基を示す)、または、置換5または6員含窒素飽和ヘテロシクリルオキシ基(当該置換基は、独立して置換基群α2から選択される1乃至4個の基を示す)であり、
置換基群α2は、C1-C4アルキル基、および、ヒドロキシ基からなる群を示す、(1)に記載された化合物またはその薬理上許容される塩。
(11) R1が、置換ピロリジニル基、置換ピペリジル基、置換ピペラジル基、置換チオモルホリニル基、置換ピロリジニルオキシ基、または、置換ピペリジルオキシ基(当該ピロリジニル基、ピペリジル基、ピペラジル基、チオモルホリニル基、ピロリジニルオキシ基、および、ピペリジルオキシ基の置換基は、独立して置換基群α3から選択される1乃至2個の基を示す)であり、
置換基群α3は、メチル基、および、ヒドロキシ基からなる群を示す、(1)に記載された化合物またはその薬理上許容される塩。
(12) (-)-4-(4,4-ジフルオロシクロヘキシル)-3-{フルオロ[4-(トリフルオロメチル)フェニル]メチル}-7,7-ジメチル-2-{1-[5-(4-メチルピペラジン-1-イル)ピリミジン-2-イル]ピペリジン-4-イル}-5,6,7,8-テトラヒドロキノリン-5-オール、
(-)-4-(4,4-ジフルオロシクロヘキシル)-3-{フルオロ[4-(トリフルオロメチル)フェニル]メチル}-2-{1-[5-(2-ヒドロキシエトキシ)ピリミジン-2-イル]ピペリジン-4-イル}-7,7-ジメチル-5,6,7,8-テトラヒドロキノリン-5-オール、
(-)-2-{1-[5-(4-カルボキシブトキシ)ピリミジン-2-イル]ピペリジン-4-イル}-4-(4,4-ジフルオロシクロヘキシル)-3-{フルオロ[4-(トリフルオロメチル)フェニル]メチル}-7,7-ジメチル-5,6,7,8-テトラヒドロキノリン-5-オール、
(-)-2-{1-[5-(4-カルボキシブチル)ピリミジン-2-イル]ピペリジン-4-イル}-4-(4,4-ジフルオロシクロヘキシル)-3-{フルオロ[4-(トリフルオロメチル)フェニル]メチル}-7,7-ジメチル-5,6,7,8-テトラヒドロキノリン-5-オール、
4-(4,4-ジフルオロシクロヘキシル)-3-{フルオロ[4-(トリフルオロメチル)フェニル]メチル}-7,7-ジメチル-2-{1-[5-(メチルカルバモイル)ピリミジン-2-イル]ピペリジン-4-イル}-5,6,7,8-テトラヒドロキノリン-5-オール、
(-)-4-(4,4-ジフルオロシクロヘキシル)-2-{1-[5-(ジメチルカルバモイル)ピリミジン-2-イル]ピペリジン-4-イル}-3-{フルオロ[4-(トリフルオロメチル)フェニル]メチル}-7,7-ジメチル-5,6,7,8-テトラヒドロキノリン-5-オール、
4-(4,4-ジフルオロシクロヘキシル)-3-{フルオロ[4-(トリフルオロメチル)フェニル]メチル}-7,7-ジメチル-2-{1-[5-(モルホリン-4-イルカルボニル)ピリミジン-2-イル]ピペリジン-4-イル}-5,6,7,8-テトラヒドロキノリン-5-オール、
(-)-4-(4,4-ジフルオロシクロヘキシル)-3-{フルオロ[4-(トリフルオロメチル)フェニル]メチル}-2-{1-(5-{[(2-ヒドロキシエチル)(メチル)アミノ]メチル}ピリミジン-2-イル)ピペリジン-4-イル}-7,7-ジメチル-5,6,7,8-テトラヒドロキノリン-5-オール、
(-)-4-(4,4-ジフルオロシクロヘキシル)-3-{フルオロ[4-(トリフルオロメチル)フェニル]メチル}-2-[1-(5-{[(2S)-2-ヒドロキシプロピル]オキシ}ピリミジン-2-イル)ピペリジン-4-イル]-7,7-ジメチル-5,6,7,8-テトラヒドロキノリン-5-オール、
4-(4,4-ジフルオロシクロヘキシル)-3-{フルオロ[4-(トリフルオロメチル)フェニル]メチル}-7,7-ジメチル-2-(1-{5-[(1-メチルピペリジン-4-イル)オキシ]ピリミジン-2-イル}ピペリジン-4-イル)-5,6,7,8-テトラヒドロキノリン-5-オール、
(-)-4-(4,4-ジフルオロシクロヘキシル)-2-[1-(5-{[(2S)-2,3-ジヒドロキシプロピル]オキシ}ピリミジン-2-イル)ピペリジン-4-イル]-3-{フルオロ[4-(トリフルオロメチル)フェニル]メチル}-7,7-ジメチル-5,6,7,8-テトラヒドロキノリン-5-オール、
(-)-4-(4,4-ジフルオロシクロヘキシル)-2-[1-(5-{[(2R)-2,3-ジヒドロキシプロピル]オキシ}ピリミジン-2-イル)ピペリジン-4-イル]-3-{フルオロ[4-(トリフルオロメチル)フェニル]メチル}-7,7-ジメチル-5,6,7,8-テトラヒドロキノリン-5-オール、
4-(4,4-ジフルオロシクロヘキシル)-3-{フルオロ[4-(トリフルオロメチル)フェニル]メチル}-7,7-ジメチル-2-[1-(5-{[(3R)-1-メチルピロリジン-3-イル]オキシ}ピリミジン-2-イル)ピペリジン-4-イル]-5,6,7,8-テトラヒドロキノリン-5-オール、
(-)-4-(4,4-ジフルオロシクロヘキシル)-3-{フルオロ[4-(トリフルオロメチル)フェニル]メチル}-2-[1-(5-{[(2R)-2-ヒドロキシプロピル]オキシ}ピリミジン-2-イル)ピペリジン-4-イル]-7,7-ジメチル-5,6,7,8-テトラヒドロキノリン-5-オール、
(-)-4-(4,4-ジフルオロシクロヘキシル)-3-{フルオロ[4-(トリフルオロメチル)フェニル]メチル}-2-{1-[5-(3-ヒドロキシ-3-メチルブトキシ)ピリミジン-2-イル]ピペリジン-4-イル}-7,7-ジメチル-5,6,7,8-テトラヒドロキノリン-5-オール、
4-(4,4-ジフルオロシクロヘキシル)-3-{フルオロ[4-(トリフルオロメチル)フェニル]メチル}-2-{1-[5-(2-ヒドロキシ-2-メチルプロポキシ)ピリミジン-2-イル]ピペリジン-4-イル}-7,7-ジメチル-5,6,7,8-テトラヒドロキノリン-5-オール、
(-)-4-(4,4-ジフルオロシクロヘキシル)-3-{フルオロ[4-(トリフルオロメチル)フェニル]メチル}-7,7-ジメチル-2-(1-{5-[3-(メチルスルホニル)プロポキシ]ピリミジン-2-イル}ピペリジン-4-イル)-5,6,7,8-テトラヒドロキノリン-5-オール、
(-)-4-(4,4-ジフルオロシクロヘキシル)-3-{フルオロ[4-(トリフルオロメチル)フェニル]メチル}-2-{1-[5-(3-ヒドロキシプロポキシ)ピリミジン-2-イル]ピペリジン-4-イル}-7,7-ジメチル-5,6,7,8-テトラヒドロキノリン-5-オール、
(-)-4-(4,4-ジフルオロシクロヘキシル)-3-{フルオロ[4-(トリフルオロメチル)フェニル]メチル}-7,7-ジメチル-2-{1-[5-(3,3,3-トリフルオロプロポキシ)ピリミジン-2-イル]ピペリジン-4-イル}-5,6,7,8-テトラヒドロキノリン-5-オール、
(-)-4-(4,4-ジフルオロシクロヘキシル)-3-{フルオロ[4-(トリフルオロメチル)フェニル]メチル}-2-(1-{5-[3-ヒドロキシ-2-(ヒドロキシメチル)プロポキシ]ピリミジン-2-イル}ピペリジン-4-イル)-7,7-ジメチル-5,6,7,8-テトラヒドロキノリン-5-オール、
(-)-4-(4,4-ジフルオロシクロヘキシル)-3-{フルオロ[4-(トリフルオロメチル)フェニル]メチル}-2-(1-{5-[3-ヒドロキシ-2-(ヒドロキシメチル)-2-メチルプロポキシ]ピリミジン-2-イル}ピペリジン-4-イル)-7,7-ジメチル-5,6,7,8-テトラヒドロキノリン-5-オール、
(-)-4-(4,4-ジフルオロシクロヘキシル)-3-{フルオロ[4-(トリフルオロメチル)フェニル]メチル}-7,7-ジメチル-2-[1-(5-{[メチル(メチルスルホニル)アミノ]メチル}ピリミジン-2-イル)ピペリジン-4-イル]-5,6,7,8-テトラヒドロキノリン-5-オール、
4-(4,4-ジフルオロシクロヘキシル)-3-{フルオロ[4-(トリフルオロメチル)フェニル]メチル}-7,7-ジメチル-2-[1-(5-{[メチル(プロパン-2-イルスルホニル)アミノ]メチル}ピリミジン-2-イル)ピペリジン-4-イル]-5,6,7,8-テトラヒドロキノリン-5-オール、
(-)-4-(4,4-ジフルオロシクロヘキシル)-3-{フルオロ[4-(トリフルオロメチル)フェニル]メチル}-7,7-ジメチル-2-[1-(5-メチルチオピリミジン-2-イル)ピペリジン-4-イル]-5,6,7,8-テトラヒドロキノリン-5-オール、
(-)-4-(4,4-ジフルオロシクロヘキシル)-3-{フルオロ[4-(トリフルオロメチル)フェニル]メチル}-7,7-ジメチル-2-{1-[5-(メチルスルホニル)ピリミジン-2-イル]ピペリジン-4-イル}-5,6,7,8-テトラヒドロキノリン-5-オール、
4-(4,4-ジフルオロシクロヘキシル)-3-{フルオロ[4-(トリフルオロメチル)フェニル]メチル}-2-(1-{5-[(2-ヒドロキシエチル)(メチル)アミノ]ピリミジン-2-イル}ピペリジン-4-イル)-7,7-ジメチル-5,6,7,8-テトラヒドロキノリン-5-オール、および、
(-)-4-(4,4-ジフルオロシクロヘキシル)-3-{フルオロ[4-(トリフルオロメチル)フェニル]メチル}-2-(1-{5-[(3S)-3-ヒドロキシピロリジン-1-イル]ピリミジン-2-イル}ピペリジン-4-イル)-7,7-ジメチル-5,6,7,8-テトラヒドロキノリン-5-オール
からなる群より選択される、(1)に記載された化合物またはその薬理上許容される塩。
(13) (1)乃至(12)のいずれかに記載された化合物またはその薬理上許容される塩を有効成分として含有する医薬組成物。
(14) 脂質異常症、高コレステロ-ル血症、低HDLコレステロール血症、高LDLコレステロール血症、高トリグリセリド血症、動脈硬化症、動脈硬化性心疾患、冠状動脈性心疾患、脳血管疾患、末梢血管疾患、または、肥満症の治療もしくは予防のための(13)に記載された医薬組成物。
(15) 脂質異常症、低HDLコレステロール血症、動脈硬化症、または、冠状動脈性心疾患の治療もしくは予防のための(13)に記載された医薬組成物。
(16) 低HDLコレステロール血症の治療もしくは予防のための(13)に記載された医薬組成物。
(17) 動脈硬化症の治療もしくは予防のための(13)に記載された医薬組成物。
(18) HDLコレステロールの血中濃度の低下により引き起こされる疾患の治療もしくは予防のための(13)に記載された医薬組成物。
(19) LDLコレステロールの血中濃度の上昇により引き起こされる疾患の治療もしくは予防のための(13)に記載された医薬組成物。
(20) (1)乃至(12)のいずれかに記載された化合物またはその薬理上許容される塩を有効成分として含有するCETP阻害剤。
(21) (1)乃至(12)のいずれかに記載された化合物またはその薬理上許容される塩を有効成分として含有するHDLコレステロール濃度上昇剤。
(22) (1)乃至(12)のいずれかに記載された化合物またはその薬理上許容される塩を有効成分として含有するLDLコレステロール濃度低下剤。
本発明の一般式(I)における各基は、下記の意味を有する。
(i)本発明の一般式(I)を有する化合物を溶媒(例えば、ジクロロメタン、アセトン、または、酢酸エチルなど)に溶解する;
(ii)反応溶液に酸または塩基を加え、反応混合物を撹拌する;
(iii)必要に応じて、反応混合物の加温および冷却、溶媒の留去、貧溶媒の添加、または、目的とする塩化合物の種結晶の添加を行う;および、
(iv)析出した固体を濾取する。
本発明の一般式(I)を有する化合物[以下、化合物(I)ともいう;他の式についても同様である]は、以下のA法(A法-1、2、3、および、4)、B法(B法-1および2)、C法、D法、E法、または、F法にしたがって製造することができる。
以下にA乃至F法の各工程の反応を説明する。
(A法)
A法は、化合物(I)に包含される化合物(Ia)および(Ib)を製造する方法である。
(A-1工程)
A-1工程は、化合物(1)を還元して、化合物(2)を製造する工程である。化合物(1)は、公知である。
(A-2工程)
A-2工程は、化合物(3)を塩基の存在下にてアセトニトリルと反応させて、化合物(4)を製造する工程である。化合物(3)は、公知である。
(A-3工程)
A-3工程は、化合物(2)および(4)を反応させ、次いで化合物(5)を反応させて、化合物(6)を製造する工程である。化合物(5)は、公知である。A-3工程において、過剰量の化合物(5)を用いることができる。
(A-4工程)
A-4工程は、化合物(6)を酸化して、化合物(7)を製造する工程である。
(A-5工程)
A-5工程は、化合物(7)を還元して、化合物(8)を製造する工程である。
(A-6工程)
A-6工程は、化合物(8)を塩基の存在下にてp-メトキシベンジルブロミドと反応させて、化合物(9)を製造する工程である。
(A-7工程)
A-7工程は、化合物(9)を4-トリフルオロメチルフェニルマグネシウムブロミドと反応させて、化合物(10)を製造する工程である。4-トリフルオロメチルフェニルマグネシウムブロミドは、4-トリフルオロメチルフェニルブロミドおよびマグネシウムから有機化学の分野で周知の方法により製造することができる。
(A-8工程)
A-8工程は、化合物(10)をフッ素化試薬と反応させて、化合物(11)を製造する工程である。
(A-9工程)
A-9工程は、化合物(11)を臭化亜鉛と反応させて、化合物(12)を製造する工程である。
(A-10工程)
A-10工程は、化合物(12)を光学活性カラムクロマトグラフィーによる光学分割に付し、単一のエナンチオマーである化合物(13)を得る工程である。
(A-11工程)
A-11工程は、化合物(13)を塩基の存在下にて5-ブロモ-2-クロロピリミジンと反応させて、化合物(14)を製造する工程である。
(A-12工程)
A-12工程は、化合物(14)をパラジウム触媒、リン試薬、および、塩基の存在下にてモルホリンと反応させて、化合物(15)を製造する工程である。
(A-13工程)
A-13工程は、化合物(15)を酸で処理して、化合物(Ia)を製造する工程である。
(A-14工程)
A-14工程は、化合物(Ia)を塩基の存在下にて化合物(16)と反応させて、化合物(Ib)を製造する工程である。
(B法)
B法は、化合物(I)に包含される化合物(Ic)を製造する方法である。
(B-1工程)
B-1工程は、化合物(13)を塩基の存在下にて2-クロロ-5-ホルミルピリミジンと反応させて、化合物(17)を製造する工程である。
(B-2工程)
B-2工程は、化合物(17)を還元して、化合物(18)を製造する工程である。
(B-3工程)
B-3工程は、化合物(18)を塩基の存在下にてメタンスルホニルクロリドと反応させ、次いで化合物(19)と反応させて、化合物(20)を製造する工程である。化合物(19)は、公知である。
(B-4工程)
B-4工程は、化合物(20)のp-メトキシベンジル基をアニソールおよび酸の存在下にて除去して、化合物(Ic)を製造する工程である。
(C法)
C法は、化合物(I)を製造する方法である。
(C-1工程)
C-1工程は、化合物(13)を塩基の存在下にて化合物(21)と反応させて、化合物(22)を製造する工程である。化合物(21)は、公知であるか、公知の化合物から容易に製造できるか、または、参考例にしたがって製造することができる。C-1工程は、A-12工程と同様のパラジウム触媒、リン試薬、および、塩基を用いて行うこともできる。
(C-2工程)
C-2工程は、化合物(22)のp-メトキシベンジル基をアニソールおよび酸の存在下にて除去して、化合物(I)を製造する工程である。
(D法)
D法は、化合物(I)に包含される化合物(Id)を製造する方法である。
(D-1工程)
D-1工程は、化合物(17)を化合物(23)と反応させて、化合物(24)を製造する工程である。化合物(23)は、公知であるか、または、公知の化合物から容易に製造できる。
(D-2工程)
D-2工程は、
(D-2A工程)酸の存在下にて化合物(24)のp-メトキシベンジル基を除去する工程;および、
(D-2B工程)D-2A工程で得られた化合物を脱水反応、または、還元反応に付すことにより化合物(Id)を製造する工程からなる。
(E法)
E法は、化合物(I)に包含される化合物(Ie)を製造する方法である。
(E-1工程)
E-1工程は、化合物(17)を酸化して、化合物(25)を製造する工程である。
(E-2工程)
E-2工程は、化合物(25)を縮合剤の存在下にて、アルコール化合物またはアミン化合物と反応させて、化合物(26)を製造する工程である。
(E-3工程)
E-3工程は、化合物(26)のp-メトキシベンジル基をアニソールおよび酸の存在下にて除去して、化合物(Ie)を製造する工程である。
F法は、化合物(I)に包含される化合物(If)を製造する方法である。
(F-1工程)
F-1工程は、
(F-1A工程)化合物(17)のp-メトキシベンジル基をアニソールおよび酸の存在下にて除去する工程;および、
(F-1B工程)F-1A工程で得られた化合物を還元剤の存在下にてアミン化合物と反応させて、化合物(If)を製造する工程からなる。
(F-1A工程)
F-1A工程は、B-4工程と同様の方法にしたがって行うことができる。
(F-1B工程)
使用される還元剤は、ホルミル基の還元的アミノ化反応に使用され得るものであれば限定はなく、好適には、トリアセトキシ水素化ホウ素ナトリウム、または、水素化ホウ素ナトリウムである。
Boc:tert-ブトキシカルボニル
PMB:p-メトキシベンジル
TBS:tert-ブチルジメチルシリル
(-)-4-(4,4-ジフルオロシクロヘキシル)-3-{フルオロ[4-(トリフルオロメチル)フェニル]メチル}-7,7-ジメチル-2-[1-(ピリミジン-2-イル)ピペリジン-4-イル]-5,6,7,8-テトラヒドロキノリン-5-オール
比旋光度:[α]D 23=-120°(C=0.13,メタノール)。
1H-NMRスペクトル(300MHz,CD2Cl2)δppm: 8.22 (2H, d, J = 5 Hz), 7.66 (2H, d, J = 8 Hz), 7.39 (2H, d, J = 8 Hz), 7.23 (1H, d, J = 47 Hz), 6.39 (1H, t, J = 5 Hz), 5.13 (1H, dt, J = 6, 6 Hz), 4.87-4.72 (1H, m), 4.57-4.43 (1H, m), 3.72-3.56 (1H, m), 2.91-2.55 (4H, m), 2.37-1.45 (15H, m), 1.13 (3H, s), 0.99 (3H, s), 0.71-0.55 (1H, m)。
マススペクトル(EI,m/z):632[M+]。
(実施例2)
2-[1-(5-ブロモピリミジン-2-イル)ピペリジン-4-イル]-4-(4,4-ジフルオロシクロヘキシル)-3-{フルオロ[4-(トリフルオロメチル)フェニル]メチル}-7,7-ジメチル-5,6,7,8-テトラヒドロキノリン-5-オール
得られた2-[1-(5-ブロモピリミジン-2-イル)ピペリジン-4-イル]-4-(4,4-ジフルオロシクロヘキシル)-3-{フルオロ[4-(トリフルオロメチル)フェニル]メチル}-5-[(4-メトキシベンジル)オキシ]-7,7-ジメチル-5,6,7,8-テトラヒドロキノリン63mg(0.076mmol)の1,4-ジオキサン0.5ml溶液に、メタノール1ml、および濃塩酸0.2mlを加え、50℃で7時間撹拌した。反応終了後、反応液を水に注加し、酢酸エチルで抽出した。有機層を飽和塩化ナトリウム水溶液で洗浄し、無水硫酸マグネシウムで乾燥した後、溶媒を減圧留去した。得られた残渣を分取薄層クロマトグラフィー[n-ヘキサン/酢酸エチル=70/30(V/V)]にて精製し、標記化合物46mgを白色固体として得た(収率85%)。
1H-NMRスペクトル(400MHz,CDCl3)δppm: 8.21 (2H, s), 7.64 (2H, d, J = 8 Hz), 7.37 (2H, d, J = 8 Hz), 7.21 (1H, d, J = 45 Hz), 5.12 (1H, q, J = 6 Hz), 4.66-4.77 (1H, m), 4.38-4.49 (1H, m), 3.68-3.55 (1H, m), 2.85-2.60 (4H, m), 2.38-2.21 (2H, m), 2.19-2.04 (4H, m), 1.98-1.48 (9H, m), 1.15 (3H, s), 1.01 (3H, s), 0.68-0.58 (1H, m)。
(実施例3)
(-)-4-(4,4-ジフルオロシクロヘキシル)-3-{フルオロ[4-(トリフルオロメチル)フェニル]メチル}-2-[1-(5-メトキシピリミジン-2-イル)ピペリジン-4-イル]-7,7-ジメチル-5,6,7,8-テトラヒドロキノリン-5-オール
比旋光度:[α]D 27=-85°(C=0.13,メタノール)。
1H-NMRスペクトル(300MHz,CDCl3)δppm:8.04 (2H, s), 7.63 (2H, d, J = 8 Hz), 7.36 (2H, d, J = 8 Hz), 7.20 (1H, d, J = 48 Hz), 5.12 (1H, dt, J = 6, 6 Hz), 4.72-4.61 (1H, m), 4.44-4.32 (1H, m), 3.77 (3H, s), 3.71-3.54 (1H, m), 2.91-2.57 (4H, m), 2.39-1.61 (15H, m), 1.15 (3H, s), 1.00 (3H, s), 0.70-0.56 (1H, m)。
マススペクトル(EI,m/z):662[M+]。
(実施例4)
(-)-4-(4,4-ジフルオロシクロヘキシル)-3-{フルオロ[4-(トリフルオロメチル)フェニル]メチル}-2-[1-(5-ヒドロキシピリミジン-2-イル)ピペリジン-4-イル]-7,7-ジメチル-5,6,7,8-テトラヒドロキノリン-5-オール
比旋光度:[α]D 28=-49°(C=0.30,クロロホルム)。
1H-NMRスペクトル(300MHz,CD2Cl2)δppm: 7.92 (2H, s), 7.66 (2H, d, J = 8 Hz), 7.39 (2H, d, J = 8 Hz), 7.23 (1H, d, J = 47 Hz), 5.80 (1H, br s), 5.12 (1H, dt, J = 6, 6 Hz), 4.68-4.53 (1H, m), 4.39-4.23 (1H, m), 3.74-3.55 (1H, m), 2.93-2.50 (4H, m), 2.37-1.42 (15H, m), 1.10 (3H, s), 0.97 (3H, s), 0.65-0.52 (1H, m)。
マススペクトル(EI,m/z):648[M+]。
(実施例5)
(-)-4-(4,4-ジフルオロシクロヘキシル)-3-{フルオロ[4-(トリフルオロメチル)フェニル]メチル}-7,7-ジメチル-2-{1-[5-(モルホリン-4-イル)ピリミジン-2-イル]ピペリジン-4-イル}-5,6,7,8-テトラヒドロキノリン-5-オール
得られた4-(4,4-ジフルオロシクロヘキシル)-3-{フルオロ[4-(トリフルオロメチル)フェニル]メチル}-5-[(4-メトキシベンジル)オキシ]-7,7-ジメチル-2-{1-[5-(モルホリン-4-イル)ピリミジン-2-イル]ピペリジン-4-イル}-5,6,7,8-テトラヒドロキノリン89mg(0.11mmol)の1,4-ジオキサン1.8ml溶液に4規定の塩化水素-1,4-ジオキサン溶液0.9mlを加え、50℃で5時間撹拌した。反応終了後、氷冷下で飽和炭酸水素ナトリウム水溶液を反応液に注加し、酢酸エチルで抽出した。有機層を飽和塩化ナトリウム水溶液で洗浄し、無水硫酸マグネシウムで乾燥した後、溶媒を減圧留去した。得られた残渣をシリカゲルカラムクロマトグラフィー[n-ヘキサン/酢酸エチル=70/30-50/50(V/V)]に付し、目的物を含む画分を減圧濃縮して、得られた固体にn-ヘキサンを加え、不溶物を濾取することにより、標記化合物63mgを白色固体として得た(収率83%)。
比旋光度:[α]D 23=-74°(C=0.12,クロロホルム)。
1H-NMRスペクトル(400MHz,CDCl3)δppm: 8.04 (2H, s), 7.63 (2H, d, J = 8 Hz), 7.36 (2H, d, J = 8 Hz), 7.21 (1H, d, J = 46 Hz), 5.15-5.08 (1H, m), 4.73-4.63 (1H, m), 4.44-4.35 (1H, m), 3.84 (4H, t, J = 5 Hz), 3.67-3.56 (1H, m), 2.96 (4H, t, J = 5 Hz), 2.84-2.59 (4H, m), 2.36-1.50 (15H, m), 1.15 (3H, s), 1.00 (3H, s), 0.67-0.59 (1H, m)。
マススペクトル(FAB,m/z):717[M+]。
(実施例6)
(-)-4-(4,4-ジフルオロシクロヘキシル)-3-{フルオロ[4-(トリフルオロメチル)フェニル]メチル}-7,7-ジメチル-2-{1-[5-(ピペリジン-1-イル)ピリミジン-2-イル]ピペリジン-4-イル}-5,6,7,8-テトラヒドロキノリン-5-オール
1H-NMRスペクトル(400MHz,CDCl3)δppm: 8.06 (2H, s), 7.63 (2H, d, J = 8 Hz), 7.36 (2H, d, J = 8 Hz), 7.20 (1H, d, J = 48 Hz), 5.16-5.08 (1H, m), 4.71-4.60 (1H, m), 4.43-4.33 (1H, m), 3.68-3.56 (1H, m), 2.92 (4H, t, J = 5 Hz), 2.84-2.60 (4H, m), 2.36-1.48 (21H, m), 1.15 (3H, s), 1.01 (3H, s), 0.67-0.59 (1H, m)。
比旋光度:[α]D 23=-70°(C=0.12,クロロホルム)。
マススペクトル(FAB,m/z):715[M+]。
(実施例7)
4-(4,4-ジフルオロシクロヘキシル)-2-(1-{5-[4-(エトキシカルボニル)ピペリジン-1-イル]ピリミジン-2-イル}ピペリジン-4-イル)-3-{フルオロ[4-(トリフルオロメチル)フェニル]メチル}-7,7-ジメチル-5,6,7,8-テトラヒドロキノリン-5-オール
1H-NMRスペクトル(500MHz,CDCl3)δppm: 8.05 (2H, s), 7.63 (2H, d, J = 8 Hz), 7.36 (2H, d, J = 8 Hz), 7.21 (1H, d, J = 53 Hz), 5.15-5.08 (1H, m), 4.72-4.62 (1H, m), 4.44-4.34 (1H, m), 4.16 (2H, q, J = 7 Hz), 3.67-3.56 (1H, m), 3.34-3.25 (2H, m), 2.83-2.59 (6H, m), 2.41-1.52 (20H, m), 1.26 (3H, t, J = 7 Hz), 1.14 (3H, s), 1.00 (3H, s), 0.66-0.60 (1H, m)。
マススペクトル(FAB,m/z):787[M+]。
(実施例8)
(-)-4-(4,4-ジフルオロシクロヘキシル)-3-{フルオロ[4-(トリフルオロメチル)フェニル]メチル}-7,7-ジメチル-2-{1-[5-(4-メチルピペラジン-1-イル)ピリミジン-2-イル]ピペリジン-4-イル}-5,6,7,8-テトラヒドロキノリン-5-オール
比旋光度:[α]D 23=-61°(C=0.13,クロロホルム)。
1H-NMRスペクトル(500MHz,CDCl3)δppm: 8.06 (2H, s), 7.63 (2H, d, J = 8 Hz), 7.36 (2H, d, J = 8 Hz), 7.21 (1H, d, J = 47 Hz), 5.18-5.06 (1H, m), 4.73-4.60 (1H, m), 4.46-4.33 (1H, m), 3.67-3.55 (1H, m), 3.01 (4H, t, J = 4 Hz), 2.91-2.49 (4H, m), 2.57 (4H, t, J = 4 Hz), 2.41-1.51 (15H, m), 2.34 (3H, s), 1.14 (3H, s), 1.00 (3H, s), 0.69-0.58 (1H, m)。
マススペクトル(FAB,m/z):730[M+]。
(実施例9)
(-)-4-(4,4-ジフルオロシクロヘキシル)-3-{フルオロ[4-(トリフルオロメチル)フェニル]メチル}-7,7-ジメチル-2-{1-[5-(チオモルホリン-4-イル)ピリミジン-2-イル]ピペリジン-4-イル}-5,6,7,8-テトラヒドロキノリン-5-オール
比旋光度:[α]D 23=-64°(C=0.22,クロロホルム)。
1H-NMRスペクトル(500MHz,CDCl3)δppm: 8.03 (2H, s), 7.63 (2H, d, J = 8 Hz), 7.36 (2H, d, J = 8 Hz), 7.21 (1H, d, J = 52 Hz), 5.15-5.07 (1H, m), 4.74-4.64 (1H, m), 4.46-4.36 (1H, m), 3.67-3.57 (1H, m), 3.22 (4H, t, J = 5 Hz), 2.84-2.58 (8H, m), 2.36-1.52 (15H, m), 1.14 (3H, s), 1.00 (3H, s), 0.67-0.60 (1H, m)。
マススペクトル(FAB,m/z):733[M+]。
(実施例10)
(-)-4-(4,4-ジフルオロシクロヘキシル)-2-{1-[5-(1,1-ジオキシドチオモルホリン-4-イル)ピリミジン-2-イル]ピペリジン-4-イル}-3-{フルオロ[4-(トリフルオロメチル)フェニル]メチル}-7,7-ジメチル-5,6,7,8-テトラヒドロキノリン-5-オール
比旋光度:[α]D 24=-67°(C=0.22,クロロホルム)。
1H-NMRスペクトル(400MHz,CDCl3)δppm: 8.08 (2H, s), 7.64 (2H, d, J = 8 Hz), 7.37 (2H, d, J = 8 Hz), 7.21 (1H, d, J = 44 Hz), 5.16-5.08 (1H, m), 4.76-4.66 (1H, m), 4.48-4.38 (1H, m), 3.68-3.57 (1H, m), 3.51 (4H, t, J = 5 Hz), 3.16 (4H, t, J = 5 Hz), 2.84-2.58 (4H, m), 2.36-1.52 (15H, m), 1.15 (3H, s), 1.01 (3H, s), 0.67-0.59 (1H, m)。
(実施例11)
(-)-4-(4,4-ジフルオロシクロヘキシル)-3-{フルオロ[4-(トリフルオロメチル)フェニル]メチル}-2-{1-[5-(4-ヒドロキシピペリジン-1-イル)ピリミジン-2-イル]ピペリジン-4-イル}-7,7-ジメチル-5,6,7,8-テトラヒドロキノリン-5-オール
比旋光度:[α]D 25=-58°(C=0.14,クロロホルム)。
1H-NMRスペクトル(400MHz,CDCl3)δppm: 8.06 (2H, s), 7.63 (2H, d, J = 8 Hz), 7.36 (2H, d, J = 8 Hz), 7.21 (1H, d, J = 47 Hz), 5.16-5.07 (1H, m), 4.72-4.61 (1H, m), 4.44-4.34 (1H, m), 3.86-3.74 (1H, m), 3.69-3.56 (1H, m), 3.29-3.20 (2H, m), 2.86-2.58 (6H, m), 2.36-1.48 (20H, m), 1.15 (3H, s), 1.00 (3H, s), 0.68-0.58 (1H, m)。
マススペクトル(FAB,m/z):731[M+]。
(実施例12)
4-(4,4-ジフルオロシクロヘキシル)-3-{フルオロ[4-(トリフルオロメチル)フェニル]メチル}-7,7-ジメチル-2-{1-[5-(プロパン-2-イル)ピリミジン-2-イル]ピペリジン-4-イル}-5,6,7,8-テトラヒドロキノリン-5-オール
1H-NMRスペクトル(400MHz,CDCl3)δppm:8.14 (2H, s), 7.64 (2H, d, J = 8 Hz), 7.37 (2H, d, J = 8 Hz), 7.21 (1H, d, J = 45 Hz), 5.12 (1H, q, J = 6 Hz), 4.80-4.69 (1H, m), 4.52-4.41 (1H, m), 3.68-3. 56 (1H, m), 2.84-2.58 (4H, m), 2.34-2.05 (6H, m), 1.97-1.48 (10H, m), 1.20 (6H, d, J = 7 Hz), 1.15 (3H, s), 1.00 (3H, s), 0.67-0.58 (1H, m)。
(実施例13)
4-(4,4-ジフルオロシクロヘキシル)-2-[1-(5-エトキシピリミジン-2-イル)ピペリジン-4-イル]-3-{フルオロ[4-(トリフルオロメチル)フェニル]メチル}-7,7-ジメチル-5,6,7,8-テトラヒドロキノリン-5-オール
1H-NMRスペクトル(400MHz,CDCl3)δppm:8.03 (2H, s), 7.63 (2H, d, J = 8 Hz), 7.36 (2H, d, J = 8 Hz), 7.21 (1H, d, J = 47 Hz), 5.12 (1H, q, J = 6 Hz), 4.71-4.59 (1H,m), 4.43-4.32 (1H, m), 3.97 (2H, q, J = 7 Hz), 3.68-3.55 (1H, m), 2.85-2.58 (4H, m), 2.36-2.02 (6H, m), 2.00-1.56 (9H, m), 1.37 (3H, t, J = 7 Hz), 1.15 (3H, s), 1.01 (3H, s), 0.67-0.58 (1H, m)。
(実施例14)
(-)-4-(4,4-ジフルオロシクロヘキシル)-3-{フルオロ[4-(トリフルオロメチル)フェニル]メチル}-7,7-ジメチル-2-{1-[5-(プロパン-2-イルオキシ)ピリミジン-2-イル]ピペリジン-4-イル}-5,6,7,8-テトラヒドロキノリン-5-オール
比旋光度:[α]D 24=-68°(C=0.26,クロロホルム)。
1H-NMRスペクトル(400MHz,CDCl3)δppm:8.01 (2H, s), 7.63 (2H, d, J = 8 Hz ,), 7.37 (2H, d, J = 8 Hz), 7.21 (1H, d, J = 46 Hz), 5.12 (1H, q, J = 6 Hz), 4.73-4.61 (1H, m), 4.46-4.33 (1H, m), 4.25 (1H, septet, J = 6 Hz), 3.70-3.56 (1H, m), 2.91-2.58 (4H, m), 2.36-2.04 (6H, m), 2.00-1.59 (9H, m), 1.29 (6H, d, J = 6 Hz), 1.15 (3H, s), 1.01 (3H, s), 0.70-0.57 (1H, m)。
(実施例15)
(-)-4-(4,4-ジフルオロシクロヘキシル)-3-{フルオロ[4-(トリフルオロメチル)フェニル]メチル}-2-{1-[5-(2-ヒドロキシエトキシ)ピリミジン-2-イル]ピペリジン-4-イル}-7,7-ジメチル-5,6,7,8-テトラヒドロキノリン-5-オール
得られた2-{1-[5-(2-{[tert-ブチル(ジメチル)シリル]オキシ}エトキシ)ピリミジン-2-イル]ピペリジン-4-イル}-4-(4,4-ジフルオロシクロヘキシル)-3-{フルオロ[4-(トリフルオロメチル)フェニル]メチル}-7,7-ジメチル-5,6,7,8-テトラヒドロキノリン-5-オール68mg(84μmol)のテトラヒドロフラン0.5ml溶液に1規定のフッ化テトラブチルアンモニウム/テトラヒドロフラン溶液0.13ml(0.13mmol)を加え、室温で1時間撹拌した。反応終了後、反応液を水に注加し、酢酸エチルで抽出した。有機層を飽和塩化ナトリウム水溶液で洗浄し、無水硫酸マグネシウムで乾燥した後、溶媒を減圧留去した。得られた残渣を分取薄層クロマトグラフィー[n-ヘキサン/酢酸エチル=50/50(V/V)]にて精製し、標記化合物52mgを白色固体として得た(収率89%)。
比旋光度:[α]D 24=-70°(C=0.17,クロロホルム)。
1H-NMRスペクトル(400MHz,CDCl3)δppm:8.06 (2H, s), 7.63 (2H, d, J = 8 Hz), 7.37 (2H, d, J = 8 Hz), 7.21 (1H, d, J = 47 Hz), 5.12 (1H, q, J = 7 Hz), 4.72-4.63 (1H, m), 4.44-4.33 (1H, m), 4.02 (2H, t, J = 5 Hz), 3.92 (2H, brs), 3.68-3.56 (1H, m), 2.84-2.58 (4H, m), 2.39-1.54 (16H, m), 1.15 (3H, s), 1.01 (3H, s), 0.70-0.58 (1H, m)。
(実施例16)
(-)-4-(4,4-ジフルオロシクロヘキシル)-3-{フルオロ[4-(トリフルオロメチル)フェニル]メチル}-7,7-ジメチル-2-[1-(5-ペンチルピリミジン-2-イル)ピペリジン-4-イル]-5,6,7,8-テトラヒドロキノリン-5-オール
比旋光度:[α]D 24=-71°(C=0.17,クロロホルム)。
1H-NMRスペクトル(500MHz,CDCl3)δppm: 8.08 (2H, s), 7.63 (2H, d, J = 8 Hz), 7.36 (2H, d, J = 8 Hz), 7.21 (1H, d, J = 46 Hz), 5.12 (1H, q, J = 6 Hz), 4.82-4.68 (1H, m), 4.53-4.41 (1H, m), 3.68-3.55 (1H, m), 2.94-2.58 (4H, m), 2.45-1.48 (19H, m), 1.36-1.21 (4H, m), 1.14 (3H, s), 1.00 (3H, s), 0.88 (3H, t, J = 7 Hz), 0.70-0.57 (1H, m)。
マススペクトル(ES,m/z):703[M+]。
(実施例17)
(-)-2-[1-(5-シアノピリミジン-2-イル)ピペリジン-4-イル]-4-(4,4-ジフルオロシクロヘキシル)-3-{フルオロ[4-(トリフルオロメチル)フェニル]メチル}-7,7-ジメチル-5,6,7,8-テトラヒドロキノリン-5-オール
比旋光度:[α]D 24=-81°(C=0.21,クロロホルム)。
1H-NMRスペクトル(400MHz,CDCl3)δppm: 8.42 (2H, s), 7.65 (2H, d, J = 8 Hz), 7.38 (2H, d, J = 8 Hz), 7.23 (1H, d, J = 47 Hz), 5.21-5.07 (1H, m), 4.95-4.82 (1H, m), 4.68-4.54 (1H, m), 3.71-3.55 (1H, m), 2.93-2.74 (3H, m), 2.63 (1H, d, J = 17 Hz), 2.38-1.59 (15H, m), 1.15 (3H, s), 1.01 (3H, s), 0.77-0.62 (1H, m)。
マススペクトル(FAB,m/z):658[(M+1)+]。
(実施例18)
(-)-2-{1-[5-(シクロヘキサ-1-エン-1-イル)ピリミジン-2-イル]ピペリジン-4-イル}-4-(4,4-ジフルオロシクロヘキシル)-3-{フルオロ[4-(トリフルオロメチル)フェニル]メチル}-7,7-ジメチル-5,6,7,8-テトラヒドロキノリン-5-オール
比旋光度:[α]D 25=-110°(C=0.050,メタノール)。
1H-NMRスペクトル(300MHz,CD2Cl2)δ: 8.27 (2H, s), 7.66 (2H, d, J = 8 Hz), 7.39 (2H, d, J = 8 Hz), 7.22 (1H, d, J = 47 Hz), 5.99-5.93 (1H, m), 5.13 (1H, dt, J = 6, 6 Hz), 4.84-4.70 (1H, m), 4.55-4.42 (1H, m), 3.72-3.56 (1H, m), 2.93-2.54 (4H, m), 2.38-1.55 (23H, m), 1.13 (3H, s), 0.99 (3H, s), 0.69-0.57 (1H, m)。
マススペクトル(EI,m/z):712[M+]。
(実施例19)
(-)-2-[1-(5-シクロプロピルピリミジン-2-イル)ピペリジン-4-イル]-4-(4,4-ジフルオロシクロヘキシル)-3-{フルオロ[4-(トリフルオロメチル)フェニル]メチル}-7,7-ジメチル-5,6,7,8-テトラヒドロキノリン-5-オール
得られた残渣25mgに1,4-ジオキサン1ml、および6規定塩酸50μlを加え、60℃で1.5時間、室温で13時間、更に60℃で5時間撹拌した。加熱撹拌後、6規定塩酸50μlを加え、60℃で更に3.5時間撹拌した。反応終了後、反応液を飽和炭酸水素ナトリウム水溶液に注加し、酢酸エチルで抽出した。有機層を飽和塩化ナトリウム水溶液で洗浄し、無水硫酸マグネシウムで乾燥した後、溶媒を減圧留去した。得られた残渣をシリカゲルカラムクロマトグラフィー[n-ヘキサン/酢酸エチル=95/5-70/30(V/V)]に付し、目的物を含む画分を減圧濃縮した。得られた残渣にジイソプロピルエーテル、およびn-ヘキサンを加え、析出物を濾取することにより、標記化合物22mgを白色固体として得た(収率27%)。
比旋光度:[α]D 25=-76°(C=0.045,メタノール)。
1H-NMRスペクトル(300MHz,CD2Cl2)δ: 8.04 (2H, s), 7.65 (2H, d, J = 8 Hz), 7.38 (2H, d, J = 8 Hz), 7.22 (1H, d, J = 48 Hz), 5.13 (1H, dt, J = 6, 6 Hz), 4.78-4.66 (1H, m), 4.48-4.38 (1H, m), 3.72-3.56 (1H, m), 2.89-2.55 (4H, m), 2.36-1.55 (16H, m), 1.13 (3H, s), 0.99 (3H, s), 0.89-0.83 (2H, m), 0.67-0.50 (3H, m)。
マススペクトル(EI,m/z):672[M+]。
(実施例20)
(-)-4-(4,4-ジフルオロシクロヘキシル)-3-{フルオロ[4-(トリフルオロメチル)フェニル]メチル}-2-[1-[5-(ヒドロキシメチル)ピリミジン-2-イル]ピペリジン-4-イル]-7,7-ジメチル-5,6,7,8-テトラヒドロキノリン-5-オール
得られた4-(4,4-ジフルオロシクロヘキシル)-3-{フルオロ[4-(トリフルオロメチル)フェニル]メチル}-2-[1-[5-(ヒドロキシメチル)ピリミジン-2-イル]ピペリジン-4-イル]-5-[(4-メトキシベンジル)オキシ]-7,7-ジメチル-5,6,7,8-テトラヒドロキノリン89mg(0.11mmol)に1,4-ジオキサン0.5ml、水0.5ml、および4規定の塩化水素-1,4-ジオキサン溶液0.5mlを加え、50℃で6時間撹拌した。反応終了後、反応液を飽和炭酸水素ナトリウム水溶液に注加し、酢酸エチルで抽出した。有機層を飽和塩化ナトリウム水溶液で洗浄し、無水硫酸マグネシウムで乾燥した後、溶媒を減圧留去した。得られた残渣をシリカゲルカラムクロマトグラフィー[n-ヘキサン/酢酸エチル=100/0-50/50(V/V)]に付し、目的物を含む画分を減圧濃縮することにより、標記化合物41mgを白色固体として得た(収率54%)。
比旋光度:[α]D 24=-81°(C=0.15,クロロホルム)。
1H-NMRスペクトル(400MHz,CDCl3)δppm:8.23 (2H, s), 7.64 (2H, d, J = 8 Hz), 7.37 (2H, d, J = 8 Hz), 7.21 (1H, d, J = 46 Hz), 5.16-5.06 (1H, m), 4.84-4.74 (1H, m), 4.56-4.44 (1H, m), 4.46 (2H, s), 3.71-3.54 (1H, m), 2.88-2.69 (3H, m), 2.63 (1H, d, J = 17 Hz), 2.37-1.50 (16H, m), 1.14 (3H, s), 1.00 (3H, s), 0.70-0.57 (1H, m)。
マススペクトル(FAB,m/z):663[(M+1)+]。
(実施例21)
(-)-4-(4,4-ジフルオロシクロヘキシル)-3-{フルオロ[4-(トリフルオロメチル)フェニル]メチル}-7,7-ジメチル-2-{1-[5-(2-メチルプロポキシ)ピリミジン-2-イル]ピペリジン-4-イル}-5,6,7,8-テトラヒドロキノリン-5-オール
比旋光度:[α]D 27=-65°(C=0.15,メタノール)。
1H-NMRスペクトル(300MHz,CD2Cl2)δ: 8.01 (2H, s), 7.65 (2H, d, J = 8 Hz), 7.38 (2H, d, J = 8 Hz), 7.22 (1H, d, J = 47 Hz), 5.13 (1H, dt, J = 6, 6 Hz), 4.71-4.59 (1H, m), 4.41-4.30 (1H, m), 3.70-3.57 (1H, m), 3.67 (2H, d, J = 7 Hz), 2.88-2.55 (4H, m), 2.37-1.57 (16H, m), 1.13 (3H, s), 1.00 (3H, s), 0.99 (6H, d, J = 7 Hz), 0.66-0.55 (1H, m)。
マススペクトル(EI,m/z):704[M+]。
(実施例22)
(-)-4-(4,4-ジフルオロシクロヘキシル)-3-{フルオロ[4-(トリフルオロメチル)フェニル]メチル}-7,7-ジメチル-2-{1-[5-(3-メチルブトキシ)ピリミジン-2-イル]ピペリジン-4-イル}-5,6,7,8-テトラヒドロキノリン-5-オール
比旋光度:[α]D 27=-69°(C=0.18,メタノール)。
1H-NMRスペクトル(300MHz,CD2Cl2)δ: 8.01 (2H, s), 7.65 (2H, d, J = 8 Hz), 7.38 (2H, d, J = 8 Hz), 7.22 (1H, d, J = 48 Hz), 5.13 (1H, dt, J = 6, 6 Hz), 4.70-4.59 (1H, m), 4.42-4.30 (1H, m), 3.93 (2H, t, J = 7 Hz), 3.72-3.56 (1H, m), 2.86-2.55 (4H, m), 2.37-1.56 (18H, m), 1.13 (3H, s), 1.00 (3H, s), 0.94 (6H, d ,J = 7 Hz), 0.67-0.57 (1H, m)。
マススペクトル(EI,m/z):718[M+]。
(実施例23)
(-)-2-{1-[5-(4-カルボキシブトキシ)ピリミジン-2-イル]ピペリジン-4-イル}-4-(4,4-ジフルオロシクロヘキシル)-3-{フルオロ[4-(トリフルオロメチル)フェニル]メチル}-7,7-ジメチル-5,6,7,8-テトラヒドロキノリン-5-オール
2-{1-[5-(4-エトキシカルボニルブトキシ)ピリミジン-2-イル]ピペリジン-4-イル}-4-(4,4-ジフルオロシクロヘキシル)-3-{フルオロ[4-(トリフルオロメチル)フェニル]メチル}-7,7-ジメチル-5,6,7,8-テトラヒドロキノリン-5-オール
(23-2)
(-)-2-{1-[5-(4-カルボキシブトキシ)ピリミジン-2-イル]ピペリジン-4-イル}-4-(4,4-ジフルオロシクロヘキシル)-3-{フルオロ[4-(トリフルオロメチル)フェニル]メチル}-7,7-ジメチル-5,6,7,8-テトラヒドロキノリン-5-オール
比旋光度:[α]D 24=-92°(C=0.13,クロロホルム)。
1H-NMRスペクトル(400MHz,CDCl3)δppm:8.01 (2H, s), 7.63 (2H, d, J = 8 Hz), 7.35 (2H, d, J = 8 Hz), 7.20 (1H, d, J = 48 Hz), 5.12 (1H, t, J = 5 Hz), 4.68-4.59 (1H, m), 4.40-4.30 (1H, m), 3.95-3.85 (2H , m), 3.67-3.55 (1H, m), 2.86-2.58 (4H, m), 2.46-1.58 (21H, m), 1.14 (3H ,s), 1.00 (3H, s), 0.67-0.56 (1H, m)。
マススペクトル(FAB,m/z):749[(M+1)+]。
(実施例24)
(-)-4-(4,4-ジフルオロシクロヘキシル)-3-{フルオロ[4-(トリフルオロメチル)フェニル]メチル}-7,7-ジメチル-2-{1-[5-(2-メチルプロピル)ピリミジン-2-イル]ピペリジン-4-イル}-5,6,7,8-テトラヒドロキノリン-5-オール
比旋光度:[α]D 24=-88°(C=0.050,メタノール)。
1H-NMRスペクトル(300MHz,CD2Cl2)δ: 8.05 (2H, s), 7.65 (2H, d, J = 8 Hz), 7.39 (2H, d, J = 8 Hz), 7.22 (1H, d, J = 47 Hz), 5.13 (1H, dt, J = 6, 6 Hz), 4.80-4.68 (1H, m), 4.51-4.39 (1H, m), 3.72-3.55 (1H, m), 2.88-2.55 (4H, m), 2.37-1.49 (18H, m), 1.13 (3H, s), 0.99 (3H, s), 0.88 (6H, d, J = 7 Hz), 0.68-0.57 (1H, m)。
マススペクトル(EI,m/z):688[M+]。
(実施例25)
(-)-2-{1-[5-(4-カルボキシブチル)ピリミジン-2-イル]ピペリジン-4-イル}-4-(4,4-ジフルオロシクロヘキシル)-3-{フルオロ[4-(トリフルオロメチル)フェニル]メチル}-7,7-ジメチル-5,6,7,8-テトラヒドロキノリン-5-オール
比旋光度:[α]D 25=-68°(C=0.14,クロロホルム)。
1H-NMRスペクトル(500MHz,CDCl3)δppm: 8.09 (2H, s), 7.63 (2H, d, J = 8 Hz), 7.36 (2H, d, J = 8 Hz), 7.21 (1H, d, J = 47 Hz), 5.15-5.08 (1H, m), 4.78-4.68 (1H, m), 4.50-4.40 (1H, m), 3.67-3.57 (1H, m), 2.84-2.59 (4H, m), 2.47-1.49 (23H, m), 1.14 (3H, s), 1.00 (3H, s), 0.67-0.59 (1H, m)。
マススペクトル(FAB,m/z):733[(M+1)+]。
(実施例26)
(-)-4-(4,4-ジフルオロシクロヘキシル)-2-{1-[5-(エトキシメチル)ピリミジン-2-イル]ピペリジン-4-イル}-3-{フルオロ[4-(トリフルオロメチル)フェニル]メチル}-7,7-ジメチル-5,6,7,8-テトラヒドロキノリン-5-オール
比旋光度:[α]D 24=-65°(C=0.055,メタノール)。
1H-NMRスペクトル(300MHz,CD2Cl2)δ: 8.20 (2H, s), 7.66 (2H, d, J = 8 Hz), 7.39 (2H, d, J = 8 Hz), 7.22 (1H, d, J = 47 Hz), 5.12 (1H, dt, J = 6, 6 Hz), 4.84-4.74 (1H, m), 4.55-4.44 (1H, m), 4.25 (2H, s), 3.71-3.56 (1H, m), 3.47 (2H, q, J = 7 Hz), 2.91-2.55 (4H, m), 2.36-1.55 (15H, m), 1.17 (3H, t, J = 7 Hz), 1.13 (3H, s), 0.99 (3H, s), 0.68-0.58 (1H, m)。
マススペクトル(EI,m/z):690[M+]。
(実施例27)
(-)-4-(4,4-ジフルオロシクロヘキシル)-3-{フルオロ[4-(トリフルオロメチル)フェニル]メチル}-2-{1-[5-(メトキシメチル)ピリミジン-2-イル]ピペリジン-4-イル}-7,7-ジメチル-5,6,7,8-テトラヒドロキノリン-5-オール
比旋光度:[α]D 24=-82°(C=0.090,メタノール)。
1H-NMRスペクトル(300MHz,CD2Cl2)δ: 8.19 (2H, s), 7.66 (2H, d, J = 8 Hz), 7.39 (2H, d, J = 8 Hz), 7.23 (1H, d, J = 47 Hz), 5.13 (1H, dt, J = 6, 6 Hz), 4.86-4.74 (1H, m), 4.56-4.45 (1H, m), 4.20 (2H, s), 3.72-3.56 (1H, m), 3.30 (3H, s), 2.90-2.55 (4H, m), 2.37-1.48 (15H, m), 1.13 (3H, s), 0.99 (3H, s), 0.68-0.58 (1H, m)。
マススペクトル(EI,m/z):676[M+]。
(実施例28)
(-)-4-(4,4-ジフルオロシクロヘキシル)-3-{フルオロ[4-(トリフルオロメチル)フェニル]メチル}-7,7-ジメチル-2-(1-{5-[(プロパン-2-イルオキシ)メチル]ピリミジン-2-イル}ピペリジン-4-イル)-5,6,7,8-テトラヒドロキノリン-5-オール
比旋光度:[α]D 24=-92°(C=0.050,メタノール)。
1H-NMRスペクトル(300MHz,CD2Cl2)δ: 8.19 (2H, s), 7.66 (2H, d, J = 8 Hz), 7.39 (2H, d, J = 8 Hz), 7.22 (1H, d, J = 47 Hz), 5.13 (1H, dt, J = 6, 6 Hz), 4.83-4.72 (1H, m), 4.56-4.43 (1H, m), 4.25 (2H, s), 3.72-3.56 (1H, m), 3.63 (1H, dq, J = 6, 6 Hz), 2.92-2.54 (4H, m), 2.38-1.44 (15H, m), 1.15 (6H, d, J = 6 Hz), 1.13 (3H, s), 0.99 (3H, s), 0.67-0.57 (1H, m)。
マススペクトル(EI,m/z):704[M+]。
(実施例29)
(-)-4-(4,4-ジフルオロシクロヘキシル)-3-{フルオロ[4-(トリフルオロメチル)フェニル]メチル}-7,7-ジメチル-2-(1-{5-[(2-メチルプロポキシ)メチル]ピリミジン-2-イル}ピペリジン-4-イル)-5,6,7,8-テトラヒドロキノリン-5-オール
比旋光度:[α]D 24=-110°(C=0.050,メタノール)。
1H-NMRスペクトル(300MHz,CD2Cl2)δ: 8.20 (2H, s), 7.66 (2H, d, J = 8 Hz), 7.39 (2H, d, J = 8 Hz), 7.23 (1H, d, J = 47 Hz), 5.13 (1H, dt, J = 6, 6 Hz), 4.84-4.74 (1H, m), 4.56-4.45 (1H, m), 4.25 (2H, s), 3.71-3.57 (1H, m), 3.17 (2H, d, J = 7 Hz), 2.89-2.55 (4H, m), 2.36-1.56 (16H, m), 1.13 (3H, s), 0.99 (3H, s), 0.88 (6H, d, J = 7 Hz), 0.67-0.57 (1H, m)。
マススペクトル(EI,m/z):718[M+]。
(実施例30)
4-(4,4-ジフルオロシクロヘキシル)-3-{フルオロ[4-(トリフルオロメチル)フェニル]メチル}-7,7-ジメチル-2-{1-[5-(メチルカルバモイル)ピリミジン-2-イル]ピペリジン-4-イル}-5,6,7,8-テトラヒドロキノリン-5-オール
1H-NMRスペクトル(500MHz,CDCl3)δppm: 8.60 (2H, s), 7.64 (2H, d, J = 8 Hz), 7.37 (2H, d, J = 8 Hz), 7.22 (1H, d, J = 46 Hz), 5.89 (1H, br s), 5.15-5.08 (1H, m), 4.92-4.84 (1H, m), 4.65-4.56 (1H, m), 3.69-3.59 (1H, m), 2.97 (3H, d, J = 5 Hz), 2.89-2.47 (4H, m), 2.35-1.55 (15H, m), 1.14 (3H, s), 1.00 (3H, s), 0.70-0.62 (1H, m)。
マススペクトル(ES,m/z):690[M+]。
(実施例31)
(-)-4-(4,4-ジフルオロシクロヘキシル)-2-{1-[5-(ジメチルカルバモイル)ピリミジン-2-イル]ピペリジン-4-イル}-3-{フルオロ[4-(トリフルオロメチル)フェニル]メチル}-7,7-ジメチル-5,6,7,8-テトラヒドロキノリン-5-オール
比旋光度:[α]D 25=-87°(C=0.12,クロロホルム)。
1H-NMRスペクトル(500MHz,CDCl3)δppm: 8.40 (2H, s), 7.64 (2H, d, J = 8 Hz), 7.37 (2H, d, J = 8 Hz), 7.22 (1H, d, J = 47 Hz), 5.15-5.09 (1H, m), 4.91-4.82 (1H, m), 4.62-4.55 (1H, m), 3.67-3.59 (1H, m), 3.08 (6H, s), 2.93-2.60 (4H, m), 2.35-1.54 (15H, m), 1.14 (3H, s), 1.00 (3H, s), 0.69-0.62 (1H, m)。
マススペクトル(ES,m/z):704[M+]。
(実施例32)
4-(4,4-ジフルオロシクロヘキシル)-3-{フルオロ[4-(トリフルオロメチル)フェニル]メチル}-7,7-ジメチル-2-{1-[5-(モルホリン-4-イルカルボニル)ピリミジン-2-イル]ピペリジン-4-イル}-5,6,7,8-テトラヒドロキノリン-5-オール
1H-NMRスペクトル(500MHz,CDCl3)δppm:8.37 (2H, s), 7.64 (2H, d, J = 8 Hz), 7.37 (2H, d, J = 8 Hz), 7.22 (1H, d, J = 47 Hz), 5.12 (1H, q, J = 6 Hz), 4.90-4.82 (1H, m), 4.63-4.54 (1H, m), 3.78-3.54 (9H, m), 2.90-2.59 (4H, m), 2.36-1.56 (15H, m), 1.14 (3H, s), 1.00 (3H, s), 0.70-0.61 (1H, m)。
マススペクトル(ES,m/z):746[M+]。
(実施例33)
4-(4,4-ジフルオロシクロヘキシル)-3-{フルオロ[4-(トリフルオロメチル)フェニル]メチル}-7,7-ジメチル-2-{1-[5-(4,4,4-トリフルオロブチル)ピリミジン-2-イル]ピペリジン-4-イル}-5,6,7,8-テトラヒドロキノリン-5-オール
1H-NMRスペクトル(400MHz,CDCl3)δppm: 8.09 (2H, s), 7.64 (2H, d, J = 8 Hz), 7.37 (2H, d, J = 8 Hz), 7.21 (1H, d, J = 45 Hz), 5.17-5.07 (1H, m), 4.81-4.71 (1H, m), 4.53-4.43 (1H, m), 3.68-3.57 (1H, m), 2.85-2.58 (4H, m), 2.47 (2H, t, J = 7 Hz), 2.37-1.59 (19H, m), 1.15 (3H, s), 1.01 (3H, s), 0.68-0.59 (1H, m)。
マススペクトル(FAB,m/z):743[(M+1)+]。
(実施例34)
(-)-4-(4,4-ジフルオロシクロヘキシル)-3-{フルオロ[4-(トリフルオロメチル)フェニル]メチル}-7,7-ジメチル-2-(1-{5-[(1E)-3-メチルブタ-1-エン-1-イル]ピリミジン-2-イル}ピペリジン-4-イル)-5,6,7,8-テトラヒドロキノリン-5-オール
比旋光度:[α]D 24=-89°(C=0.15,メタノール)。
1H-NMRスペクトル(300MHz,CD2Cl2)δ: 8.24 (2H, s), 7.66 (2H, d, J = 8 Hz), 7.39 (2H, d, J = 8 Hz), 7.23 (1H, d, J = 47 Hz), 6.11 (1H, d, J = 16 Hz), 6.02 (1H, dd, J = 16, 6 Hz), 5.13 (1H, dt, J = 6, 6 Hz), 4.85-4.71 (1H, m), 4.56-4.41 (1H, m), 3.73-3.56 (1H, m), 2.89-2.54 (4H, m), 2.49-1.55 (16H, m), 1.13 (3H, s), 1.06 (6H, d, J = 7 Hz), 0.99 (3H, s), 0.69-0.57 (1H, m)。
マススペクトル(EI,m/z):700[M+]。
(実施例35)
4-(4,4-ジフルオロシクロヘキシル)-3-{フルオロ[4-(トリフルオロメチル)フェニル]メチル}-7,7-ジメチル-2-{1-[5-(3-メチル-1,2,4-オキサジアゾール-5-イル)ピリミジン-2-イル]ピペリジン-4-イル}-5,6,7,8-テトラヒドロキノリン-5-オール
得られた粗生成物をN,N-ジメチルアセトアミド2mlに溶解し、120℃で2時間攪拌した。反応終了後、反応液を水に注加し、酢酸エチルで抽出した。有機層を飽和重曹水、および、飽和塩化ナトリウム水溶液で洗浄し、無水硫酸ナトリウムで乾燥した後、溶媒を減圧留去した。得られた残渣をシリカゲルカラムクロマトグラフィー[n-ヘキサン/酢酸エチル=97/3-4/1(V/V)]に付し、目的物を含む画分を減圧濃縮することにより、4-(4,4-ジフルオロシクロヘキシル)-3-{フルオロ[4-(トリフルオロメチル)フェニル]メチル}-5-[(4-メトキシベンジル)オキシ]-7,7-ジメチル-2-{1-[5-(3-メチル-1,2,4-オキサジアゾール-5-イル)ピリミジン-2-イル]ピペリジン-4-イル}-5,6,7,8-テトラヒドロキノリン57mg(0.068mmol)を得た。
得られた4-(4,4-ジフルオロシクロヘキシル)-3-{フルオロ[4-(トリフルオロメチル)フェニル]メチル}-5-[(4-メトキシベンジル)オキシ]-7,7-ジメチル-2-{1-[5-(3-メチル-1,2,4-オキサジアゾール-5-イル)ピリミジン-2-イル]ピペリジン-4-イル}-5,6,7,8-テトラヒドロキノリン57mg(0.068mmol)から実施例38と同様の反応を行ない、標記化合物35mgを白色固体として得た(収率72%)。
1H-NMRスペクトル(400MHz,CDCl3)δppm: 8.87 (2H, s), 7.65 (2H, d, J = 8 Hz), 7.38 (2H, d, J = 8 Hz), 7.22 (1H, d, J = 47 Hz), 5.16-5.08 (1H, m), 4.99-4.90 (1H, m), 4.73-4.63 (1H, m), 3.69-3.57 (1H, m), 2.90-2.58 (4H, m), 2.43 (3H, s), 2.36-2.06 (6H, m), 1.98-1.58 (9H, m), 1.14 (3H, s), 1.00 (3H, s), 0.73-0.64 (1H, m)。
マススペクトル(FAB,m/z):715[(M+1)+]。
(実施例36)
(-)-4-(4,4-ジフルオロシクロヘキシル)-3-{フルオロ[4-(トリフルオロメチル)フェニル]メチル}-2-{1-(5-{[(2-ヒドロキシエチル)(メチル)アミノ]メチル}ピリミジン-2-イル)ピペリジン-4-イル}-7,7-ジメチル-5,6,7,8-テトラヒドロキノリン-5-オール
4-(4,4-ジフルオロシクロヘキシル)-3-{フルオロ[4-(トリフルオロメチル)フェニル]メチル}-2-[1-(5-ホルミルピリミジン-2-イル)ピペリジン-4-イル]-7,7-ジメチル-5,6,7,8-テトラヒドロキノリン-5-オール
(36-2)
(-)-4-(4,4-ジフルオロシクロヘキシル)-3-{フルオロ[4-(トリフルオロメチル)フェニル]メチル}-2-{1-(5-{[(2-ヒドロキシエチル)(メチル)アミノ]メチル}ピリミジン-2-イル)ピペリジン-4-イル}-7,7-ジメチル-5,6,7,8-テトラヒドロキノリン-5-オール
比旋光度:[α]D 25=-80°(C=0.11,クロロホルム)。
1H-NMRスペクトル(500MHz,CDCl3)δppm:8.15 (2H, s), 7.64 (2H, d, J = 8 Hz), 7.37 (2H, d, J = 8 Hz), 7.21 (1H, d, J = 49 Hz), 5.16-5.09 (1H, m), 4.83-4.74 (1H, m), 4.55-4.47 (1H, m), 3.68-3.57 (3H,m), 3.38 (2H, s), 2.94-2.60 (5H, m), 2.57 (2H, t, J = 5 Hz), 2.37-1.56 (15H, m), 2.20 (3H, s), 1.14 (3H, s), 1.00 (3H, s), 0.68-0.61 (1H, m)。
マススペクトル(ES,m/z):720[M+]。
(実施例37)
(-)-4-(4,4-ジフルオロシクロヘキシル)-3-{フルオロ[4-(トリフルオロメチル)フェニル]メチル}-2-[1-(5-{[(2S)-2-ヒドロキシプロピル]オキシ}ピリミジン-2-イル)ピペリジン-4-イル]-7,7-ジメチル-5,6,7,8-テトラヒドロキノリン-5-オール
得られた4-(4,4-ジフルオロシクロヘキシル)-3-{フルオロ[4-(トリフルオロメチル)フェニル]メチル}-7,7-ジメチル-2-{1-(5-{[(2S)-2-(テトラヒドロ-2H-ピラン-2-イルオキシ)プロピル]オキシ}ピリミジン-2-イル)ピペリジン-4-イル}-5,6,7,8-テトラヒドロキノリン-5-オール49mg(62μmol)のメタノール1.0ml溶液に、p-トルエンスルホン酸一水和物0.1mg(0.6μmol)を加え、60℃で2時間撹拌した。反応終了後、反応液に飽和炭酸水素ナトリウム水溶液を加え、酢酸エチルで抽出した。有機層を飽和塩化ナトリウム水溶液で洗浄し、無水硫酸ナトリウムで乾燥した後、溶媒を減圧留去した。得られた残渣をシリカゲルカラムクロマトグラフィー[n-ヘキサン/酢酸エチル=9/1-3/2(V/V)]に付し、目的物を含む画分を減圧濃縮することにより、標記化合物41mgを白色固体として得た(収率93%)。
比旋光度:[α]D 24=-64°(C=0.24,クロロホルム)。
1H-NMRスペクトル(500MHz,CDCl3)δppm:8.04 (2H, s), 7.63 (2H, d, J = 8 Hz), 7.36 (2H, d, J = 8 Hz), 7.21 (1H, d, J = 47 Hz), 5.12 (1H, q, J = 6 Hz), 4.71-4.63 (1H, m), 4.42-4.35 (1H, m), 4.18-4.10 (1H, m), 3.86 (1H, dd, J = 3, 9 Hz), 3.73 (1H, dd, J = 8, 9 Hz), 3.67-3.58 (1H, m), 2.91-2.62 (4H, m), 2.37-1.59 (16H, m), 1.25 (3H, d, J = 6 Hz), 1.14 (3H, s), 1.00 (3H, s), 0.67-0.59 (1H, m)。
マススペクトル(ES,m/z):707[M+]。
(実施例38)
4-(4,4-ジフルオロシクロヘキシル)-3-{フルオロ[4-(トリフルオロメチル)フェニル]メチル}-7,7-ジメチル-2-(1-{5-[(1-メチルピペリジン-4-イル)オキシ]ピリミジン-2-イル}ピペリジン-4-イル)-5,6,7,8-テトラヒドロキノリン-5-オール
1H-NMRスペクトル(400MHz,CDCl3)δppm:8.03 (2H, s), 7.63 (2H, d, J = 8 Hz), 7.36 (2H, d, J = 8 Hz), 7.21 (1H, d, J = 46 Hz), 5.17-5.06 (1H, m), 4.73-4.62 (1H, m), 4.45-4.34 (1H, m), 4.06-3.92 (1H, m), 3.70-3.56 (1H, m), 2.88-2.57 (6H, m), 2.38-1.53 (21H, m), 2.28 (3H, s), 1.15 (3H, s), 1.01 (3H, s), 0.69-0.59 (1H, m)。
マススペクトル(FAB,m/z):746[(M+1)+]。
(実施例39)
(-)-4-(4,4-ジフルオロシクロヘキシル)-2-[1-(5-{[(2S)-2,3-ジヒドロキシプロピル]オキシ}ピリミジン-2-イル)ピペリジン-4-イル]-3-{フルオロ[4-(トリフルオロメチル)フェニル]メチル}-7,7-ジメチル-5,6,7,8-テトラヒドロキノリン-5-オール
得られた4-(4,4-ジフルオロシクロヘキシル)-2-[1-(5-{[(4R)-2,2-ジメチル-1,3-ジオキソラン-4-イル]メトキシ}ピリミジン-2-イル)ピペリジン-4-イル]-3-{フルオロ[4-(トリフルオロメチル)フェニル]メチル}-7,7-ジメチル-5,6,7,8-テトラヒドロキノリン-5-オール400mg(0.524mmol)に、メタノール5.2ml、および2規定塩酸1.3mlを加え、60℃で2時間撹拌した。反応終了後、反応液に2規定水酸化ナトリウム水溶液1.3ml、飽和塩化ナトリウム水溶液、および酢酸エチルを注加し、酢酸エチルで抽出した。有機層を飽和塩化ナトリウム水溶液で洗浄し、無水硫酸ナトリウムで乾燥した後、溶媒を減圧留去した。得られた残渣にn-ヘキサンを加え、析出物を濾取することにより、標記化合物307mgを白色固体として得た(収率71%)
比旋光度:[α]D 27=-72°(C=0.12,メタノール)。
1H-NMRスペクトル(300MHz,CD2Cl2)δ: 8.05 (2H, s), 7.65 (2H, d, J = 8 Hz), 7.38 (2H, d, J = 8 Hz), 7.22 (1H, d, J = 47 Hz), 5.13 (1H, dt, J = 6, 6 Hz), 4.72-4.60 (1H, m), 4.43-4.31 (1H, m), 4.07-3.90 (3H, m), 3.76 (1H, ddd, J = 11, 6, 4 Hz), 3.67 (1H, dt, J = 11, 5 Hz), 3.64-3.57 (1H, m), 2.85-2.56 (4H, m), 2.51 (1H, d, J = 5 Hz), 2.36-1.58 (16H, m), 1.13 (3H, s), 1.00 (3H, s), 0.67-0.57 (1H, m)。
マススペクトル(EI,m/z):722[M+]。
(実施例40)
(-)-4-(4,4-ジフルオロシクロヘキシル)-2-[1-(5-{[(2R)-2,3-ジヒドロキシプロピル]オキシ}ピリミジン-2-イル)ピペリジン-4-イル]-3-{フルオロ[4-(トリフルオロメチル)フェニル]メチル}-7,7-ジメチル-5,6,7,8-テトラヒドロキノリン-5-オール
比旋光度:[α]D 27=-102°(C=0.14,メタノール)。
1H-NMRスペクトル(300MHz,CD2Cl2)δ: 8.05 (2H, s), 7.65 (2H, d, J = 8 Hz), 7.39 (2H, d, J = 8 Hz), 7.22 (1H, d, J = 47 Hz), 5.13 (1H, dt, J = 6, 6 Hz), 4.72-4.60 (1H, m), 4.43-4.31 (1H, m), 4.07-3.90 (3H, m), 3.76 (1H, ddd, J = 11, 6, 4 Hz), 3.67 (1H, dt, J = 11, 6 Hz), 3.64-3.57 (1H, m), 2.86-2.56 (4H, m), 2.52 (1H, d, J = 4 Hz), 2.35-1.57 (16H, m), 1.13 (3H, s), 1.00 (3H, s), 0.68-0.56 (1H, m)。
マススペクトル(EI,m/z):722[M+]。
(実施例41)
4-(4,4-ジフルオロシクロヘキシル)-3-{フルオロ[4-(トリフルオロメチル)フェニル]メチル}-7,7-ジメチル-2-[1-(5-{[(3R)-1-メチルピロリジン-3-イル]オキシ}ピリミジン-2-イル)ピペリジン-4-イル]-5,6,7,8-テトラヒドロキノリン-5-オール
1H-NMRスペクトル(400MHz,CDCl3)δppm:7.99 (2H, s), 7.63 (2H, d, J = 8 Hz), 7.36 (2H, d, J = 8 Hz), 7.21 (1H, d, J = 48 Hz), 5.16-5.06 (1H, m), 4.72-4.57 (2H, m), 4.43-4.31 (1H, m), 3.70-3.55 (1H, m), 2.90-2.57 (6H, m), 2.47-1.57 (19H, m), 2,38 (3H, s), 1.15 (3H, s), 1.00 (3H, s), 0.70-0.58 (1H, m)。
マススペクトル(FAB,m/z):732[(M+1)+]。
(実施例42)
(-)-4-(4,4-ジフルオロシクロヘキシル)-3-{フルオロ[4-(トリフルオロメチル)フェニル]メチル}-2-[1-(5-{[(2R)-2-ヒドロキシプロピル]オキシ}ピリミジン-2-イル)ピペリジン-4-イル]-7,7-ジメチル-5,6,7,8-テトラヒドロキノリン-5-オール
比旋光度:[α]D 24=-80°(C=0.14,クロロホルム)。
1H-NMRスペクトル(500MHz,CDCl3)δppm:8.04 (2H, s), 7.63 (2H, d, J = 8 Hz), 7.36 (2H, d, J = 8 Hz), 7.21 (1H, d, J = 47 Hz), 5.12 (1H, q J = 6 Hz), 4.71-4.62 (1H, m), 4.43-4.34 (1H, m), 4.19-4.11 (1H, m), 3.87 (1H, dd, J = 3, 9 Hz), 3.73 (1H, dd, J = 8, 9 Hz), 3.67-3.57 (1H, m), 2.93-2.60 (4H, m), 2.40-1.56 (16H, m), 1.25 (3H, d, J = 6 Hz), 1.14 (3H, s), 1.00 (3H, s), 0.67-0.59 (1H, m)。
マススペクトル(ES,m/z):707[M+]。
(実施例43)
(-)-4-(4,4-ジフルオロシクロヘキシル)-3-{フルオロ[4-(トリフルオロメチル)フェニル]メチル}-2-{1-[5-(3-ヒドロキシ-3-メチルブトキシ)ピリミジン-2-イル]ピペリジン-4-イル}-7,7-ジメチル-5,6,7,8-テトラヒドロキノリン-5-オール
比旋光度:[α]D 20=-72.2°(C=1.03,クロロホルム)。
1H-NMRスペクトル(300MHz,CDCl3)δ: 8.04 (2H, s), 7.63 (2H, d, J = 8 Hz), 7.36 (2H, d, J = 8 Hz), 7.20 (1H, d, J = 46 Hz), 5.12 (1H, dt, J = 6, 6 Hz), 4.74-4.61 (1H, m), 4.46-4.33 (1H, m), 4.11 (2H, t, J = 6 Hz), 3.70-3.54 (1H, m), 2.91-2.58 (4H, m), 2.40-1.62 (18H, m), 1.30 (6H, s), 1.15 (3H, s), 1.00 (3H, s), 0.68-0.58 (1H, m)。
マススペクトル(EI,m/z):734[M+]。
(実施例44)
4-(4,4-ジフルオロシクロヘキシル)-3-{フルオロ[4-(トリフルオロメチル)フェニル]メチル}-2-{1-[5-(2-ヒドロキシ-2-メチルプロポキシ)ピリミジン-2-イル]ピペリジン-4-イル}-7,7-ジメチル-5,6,7,8-テトラヒドロキノリン-5-オール
得られた4-(4,4-ジフルオロシクロヘキシル)-2-{1-[5-(2-エトキシ-2-オキソエトキシ)ピリミジン-2-イル]ピペリジン-4-イル}-3-{フルオロ[4-(トリフルオロメチル)フェニル]メチル}-7,7-ジメチル-5,6,7,8-テトラヒドロキノリン-5-オール61mg(0.083mmol)のジエチルエーテル5ml溶液に0℃で、1.1規定のメチルマグネシウムブロマイド-ジエチルエーテル溶液0.30ml(0.33mmol)を加えた。反応液を室温に昇温して1時間撹拌した。反応終了後、反応液に塩化アンモニウム水溶液を注加し、酢酸エチルで抽出した。有機層を飽和塩化ナトリウム水溶液で洗浄し、無水硫酸ナトリウムで乾燥した後、溶媒を減圧留去した。得られた残渣を薄層シリカゲルクロマトグラフィー[n-ヘキサン/酢酸エチル=5/6(V/V)]にて精製し、標記化合物18mgを白色固体として得た(収率30%)。
1H-NMRスペクトル(400MHz,CDCl3)δppm: 8.05 (2H, s), 7.63 (2H, d, J = 8 Hz), 7.37 (2H, d, J = 8 Hz), 7.21 (1H, d, J = 47 Hz), 5.16-5.08 (1H, m), 4.71-4.63 (1H, m), 4.43-4.34 (1H, m), 3.73 (2H, s), 3.68-3.56 (1H, m), 2.84-2.59 (4H, m), 2.37-1.47 (16H, m), 1.32 (6H, s), 1.15 (3H, s), 1.01 (3H, s), 0.67-0.58 (1H, m)。
マススペクトル(FAB,m/z):721[(M+1)+]。
(実施例45)
(-)-4-(4,4-ジフルオロシクロヘキシル)-3-{フルオロ[4-(トリフルオロメチル)フェニル]メチル}-7,7-ジメチル-2-(1-{5-[3-(メチルスルホニル)プロポキシ]ピリミジン-2-イル}ピペリジン-4-イル)-5,6,7,8-テトラヒドロキノリン-5-オール
比旋光度:[α]D 27=-74°(C=0.16,クロロホルム)。
1H-NMRスペクトル(300MHz,CD2Cl2)δ: 8.03 (2H, s), 7.65 (2H, d, J = 8 Hz), 7.39 (2H, d, J = 8 Hz), 7.22 (1H, d, J = 47 Hz), 5.13 (1H, dt, J = 6, 6 Hz), 4.71-4.60 (1H, m), 4.43-4.31 (1H, m), 4.04 (2H, t, J = 6 Hz), 3.72-3.56 (1H, m), 3.20 (2H, dd, J = 9, 7 Hz), 2.91 (3H, s), 2.85-2.55 (4H, m), 2.35-1.57 (17H, m), 1.13 (3H, s), 1.00 (3H, s), 0.68-0.56 (1H, m)。
マススペクトル(EI,m/z):768[M+]。
(実施例46)
(-)-4-(4,4-ジフルオロシクロヘキシル)-3-{フルオロ[4-(トリフルオロメチル)フェニル]メチル}-2-{1-[5-(3-ヒドロキシプロポキシ)ピリミジン-2-イル]ピペリジン-4-イル}-7,7-ジメチル-5,6,7,8-テトラヒドロキノリン-5-オール
得られた2-{1-[5-(3-{[tert-ブチル(ジメチル)シリル]オキシ}プロポキシ)ピリミジン-2-イル]ピペリジン-4-イル}-4-(4,4-ジフルオロシクロヘキシル)-3-{フルオロ[4-(トリフルオロメチル)フェニル]メチル}-7,7-ジメチル-5,6,7,8-テトラヒドロキノリン-5-オール71mg(87μmol)のテトラヒドロフラン1ml溶液に、1規定のフッ化テトラブチルアンモニウム-テロラヒドロフラン溶液0.5ml(0.5mmol)を加え、室温で1時間撹拌した。反応終了後、反応液を水に注加し、酢酸エチルで抽出した。有機層を飽和塩化ナトリウム水溶液で洗浄し、無水硫酸マグネシウムで乾燥した後、溶媒を減圧留去した。得られた残渣をシリカゲルカラムクロマトグラフィー[n-ヘキサン/酢酸エチル=3/1(V/V)]に付し、目的物を含む画分を減圧濃縮することにより、標記化合物59mgを白色固体として得た(収率88%)。
比旋光度:[α]D 24=-74°(C=0.15,クロロホルム)。
1H-NMRスペクトル(400MHz,CDCl3)δppm:8.03 (2H, s), 7.63 (2H, d, J = 8 Hz), 7.36 (2H, d, J = 8 Hz), 7.21 (1H, d, J= 48 Hz), 5.16-5.07 (1H, m), 4.72-4.62 (1H, m), 4.43-4.33 (1H, m), 4.05 (2H ,t, J = 6 Hz), 3.84 (2H, t, J = 6Hz), 3.68-3.55 (1H ,m), 2.93-2.57 (4H, m), 2.38-1.57 (18H, m), 1.14 (3H, s), 1.00 (3H, s), 0.67-0.58 (1H, m)。
マススペクトル(FAB,m/z):707[(M+1)+]。
(実施例47)
(-)-4-(4,4-ジフルオロシクロヘキシル)-3-{フルオロ[4-(トリフルオロメチル)フェニル]メチル}-7,7-ジメチル-2-{1-[5-(3,3,3-トリフルオロプロポキシ)ピリミジン-2-イル]ピペリジン-4-イル}-5,6,7,8-テトラヒドロキノリン-5-オール
比旋光度:[α]D 25=-69°(C=0.20,クロロホルム)。
1H-NMRスペクトル(400MHz,CDCl3)δppm:8.03 (2H, s), 7.63 (2H, d, J = 8 Hz), 7.37 (2H, d, J = 8 Hz), 7.21 (1H, d, J = 46 Hz), 5.17-5.07 (1H , m), 4.73-4.66 (1H ,m), 4.45-4.34 (1H ,m), 4.18-4.06 (2H, m), 3.69-3.56 (1H , m), 2.86-2.48 (6H, m), 2.30-1.54 (15H, m), 1.15 (3H, s), 1.01 (3H, s), 0.69-0.58 (1H, m)。
マススペクトル(FAB,m/z):745[(M+1)+]。
(実施例48)
(-)-4-(4,4-ジフルオロシクロヘキシル)-2-{1-[5-(ジフルオロメトキシ)ピリミジン-2-イル]ピペリジン-4-イル}-3-{フルオロ[4-(トリフルオロメチル)フェニル]メチル}-7,7-ジメチル-5,6,7,8-テトラヒドロキノリン-5-オール
比旋光度:[α]D 25=-77°(C=0.15,クロロホルム)。
1H-NMRスペクトル(400MHz,CDCl3)δppm:8.12 (2H, s), 7.64 (2H, d, J = 8 Hz), 7.37 (2H, d, J = 8 Hz), 7,21 (1H , d, J = 47 Hz), 6.36 (1H, t, J = 73 Hz), 5.16-5.08 (1H, m), 4.80-4.70 (1H, m), 4.52-4.43 (1H, m), 3.68-3.57 (1H, m), 2.86-2.59 (4H, m), 2.35-1.54 (15H, m), 1.15 (3H, s), 1.01 (3H, s), 0.69-0.60 (1H, m)。
マススペクトル(FAB,m/z):699[(M+1)+]。
(実施例49)
(-)-4-(4,4-ジフルオロシクロヘキシル)-3-{フルオロ[4-(トリフルオロメチル)フェニル]メチル}-2-(1-{5-[3-ヒドロキシ-2-(ヒドロキシメチル)プロポキシ]ピリミジン-2-イル}ピペリジン-4-イル)-7,7-ジメチル-5,6,7,8-テトラヒドロキノリン-5-オール
比旋光度:[α]D 28=-91°(C=0.21,メタノール)。
1H-NMRスペクトル(300MHz,CD2Cl2)δ: 8.04 (2H, s), 7.65 (2H, d, J = 8 Hz), 7.38 (2H, d, J = 8 Hz), 7.22 (1H, d, J = 47 Hz), 5.13 (1H, dt, J = 6, 6 Hz), 4.71-4.59 (1H, m), 4.42-4.32 (1H, m), 4.03 (2H, d, J = 6 Hz), 3.91-3.78 (4H, m), 3.71-3.57 (1H, m), 2.86-2.55 (4H, m), 2.36-1.58 (18H, m), 1.13 (3H, s), 1.00 (3H, s), 0.68-0.57 (1H, m)。
マススペクトル(EI,m/z):736[M+]。
(実施例50)
(-)-4-(4,4-ジフルオロシクロヘキシル)-3-{フルオロ[4-(トリフルオロメチル)フェニル]メチル}-2-(1-{5-[3-ヒドロキシ-2-(ヒドロキシメチル)-2-メチルプロポキシ]ピリミジン-2-イル}ピペリジン-4-イル)-7,7-ジメチル-5,6,7,8-テトラヒドロキノリン-5-オール
比旋光度:[α]D 27=-60.8°(C=0.530,クロロホルム)。
1H-NMRスペクトル(300MHz,CDCl3)δ: 8.04 (2H, s), 7.63 (2H, d, J = 8 Hz), 7.36 (2H, d, J = 8 Hz), 7.20 (1H, d, J = 46 Hz), 5.12 (1H, dt, J = 6, 6 Hz), 4.72-4.60 (1H, m), 4.45-4.32 (1H, m), 3.92 (2H, s), 3.77 (2H, dd, J = 11, 5 Hz), 3.70 (2H, dd, J = 11, 5 Hz), 3.66-3.54 (1H, m), 2.89-2.58 (4H, m), 2.38-1.57 (17H, m), 1.15 (3H, s), 1.00 (3H, s), 0.94 (3H, s), 0.68-0.57 (1H, m)。
マススペクトル(EI,m/z):750[M+]。
(実施例51)
(-)-4-(4,4-ジフルオロシクロヘキシル)-3-{フルオロ[4-(トリフルオロメチル)フェニル]メチル}-7,7-ジメチル-2-[1-(5-{[メチル(メチルスルホニル)アミノ]メチル}ピリミジン-2-イル)ピペリジン-4-イル]-5,6,7,8-テトラヒドロキノリン-5-オール
比旋光度:[α]D 25=-76°(C=0.16,クロロホルム)。
1H-NMRスペクトル(500MHz,CDCl3)δppm:8.22 (2H, s), 7.64 (2H, d, J = 8 Hz), 7.37 (2H, d, J = 8 Hz), 7.22 (1H, d, J = 48 Hz), 5.16-5.07 (1H, m), 4.85-4.76 (1H, m), 4.59-4.47 (1H, m), 4.11 (2H, s), 3.70-3.54 (1H, m), 2.88-2.71 (3H, m), 2.82 (3H, s), 2.75 (3H, s), 2.63 (1H, d, J = 17 Hz), 2.37-2.21 (2H, m), 2.21-2.07 (4H, m), 1.98-1.52 (9H, m), 1.14 (3H, s), 1.00 (3H, s), 0.72-0.61 (1H, m)。
マススペクトル(FAB,m/z):754[(M+1)+]。
(実施例52)
4-(4,4-ジフルオロシクロヘキシル)-3-{フルオロ[4-(トリフルオロメチル)フェニル]メチル}-7,7-ジメチル-2-[1-(5-{[メチル(プロパン-2-イルスルホニル)アミノ]メチル}ピリミジン-2-イル)ピペリジン-4-イル]-5,6,7,8-テトラヒドロキノリン-5-オール
1H-NMRスペクトル(400MHz,CDCl3)δppm:8.23 (2H, s), 7.64 (2H, d, J = 8 Hz), 7.37 (2H, d, J = 8 Hz), 7.21 (1H, d, J = 45 Hz), 5.21-5.06 (1H, m), 4.85-4.76 (1H, m), 4.59-4.47 (1H, m), 4.18 (2H, s), 3.71-3.55 (1H, m), 3.24 (1H, septet, J = 7 Hz), 2.87-2.70 (3H, m), 2.77 (3H, s), 2.63 (1H, d, J = 17 Hz), 2.42-1.56 (15H, m), 1.37 (6H, d, J = 7 Hz), 1.14 (3H, s), 1.00 (3H, s), 0.71-0.59 (1H, m)。
マススペクトル(FAB,m/z):782[(M+1)+]。
(実施例53)
(-)-4-(4,4-ジフルオロシクロヘキシル)-3-{フルオロ[4-(トリフルオロメチル)フェニル]メチル}-7,7-ジメチル-2-[1-(5-メチルチオピリミジン-2-イル)ピペリジン-4-イル]-5,6,7,8-テトラヒドロキノリン-5-オール
比旋光度:[α]D 26=-89°(C=0.17,クロロホルム)。
1H-NMRスペクトル(500MHz,CDCl3)δppm:8.31 (2H, s), 7.64 (2H, d, J = 8 Hz), 7.37 (2H, d, J = 8 Hz), 7.21 (1H, d, J = 47 Hz), 5.15-5.09 (1H, m), 4.83-4.74 (1H, m), 4.57-4.47 (1H, m), 3.68-3.57 (1H, m), 2.94-2.59 (4H, m), 2.42-1.47 (15H, m), 2.32 (3H, s), 1.14 (3H, s), 1.00 (3H, s), 0.69-0.60 (1H, m)。
マススペクトル(ES,m/z):679[M+]。
(実施例54)
(-)-4-(4,4-ジフルオロシクロヘキシル)-3-{フルオロ[4-(トリフルオロメチル)フェニル]メチル}-7,7-ジメチル-2-{1-[5-(メチルスルホニル)ピリミジン-2-イル]ピペリジン-4-イル}-5,6,7,8-テトラヒドロキノリン-5-オール
比旋光度:[α]D 26=-88°(C=0.16,クロロホルム)。
1H-NMRスペクトル(500MHz,CDCl3)δppm:8.62 (2H, s), 7.65 (2H, d, J= 8 Hz), 7.38 (2H, d, J = 8 Hz), 7.22 (1H, d, J = 47 Hz), 5.13 (1H, q, J = 6 Hz), 4.98-4.89 (1H, m), 4.72-4.63 (1H, m), 3.69-3.58 (1H, m), 3.04 (3H, s), 2.93-2.59 (4H, m), 2.36-1.55 (15H, m), 1.14 (3H, s), 1.00 (3H, s), 0.75-0.65 (1H, m)。
マススペクトル(ES,m/z):711[M+]。
(実施例55)
(-)-2-{1-[5-(3-カルボキシフェニル)ピリミジン-2-イル]ピペリジン-4-イル}-4-(4,4-ジフルオロシクロヘキシル)-3-{フルオロ[4-(トリフルオロメチル)フェニル]メチル}-7,7-ジメチル-5,6,7,8-テトラヒドロキノリン-5-オール
得られた4-(4,4-ジフルオロシクロヘキシル)-3-{フルオロ[4-(トリフルオロメチル)フェニル]メチル}-5-[(4-メトキシベンジル)オキシ]-2-(1-{5-[3-(メトキシカルボニル)フェニル]ピリミジン-2-イル}ピペリジン-4-イル)-7,7-ジメチル-5,6,7,8-テトラヒドロキノリン351mgに、ジクロロメタン2ml、アニソール0.24ml、およびトリフルオロ酢酸1mlを加え、室温で12.5時間撹拌した。反応終了後、反応液を飽和炭酸水素ナトリウム水溶液に注加し、酢酸エチルで抽出した。有機層を飽和塩化ナトリウム水溶液で洗浄し、無水硫酸マグネシウムで乾燥した後、溶媒を減圧留去した。得られた残渣をシリカゲルカラムクロマトグラフィー[n-ヘキサン/酢酸エチル=95/5-50/50(V/V)]に付し、目的物を含む画分を減圧濃縮することにより、4-(4,4-ジフルオロシクロヘキシル)-3-{フルオロ[4-(トリフルオロメチル)フェニル]メチル}-2-(1-{5-[3-(メトキシカルボニル)フェニル]ピリミジン-2-イル}ピペリジン-4-イル)-7,7-ジメチル-5,6,7,8-テトラヒドロキノリン-5-オール257mgを白色固体として得た。
得られた4-(4,4-ジフルオロシクロヘキシル)-3-{フルオロ[4-(トリフルオロメチル)フェニル]メチル}-2-(1-{5-[3-(メトキシカルボニル)フェニル]ピリミジン-2-イル}ピペリジン-4-イル)-7,7-ジメチル-5,6,7,8-テトラヒドロキノリン-5-オール257mgに、テトラヒドロフラン2ml、エタノール3ml、および2規定水酸化ナトリウム水溶液1mlを加え、室温で3.5時間撹拌した。反応終了後、反応液に2規定塩酸1mlを加え、室温撹拌後、飽和塩化ナトリウム水溶液、および酢酸エチルを注加し、酢酸エチルで抽出した。有機層を飽和塩化ナトリウム水溶液で洗浄し、無水硫酸マグネシウムで乾燥した後、溶媒を減圧留去した。得られた残渣にn-ヘプタンを加え、析出物を濾取することにより、標記化合物240mgを白色固体として得た(収率71%)。
比旋光度:[α]D 28=-67.8°(C=0.520,クロロホルム)。
1H-NMRスペクトル(300MHz,CDCl3)δ: 8.44 (2H, s), 8.07 (1H, s), 7.98 (1H, d, J = 7 Hz), 7.66 (2H, d, J = 8 Hz), 7.47 (1H, d, J = 7 Hz), 7.46 (1H, t, J = 7 Hz), 7.39 (2H, d, J = 8 Hz), 7.24 (1H, d, J = 47 Hz), 5.13 (1H, t, J = 6 Hz), 4.93-4.81 (1H, m), 4.65-4.52 (1H, m), 3.72-3.56 (1H, m), 3.01-2.61 (4H, m), 2.41-1.61 (15H, m), 1.13 (3H, s), 0.99 (3H, s), 0.72-0.58 (1H, m)。
マススペクトル(EI,m/z):752[M+]。
(実施例56)
4-(4,4-ジフルオロシクロヘキシル)-3-{フルオロ[4-(トリフルオロメチル)フェニル]メチル}-2-(1-{5-[(2-ヒドロキシエチル)(メチル)アミノ]ピリミジン-2-イル}ピペリジン-4-イル)-7,7-ジメチル-5,6,7,8-テトラヒドロキノリン-5-オール
得られた4-(4,4-ジフルオロシクロヘキシル)-3-{フルオロ[4-(トリフルオロメチル)フェニル]メチル}-2-(1-{5-[(2-ヒドロキシエチル)(メチル)アミノ]ピリミジン-2-イル}ピペリジン-4-イル)-5-[(4-メトキシベンジル)オキシ]-7,7-ジメチル-5,6,7,8-テトラヒドロキノリン25mg(30μmol)のジクロロメタン1.0ml溶液に、ピリジン0.1ml、無水酢酸15μl(0.16mmol)、および4-ジメチルアミノピリジン0.4mg(3μmol)を加え、室温で10分間撹拌した。反応終了後、反応液に水を加え、酢酸エチルで抽出した。有機層を飽和塩化ナトリウム水溶液で洗浄し、無水硫酸ナトリウムで乾燥した後、溶媒を減圧留去することにより得られた残渣をシリカゲルカラムクロマトグラフィー[n-ヘキサン/酢酸エチル=3/1-1/1(V/V)]に付し、目的を含む画分を減圧濃縮することにより、2-(1-{5-[(2-アセトキシエチル)(メチル)アミノ]ピリミジン-2-イル}ピペリジン-4-イル)-4-(4,4-ジフルオロシクロヘキシル)-3-{フルオロ[4-(トリフルオロメチル)フェニル]メチル}-5-[(4-メトキシベンジル)オキシ]-7,7-ジメチル-5,6,7,8-テトラヒドロキノリン25mgを白色固体として得た(収率93%)。
得られた2-(1-{5-[(2-アセトキシエチル)(メチル)アミノ]ピリミジン-2-イル}ピペリジン-4-イル)-4-(4,4-ジフルオロシクロヘキシル)-3-{フルオロ[4-(トリフルオロメチル)フェニル]メチル}-5-[(4-メトキシベンジル)オキシ]-7,7-ジメチル-5,6,7,8-テトラヒドロキノリン25mg(29μmol)から、実施例38、および実施例(23-2)と同様の反応を行ない、標記化合物13mgを白色固体として得た(収率65%)。ただし、実施例(23-2)に対応する工程において、1規定水酸化ナトリウム水溶液に代えて炭酸カリウム水溶液を用いた。
1H-NMRスペクトル(500MHz,CD3OD)δppm:8.02 (2H, s), 7.73 (2H, d, J = 8 Hz), 7.46 (2H, d, J = 8 Hz), 7.28 (1H, d, J = 47 Hz), 5.20-5.12 (1H, m), 4.60-5.50 (1H, m), 4.28-4.18 (1H, m), 3.77-3.63 (3H, m), 3.36-3.23 (2H, m), 2.95-2.56 (4H, m), 2.87 (3H, s), 2.36-1.53 (14H, m), 1.13 (3H, s), 0.97 (3H, s), 0.64-0.55 (1H, m)。
マススペクトル(ES,m/z):706[M+]。
(実施例57)
(-)-4-(4,4-ジフルオロシクロヘキシル)-3-{フルオロ[4-(トリフルオロメチル)フェニル]メチル}-2-(1-{5-[(3S)-3-ヒドロキシピロリジン-1-イル]ピリミジン-2-イル}ピペリジン-4-イル)-7,7-ジメチル-5,6,7,8-テトラヒドロキノリン-5-オール
比旋光度:[α]D 26=-63°(C=0.13,クロロホルム)。
1H-NMRスペクトル(500MHz,DMSO-D6)δppm:7.84 (2H, d, J = 8 Hz), 7.83 (2H, s), 7.42 (2H, d, J = 8 Hz), 7.19 (1H, d, J = 46 Hz), 5.19-5.11 (1H, m), 5.09-5.00 (1H, m), 4.93-4.90 (1H, m), 4.56-4.48 (1H, m), 4.39-4.34 (1H, m), 4.23-4.16 (1H, m), 3.75-3.67 (1H, m), 3.39-3.14 (4H, m), 3.00-2.95 (1H, m), 2.77-2.46 (4H, m), 2.24-1.39 (15H, m), 1.06 (3H, s), 0.90 (3H, s), 0.44-0.38 (1H, m)。
(実施例58)
4-(4,4-ジフルオロシクロヘキシル)-3-{フルオロ[4-(トリフルオロメチル)フェニル]メチル}-7,7-ジメチル-2-(1-{5-[(メチルアミノ)メチル]ピリミジン-2-イル}ピペリジン-4-イル)-5,6,7,8-テトラヒドロキノリン-5-オール
1H-NMRスペクトル(400MHz,CDCl3)δppm:8.23 (2H, s), 7.64 (2H, d, J = 8 Hz), 7.37 (2H, d, J = 8 Hz), 7.21 (1H, d, J = 49 Hz), 5.16-5.06 (1H, m), 4.83-4.72 (1H, m), 4.56-4.42 (1H, m), 3.71-3.50 (1H, m), 3.58 (2H, s), 2.87-2.49 (4H, m), 2.43 (3H, s), 2.34-1.54 (16H, m), 1.14 (3H, s), 0.99 (3H, s), 0.68-0.57 (1H, m)。
(参考例1)
4,4-ジフルオロシクロヘキサンカルボアルデヒド
1H-NMRスペクトル(300MHz,CDCl3)δppm: 9.68 (1H, d, J = 1 Hz), 2.42-2.28 (1H, m), 2.16-1.70 (8H, m)。
(参考例2)
4-(1-アミノ-2-シアノエテニル)ピペリジン-1-カルボン酸 tert-ブチルエステル
1H-NMRスペクトル(300MHz,CDCl3)δppm: 4.65 (2H, br s), 4.34-4.15 (2H, m), 3.87 (1H, s), 2.77-2.59 (2H, m), 2.16 (1H, tt, J = 12, 4 Hz), 1.84-1.73 (2H, m), 1.53-1.40 (2H, m), 1.46 (9H, s)。
マススペクトル(EI,m/z):251[M+]。
(参考例3)
2-[(1-tert-ブチルオキシカルボニル)ピペリジン-4-イル]-3-シアノ-4-(4,4-ジフルオロシクロヘキシル)-7,7-ジメチル-5-オキソ-1,4,5,6,7,8-ヘキサヒドロキノリン
1H-NMRスペクトル(300MHz,CDCl3)δppm : 6.27 (1H, s), 4.36-4.13 (2H, m), 3.70 (1H, d, J = 2 Hz), 3.03 (1H, tt, J = 12, 3 Hz), 2.91-2.73 (2H, m), 2.40-2.19 (5H, m), 2.17-1.98 (2H, m), 1.84-1.40 (9H, m), 1.48 (9H, s), 1.35-1.20 (1H, m), 1.10 (3H, s), 1.09 (3H, s)。
マススペクトル(CI,m/z):504[(M+1)+]。
(参考例4)
2-[(1-tert-ブチルオキシカルボニル)ピペリジン-4-イル]-3-シアノ-4-(4,4-ジフルオロシクロヘキシル)-7,7-ジメチル-5-オキソ-5,6,7,8-テトラヒドロキノリン
1H-NMRスペクトル(300MHz,CDCl3)δppm: 4.38-4.15 (2H, m), 4.13-3.97 (1H, m), 3.38 (1H, tt, J = 11, 4 Hz), 3.06 (2H, s), 2.97-2.80 (2H, m), 2.69-2.52 (2H, m), 2.61 (2H, s), 2.33-2.17 (2H, m), 2.01-1.72 (8H, m), 1.48 (9H, s), 1.11 (6H, s)。
マススペクトル(EI,m/z):501[M+]。
(参考例5)
2-[(1-tert-ブチルオキシカルボニル)ピペリジン-4-イル]-4-(4,4-ジフルオロシクロヘキシル)-3-ホルミル-7,7-ジメチル-5,6,7,8-テトラヒドロキノリン-5-オール
1H-NMRスペクトル(300MHz,CDCl3)δppm: 10.81 (1H, s), 5.09 (1H, q, J = 6 Hz), 4.32-4.09 (2H, m), 3.53-3.37 (1H, m), 3.11 (1H, tt, J = 11, 4 Hz), 2.97-2.56 (2H, m), 2.88 (1H, d, J = 17 Hz), 2.65 (1H, d, J = 17 Hz), 2.31-1.50 (15H, m), 1.47 (9H, s), 1.15 (3H, s), 1.00 (3H, s)。
マススペクトル(CI,m/z):507[(M+1)+]。
(参考例6)
2-[(1-tert-ブチルオキシカルボニル)ピペリジン-4-イル]-4-(4,4-ジフルオロシクロヘキシル)-3-ホルミル-5-[(4-メトキシベンジル)オキシ]-7,7-ジメチル-5,6,7,8-テトラヒドロキノリン
1H-NMRスペクトル(300MHz,CDCl3)δppm: 10.76 (1H, s), 7.23 (2H, d, J = 9 Hz), 6.86 (2H, d, J = 9 Hz), 4.80 (1H, dd, J = 9, 5 Hz), 4.77 (1H, d, J = 11 Hz), 4.36 (1H, d, J = 11 Hz), 4.29-4.08 (2H, m), 3.79 (3H, s), 3.14-2.67 (3H, m), 3.08 (1H, tt, J = 11, 3 Hz), 2.92 (1H, d, J = 17 Hz), 2.67 (1H, d, J = 17 Hz), 2.26-1.50 (14H, m), 1.47 (9H, s), 1.19 (3H, s), 1.04 (3H, s)。
マススペクトル(CI,m/z):627[(M+1)+]。
(参考例7)
2-[(1-tert-ブチルオキシカルボニル)ピペリジン-4-イル]-4-(4,4-ジフルオロシクロヘキシル)-3-{ヒドロキシ[4-(トリフルオロメチル)フェニル]メチル}-5-[(4-メトキシベンジル)オキシ]-7,7-ジメチル-5,6,7,8-テトラヒドロキノリン
[ジアステレオマー1]
Rf値:0.29[n-ヘキサン/酢酸エチル=7/3(V/V)]。
1H-NMRスペクトル(300MHz,CDCl3)δppm: 7.57 (2H, d, J = 8 Hz), 7.37 (2H, d, J = 8 Hz), 7.25 (2H, d, J = 9 Hz), 6.87 (2H, d, J = 9 Hz), 6.43 (1H, s), 4.83 (1H, d, J = 11 Hz), 4.81 (1H, t, J = 5 Hz), 4.38 (1H, d, J = 11 Hz), 4.25-4.02 (1H, m), 3.83-3.75 (1H, m), 3.80 (3H, s), 3.24-2.42 (3H, m), 2.86 (1H, d, J = 17 Hz), 2.65 (1H, d, J = 17 Hz), 2.29-1.52 (15H, m), 1.41 (9H, s), 1.20 (3H, s), 1.09 (3H, s), 0.50-0.40 (1H, m)。
マススペクトル(CI,m/z):773[(M+1)+]。
[ジアステレオマー2]
Rf値:0.21[n-ヘキサン/酢酸エチル=7/3(V/V)]。
1H-NMRスペクトル(300MHz,CDCl3)δppm: 7.56 (2H, d, J = 8 Hz), 7.39 (2H, d, J = 8 Hz), 7.26 (2H, d, J = 9 Hz), 6.88 (2H, d, J = 9 Hz), 6.43 (1H, s), 4.83 (1H, t, J = 5 Hz), 4.81 (1H, d, J = 11 Hz), 4.39 (1H, d, J = 11 Hz), 4.27-4.02 (1H, m), 3.84-3.70 (1H, m), 3.80 (3H, s), 3.23-2.47 (3H, m), 2.86 (1H, d, J = 17 Hz), 2.65 (1H, d, J = 17 Hz), 2.32-2.06 (4H, m), 2.03-1.50 (11H, m), 1.41 (9H, s), 1.21 (3H, s), 1.04 (3H, s), 0.47-0.37 (1H, m)。
マススペクトル(CI,m/z):773[(M+1)+]。
(参考例8)
2-[(1-tert-ブチルオキシカルボニル)ピペリジン-4-イル]-4-(4,4-ジフルオロシクロヘキシル)-3-{フルオロ[4-(トリフルオロメチル)フェニル]メチル}-5-[(4-メトキシベンジル)オキシ]-7,7-ジメチル-5,6,7,8-テトラヒドロキノリン(ジアステレオマー2)
1H-NMRスペクトル(300MHz,CDCl3)δppm:7.60 (2H, d, J = 8 Hz), 7.33 (2H, d, J = 8 Hz), 7.25 (2H, d, J = 9 Hz), 7.12 (1H, d, J = 49 Hz), 6.87 (2H, d, J = 9 Hz), 4.83 (1H, t, J = 5 Hz), 4.81 (1H, d, J = 11 Hz), 4.39 (1H, d, J = 11 Hz), 4.20-4.01 (1H, m), 3.90-3.74 (1H, m), 3.79 (3H, s), 3.24-3.08 (1H, m), 2.88 (1H, d, J = 17 Hz), 2.68 (1H, d, J = 17 Hz), 2.68-2.46 (2H, m), 2.32-2.08 (3H, m), 2.00-1.37 (11H, m), 1.41 (9H, s), 1.21 (3H, s), 1.05 (3H, s), 0.63-0.51 (1H, m)。
マススペクトル(CI,m/z):775[(M+1)+]。
(参考例9)
4-(4,4-ジフルオロシクロヘキシル)-3-{フルオロ[4-(トリフルオロメチル)フェニル]メチル}-5-[(4-メトキシベンジル)オキシ]-7,7-ジメチル-2-(ピペリジン-4-イル)-5,6,7,8-テトラヒドロキノリン(ジアステレオマー2)
1H-NMRスペクトル(300MHz,CDCl3)δppm: 7.60 (2H, d, J = 8 Hz), 7.33 (2H, d, J = 8 Hz), 7.25 (2H, d, J = 9 Hz), 7.11 (1H, d, J = 47 Hz), 6.87 (2H, d, J = 9 Hz), 4.83 (1H, t, J = 5 Hz), 4.81 (1H, d, J = 11 Hz), 4.39 (1H, d, J = 11 Hz), 3.79 (3H, s), 3.23-2.98 (2H, m), 2.95-2.55 (4H, m), 2.48 (1H, td, J = 12, 2 Hz), 2.33-2.08 (3H, m), 2.01-1.47 (11H, m), 1.22 (3H, s), 1.06 (3H, s), 0.62-0.51 (1H, m)。
マススペクトル(CI,m/z):675[(M+1)+]。
(参考例10)
(-)-4-(4,4-ジフルオロシクロヘキシル)-3-{フルオロ[4-(トリフルオロメチル)フェニル]メチル}-5-[(4-メトキシベンジル)オキシ]-7,7-ジメチル-2-(ピペリジン-4-イル)-5,6,7,8-テトラヒドロキノリン
[標記化合物]
比旋光度:[α]D 24=-101°(C=0.25,メタノール)。
1H-NMRスペクトル(300MHz,CD2Cl2)δppm:7.61 (2H, d, J = 8 Hz), 7.35 (2H, d, J = 8 Hz), 7.26 (2H, d, J = 9 Hz), 7.14 (1H, d, J = 47 Hz), 6.86 (2H, d, J = 9 Hz), 4.85 (1H, t, J = 5 Hz), 4.80 (1H, d, J = 11 Hz), 4.39 (1H, d, J = 11 Hz), 3.77 (3H, s), 3.25-3.09 (1H, m), 3.03-2.93 (1H, m), 2.92-2.80 (1H, m), 2.75-2.53 (3H, m), 2.45 (1H, td, J = 12, 3 Hz), 2.30-2.11 (3H, m), 2.00-1.39 (11H, m), 1.20 (3H, s), 1.07 (3H, s), 0.61-0.51 (1H, m)。
マススペクトル(CI,m/z):675[(M+1)+]。
高速液体クロマトグラフィー分析条件:
カラム:CHIRALPAK(商品名) AD-H(0.46cmID×25cm、ダイセル化学製)
溶離液:n-ヘキサン/2-プロパノール/イソプロピルアミン=80/20/0.1(V/V/V)
流速:1.0ml/min
カラム温度:40℃
検出波長:271nm
保持時間:5.5分。
[標記化合物の対掌体]
比旋光度:[α]D 24=100°(C=0.25,メタノール)。
1H-NMRスペクトル(300MHz,CD2Cl2)δppm:7.61 (2H, d, J = 8 Hz), 7.35 (2H, d, J = 8 Hz), 7.26 (2H, d, J = 9 Hz), 7.14 (1H, d, J = 47 Hz), 6.86 (2H, d, J = 9 Hz), 4.85 (1H, t, J = 5 Hz), 4.80 (1H, d, J = 11 Hz), 4.39 (1H, d, J = 11 Hz), 3.77 (3H, s), 3.25-3.08 (1H, m), 3.04-2.92 (1H, m), 2.91-2.80 (1H, m), 2.76-2.53 (3H, m), 2.45 (1H, td, J = 12, 3 Hz), 2.28-2.10 (3H, m), 2.00-1.39 (11H, m), 1.20 (3H, s), 1.07 (3H, s), 0.61-0.50 (1H, m)。
マススペクトル(CI,m/z):675[(M+1)+]。
高速液体クロマトグラフィー分析条件:
カラム:CHIRALPAK(商品名) AD-H(0.46cmID×25cm、ダイセル化学製)
溶離液:n-ヘキサン/2-プロパノール/イソプロピルアミン=80/20/0.1(V/V/V)
流速:1.0ml/min
カラム温度:40℃
検出波長:271nm
保持時間:4.0分。
(参考例11)
(-)-2-[1-(5-ブロモピリミジン-2-イル)ピペリジン-4-イル]-4-(4,4-ジフルオロシクロヘキシル)-3-{フルオロ[4-(トリフルオロメチル)フェニル]メチル}-5-[(4-メトキシベンジル)オキシ]-7,7-ジメチル-5,6,7,8-テトラヒドロキノリン
1H-NMRスペクトル(300MHz,CD2Cl2)δppm: δ: 8.22 (2H, s), 7.64 (2H, d, J = 8 Hz), 7.38 (2H, d, J = 8 Hz), 7.26 (2H, d, J = 9 Hz), 7.17 (1H, d, J = 46 Hz), 6.86 (2H, d, J = 9 Hz), 4.85 (1H, t, J = 5 Hz), 4.80 (1H, d, J = 11 Hz), 4.75-4.63 (1H, m), 4.48-4.38 (1H, m), 4.39 (1H, d, J = 11 Hz), 3.77 (3H, s), 3.26-3.07 (1H, m), 2.90-2.55 (4H, m), 2.32-1.35 (14H, m), 1.17 (3H, s), 1.04 (3H, s), 0.74-0.61 (1H, m)。
(参考例12)
(-)-4-(4,4-ジフルオロシクロヘキシル)-3-{フルオロ[4-(トリフルオロメチル)フェニル]メチル}-5-[(4-メトキシベンジル)オキシ]-7,7-ジメチル-2-{1-[5-(モルホリン-4-イル)ピリミジン-2-イル]ピペリジン-4-イル}-5,6,7,8-テトラヒドロキノリン
比旋光度:[α]D 28=-119°(C=0.645,クロロホルム)。
1H-NMRスペクトル(300MHz,CD2Cl2)δppm: 8.03 (2H, s), 7.63 (2H, d, J = 8 Hz), 7.38 (2H, d, J = 8 Hz), 7.26 (2H, d, J = 9 Hz), 7.17 (1H, d, J = 46 Hz), 6.86 (2H, d, J = 9 Hz), 4.85 (1H, t, J = 5 Hz), 4.80 (1H, d, J = 11 Hz), 4.70-4.60 (1H, m), 4.43-4.32 (1H, m), 4.39 (1H, d, J = 11 Hz), 3.86-3.71 (4H, m), 3.77 (3H, s), 3.26-3.09 (1H, m), 3.02-2.89 (4H, m), 2.87-2.57 (4H, m), 2.33-1.45 (14H, m), 1.18 (3H, s), 1.04 (3H, s), 0.72-0.59 (1H, m)。
(参考例13)
4-(4,4-ジフルオロシクロヘキシル)-2-(1-{5-[4-(エトキシカルボニル)ピペリジン-1-イル]ピリミジン-2-イル}ピペリジン-4-イル)-3-{フルオロ[4-(トリフルオロメチル)フェニル]メチル}-5-[(4-メトキシベンジル)オキシ]-7,7-ジメチル-5,6,7,8-テトラヒドロキノリン
1H-NMRスペクトル(400MHz,CDCl3)δppm: 8.05 (2H, s), 7.61 (2H, d, J = 8 Hz), 7.36 (2H, d, J = 8 Hz), 7.26 (2H, d, J = 9 Hz), 7.15 (1H, d, J = 47 Hz), 6.87 (2H, d, J = 9 Hz), 4.86-4.76 (2H, m), 4.71-4.62 (1H, m), 4.43-4.34 (2H, m), 4.16 (2H, q, J = 7 Hz), 3.79 (3H, s), 3.34-3.08 (3H, m), 2.88-2.58 (6H, m), 2.42-1.49 (19H, m), 1.27 (3H, t, J = 7 Hz), 1.19 (3H, s), 1.04 (3H, s), 0.70-0.60 (1H, m)。
マススペクトル(FAB,m/z):907[M+]。
(参考例14)
2-クロロ-5-(メチルスルホニル)ピリミジン
1H-NMRスペクトル(500MHz,CDCl3)δppm:9.11 (2H, s), 3.19 (3H, s)。
(参考例15)
4-(4,4-ジフルオロシクロヘキシル)-3-{フルオロ[4-(トリフルオロメチル)フェニル]メチル}-5-[(4-メトキシベンジル)オキシ]-7,7-ジメチル-2-[1-(ピリミジン-2-イル)ピペリジン-4-イル]-5,6,7,8-テトラヒドロキノリン
1H-NMRスペクトル(300MHz,CD2Cl2)δppm: 8.22 (2H, d, J = 5 Hz), 7.64 (2H, d, J = 8 Hz), 7.38 (2H, d, J = 8 Hz), 7.26 (2H, d, J = 9 Hz), 7.18 (1H, d, J = 46 Hz), 6.86 (2H, d, J = 9 Hz), 6.39 (1H, t, J = 5 Hz), 4.85 (1H, t, J = 5 Hz), 4.81-4.72 (1H, m), 4.80 (1H, d, J = 11 Hz), 4.56-4.44 (1H, m), 4.39 (1H, d, J = 11 Hz), 3.77 (3H, s), 3.26-3.10 (1H, m), 2.90-2.56 (4H, m), 2.32-2.02 (4H, m), 2.00-1.31 (10H, m), 1.17 (3H, s), 1.04 (3H, s), 0.74-0.62 (1H, m)。
マススペクトル(CI,m/z):753[(M+1)+]。
(参考例16)
4-(4,4-ジフルオロシクロヘキシル)-3-{フルオロ[4-(トリフルオロメチル)フェニル]メチル}-2-[1-(5-ホルミルピリミジン-2-イル)ピペリジン-4-イル]-5-[(4-メトキシベンジル)オキシ]-7,7-ジメチル-5,6,7,8-テトラヒドロキノリン
1H-NMRスペクトル(300MHz,CDCl3)δppm: 9.71 (1H, s), 8.65 (2H, s), 7.63 (2H, d, J = 8 Hz), 7.37 (2H, d, J = 8 Hz), 7.25 (2H, d, J = 9 Hz), 7.16 (1H, d, J = 48 Hz), 6.87 (2H, d, J = 9 Hz), 5.03-4.91 (1H, m), 4.83 (1H, t, J = 5 Hz), 4.81 (1H, d, J = 11 Hz), 4.77-4.67 (1H, m), 4.39 (1H, d, J = 11 Hz), 3.79 (3H, s), 3.25-3.09 (1H, m), 2.92-2.74 (2H, m), 2.84 (1H, d, J = 17 Hz), 2.65 (1H, d, J = 17 Hz), 2.34-1.46 (14H, m), 1.19 (3H, s), 1.03 (3H, s), 0.79-0.68 (1H, m)。
マススペクトル(EI,m/z):780[M+]。
(参考例17)
(-)-4-(4,4-ジフルオロシクロヘキシル)-3-{フルオロ[4-(トリフルオロメチル)フェニル]メチル}-2-[1-[5-(ヒドロキシメチル)ピリミジン-2-イル]ピペリジン-4-イル]-5-[(4-メトキシベンジル)オキシ]-7,7-ジメチル-5,6,7,8-テトラヒドロキノリン
比旋光度:[α]D 28=-125°(C=0.600,クロロホルム)。
1H-NMRスペクトル(300MHz,CDCl3)δppm: 8.25 (2H, s), 7.62 (2H, d, J = 8 Hz), 7.36 (2H, d, J = 8 Hz), 7.25 (2H, d, J = 9 Hz), 7.15 (1H, d, J = 47 Hz), 6.87 (2H, d, J = 9 Hz), 4.85-4.74 (1H, m), 4.83 (1H, t, J = 5 Hz), 4.81 (1H, d, J = 11 Hz), 4.57-4.44 (3H, m), 4.39 (1H, d, J = 11 Hz), 3.79 (3H, s), 3.25-3.08 (1H, m), 2.90-2.59 (4H, m), 2.33-2.06 (4H, m), 2.01-1.42 (11H, m), 1.19 (3H, s), 1.03 (3H, s), 0.72-0.62 (1H, m)。
マススペクトル(EI,m/z):782[M+]。
(参考例18)
2-{1-[5-(シクロヘキサ-1-エン-1-イル)ピリミジン-2-イル]ピペリジン-4-イル}-4-(4,4-ジフルオロシクロヘキシル)-3-{フルオロ[4-(トリフルオロメチル)フェニル]メチル}-5-[(4-メトキシベンジル)オキシ]-7,7-ジメチル-5,6,7,8-テトラヒドロキノリン
1H-NMRスペクトル(300MHz,CD2Cl2)δppm: 8.27 (2H, s), 7.64 (2H, d, J = 8 Hz), 7.38 (2H, d, J = 8 Hz), 7.26 (2H, d, J = 9 Hz), 7.17 (1H, d, J = 45 Hz), 6.86 (2H, d, J = 9 Hz), 6.02-5.91 (1H, m), 4.85 (1H, t, J = 5 Hz), 4.81-4.70 (1H, m), 4.80 (1H, d, J = 11 Hz), 4.54-4.44 (1H, m), 4.39 (1H, d, J = 11 Hz), 3.77 (3H, s), 3.26-3.10 (1H, m), 2.91-2.54 (4H, m), 2.39-1.46 (22H, m), 1.17 (3H, s), 1.04 (3H, s), 0.74-0.61 (1H, m)。
(参考例19)
4-(4,4-ジフルオロシクロヘキシル)-3-{フルオロ[4-(トリフルオロメチル)フェニル]メチル}-2-{1-[5-(1-ヒドロキシ-2-メチルプロピル)ピリミジン-2-イル]ピペリジン-4-イル}-5-[(4-メトキシベンジル)オキシ]-7,7-ジメチル-5,6,7,8-テトラヒドロキノリン
1H-NMRスペクトル(300MHz,CD2Cl2)δppm: 8.18 (2H, s), 7.64 (2H, d, J = 8 Hz), 7.38 (2H, d, J = 8 Hz), 7.26 (2H, d, J = 9 Hz), 7.18 (1H, d, J = 45 Hz), 6.86 (2H, d, J = 9 Hz), 4.85 (1H, t, J = 5 Hz), 4.81-4.71 (1H, m), 4.80 (1H, d, J = 11 Hz), 4.54-4.45 (1H, m), 4.39 (1H, d, J = 11 Hz), 4.19 (1H, d, J = 7 Hz), 3.77 (3H, s), 3.26-3.10 (1H, m), 2.89-2.57 (4H, m), 2.29-1.44 (16H, m), 1.17 (3H, s), 1.04 (3H, s), 0.97 (3H, d, J = 7 Hz), 0.79 (3H, d, J = 7 Hz), 0.72-0.63 (1H, m)。
(参考例20)
メチル 5-(2-クロロピリミジン-5-イル)ペンタノエート
得られたメチル 5-(2-クロロピリミジン-5-イル)-4-ペンチノエート337mg(1.50mmol)の酢酸エチル7ml溶液に10%パラジウム炭素70mgを加え、水素ガス雰囲気下、室温で20時間撹拌した。触媒を濾過により除去した後、溶媒を減圧留去することにより、標記化合物177mgを無色油状物として得た(収率52%)。
1H-NMRスペクトル(500MHz,CDCl3)δppm: 8.46 (2H, s), 3.68 (3H, s), 2.63 (2H, t, J = 7 Hz), 2.36 (2H, t, J = 7 Hz), 1.74-1.63 (4H, m)。
マススペクトル(EI,m/z):228[M+]。
(参考例21)
4-(4,4-ジフルオロシクロヘキシル)-2-{1-[5-(エトキシメチル)ピリミジン-2-イル]ピペリジン-4-イル}-3-{フルオロ[4-(トリフルオロメチル)フェニル]メチル}-5-[(4-メトキシベンジル)オキシ]-7,7-ジメチル-5,6,7,8-テトラヒドロキノリン
1H-NMRスペクトル(300MHz,CDCl3)δppm: 8.22 (2H, s), 7.62 (2H, d, J = 8 Hz), 7.36 (2H, d, J = 8 Hz), 7.25 (2H, d, J = 9 Hz), 7.15 (1H, d, J = 48 Hz), 6.87 (2H, d, J = 9 Hz), 4.87-4.73 (2H, m), 4.81 (1H, d, J = 11 Hz), 4.56-4.46 (1H, m), 4.38 (1H, d, J = 11 Hz), 4.28 (2H, s), 3.79 (3H, s), 3.48 (2H, q, J = 7 Hz), 3.24-3.08 (1H, m), 2.91-2.59 (4H, m), 2.31-2.05 (4H, m), 2.02-1.47 (10H, m), 1.21 (3H, t, J = 7 Hz), 1.19 (3H, s), 1.03 (3H, s), 0.70-0.60 (1H, m)。
マススペクトル(EI,m/z):810[M+]。
(参考例22)
4-(4,4-ジフルオロシクロヘキシル)-3-{フルオロ[4-(トリフルオロメチル)フェニル]メチル}-5-[(4-メトキシベンジル)オキシ]-2-{1-[5-(メトキシメチル)ピリミジン-2-イル]ピペリジン-4-イル}-7,7-ジメチル-5,6,7,8-テトラヒドロキノリン
1H-NMRスペクトル(300MHz,CD2Cl2)δppm: 8.19 (2H, s), 7.64 (2H, d, J = 8 Hz), 7.38 (2H, d, J = 8 Hz), 7.26 (2H, d, J = 9 Hz), 7.18 (1H, d, J = 48 Hz), 6.86 (2H, d, J = 9 Hz), 4.89-4.72 (1H, m), 4.85 (1H, t, J = 5 Hz), 4.80 (1H, d, J = 11 Hz), 4.56-4.46 (1H, m), 4.39 (1H, d, J = 11 Hz), 4.20 (2H, s), 3.77 (3H, s), 3.29 (3H, s), 3.24-3.09 (1H, m), 2.89-2.58 (4H, m), 2.29-2.03 (4H, m), 2.00-1.46 (10H, m), 1.17 (3H, s), 1.04 (3H, s), 0.72-0.63 (1H, m)。
マススペクトル(EI,m/z):796[M+]。
(参考例23)
4-(4,4-ジフルオロシクロヘキシル)-3-{フルオロ[4-(トリフルオロメチル)フェニル]メチル}-5-[(4-メトキシベンジル)オキシ]-7,7-ジメチル-2-(1-{5-[(プロパン-2-イルオキシ)メチル]ピリミジン-2-イル}ピペリジン-4-イル)-5,6,7,8-テトラヒドロキノリン
1H-NMRスペクトル(300MHz,CDCl3)δppm: 8.22 (2H, s), 7.62 (2H, d, J = 8 Hz), 7.36 (2H, d, J = 8 Hz), 7.25 (2H, d, J = 9 Hz), 7.15 (1H, d, J = 48 Hz), 6.87 (2H, d, J = 9 Hz), 4.86-4.72 (1H, m), 4.82 (1H, t, J = 5 Hz), 4.81 (1H, d, J = 11 Hz), 4.55-4.46 (1H, m), 4.38 (1H, d, J = 11 Hz), 4.28 (2H, s), 3.79 (3H, s), 3.64 (1H, dq, J = 6, 6 Hz), 3.22-3.08 (1H, m), 2.91-2.60 (4H, m), 2.31-2.05 (4H, m), 2.01-1.46 (10H, m), 1.19 (3H, s), 1.18 (6H, d, J = 6 Hz), 1.03 (3H, s), 0.70-0.59 (1H, m)。
マススペクトル(EI,m/z):824[M+]。
(参考例24)
4-(4,4-ジフルオロシクロヘキシル)-3-{フルオロ[4-(トリフルオロメチル)フェニル]メチル}-5-[(4-メトキシベンジル)オキシ]-7,7-ジメチル-2-(1-{5-[(2-メチルプロポキシ)メチル]ピリミジン-2-イル}ピペリジン-4-イル)-5,6,7,8-テトラヒドロキノリン
1H-NMRスペクトル(300MHz,CDCl3)δppm: 8.22 (2H, s), 7.62 (2H, d, J = 8 Hz), 7.36 (2H, d, J = 8 Hz), 7.25 (2H, d, J = 9 Hz), 7.15 (1H, d, J = 47 Hz), 6.87 (2H, d, J = 9 Hz), 4.86-4.73 (2H, m), 4.81 (1H, d, J = 11 Hz), 4.57-4.47 (1H, m), 4.39 (1H, d, J = 11 Hz), 4.27 (2H, s), 3.79 (3H, s), 3.23-3.08 (1H, m), 3.17 (2H, d, J = 7 Hz), 2.91-2.59 (4H, m), 2.32-2.06 (4H, m), 1.99-1.49 (11H, m), 1.19 (3H, s), 1.03 (3H, s), 0.89 (6H, d, J = 7 Hz), 0.71-0.61 (1H, m)。
マススペクトル(EI,m/z):838[M+]。
(参考例25)
4-(4,4-ジフルオロシクロヘキシル)-3-{フルオロ[4-(トリフルオロメチル)フェニル]メチル}-5-[(4-メトキシベンジル)オキシ]-7,7-ジメチル-2-{1-[5-(メチルカルバモイル)ピリミジン-2-イル]ピペリジン-4-イル}-5,6,7,8-テトラヒドロキノリン
得られた粗生成物70mgのテトラヒドロフラン0.5ml溶液に、1,1’-カルボニルジイミダゾール21mg(0.13mmol)を加え、室温にて30分間攪拌した。この反応溶液に、約40%メチルアミン水溶液0.5mlを加え、室温にて更に30分間攪拌した。反応終了後、反応液に水を加え、酢酸エチルで抽出した。有機層を飽和塩化ナトリウム水溶液で洗浄し、無水硫酸ナトリウムで乾燥した後、溶媒を減圧留去することにより標記化合物の粗生成物を得た。
1H-NMRスペクトル(500MHz,CDCl3)δppm: 8.61 (2H, s), 7.63 (2H, d, J = 8 Hz), 7.36 (2H, d, J= 8 Hz), 7.25 (2H, d, J = 9 Hz), 7.16 (1H, d, J = 47 Hz), 6.87 (2H, d, J= 9 Hz), 5.88-5.79 (1H, m), 4.91-4.76 (2H, m), 4.81 (1H, d, J = 11 Hz), 4.64-4.57 (1H, m), 4.39 (1H, d, J= 11 Hz), 3.79 (3H, s), 3.22-3.10 (1H, m), 2.97 (3H, d, J = 5 Hz), 2.89-2.59 (4H, m), 2.32-1.49 (14H, m), 1.19 (3H, s), 1.03 (3H, s), 0.73-0.64 (1H, m)。
(参考例26)
2-クロロ-5-(4,4,4-トリフルオロブチル)ピリミジン
得られた2-クロロ-5-(4,4,4-トリフルオロ-1-ブテン-1-イル)ピリミジン0.17g(0.78mmol)のエタノール7ml溶液に10%パラジウム炭素35mgを加え、水素ガス雰囲気下、室温で45分間撹拌した。触媒を濾過により除去した後、溶媒を減圧留去することにより、標記化合物0.14gを無色油状物として得た(収率30%)。
1H-NMRスペクトル(400MHz,CDCl3)δppm: 8.49 (2H, s), 2.72 (2H, t, J = 8 Hz), 2.23-2.09 (2H, m), 1.99-1.87 (2H, m)。
(参考例27)
4-(4,4-ジフルオロシクロヘキシル)-3-{フルオロ[4-(トリフルオロメチル)フェニル]メチル}-2-{1-[5-(1-ヒドロキシ-3-メチルブチル)ピリミジン-2-イル]ピペリジン-4-イル}-5-[(4-メトキシベンジル)オキシ]-7,7-ジメチル-5,6,7,8-テトラヒドロキノリン
1H-NMRスペクトル(300MHz,CD2Cl2)δppm: 8.22 (2H, s), 7.64 (2H, d, J = 8 Hz), 7.38 (2H, d, J = 8 Hz), 7.26 (2H, d, J = 9 Hz), 7.18 (1H, d, J = 47 Hz), 6.86 (2H, d, J = 9 Hz), 4.91-4.72 (1H, m), 4.85 (1H, t, J = 5 Hz), 4.80 (1H, d, J = 11 Hz), 4.61-4.43 (2H, m), 4.39 (1H, d, J = 11 Hz), 3.77 (3H, s), 3.25-3.11 (1H, m), 2.89-2.57 (4H, m), 2.31-2.02 (4H, m), 1.99-1.42 (14H, m), 1.17 (3H, s), 1.04 (3H, s), 0.93 (6H, d, J = 6 Hz), 0.73-0.63 (1H, m)。
マススペクトル(CI,m/z):839[(M+1)+]。
(参考例28)
2-クロロ-5-[(1-メチルピペリジン-4-イル)オキシ]ピリミジン
1H-NMRスペクトル(400MHz,CDCl3)δppm:8.22 (2H, s), 4.33 (1H, tt, J = 7.5, 3.8 Hz), 2.65-2.57 (2H, m), 2.30-2.22 (5H, m), 2.01-1.93 (2H, m), 1.85-1.75 (2H, m)。
(参考例29)
4-(4,4-ジフルオロシクロヘキシル)-3-{フルオロ[4-(トリフルオロメチル)フェニル]メチル}-5-[(4-メトキシベンジル)オキシ]-7,7-ジメチル-2-(1-{5-[(1-メチルピペリジン-4-イル)オキシ]ピリミジン-2-イル}ピペリジン-4-イル)-5,6,7,8-テトラヒドロキノリン
1H-NMRスペクトル(400MHz,CDCl3)δppm:8.03 (2H, s), 7.62 (2H, d, J = 8 Hz), 7.37 (2H, d, J = 8 Hz), 7.26 (2H, d, J = 9 Hz), 7.16 (1H, d, J = 47 Hz), 6.88 (2H, d, J = 9 Hz), 4.88-4.77 (2H, m), 4.73-4.62 (1H, m), 4.45-4.32 (2H, m), 4.05-3.95 (1H, m), 3.79 (3H, s), 3.22-3.10 (1H, m), 2.93-2.57 (6H, m), 2.37-1.52 (23H, m), 1.20 (3H, s), 1.04 (3H, s), 0.73-0.60 (1H, m)。
(参考例30)
2-クロロ-5-{[(3R)-1-メチルピロリジン-3-イル]オキシ}ピリミジン
1H-NMRスペクトル(400MHz,CDCl3)δppm:8.25 (2H, s), 4.89-4.84 (1H, m), 2.93-2.86 (2H, m), 2.78 (1H, dd, J = 11.0, 5.9 Hz), 2.45-2.34 (5H, m), 2.05-1.97 (1H, m)。
(参考例31)
2-クロロ-5-(3,3,3-トリフルオロプロポキシ)ピリミジン
1H-NMRスペクトル(500MHz,CDCl3)δppm:8.33 (2H, s), 4.30 (2H, t, J = 6.5 Hz), 2.74-2.64 (2H, m)。
(参考例32)
2-クロロ-5-(ジフルオロメトキシ)ピリミジン
1H-NMRスペクトル(500MHz,CDCl3)δppm:8.53 (2H, s), 6.62 (1H, t, J = 71 Hz)。
(参考例33)
2-クロロ-5-[(2,2,5-トリメチル-1,3-ジオキサン-5-イル)メトキシ]ピリミジン
1H-NMRスペクトル(300MHz,CDCl3)δppm: 8.34 (2H, s), 4.16 (2H, s), 3.73 (4H, s), 1.47 (3H, s), 1.41 (3H, s), 0.94 (3H, s)。
(参考例34)
4-(4,4-ジフルオロシクロヘキシル)-3-{フルオロ[4-(トリフルオロメチル)フェニル]メチル}-5-[(4-メトキシベンジル)オキシ]-7,7-ジメチル-2-(1-{5-[(2,2,5-トリメチル-1,3-ジオキサン-5-イル)メトキシ]ピリミジン-2-イル}ピペリジン-4-イル)-5,6,7,8-テトラヒドロキノリン
1H-NMRスペクトル(300MHz,CDCl3)δppm: 8.04 (2H, s), 7.61 (2H, d, J = 8 Hz), 7.35 (2H, d, J = 8 Hz), 7.25 (2H, d, J = 9 Hz), 7.14 (1H, d, J = 47 Hz), 6.87 (2H, d, J = 9 Hz), 4.82 (1H, t, J = 4 Hz), 4.81 (1H, d, J = 11 Hz), 4.70-4.60 (1H, m), 4.43-4.33 (1H, m), 4.38 (1H, d, J = 11 Hz), 3.95 (2H, s), 3.79 (3H, s), 3.76 (2H, d, J = 12 Hz), 3.65 (2H, d, J = 12 Hz), 3.23-3.08 (1H, m), 2.91-2.61 (4H, m), 2.32-1.50 (14H, m), 1.45 (3H, s), 1.40 (3H, s), 1.19 (3H, s), 1.03 (3H, s), 0.93 (3H, s), 0.70-0.60 (1H, m)。
マススペクトル(EI,m/z):910[M+]。
(参考例35)
2-クロロ-5-[3-(メトキシカルボニル)フェニル]ピリミジン
1H-NMRスペクトル(300MHz,CDCl3)δppm: 8.87 (2H, s), 8.25 (1H, t, J = 2 Hz), 8.16 (1H, dt, J = 8, 2 Hz), 7.75 (1H, ddd, J = 8, 2, 1 Hz), 7.62 (1H, t, J = 8 Hz), 3.98 (3H, s)。
マススペクトル(CI,m/z):249[(M+1)+]。
(参考例36)
2-クロロ-5-メチルチオピリミジン
1H-NMRスペクトル(500MHz,CDCl3)δppm:8.49 (2H, s), 2.54(3H, s)。
(参考例37)
(5S)-4-(4,4-ジフルオロシクロヘキシル)-3-{(S)-フルオロ[4-(トリフルオロメチル)フェニル]メチル}-2-[1-((R)-2-ヒドロキシ-2-フェニルアセチル)ピペリジン-4-イル]-5-[(4-メトキシベンジル)オキシ]-7,7-ジメチル-5,6,7,8-テトラヒドロキノリン
参考例10と同様にして得られた(-)-4-(4,4-ジフルオロシクロヘキシル)-3-{フルオロ[4-(トリフルオロメチル)フェニル]メチル}-5-[(4-メトキシベンジル)オキシ]-7,7-ジメチル-2-(ピペリジン-4-イル)-5,6,7,8-テトラヒドロキノリン501mg(0.742mmol)に、(R)-D-(-)-マンデル酸113mg(0.743mmol)、ジイソプロピルエチルアミン255μl(1.46mmol)、及び、塩化メチレン5mlを加えた。次に、反応溶液に1-(3-ジメチルアミノプロピル)-3-エチルカルボジイミド塩酸塩143mg(0.746mmol)を加えて、室温で20時間撹拌した。更に、1-(3-ジメチルアミノプロピル)-3-エチルカルボジイミド塩酸塩143mg(0.746mmol)及び4-ジメチルアミノピリジン133mg(1.09mmol)を加え、室温で4日間撹拌した。反応液に水を加え、塩化メチレンで3回抽出した。無水硫酸マグネシウムで乾燥後、溶媒を減圧留去した。得られた残渣をシリカゲルカラムクロマトグラフィー[n-ヘキサン/酢酸エチル=80/20(V/V)]に付し、標記化合物156mgを白色固体として得た(収率26%)。
1H-NMRスペクトル(300MHz,CD2Cl2)δppm: 7.61, 7.54 (合計2H, 各々d, J = 8 Hz), 7.42-6.98 (10H, m), 6.85 (2H, d, J = 8 Hz), 5.11 (1H, d, J = 6 Hz), 4.88-4.28 (2H, m), 4.80, 4.78 (合計1H, 各々d, J = 10, 11 Hz), 4.71, 4.66 (合計1H, 各々d, J =6, 7 Hz), 4.38, 4.37 (合計1H, 各々d, J = 11 Hz), 3.76 (3H, s), 3.63-3.53, 3.45-3.34 (合計1H, 各々m), 3.24-3.05 (1H, m), 2.91-2.39 (4H, m), 2.29-2.06 (3H, m), 2.01-1.43 (11H, m), 1.19 (3H, s), 1.06, 1.05 (合計3H, 各々s), 0.76-0.58 (1H, m)。
マススペクトル(APCI POSITIVE,m/z):809[(M+1)+]。
(37-2)標記化合物の絶対立体配置の決定
参考例(37-1)で得られた標記化合物3.5mgにメタノール800μlを加えて溶解した後、メタノールをゆっくり自然蒸発させることにより針状の単結晶を得た。得られた単結晶についてX線結晶構造解析を行った。
(1)再構成HDLの調製
コレステロール(1.125μmol)、ホスファチジルコリン(4.5μmol)、および、[14C]-標識コレステリルエステル(2.0μCi;40μl)をガラス試験管にとり、ボルテックスでよく混合し、窒素ガス気流下で薄膜状になるように乾燥させた。得られた混合物をエタノール(200μl)で溶解して溶液Aとした。PBS溶液[Na2HPO4(30 mM)、KH2PO4(8.8 mM)、NaCl(60 mM)、および、EDTA(pH 7.4;0.67 mM)の混合溶液;4 ml]をチューブにとり、窒素気流下でボルテックスにより激しく攪拌した。この混合物に上記溶液Aをシリンジで静かに注入し、窒素気流下で5分間、ボルテックスにより激しく攪拌した。得られた混合物にコール酸ナトリウム(200 mM;0.38 ml)を加え、2分間攪拌した。得られた混合物にApoA-Iタンパク質(3 mg)を加え、2分間攪拌した。得られた混合物をPBS溶液で5 mlに調製した後、PBS溶液で透析して、得られた混合物を再構成HDLとした。
(2)アクセプターリポタンパク質の調製
健常人の血漿にNaBrを加え、比重を1.019に調製し、密度勾配遠心分離(40000 rpm、16時間)を行い、比重が1.019未満の画分を除去した。得られた混合物にNaBrを加え、比重を1.063に調製し、密度勾配遠心分離(40000 rpm、18時間)を行い、IDL(中間比重リポタンパク質)およびLDLからなる画分(1.019<比重<1.063)を得た。得られた画分をPBS溶液で透析して、得られた混合物をアクセプターリポタンパク質とした。
(3)CETP阻害活性の測定
組み換え体ヒトCETPタンパク質(Roar Biomedical Inc.製;4.5 ng)、上記(2)のアクセプターリポタンパク質(32.5μg)、および、5,5'-dithio-bis-(2-nitrobenzoic acid)(7 mM,15μl)を96ウェルプレートに取り、PBS溶液で全量を48.5μlとした。各ウェルに試験化合物[DMSO溶液(濃度:0.15、0.5、1.5、5、15、50、150、および、500μM;1.5μl]を加え、37℃の恒温槽中で60分間インキュベートした。各ウェルに上記(1)の再構成HDL(50μl)を加え、37℃の恒温槽中で、60分間反応させた。96ウェルプレートを氷上に移し、沈澱試薬[塩化マグネシウム(60 mM)、および、0.1%dextran sulfate[1/1(v/v)]の混合溶液;15μl]を各ウェルに加えた後、氷上で15分間放置した。各ウェルの反応液(80μl)をフィルタープレートに移し、1500 rpmで1分間遠心し、フィルターを通過した濾液をHDL画分として、その放射活性をシンチレーションカウンターで測定した。試験化合物を加えない場合と比較した試験化合物を加えた場合の放射活性の低下率をCETP阻害率とした。CETP阻害率よりIC50値を算出した。
(4)結果
本発明の化合物の試験結果を表1に示す。
[表2]
_________________
実施例番号 IC50(nM)
 ̄ ̄ ̄ ̄ ̄ ̄ ̄ ̄ ̄ ̄ ̄ ̄ ̄ ̄ ̄ ̄ ̄
1 83
2 150
3 51
4 73
5 250
6 66
8 19
9 122
10 49
11 46
12 103
13 92
14 97
15 37
16 243
17 217
18 177
19 198
20 255
21 99
22 111
23 37
24 54
25 19
26 45
27 40
28 78
29 62
30 32
31 29
32 19
33 48
34 54
35 88
36 35
37 25
38 10
39 32
40 11
41 16
42 22
43 9
44 21
45 13
46 16
47 31
48 42
49 8
50 13
51 6
52 6
53 34
54 32
55 59
56 28
57 33
 ̄ ̄ ̄ ̄ ̄ ̄ ̄ ̄ ̄ ̄ ̄ ̄ ̄ ̄ ̄ ̄ ̄
本発明の化合物は、本試験において優れたCETP阻害活性を示し、脂質異常症、高コレステロ-ル血症、低HDLコレステロール血症、高LDLコレステロール血症、動脈硬化症、動脈硬化性心疾患、または、冠状動脈性心疾患等の治療もしくは予防のための医薬として有用である。
(試験例2)CETP阻害活性試験(in vitro, plasma系)
(1)ドナーリポタンパク質の調製
ヒトの血漿にNaBrを加え、比重を1.125に調製し、密度勾配遠心分離(40000 rpm、40時間)を行い、比重が1.125未満の画分を除去した。得られた混合物にNaBrを加え、比重を1.21に調製し、密度勾配遠心分離(40000 rpm、40時間)を行い、1.125<比重<1.21の画分を得た。得られた画分をPBS溶液で透析して、得られた混合物をHDL3画分とした。ホスファチジルコリン(5 mg)、および、 [3H]-標識コレステリルエステル(0.5 mCi;0.5 ml)をガラス試験管に取り、窒素気流下で乾燥させた。得られた混合物にPBS溶液(500μl)を加え、30分間超音波照射下にて混合した。得られた混合物にHDL3画分(1.75 mg)、および、リポタンパク質除去ヒト血清(LPDS; 12 mg)を加え、PBS溶液で全量が3.5 mlになるように調製した。得られた混合物を37°Cで48時間インキュベートした。得られた混合物にNaBrを加え、比重を1.063に調製し、密度勾配遠心分離(40000 rpm、18時間)を行い、比重が1.063未満の画分を除去した。得られた画分にNaBrを加え、比重を1.21に調製し、密度勾配遠心分離(40000 rpm、40時間)を行い、1.063<比重<1.21の画分を得た。得られた画分をPBS溶液で透析し、混合物をドナーリポタンパク質とした。
(2)CETP阻害活性の測定
ヒト血漿、あるいは、ヒトApo BおよびヒトCETP遺伝子を導入されたダブルトランスジェニックマウス(以下、CETP/apoB Tgマウス;J. Lipid Res., 1995年,第36巻,p.1082-1091)より採取した血漿(37 μL)に、上記(1)のドナーリポタンパク質(2 μL)、および、試験化合物[DMSO溶液(濃度:0.15、0.5、1.5、5、15、50、150、および500 μM;1 μL]を混合し、96ウェルV底プレートに添加した(計40μL)。軽く混合した後、37℃で2時間反応した。96ウェルV底プレートを氷上に移し、沈澱試薬[塩化マグネシウム(200 mM)、および、0.2%dextran sulfate[1/1(v/v)]の混合溶液;10 μl]を各ウェルに加えた後、氷上で15分間放置した。各ウェルの反応液(40 μl)をフィルタープレートに移し、1500 rpmで1分間遠心し、フィルターを通過した濾液をHDL画分、フィルター上に残った画分をLDL画分として、それぞれの放射活性をシンチレーションカウンターで測定した。コレステリルエステル転送率は、未反応および37℃で反応後のHDL画分およびLDL画分の放射活性より、以下の式にしたがって算出した。
=[[LDL画分(反応後)の放射活性-LDL画分(未反応)の放射活性]/[LDL画分(反応後)の放射活性+HDL画分(反応後)の放射活性]]×100
試験化合物を加えない場合と比較した試験化合物を加えた場合のコレステリルエステル転送率の低下率をCETP阻害率とした。CETP阻害率よりIC50値を算出した。
(試験例3)CETP阻害活性試験(in vitro、蛍光、plasma系)
Roar Biomedical Inc.製のEx vivo CETP Activity Assay(RB-EVAK)のReagent A(73 μl)に同Reagent B(311 μl)を混合してReagent Cを作成した。2.5 μlのReagent Cをヒト血漿、または、CETP/ApoB Tgマウスより採取した血漿(46.5 μl)に混合し、96ウェル黒色プレート(Half Area, Corning製No.3694)に添加した。各ウェルに試験化合物[DMSO溶液(濃度:0.15、0.5、1.5、5、15、50、150、および500 μM;1 μl]を加え、軽く混合した。37℃の恒温槽中で90分間反応させ、各ウェル中のサンプルの蛍光強度を蛍光プレートリーダー(LJL Biosystems製;Analyst HT)にて測定した(励起波長:485 nm、蛍光波長:530 nm)。野生型マウスの血漿を用いた反応の蛍光強度をブランクとして差し引き、試験化合物を加えない場合と比較した試験化合物を加えた場合の蛍光強度の低下率をCETP阻害率とした。CETP阻害率よりIC50値を算出した。
(試験例4)マウス薬効試験(マウスin vivo、および、マウスex vivo)
(1)化合物の投与
試験化合物をpropylene glycol-Tween 80(商品名)混合溶媒[4/1(v/v)]に溶解し、CETP/apoB Tgマウスに、2または7日間経口投与した。投与2または7日目の投与前および投与14または24時間後に血液を採取した。
(2)血漿中コレステロール含有量の測定
血漿中コレステロール含有量は、市販の測定キット(コレステロール-Eワコー、和光純薬製)を用いて測定した。
(3)HDLコレステロール、および、non-HDLコレステロールの含有量の測定
リポタンパク質プロファイルを、HPLC(カラム:LipopropackXL、東ソー製)によって分析した。HDLコレステロール、および、non-HDLコレステロールの含有量は、以下の計算式にしたがって算出した。
non-HDLコレステロール含有量 = 血漿中コレステロール含有量 × (non-HDLコレステロールのピーク面積 / 各ピーク面積の和)
(4)ドナーリポタンパク質の調製
ヒトの血漿にNaBrを加え、比重を1.125に調製し、密度勾配遠心分離(40000 rpm、40時間)を行い、比重が1.125未満の画分を除去した。得られた混合物にNaBrを加え、比重を1.21に調製し、密度勾配遠心分離(40000 rpm、40時間)を行い、1.125<比重<1.21の画分を得た。得られた画分をPBS溶液で透析して、得られた混合物をHDL3画分とした。ホスファチジルコリン(5 mg)、および、トリチウム標識コレステリルエステル(0.5 mCi;0.5 ml)をガラス試験管に取り、窒素気流下で乾燥させた。得られた混合物にPBS溶液(500μl)を加え、30分間超音波照射下にて混合した。得られた混合物にHDL3画分(1.75 mg)、および、リポタンパク質除去ヒト血清(12 mg)を加え、PBS溶液で全量が3.5 mlになるように調製した。得られた混合物を37℃で48時間インキュベートした。得られた混合物にNaBrを加え、比重を1.063に調製し、密度勾配遠心分離(40000 rpm、18時間)を行い、比重が1.063未満の画分を除去した。得られた画分にNaBrを加え、比重を1.21に調製し、密度勾配遠心分離(40000 rpm、40時間)を行い、1.063<比重<1.21の画分を得た。得られた画分をPBS溶液で透析して、得られた混合物をドナーリポタンパク質とした。
(5)CETP阻害活性の測定(蛍光、ex vivo)
Roar Biomedical Inc.社のEx vivo CETP Activity Assay(RB-EVAK)のReagent A(73 μl)とReagent B(311 μl)を混合し、Reagent Cを作成した。1 μlのReagent Cと試験動物より採取した血漿(19 μl)を黒色384 ウェル丸底プレート(corning製No.3676)に添加した。37℃の恒温槽中で90分間反応させ、各ウェル中のサンプルの蛍光強度を蛍光プレートリーダー(LJL Biosystems製:Analyst HT)にて測定した(励起波長:485 nm、蛍光波長:530 nm)。野生型マウスの血漿を用いた反応の蛍光強度をブランクとして差し引き、試験化合物を投与しない場合と比較した試験化合物を投与した場合の蛍光強度の低下率をCETP阻害率とした。
(製剤例1)ハ-ドカプセル剤
標準二分式ハ-ドゼラチンカプセルに、粉末状の実施例1の化合物(100mg)、ラクト-ス(150mg)、セルロ-ス(50mg)、および、ステアリン酸マグネシウム(6mg)を充填して、ハ-ドカプセルを製造し、洗浄した後、乾燥する。
(製剤例2)ソフトカプセル剤
大豆油、オリ-ブ油のような消化性油状物、および、実施例2の化合物の混合物を、100mgの活性成分を含有するようにゼラチン中に注入してソフトカプセルを製造し、洗浄した後、乾燥する。
(製剤例3)錠剤
実施例3の化合物(100mg)、コロイド性二酸化ケイ素(0.2mg)、ステアリン酸マグネシウム(0.2mg)、微結晶性セルロ-ス(0.2mg)、デンプン(0.2mg)、および、ラクト-ス(98.8mg)を用いて、製剤学の分野で周知の方法に従って錠剤を製造する。得られた錠剤には、必要に応じてコーティングを施すことができる。
Claims (41)
- 一般式(I)
[式中、R1は、水素原子、C1-C6アルキル基、ヒドロキシ(C1-C6アルキル)基、(C1-C6アルコキシ)-(C1-C6アルキル)基、ヒドロキシ(C1-C6アルコキシ)-(C1-C6アルキル)基、(C1-C6アルキル)アミノ-(C1-C6アルキル)基、ヒドロキシ(C1-C6アルキル)アミノ-(C1-C6アルキル)基、[N-(C1-C6アルキル)-N-ヒドロキシ(C1-C6アルキル)アミノ]-(C1-C6アルキル)基、(C1-C6アルキル)スルホニルアミノ-(C1-C6アルキル)基、[N-(C1-C6アルキル)-N-(C1-C6アルキル)スルホニルアミノ]-(C1-C6アルキル)基、カルボキシ(C1-C6アルキル)基、ハロゲノ(C1-C6アルキル)基、(C3-C8シクロアルキル)-(C1-C6アルキル)基、C2-C6アルケニル基、C2-C6アルキニル基、C3-C8シクロアルキル基、C3-C8シクロアルケニル基、ヒドロキシ基、C1-C6アルコキシ基、ヒドロキシ(C1-C6アルコキシ)基、(C1-C6アルコキシ)-(C1-C6アルコキシ)基、(C1-C6アルキル)スルホニル-(C1-C6アルコキシ)基、カルボキシ(C1-C6アルコキシ)基、ハロゲノ(C1-C6アルコキシ)基、C1-C6アルキルチオ基、C1-C6アルキルスルフィニル基、C1-C6アルキルスルホニル基、アミノ基、C1-C6アルキルアミノ基、ジ(C1-C6アルキル)アミノ基、ヒドロキシ(C1-C6アルキル)アミノ基、N-(C1-C6アルキル)-N-ヒドロキシ(C1-C6アルキル)アミノ基、ホルミルアミノ基、(C1-C6アルキル)カルボニルアミノ基、カルボキシ基、(C1-C6アルコキシ)カルボニル基、カルバモイル基、(C1-C6アルキルアミノ)カルボニル基、ジ(C1-C6アルキル)アミノカルボニル基、シアノ基、ハロゲノ基、フェニル基、置換フェニル基(当該置換基は、独立して置換基群αから選択される1乃至4個の基を示す)、5または6員芳香族ヘテロシクリル基、置換5または6員芳香族ヘテロシクリル基(当該置換基は、独立して置換基群αから選択される1乃至4個の基を示す)、5または6員飽和ヘテロシクリル基、置換5または6員飽和ヘテロシクリル基(当該置換基は、独立して置換基群αから選択される1乃至4個の基を示す)、5または6員飽和ヘテロシクリル-(C1-C6アルキル)基、置換5または6員飽和ヘテロシクリル-(C1-C6アルキル)基(当該置換基は、独立して置換基群αから選択される1乃至4個の基を示す)、5または6員飽和ヘテロシクリルオキシ基、置換5または6員飽和ヘテロシクリルオキシ基(当該置換基は、独立して置換基群αから選択される1乃至4個の基を示す)、5または6員飽和ヘテロシクリルカルボニル基、または、置換5または6員飽和ヘテロシクリルカルボニル基(当該置換基は、独立して置換基群αから選択される1乃至4個の基を示す)を示し、
置換基群αは、C1-C6アルキル基、ヒドロキシ(C1-C6アルキル)基、ハロゲノ(C1-C6アルキル)基、(C3-C8シクロアルキル)-(C1-C6アルキル)基、C3-C8シクロアルキル基、ヒドロキシ基、C1-C6アルコキシ基、ハロゲノ(C1-C6アルコキシ)基、C1-C6アルキルアミノ基、ジ(C1-C6アルキル)アミノ基、カルボキシ基、(C1-C6アルコキシ)カルボニル基、カルバモイル基、(C1-C6アルキルアミノ)カルボニル基、ジ(C1-C6アルキル)アミノカルボニル基、シアノ基、ハロゲノ基、および、オキソ基からなる群を示す。]
を有する化合物またはその薬理上許容される塩。
- R1が、水素原子、C1-C6アルキル基、ヒドロキシ(C1-C6アルキル)基、(C1-C6アルコキシ)-(C1-C6アルキル)基、(C1-C6アルキル)アミノ-(C1-C6アルキル)基、[N-(C1-C6アルキル)-N-ヒドロキシ(C1-C6アルキル)アミノ]-(C1-C6アルキル)基、[N-(C1-C6アルキル)-N-(C1-C6アルキル)スルホニルアミノ]-(C1-C6アルキル)基、カルボキシ(C1-C6アルキル)基、ハロゲノ(C1-C6アルキル)基、C2-C6アルケニル基、C3-C8シクロアルキル基、C3-C8シクロアルケニル基、ヒドロキシ基、C1-C6アルコキシ基、ヒドロキシ(C1-C6アルコキシ)基、(C1-C6アルキル)スルホニル-(C1-C6アルコキシ)基、カルボキシ(C1-C6アルコキシ)基、ハロゲノ(C1-C6アルコキシ)基、C1-C6アルキルチオ基、C1-C6アルキルスルホニル基、N-(C1-C6アルキル)-N-ヒドロキシ(C1-C6アルキル)アミノ基、(C1-C6アルキルアミノ)カルボニル基、ジ(C1-C6アルキル)アミノカルボニル基、シアノ基、または、ハロゲノ基である、請求項2に記載された化合物またはその薬理上許容される塩。
- R1が、水素原子、C1-C4アルキル基、ヒドロキシ(C1-C4アルキル)基、(C1-C4アルコキシ)-(C1-C4アルキル)基、ハロゲノ(C1-C4アルキル)基、C1-C4アルコキシ基、ヒドロキシ(C1-C6アルコキシ)基、または、(C1-C4アルキル)スルホニル-(C1-C4アルコキシ)基である、請求項2に記載された化合物またはその薬理上許容される塩。
- R1が、C1-C4アルキル基、ハロゲノ(C1-C4アルキル)基、C1-C4アルコキシ基、または、ヒドロキシ(C1-C6アルコキシ)基である、請求項2に記載された化合物またはその薬理上許容される塩。
- R1が、C1-C4アルキル基である、請求項2に記載された化合物またはその薬理上許容される塩。
- R1が、ハロゲノ(C1-C4アルキル)基である、請求項2に記載された化合物またはその薬理上許容される塩。
- R1が、C1-C4アルコキシ基である、請求項2に記載された化合物またはその薬理上許容される塩。
- R1が、ヒドロキシ(C1-C6アルコキシ)基である、請求項2に記載された化合物またはその薬理上許容される塩。
- R1が、(C1-C4アルキル)スルホニル-(C1-C4アルコキシ)基である、請求項2に記載された化合物またはその薬理上許容される塩。
- R1が、置換フェニル基(当該置換基は、独立して置換基群α1から選択される1乃至4個の基を示す)、置換5または6員芳香族ヘテロシクリル基(当該置換基は、独立して置換基群α1から選択される1乃至4個の基を示す)、5または6員飽和ヘテロシクリル基、置換5または6員飽和ヘテロシクリル基(当該置換基は、独立して置換基群α1から選択される1乃至4個の基を示す)、置換5または6員飽和ヘテロシクリルオキシ基(当該置換基は、独立して置換基群α1から選択される1乃至4個の基を示す)、または、5または6員飽和ヘテロシクリルカルボニル基であり、
置換基群α1は、C1-C6アルキル基、ヒドロキシ基、カルボキシ基、および、オキソ基からなる群を示す、請求項2に記載された化合物またはその薬理上許容される塩。
- R1が、5または6員含窒素飽和ヘテロシクリル基、置換5または6員含窒素飽和ヘテロシクリル基(当該置換基は、独立して置換基群α2から選択される1乃至4個の基を示す)、置換5または6員含窒素飽和ヘテロシクリルオキシ基(当該置換基は、独立して置換基群α2から選択される1乃至4個の基を示す)、または、5または6員含窒素飽和ヘテロシクリルカルボニル基であり、
置換基群α2は、C1-C4アルキル基、および、ヒドロキシ基からなる群を示す、請求項2に記載された化合物またはその薬理上許容される塩。
- R1が、置換ピロリジニル基、置換ピペラジル基、置換ピロリジニルオキシ基、置換ピペリジルオキシ基(当該ピロリジニル基、ピペラジル基、ピロリジニルオキシ基、および、ピペリジルオキシ基の置換基は、独立して置換基群α3から選択される1乃至2個の基を示す)、または、モルホリニルカルボニル基であり、
置換基群α3は、メチル基、および、ヒドロキシ基からなる群を示す、請求項2に記載された化合物またはその薬理上許容される塩。
- R1が、置換フェニル基(当該置換基は、独立して置換基群α1から選択される1乃至2個の基を示す)である、請求項2に記載された化合物またはその薬理上許容される塩。
- (5S)-4-(4,4-ジフルオロシクロヘキシル)-3-{(S)-フルオロ[4-(トリフルオロメチル)フェニル]メチル}-7,7-ジメチル-2-{1-[5-(4-メチルピペラジン-1-イル)ピリミジン-2-イル]ピペリジン-4-イル}-5,6,7,8-テトラヒドロキノリン-5-オール、
(5S)-4-(4,4-ジフルオロシクロヘキシル)-3-{(S)-フルオロ[4-(トリフルオロメチル)フェニル]メチル}-2-{1-[5-(2-ヒドロキシエトキシ)ピリミジン-2-イル]ピペリジン-4-イル}-7,7-ジメチル-5,6,7,8-テトラヒドロキノリン-5-オール、
(5S)-2-{1-[5-(4-カルボキシブトキシ)ピリミジン-2-イル]ピペリジン-4-イル}-4-(4,4-ジフルオロシクロヘキシル)-3-{(S)-フルオロ[4-(トリフルオロメチル)フェニル]メチル}-7,7-ジメチル-5,6,7,8-テトラヒドロキノリン-5-オール、
(5S)-2-{1-[5-(4-カルボキシブチル)ピリミジン-2-イル]ピペリジン-4-イル}-4-(4,4-ジフルオロシクロヘキシル)-3-{(S)-フルオロ[4-(トリフルオロメチル)フェニル]メチル}-7,7-ジメチル-5,6,7,8-テトラヒドロキノリン-5-オール、
(5S)-4-(4,4-ジフルオロシクロヘキシル)-3-{(S)-フルオロ[4-(トリフルオロメチル)フェニル]メチル}-7,7-ジメチル-2-{1-[5-(メチルカルバモイル)ピリミジン-2-イル]ピペリジン-4-イル}-5,6,7,8-テトラヒドロキノリン-5-オール、
(5S)-4-(4,4-ジフルオロシクロヘキシル)-2-{1-[5-(ジメチルカルバモイル)ピリミジン-2-イル]ピペリジン-4-イル}-3-{(S)-フルオロ[4-(トリフルオロメチル)フェニル]メチル}-7,7-ジメチル-5,6,7,8-テトラヒドロキノリン-5-オール、
(5S)-4-(4,4-ジフルオロシクロヘキシル)-3-{(S)-フルオロ[4-(トリフルオロメチル)フェニル]メチル}-7,7-ジメチル-2-{1-[5-(モルホリン-4-イルカルボニル)ピリミジン-2-イル]ピペリジン-4-イル}-5,6,7,8-テトラヒドロキノリン-5-オール、
(5S)-4-(4,4-ジフルオロシクロヘキシル)-3-{(S)-フルオロ[4-(トリフルオロメチル)フェニル]メチル}-2-{1-(5-{[(2-ヒドロキシエチル)(メチル)アミノ]メチル}ピリミジン-2-イル)ピペリジン-4-イル}-7,7-ジメチル-5,6,7,8-テトラヒドロキノリン-5-オール、
(5S)-4-(4,4-ジフルオロシクロヘキシル)-3-{(S)-フルオロ[4-(トリフルオロメチル)フェニル]メチル}-2-[1-(5-{[(2S)-2-ヒドロキシプロピル]オキシ}ピリミジン-2-イル)ピペリジン-4-イル]-7,7-ジメチル-5,6,7,8-テトラヒドロキノリン-5-オール、
(5S)-4-(4,4-ジフルオロシクロヘキシル)-3-{(S)-フルオロ[4-(トリフルオロメチル)フェニル]メチル}-7,7-ジメチル-2-(1-{5-[(1-メチルピペリジン-4-イル)オキシ]ピリミジン-2-イル}ピペリジン-4-イル)-5,6,7,8-テトラヒドロキノリン-5-オール、
(5S)-4-(4,4-ジフルオロシクロヘキシル)-2-[1-(5-{[(2S)-2,3-ジヒドロキシプロピル]オキシ}ピリミジン-2-イル)ピペリジン-4-イル]-3-{(S)-フルオロ[4-(トリフルオロメチル)フェニル]メチル}-7,7-ジメチル-5,6,7,8-テトラヒドロキノリン-5-オール、
(5S)-4-(4,4-ジフルオロシクロヘキシル)-2-[1-(5-{[(2R)-2,3-ジヒドロキシプロピル]オキシ}ピリミジン-2-イル)ピペリジン-4-イル]-3-{(S)-フルオロ[4-(トリフルオロメチル)フェニル]メチル}-7,7-ジメチル-5,6,7,8-テトラヒドロキノリン-5-オール、
(5S)-4-(4,4-ジフルオロシクロヘキシル)-3-{(S)-フルオロ[4-(トリフルオロメチル)フェニル]メチル}-7,7-ジメチル-2-[1-(5-{[(3R)-1-メチルピロリジン-3-イル]オキシ}ピリミジン-2-イル)ピペリジン-4-イル]-5,6,7,8-テトラヒドロキノリン-5-オール、
(5S)-4-(4,4-ジフルオロシクロヘキシル)-3-{(S)-フルオロ[4-(トリフルオロメチル)フェニル]メチル}-2-[1-(5-{[(2R)-2-ヒドロキシプロピル]オキシ}ピリミジン-2-イル)ピペリジン-4-イル]-7,7-ジメチル-5,6,7,8-テトラヒドロキノリン-5-オール、
(5S)-4-(4,4-ジフルオロシクロヘキシル)-3-{(S)-フルオロ[4-(トリフルオロメチル)フェニル]メチル}-2-{1-[5-(3-ヒドロキシ-3-メチルブトキシ)ピリミジン-2-イル]ピペリジン-4-イル}-7,7-ジメチル-5,6,7,8-テトラヒドロキノリン-5-オール、
(5S)-4-(4,4-ジフルオロシクロヘキシル)-3-{(S)-フルオロ[4-(トリフルオロメチル)フェニル]メチル}-2-{1-[5-(2-ヒドロキシ-2-メチルプロポキシ)ピリミジン-2-イル]ピペリジン-4-イル}-7,7-ジメチル-5,6,7,8-テトラヒドロキノリン-5-オール、
(5S)-4-(4,4-ジフルオロシクロヘキシル)-3-{(S)-フルオロ[4-(トリフルオロメチル)フェニル]メチル}-7,7-ジメチル-2-(1-{5-[3-(メチルスルホニル)プロポキシ]ピリミジン-2-イル}ピペリジン-4-イル)-5,6,7,8-テトラヒドロキノリン-5-オール、
(5S)-4-(4,4-ジフルオロシクロヘキシル)-3-{(S)-フルオロ[4-(トリフルオロメチル)フェニル]メチル}-2-{1-[5-(3-ヒドロキシプロポキシ)ピリミジン-2-イル]ピペリジン-4-イル}-7,7-ジメチル-5,6,7,8-テトラヒドロキノリン-5-オール、
(5S)-4-(4,4-ジフルオロシクロヘキシル)-3-{(S)-フルオロ[4-(トリフルオロメチル)フェニル]メチル}-7,7-ジメチル-2-{1-[5-(3,3,3-トリフルオロプロポキシ)ピリミジン-2-イル]ピペリジン-4-イル}-5,6,7,8-テトラヒドロキノリン-5-オール、
(5S)-4-(4,4-ジフルオロシクロヘキシル)-3-{(S)-フルオロ[4-(トリフルオロメチル)フェニル]メチル}-2-(1-{5-[3-ヒドロキシ-2-(ヒドロキシメチル)プロポキシ]ピリミジン-2-イル}ピペリジン-4-イル)-7,7-ジメチル-5,6,7,8-テトラヒドロキノリン-5-オール、
(5S)-4-(4,4-ジフルオロシクロヘキシル)-3-{(S)-フルオロ[4-(トリフルオロメチル)フェニル]メチル}-2-(1-{5-[3-ヒドロキシ-2-(ヒドロキシメチル)-2-メチルプロポキシ]ピリミジン-2-イル}ピペリジン-4-イル)-7,7-ジメチル-5,6,7,8-テトラヒドロキノリン-5-オール、
(5S)-4-(4,4-ジフルオロシクロヘキシル)-3-{(S)-フルオロ[4-(トリフルオロメチル)フェニル]メチル}-7,7-ジメチル-2-[1-(5-{[メチル(メチルスルホニル)アミノ]メチル}ピリミジン-2-イル)ピペリジン-4-イル]-5,6,7,8-テトラヒドロキノリン-5-オール、
(5S)-4-(4,4-ジフルオロシクロヘキシル)-3-{(S)-フルオロ[4-(トリフルオロメチル)フェニル]メチル}-7,7-ジメチル-2-[1-(5-{[メチル(プロパン-2-イルスルホニル)アミノ]メチル}ピリミジン-2-イル)ピペリジン-4-イル]-5,6,7,8-テトラヒドロキノリン-5-オール、
(5S)-4-(4,4-ジフルオロシクロヘキシル)-3-{(S)-フルオロ[4-(トリフルオロメチル)フェニル]メチル}-7,7-ジメチル-2-[1-(5-メチルチオピリミジン-2-イル)ピペリジン-4-イル]-5,6,7,8-テトラヒドロキノリン-5-オール、
(5S)-4-(4,4-ジフルオロシクロヘキシル)-3-{(S)-フルオロ[4-(トリフルオロメチル)フェニル]メチル}-7,7-ジメチル-2-{1-[5-(メチルスルホニル)ピリミジン-2-イル]ピペリジン-4-イル}-5,6,7,8-テトラヒドロキノリン-5-オール、
(5S)-2-{1-[5-(3-カルボキシフェニル)ピリミジン-2-イル]ピペリジン-4-イル}-4-(4,4-ジフルオロシクロヘキシル)-3-{(S)-フルオロ[4-(トリフルオロメチル)フェニル]メチル}-7,7-ジメチル-5,6,7,8-テトラヒドロキノリン-5-オール、
(5S)-4-(4,4-ジフルオロシクロヘキシル)-3-{(S)-フルオロ[4-(トリフルオロメチル)フェニル]メチル}-2-(1-{5-[(2-ヒドロキシエチル)(メチル)アミノ]ピリミジン-2-イル}ピペリジン-4-イル)-7,7-ジメチル-5,6,7,8-テトラヒドロキノリン-5-オール、および、
(5S)-4-(4,4-ジフルオロシクロヘキシル)-3-{(S)-フルオロ[4-(トリフルオロメチル)フェニル]メチル}-2-(1-{5-[(3S)-3-ヒドロキシピロリジン-1-イル]ピリミジン-2-イル}ピペリジン-4-イル)-7,7-ジメチル-5,6,7,8-テトラヒドロキノリン-5-オール
からなる群より選択される、請求項2に記載された化合物またはその薬理上許容される塩。
- 請求項1乃至15のいずれかに記載された化合物またはその薬理上許容される塩を有効成分として含有する医薬組成物。
- 脂質異常症、高コレステロ-ル血症、低HDLコレステロール血症、高LDLコレステロール血症、高トリグリセリド血症、動脈硬化症、動脈硬化性心疾患、冠状動脈性心疾患、脳血管疾患、末梢血管疾患、または、肥満症の治療もしくは予防のための請求項16に記載された医薬組成物。
- 脂質異常症、低HDLコレステロール血症、動脈硬化症、または、冠状動脈性心疾患の治療もしくは予防のための請求項16に記載された医薬組成物。
- 低HDLコレステロール血症の治療もしくは予防のための請求項16に記載された医薬組成物。
- 動脈硬化症の治療もしくは予防のための請求項16に記載された医薬組成物。
- HDLコレステロールの血中濃度の低下により引き起こされる疾患の治療もしくは予防のための請求項16に記載された医薬組成物。
- LDLコレステロールの血中濃度の上昇により引き起こされる疾患の治療もしくは予防のための請求項16に記載された医薬組成物。
- 請求項1乃至15のいずれかに記載された化合物またはその薬理上許容される塩を有効成分として含有するCETP阻害剤。
- 請求項1乃至15のいずれかに記載された化合物またはその薬理上許容される塩を有効成分として含有するHDLコレステロール濃度上昇剤。
- 請求項1乃至15のいずれかに記載された化合物またはその薬理上許容される塩を有効成分として含有するLDLコレステロール濃度低下剤。
- 医薬組成物の製造のための、請求項1乃至15のいずれかに記載された化合物またはその薬理上許容される塩の使用。
- 脂質異常症、高コレステロ-ル血症、低HDLコレステロール血症、高LDLコレステロール血症、高トリグリセリド血症、動脈硬化症、動脈硬化性心疾患、冠状動脈性心疾患、脳血管疾患、末梢血管疾患、または、肥満症の治療もしくは予防のための医薬組成物の製造のための、請求項26に記載された使用。
- 脂質異常症、低HDLコレステロール血症、動脈硬化症、または、冠状動脈性心疾患の治療もしくは予防のための医薬組成物の製造のための、請求項26に記載された使用。
- 低HDLコレステロール血症の治療もしくは予防のための医薬組成物の製造のための、請求項26に記載された使用。
- 動脈硬化症の治療もしくは予防のための医薬組成物の製造のための、請求項26に記載された使用。
- 疾患の治療もしくは予防のための方法における使用のための、請求項1乃至15のいずれかに記載された化合物またはその薬理上許容される塩。
- 疾患が、脂質異常症、高コレステロ-ル血症、低HDLコレステロール血症、高LDLコレステロール血症、高トリグリセリド血症、動脈硬化症、動脈硬化性心疾患、冠状動脈性心疾患、脳血管疾患、末梢血管疾患、または、肥満症である、請求項31に記載された化合物またはその薬理上許容される塩。
- 疾患が、脂質異常症、低HDLコレステロール血症、動脈硬化症、または、冠状動脈性心疾患である、請求項31に記載された化合物またはその薬理上許容される塩。
- 疾患が、低HDLコレステロール血症である、請求項31に記載された化合物またはその薬理上許容される塩。
- 疾患が、動脈硬化症である、請求項31に記載された化合物またはその薬理上許容される塩。
- 請求項1乃至15のいずれかに記載された化合物またはその薬理上許容される塩の薬理的有効量を温血動物に投与することによる、疾患の治療もしくは予防のための方法。
- 疾患が、脂質異常症、高コレステロ-ル血症、低HDLコレステロール血症、高LDLコレステロール血症、高トリグリセリド血症、動脈硬化症、動脈硬化性心疾患、冠状動脈性心疾患、脳血管疾患、末梢血管疾患、または、肥満症である、請求項36に記載された方法。
- 疾患が、脂質異常症、低HDLコレステロール血症、動脈硬化症、または、冠状動脈性心疾患である、請求項36に記載された方法。
- 疾患が、低HDLコレステロール血症である、請求項36に記載された方法。
- 疾患が、動脈硬化症である、請求項36に記載された方法。
- 温血動物が、ヒトである、請求項36乃至40のいずれかに記載された方法。
Priority Applications (16)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP20110803677 EP2592076B1 (en) | 2010-07-09 | 2011-07-08 | Substituted pyridine compound |
AU2011274903A AU2011274903B2 (en) | 2010-07-09 | 2011-07-08 | Substituted pyridine compound |
MX2013000359A MX2013000359A (es) | 2010-07-09 | 2011-07-08 | Compuesto de piridina sustituida. |
JP2012523924A JP5739426B2 (ja) | 2010-07-09 | 2011-07-08 | 置換ピリジン化合物 |
SG2013000385A SG186493A1 (en) | 2010-07-09 | 2011-07-08 | Substituted pyridine compound |
US13/809,115 US9187450B2 (en) | 2010-07-09 | 2011-07-08 | Substituted pyridine compound |
CA2804924A CA2804924C (en) | 2010-07-09 | 2011-07-08 | Substituted pyridine compound |
ES11803677.1T ES2543176T3 (es) | 2010-07-09 | 2011-07-08 | Compuesto de piridina sustituido |
KR1020137000015A KR101764458B1 (ko) | 2010-07-09 | 2011-07-08 | 치환 피리딘 화합물 |
NZ606100A NZ606100A (en) | 2010-07-09 | 2011-07-08 | Substituted pyridine compound |
CN201180043361.9A CN103221405B (zh) | 2010-07-09 | 2011-07-08 | 取代的吡啶化合物 |
RU2013105475/04A RU2572606C2 (ru) | 2010-07-09 | 2011-07-08 | Замещенное пиридиновое соединение |
BR112013000389A BR112013000389A2 (pt) | 2010-07-09 | 2011-07-08 | composto, composição farmacêutica, medicamento para inibir o cetp, medicamentos para aumentar a concentração o colesterol de hdl, e para diminuir a concentração do colesterol de ldl, uso do composto, e, método de tratamento ou profilaxia de uma doença |
IL223866A IL223866A (en) | 2010-07-09 | 2012-12-25 | Converted pyridine compounds, preparations containing them and their uses |
ZA2013/00155A ZA201300155B (en) | 2010-07-09 | 2013-01-07 | Substituted pyridine compound |
HK13111517.6A HK1183877A1 (en) | 2010-07-09 | 2013-10-11 | Substituted pyridine compound |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2010156590 | 2010-07-09 | ||
JP2010-156590 | 2010-07-09 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2012005343A1 true WO2012005343A1 (ja) | 2012-01-12 |
Family
ID=45441319
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2011/065651 WO2012005343A1 (ja) | 2010-07-09 | 2011-07-08 | 置換ピリジン化合物 |
Country Status (20)
Country | Link |
---|---|
US (1) | US9187450B2 (ja) |
EP (1) | EP2592076B1 (ja) |
JP (1) | JP5739426B2 (ja) |
KR (1) | KR101764458B1 (ja) |
CN (1) | CN103221405B (ja) |
AU (1) | AU2011274903B2 (ja) |
BR (1) | BR112013000389A2 (ja) |
CA (1) | CA2804924C (ja) |
CO (1) | CO6670582A2 (ja) |
ES (1) | ES2543176T3 (ja) |
HK (1) | HK1183877A1 (ja) |
IL (1) | IL223866A (ja) |
MX (1) | MX2013000359A (ja) |
MY (1) | MY158199A (ja) |
NZ (1) | NZ606100A (ja) |
RU (1) | RU2572606C2 (ja) |
SG (1) | SG186493A1 (ja) |
TW (1) | TWI506025B (ja) |
WO (1) | WO2012005343A1 (ja) |
ZA (1) | ZA201300155B (ja) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2013103150A1 (ja) * | 2012-01-06 | 2013-07-11 | 第一三共株式会社 | 置換ピリジン化合物の酸付加塩 |
WO2015060422A1 (ja) * | 2013-10-25 | 2015-04-30 | 第一三共株式会社 | 置換ピリジン化合物および他の医薬の組み合わせ |
JPWO2015087994A1 (ja) * | 2013-12-13 | 2017-03-16 | 第一三共株式会社 | 5−ヒドロキシ−4−(トリフルオロメチル)ピラゾロピリジン誘導体 |
Citations (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH1067746A (ja) | 1996-07-08 | 1998-03-10 | Bayer Ag | シクロアルカノ−ピリジン類 |
JPH10167967A (ja) | 1996-07-08 | 1998-06-23 | Bayer Ag | 複素環式−縮合ピリジン類 |
WO1999014215A1 (de) * | 1997-09-18 | 1999-03-25 | Bayer Aktiengesellschaft | 4-heteroaryl-tetrahydrochinoline und ihre verwendung als inhibitoren des cholesterin-ester-transfer-proteins (ctep) |
WO1999041237A1 (en) * | 1998-02-13 | 1999-08-19 | G.D. Searle & Co. | Substituted pyridines useful for inhibiting cholesteryl ester transfer protein activity |
US6207671B1 (en) | 1996-07-08 | 2001-03-27 | Bayer Aktiengesellschaft | Cycloalkano-pyridines |
US6291477B1 (en) | 1997-09-19 | 2001-09-18 | Bayer Aktiengesellschaft | Tetrahydroquinolines, processes for their preparation, pharmaceutical compositions containing them, and their use to prevent or treat hyperlipoproteinaemia |
US6593333B1 (en) | 1998-10-01 | 2003-07-15 | Astrazeneca Ab | Substituted anilino-quinazoline (or quinoline) compounds and use thereof |
JP2005508341A (ja) | 2001-10-01 | 2005-03-31 | バイエル・ヘルスケア・アクチェンゲゼルシャフト | 3−ヒドロキシ−(4−トリフルオロメチルフェニル)−メチル−7−スピロシクロブチル−5,6,7,8−テトラヒドロキノリン−5−オール誘導体およびコレステロールエステル転送タンパク質(cetp)阻害剤としてのその使用 |
WO2006063828A1 (de) * | 2004-12-18 | 2006-06-22 | Bayer Healthcare Ag | 4-cycloalkyl-substituierte tetrahydrochinolinderivate und deren verwendung als medikamente |
WO2008009435A1 (en) | 2006-07-20 | 2008-01-24 | Novartis Ag | Amino-piperidine derivatives as cetp inhibitors |
JP2008524137A (ja) | 2004-12-18 | 2008-07-10 | バイエル・ヘルスケア・アクチェンゲゼルシャフト | (5s)−3−[(s)−フルオロ(4−トリフルオロメチルフェニル)メチル−5,6,7,8−テトラヒドロキノリン−5−オール誘導体およびcetp阻害剤としてのそれらの使用 |
WO2008156715A1 (en) | 2007-06-20 | 2008-12-24 | Merck & Co., Inc. | Cetp inhibitors derived from benzoxazole arylamides |
US20090023729A1 (en) | 2006-01-31 | 2009-01-22 | Mitsubishi Tanabe Pharma Corporation | Trisubstituted amine compound |
JP2009516649A (ja) | 2005-10-31 | 2009-04-23 | メルク エンド カムパニー インコーポレーテッド | Cetp阻害薬 |
WO2009071509A1 (en) | 2007-12-03 | 2009-06-11 | Novartis Ag | 1,2-disubstituted-4-benzylamino-pyrrolidine derivatives as cetp inhibitors useful for the treatment of diseases such as hyperli pidemia or arteriosclerosis |
WO2009109549A1 (en) | 2008-03-05 | 2009-09-11 | Boehringer Ingelheim International Gmbh | Tricyclic pyridine derivatives, medicaments containing such compounds, their use and process for their preparation |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MA24643A1 (fr) | 1997-09-18 | 1999-04-01 | Bayer Ag | Tetrahydro-naphtalenes substitues et composes analogues |
UA90269C2 (ru) * | 2004-04-02 | 2010-04-26 | Мицубиси Танабе Фарма Корпорейшн | Тетрагидрохинолиновые производные и способ их получения |
-
2011
- 2011-07-08 MX MX2013000359A patent/MX2013000359A/es active IP Right Grant
- 2011-07-08 KR KR1020137000015A patent/KR101764458B1/ko active IP Right Grant
- 2011-07-08 MY MYPI2013000039A patent/MY158199A/en unknown
- 2011-07-08 WO PCT/JP2011/065651 patent/WO2012005343A1/ja active Application Filing
- 2011-07-08 NZ NZ606100A patent/NZ606100A/en not_active IP Right Cessation
- 2011-07-08 ES ES11803677.1T patent/ES2543176T3/es active Active
- 2011-07-08 CA CA2804924A patent/CA2804924C/en not_active Expired - Fee Related
- 2011-07-08 CN CN201180043361.9A patent/CN103221405B/zh not_active Expired - Fee Related
- 2011-07-08 SG SG2013000385A patent/SG186493A1/en unknown
- 2011-07-08 RU RU2013105475/04A patent/RU2572606C2/ru not_active IP Right Cessation
- 2011-07-08 TW TW100124148A patent/TWI506025B/zh not_active IP Right Cessation
- 2011-07-08 BR BR112013000389A patent/BR112013000389A2/pt not_active IP Right Cessation
- 2011-07-08 JP JP2012523924A patent/JP5739426B2/ja not_active Expired - Fee Related
- 2011-07-08 US US13/809,115 patent/US9187450B2/en not_active Expired - Fee Related
- 2011-07-08 EP EP20110803677 patent/EP2592076B1/en not_active Not-in-force
- 2011-07-08 AU AU2011274903A patent/AU2011274903B2/en not_active Ceased
-
2012
- 2012-12-25 IL IL223866A patent/IL223866A/en active IP Right Grant
-
2013
- 2013-01-07 ZA ZA2013/00155A patent/ZA201300155B/en unknown
- 2013-02-06 CO CO13024408A patent/CO6670582A2/es active IP Right Grant
- 2013-10-11 HK HK13111517.6A patent/HK1183877A1/xx not_active IP Right Cessation
Patent Citations (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6207671B1 (en) | 1996-07-08 | 2001-03-27 | Bayer Aktiengesellschaft | Cycloalkano-pyridines |
JPH10167967A (ja) | 1996-07-08 | 1998-06-23 | Bayer Ag | 複素環式−縮合ピリジン類 |
US5932587A (en) | 1996-07-08 | 1999-08-03 | Bayer Aktiengesellschaft | Heterocyclic-fused pyridines |
US6069148A (en) | 1996-07-08 | 2000-05-30 | Bayer Aktiengesellschaft | Cycloalkano-pyridines |
JPH1067746A (ja) | 1996-07-08 | 1998-03-10 | Bayer Ag | シクロアルカノ−ピリジン類 |
WO1999014215A1 (de) * | 1997-09-18 | 1999-03-25 | Bayer Aktiengesellschaft | 4-heteroaryl-tetrahydrochinoline und ihre verwendung als inhibitoren des cholesterin-ester-transfer-proteins (ctep) |
JP2001516757A (ja) | 1997-09-18 | 2001-10-02 | バイエル・アクチエンゲゼルシヤフト | 4−ヘテロアリール−テトラヒドロキノリン及びコレステリン−エステル輸送タンパク質のインヒビターとしてのそれらの使用 |
US6387929B1 (en) | 1997-09-18 | 2002-05-14 | Bayer Aktiengesellschaft | 4-heteroaryl-tetrahydroquinolines and their use as inhibitors of the cholesterin-ester transfer protein |
US6897317B2 (en) | 1997-09-19 | 2005-05-24 | Bayer Aktiengesellschaft | 4-Phenyltetrahydrochinoline utilized as an inhibitor of the cholesterol ester transfer protein |
US6291477B1 (en) | 1997-09-19 | 2001-09-18 | Bayer Aktiengesellschaft | Tetrahydroquinolines, processes for their preparation, pharmaceutical compositions containing them, and their use to prevent or treat hyperlipoproteinaemia |
JP2001517655A (ja) | 1997-09-19 | 2001-10-09 | バイエル・アクチエンゲゼルシヤフト | コレステロールエステル輸送タンパク質のインヒビターとして利用される4−フェニルテトラヒドロキノリン |
US6562976B2 (en) | 1997-09-19 | 2003-05-13 | Bayer Aktiengesellschaft | 4-phenyltetrahydrochinoline utilized as an inhibitor of the cholesterol ester transfer protein |
WO1999041237A1 (en) * | 1998-02-13 | 1999-08-19 | G.D. Searle & Co. | Substituted pyridines useful for inhibiting cholesteryl ester transfer protein activity |
US6593333B1 (en) | 1998-10-01 | 2003-07-15 | Astrazeneca Ab | Substituted anilino-quinazoline (or quinoline) compounds and use thereof |
JP2005508341A (ja) | 2001-10-01 | 2005-03-31 | バイエル・ヘルスケア・アクチェンゲゼルシャフト | 3−ヒドロキシ−(4−トリフルオロメチルフェニル)−メチル−7−スピロシクロブチル−5,6,7,8−テトラヒドロキノリン−5−オール誘導体およびコレステロールエステル転送タンパク質(cetp)阻害剤としてのその使用 |
US20080255068A1 (en) | 2004-12-18 | 2008-10-16 | Bayer Healthcare Ag | Chemical Compound and Its Use |
JP2008524145A (ja) | 2004-12-18 | 2008-07-10 | バイエル・ヘルスケア・アクチェンゲゼルシャフト | 4−シクロアルキル置換テトラヒドロキノリン誘導体および医薬としてのそれらの使用 |
JP2008524137A (ja) | 2004-12-18 | 2008-07-10 | バイエル・ヘルスケア・アクチェンゲゼルシャフト | (5s)−3−[(s)−フルオロ(4−トリフルオロメチルフェニル)メチル−5,6,7,8−テトラヒドロキノリン−5−オール誘導体およびcetp阻害剤としてのそれらの使用 |
US20080194609A1 (en) | 2004-12-18 | 2008-08-14 | Bayer Heathcare Ag | Chemical Compound and Its Use |
WO2006063828A1 (de) * | 2004-12-18 | 2006-06-22 | Bayer Healthcare Ag | 4-cycloalkyl-substituierte tetrahydrochinolinderivate und deren verwendung als medikamente |
JP2009516649A (ja) | 2005-10-31 | 2009-04-23 | メルク エンド カムパニー インコーポレーテッド | Cetp阻害薬 |
US20090023729A1 (en) | 2006-01-31 | 2009-01-22 | Mitsubishi Tanabe Pharma Corporation | Trisubstituted amine compound |
JP2009524579A (ja) | 2006-01-31 | 2009-07-02 | 田辺三菱製薬株式会社 | 三置換アミン化合物 |
WO2008009435A1 (en) | 2006-07-20 | 2008-01-24 | Novartis Ag | Amino-piperidine derivatives as cetp inhibitors |
WO2008156715A1 (en) | 2007-06-20 | 2008-12-24 | Merck & Co., Inc. | Cetp inhibitors derived from benzoxazole arylamides |
WO2009071509A1 (en) | 2007-12-03 | 2009-06-11 | Novartis Ag | 1,2-disubstituted-4-benzylamino-pyrrolidine derivatives as cetp inhibitors useful for the treatment of diseases such as hyperli pidemia or arteriosclerosis |
WO2009109549A1 (en) | 2008-03-05 | 2009-09-11 | Boehringer Ingelheim International Gmbh | Tricyclic pyridine derivatives, medicaments containing such compounds, their use and process for their preparation |
Non-Patent Citations (15)
Title |
---|
A. TAKAMIZAWA ET AL., JOURNAL OF ORGANIC CHEMISTRY, vol. 29, 1964, pages 1740 - 1742 |
B. A. JONES ET AL., JOURNAL OF HETEROCYCLIC CHEMISTRY, vol. 19, 1982, pages 551 - 556 |
BADIMON, J. CLIN. INVEST., vol. 85, 1990, pages 1234 - 1241 |
J. DUBOIS ET AL., TETRAHEDRON, vol. 47, 1991, pages 1001 - 1012 |
J. LIPID RES., vol. 36, 1995, pages 1082 - 1091 |
J. TSUJI: "Palladium Reagents and Catalysis: New Perspectives for the 21st Century", 2004, JOHN WILEY & SONS, INC |
M. ZHANG ET AL., BIOORGANIC AND MEDICINAL CHEMISTRY LETTERS, vol. 17, 2007, pages 2401 - 2403 |
N. ENGL. J. MED., vol. 350, 2004, pages 1505 - 1515 |
P. HUSZTHY ET AL., JOURNAL OF ORGANIC CHEMISTRY, vol. 57, 1992, pages 5383 - 5394 |
See also references of EP2592076A4 * |
T. W. GREENE; P. G. WUTS: "Greene's Protective Groups in Organic Synthesis, Fourth Edition,", 2007, JOHN WILEY & SONS |
T. W. GREENE; P. G. WUTS: "Greene's Protective Groups in Organic Synthesis, Fourth Edition,", 2007, JOHN WILEY & SONS, INC. |
V. W. GASH, JOURNAL OF ORGANIC CHEMISTRY, vol. 37, 1972, pages 2197 - 2201 |
W. D. WULFF ET AL., JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, vol. 110, 1988, pages 7419 - 7434 |
YAGAMARE FALL ET AL., TETRAHEDRON LETTERS, vol. 41, 2000, pages 7337 - 7340 |
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2013103150A1 (ja) * | 2012-01-06 | 2013-07-11 | 第一三共株式会社 | 置換ピリジン化合物の酸付加塩 |
EP2801574A1 (en) * | 2012-01-06 | 2014-11-12 | Daiichi Sankyo Company, Limited | Acid adduct salt of substituted pyridine compound |
EP2801574A4 (en) * | 2012-01-06 | 2015-04-29 | Daiichi Sankyo Co Ltd | ACID ADDITIONAL SALT OF A SUBSTITUTED PYRIDINE COMPOUND |
US9321747B2 (en) | 2012-01-06 | 2016-04-26 | Daiichi Sankyo Company, Limited | Acid addition salt of substituted pyridine compound |
TWI570118B (zh) * | 2012-01-06 | 2017-02-11 | 第一三共股份有限公司 | 經取代之吡啶化合物的酸加成鹽 |
WO2015060422A1 (ja) * | 2013-10-25 | 2015-04-30 | 第一三共株式会社 | 置換ピリジン化合物および他の医薬の組み合わせ |
JPWO2015087994A1 (ja) * | 2013-12-13 | 2017-03-16 | 第一三共株式会社 | 5−ヒドロキシ−4−(トリフルオロメチル)ピラゾロピリジン誘導体 |
Also Published As
Publication number | Publication date |
---|---|
JPWO2012005343A1 (ja) | 2013-09-05 |
BR112013000389A2 (pt) | 2016-06-07 |
ZA201300155B (en) | 2013-09-25 |
MY158199A (en) | 2016-09-15 |
SG186493A1 (en) | 2013-01-30 |
IL223866A (en) | 2016-07-31 |
EP2592076A4 (en) | 2013-10-16 |
CO6670582A2 (es) | 2013-05-15 |
US20130109653A1 (en) | 2013-05-02 |
KR20130093068A (ko) | 2013-08-21 |
ES2543176T3 (es) | 2015-08-17 |
CA2804924C (en) | 2016-06-28 |
US20140005143A2 (en) | 2014-01-02 |
TW201206904A (en) | 2012-02-16 |
RU2572606C2 (ru) | 2016-01-20 |
AU2011274903A1 (en) | 2013-02-14 |
EP2592076B1 (en) | 2015-05-13 |
AU2011274903B2 (en) | 2016-09-08 |
NZ606100A (en) | 2014-08-29 |
US20140213549A9 (en) | 2014-07-31 |
JP5739426B2 (ja) | 2015-06-24 |
HK1183877A1 (en) | 2014-01-10 |
KR101764458B1 (ko) | 2017-08-02 |
TWI506025B (zh) | 2015-11-01 |
CN103221405B (zh) | 2015-04-22 |
US9187450B2 (en) | 2015-11-17 |
RU2013105475A (ru) | 2014-08-20 |
CA2804924A1 (en) | 2012-01-12 |
MX2013000359A (es) | 2013-02-11 |
EP2592076A1 (en) | 2013-05-15 |
CN103221405A (zh) | 2013-07-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
TWI736566B (zh) | Tlr7/8拮抗劑及其用途 | |
JP2019532995A (ja) | タウタンパク質標的化protac、および関連使用方法 | |
TW201802085A (zh) | 經雜芳基取代之吡啶及使用方法 | |
TW201838966A (zh) | 取代的二氫茚-4-甲醯胺及其類似物以及其使用方法 | |
JP2017537122A (ja) | 1,3−チアゾール−2−イル置換ベンズアミド | |
US20180170928A1 (en) | Methyl- and Trifluoromethyl-Substituted Pyrrolopyridine Modulators of RORC2 and Methods of Use Thereof | |
JP2015520158A (ja) | Abl1、abl2およびbcr−abl1の活性を阻害するためのベンズアミド誘導体 | |
JP2023541612A (ja) | Egfr突然変異癌の抑制用化合物及びその医薬用途 | |
KR20240024060A (ko) | 인테그린 억제제에 대한 확장된 투여량 요법 | |
JP5739426B2 (ja) | 置換ピリジン化合物 | |
KR102616949B1 (ko) | 고리형 구조를 갖는 화합물 | |
JP6097225B2 (ja) | 置換ピリジン化合物の酸付加塩 | |
WO2021218997A1 (zh) | 取代的氮杂五元环类化合物及其在药物中的应用 | |
JP2023509496A (ja) | RORγt阻害剤、その製造方法及び使用 | |
JP2022533818A (ja) | ブルトン型チロシンキナーゼ阻害剤としての置換されている1-アミノ-1h-イミダゾール-5-カルボキサミド | |
US11970493B2 (en) | Autotaxin inhibitor compounds | |
TW202408507A (zh) | 用於治療癌症之鹵炔基化合物 | |
US20240207263A1 (en) | Selective modulators of ataxia telangiectasia mutated (atm) kinase and uses thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 11803677 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2012523924 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2011803677 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 223866 Country of ref document: IL |
|
ENP | Entry into the national phase |
Ref document number: 20137000015 Country of ref document: KR Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 12013500047 Country of ref document: PH |
|
WWE | Wipo information: entry into national phase |
Ref document number: 13809115 Country of ref document: US |
|
ENP | Entry into the national phase |
Ref document number: 2804924 Country of ref document: CA |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: MX/A/2013/000359 Country of ref document: MX |
|
WWE | Wipo information: entry into national phase |
Ref document number: 13024408 Country of ref document: CO |
|
ENP | Entry into the national phase |
Ref document number: 2013105475 Country of ref document: RU Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 2011274903 Country of ref document: AU Date of ref document: 20110708 Kind code of ref document: A |
|
REG | Reference to national code |
Ref country code: BR Ref legal event code: B01A Ref document number: 112013000389 Country of ref document: BR |
|
ENP | Entry into the national phase |
Ref document number: 112013000389 Country of ref document: BR Kind code of ref document: A2 Effective date: 20130107 |